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90-90-90: An ambitious treatment target to help end the AIDS epidemic. By 2020, 90% of all people 
living with HIV (PLHIV) will know their HIV status; 90% of all people with diagnosed HIV infection will 
receive sustained antiretroviral therapy (ART); and 90% of all people receiving ART will have viral load 
(VL) suppression (VLS). 
 
Acquired Immunodeficiency Syndrome (AIDS): AIDS is a disease caused by infection with HIV. AIDS is 
the result of severe damage to the immune system that leaves the body vulnerable to life-threatening 
conditions such as infections and cancers. 
 
Antiretroviral Therapy (ART): Treatment with antiretroviral drugs that inhibit the ability of HIV to 
multiply in the body, leading to improved health and survival among people living with HIV. 
 
CD4+ T-Cells: CD4+ T-cells (CD4) are white blood cells that are an essential part of the human immune 
system. These cells are often referred to as T-helper cells. HIV attacks and kills CD4 cells leaving the body 
vulnerable to a wide range of infections. The CD4 count is used to determine the degree of weakness of 
the immune system from HIV infection. 
 
De Facto Household Resident: A person who slept in the household the night prior to the survey. 
 
Enumeration Area (EA): A limited geographic area defined by the national statistical authority and the 
primary sampling unit for the Population-based HIV Impact Assessment (PHIA) surveys.  
 
Head of Household: The head of household is defined as the person who is recognized within the 
household as being the head and is 18 years of age or older or, in special cases, a person between the 
ages of 15 and 17 years who is either married, has one or more children or living alone. This person may 
be acknowledged as the head on the basis of age (older), sex (generally, but not necessarily, male), 
economic status (main provider), or some other reason.  
 
Human Immunodeficiency Virus (HIV): HIV is the virus that causes AIDS. The virus is passed from person 
to person through blood, semen, vaginal fluids and breast milk. HIV attacks CD4 cells in the body, leaving 
the infected person vulnerable to illnesses that would have otherwise been eliminated by a healthy 
immune system. 
 
HIV Incidence: A measure of the frequency with which new cases of HIV occur in a population over a 
period of time. The denominator is the population at risk; the numerator is the number of new cases 
that occur during a given time period. 
 
HIV Prevalence: The proportion of living persons in a population who are infected with HIV at a specific 
point in time. 
 
HIV Viral Load (VL): The concentration of HIV in the blood, usually expressed as copies/milliliter (mL). 
 
GLOSSARY OF TERMS 
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HIV Viral Load Suppression (VLS) or Suppressed Viral Load: An HIV VL of less than 1,000 copies/mL. 
 
Household: A person or group of persons, related or unrelated to each other, who live in the same 
compound (fenced or unfenced), share the same cooking arrangements, and have one person whom 
they identify as head of that household.  
 
Informed Consent: Informed consent is a legal condition whereby a person can give consent based upon 
a clear understanding of the facts, implications and future consequences of an action. In order to give 
informed consent, the individual concerned must have adequate reasoning faculties and be in 
possession of all relevant facts at the time he or she gives consent. 
 
Male Circumcision: Male circumcision is the removal of some or the entire foreskin (prepuce) from the 
penis. Medically supervised adult male circumcision is a scientifically proven method for reducing a 
man’s risk of acquiring HIV infection through heterosexual intercourse. Voluntary medical male 
circumcision (VMMC) is an important part of national HIV prevention programs in most HIV high burden 
countries. 
 
Prevention of Mother-to-Child Transmission (PMTCT): Mother-to-child transmission (MTCT) is when an 
HIV-positive woman passes the HIV virus to her baby during pregnancy, labor or delivery or while 
breastfeeding. The United Nations recommends effective PMTCT to include a four-fold approach: (1) 
primary prevention of HIV infection among women of childbearing age; (2) preventing unintended 
pregnancies among women living with HIV; (3) preventing HIV transmission from women living with HIV 
to their infants; and (4) providing appropriate treatment, care, and support to mothers living with HIV 
and their children and families. 
 
Sexually Transmitted Infections: Sexually transmitted infections (STIs) are infections transmitted 
through person-to-person sexual contact. They are sometimes called sexually transmitted diseases 
(STDs). 
 
Syphilis: Syphilis is a curable STI caused by a bacterium, Treponema pallidum. Syphilis can be 
transmitted to a fetus during pregnancy or to an infant during delivery. 
 
Tuberculosis: Tuberculosis (TB) is a contagious bacterial disease that spreads through the air and is the 
leading cause of death among people living with HIV in Africa.  
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Survey Household Characteristics 
▪ Among all households, 74.5% were headed by males and 25.5% were headed by females. 
▪ Among female household heads, 31.5% were HIV positive, as compared to 14.0% of male household 
heads. 
▪ Among all households, 21.5% have at least one HIV-positive household member. 
 
Survey Respondent Characteristics 
▪ The largest proportion of the population was located in Lusaka Province (20.1%) and the smallest in 
North-Western Province (5.2%). 
▪ Among males, 49.4% reported secondary education as their highest level of schooling, compared to 
39.6% of the female population. 
 
HIV Incidence 
▪ The annual incidence of HIV among adults aged 15-59 years in Zambia is 0.61%: 0.93% among 
females and 0.29% among males. This corresponds to approximately 43,000 new cases of HIV 
infection annually among adults aged 15-59 years in Zambia. 
 
HIV Prevalence 
▪ The prevalence of HIV among adults aged 15-59 years in Zambia is 12.0%: 14.6% among females and 
9.3% among males. This corresponds to approximately 960,000 people living with HIV (PLHIV) aged 
15-59 years in Zambia. 
▪ The prevalence among adults aged 15-49 years was higher among females (14.3%) than among 
males (8.3%), as well as among those residing in urban areas (14.4%) compared to those living in 
rural areas (8.7%). 
▪ HIV prevalence peaked between the ages of 40-44 years for females (29.6%) and between 45-49 
years of age for males (23.0%). 
▪ Among young adults (20-24 years of age), HIV prevalence was four times higher among females 
(8.3%) than among males (2.0%). 
 
HIV Testing 
▪ Almost two-thirds of males (65.1%) and 79.2% of females aged 15-59 years reported ever having 
been tested for HIV and having received their results. In this sample, 34.8% of all males and 42.0% of 
females in the same age bracket reported receiving an HIV test in the 12 months preceding the 
survey. 
▪ Among males and females aged 15-59 years who tested positive in the survey, 85.9% and 92.9%, 
respectively, reported they had ever been tested for HIV and received their results. 
SUMMARY OF KEY FINDINGS 
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▪ Among adults in urban areas, 75.9% reported ever testing for HIV while 40.5% reported testing for 
HIV in the 12 months prior to survey, compared 69.3% and 36.7% of adults in rural areas, 
respectively.  
 
HIV Diagnosis and Treatment 
▪ Over two-thirds (67.1%) of HIV-positive males 25-29 years of age reported being unaware of their 
HIV status. 
▪ Based on self-report, among HIV-positive men 15-59 years of age, awareness varied geographically, 
from 26.6% unaware of their HIV status in Eastern Province to 57.1% in Luapula Province. As among 
HIV-positive men, awareness of HIV status among HIV-positive females varied geographically, from 
23.5% unaware in Southern Province to 42.8% in Luapula Province. 
▪ Concordance between self-report of ART and detection of ARVs was high among adults aged 15-59 
years, with 96.3% of those who reported current ART use having detectable ARVs in blood. 
However, self-report of HIV status was less accurate, with 18.1% of those who reported that they 
had not been previously diagnosed with HIV having ARVs detected in their blood. 
 
Viral Load Suppression (VLS) 
▪ Among people living with HIV 15-59 years of age in Zambia, the prevalence of VLS (defined as an HIV 
of less than 1,000 copies/mL) was 59.2%. 
▪ The prevalence of VLS ranged from 30.7% among HIV-positive individuals aged 15-19 years to 79.0% 
among those aged 55-59 years. 
▪ Among HIV-positive adults aged 15-59 years, the prevalence of VLS varies geographically across 
Zambia, ranging from 47.3% in Western Province to 67.1% in Eastern Province. 
 
90-90-90 
▪ Diagnosed: In Zambia, 71.4% of people living with HIV aged 15-59 years report knowing their HIV 
status and/or had detectable ARVs in their blood (72.6% of HIV-positive females and 69.2% of HIV-
positive males). 
▪ On Treatment: Among people living with HIV aged 15-59 years who know their HIV status, 87.1% 
self-reported current use of ART and/or had detectable ARVs in their blood (86.5% of HIV-positive 
females and 88.2% of HIV-positive males). 
▪ Suppressed Viral Load: Among people living with HIV aged 15-59 years who self-report current use 
of ART and/or had detectable ARVs in their blood, 89.2% have suppressed viral loads (90.2% of HIV-
positive females and 87.7% of HIV-positive males).  
 
Clinical Perspectives on People Living with HIV 
▪ The median CD4+ T-cell (CD4) count among HIV-positive adults aged 15-59 years was 421 cells/μL. 
Nearly two-thirds (64.3%) of those had CD4 counts < 500 cells/µL. The proportion of 
immunosuppression (defined as CD4 count < 500 cells/μL) among HIV-positive persons who 
reported having been previously diagnosed and on ART was 59.2%, compared to 76.0% among 
those who reported having been previously diagnosed but not on ART. 
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▪ Among HIV-positive adults 15-59 years of age, the prevalence of immunosuppression was 58.9% in 
females compared to 73.2% in males. 
▪ Overall, among newly diagnosed HIV-positive persons aged 15-59 years, 45.5% had a CD4 count less 
than 350 cells/µL and 17.7% had a CD4 count less than 200 cells/µL.  
 
Prevention of Mother-to-Child Transmission 
▪ In Zambia, 99.0% of women aged 15-49 years who delivered in the three years preceding the survey 
attended at least one ANC visit for their most recent birth. 
▪ Prevention of mother-to-child transmission: Among women aged 15-49 years who delivered in the 
12 months preceding the survey, 93.1% knew their HIV status; while 98.9% of HIV-positive women 
who gave birth in the 12 months preceding the survey received antiretrovirals (ARVs).  
▪ 9.3% of the infants born in the previous 17 months to HIV-positive mothers who reported ever 
breastfeeding were confirmed to be HIV positive. 
 
Adolescents and Young Adults 
▪ Nearly twice the proportion of males (17.1%) aged 15-24 years compared to females (9.5%) in the 
same age bracket reported having sexual intercourse before the age of 15 years.  
▪ The percentage of young people aged 15-24 years who reported sex before the age of 15 years, was 
nearly twice as high in rural areas compared to urban areas (17.3% and 8.6%, respectively). 
▪ Less than half of people aged 15-24 years in both urban (46.7%) and rural (32.4%) areas had 
comprehensive knowledge on HIV transmission and prevention. 
 
Children 
▪ The prevalence of HIV among children aged 0-14 years in Zambia was 1.1%. 
▪ Only 50.6% of HIV-positive children aged 0-14 years were previously diagnosed. Of the previously 
diagnosed, 92.3% were on treatment. However, of those on treatment only 54.3% had suppressed 
viral loads. 
 
HIV Risk Factors 
▪ HIV prevalence was twice as high among women who reported paid sexual intercourse in the 
previous 12 months (32.2%) as among those who did not (14.7%). 
▪ Only two in 10 (21.2%) males aged 15-59 years reported having undergone medical circumcision. 
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Discriminatory Attitudes Towards People Living with HIV 
▪ In rural areas, 25.3% of people held discriminatory attitudes towards people living with HIV 
compared to 14.5% in urban areas. 
▪ Discriminatory attitudes towards people living with HIV are more common among those with less 
education, ranging from 34.3% among those with no education to 5.7% among those with more 
than secondary education. 
 
Tuberculosis, Syphilis, HBV, STI Symptoms, and Cervical Cancer Screening  
▪ Based on self-report, among adults aged 15-59 years who visited a TB clinic, 60.9% reported testing 
for HIV at the TB clinic while 30.7% neither tested at the clinic nor were aware of their HIV status. 
▪ Among adults living with HIV who had ever visited a TB clinic, 54.3% were diagnosed with TB and 
98.4% of these were treated for TB. 
▪ Overall, 39.4% of HIV-positive persons were screened for TB at their last HIV clinic visit. 
▪ The prevalence of having ever been infected with syphilis among those aged 15-59 years was 6.8% 
(7.2% among females and 6.3% among males). 
▪ The overall prevalence of active syphilis infection was 3.0% (3.4% among females and 2.7% among 
males).  
▪ The prevalence of ever having been infected with syphilis was lower among HIV-negative (5.5%). 
than among HIV-positive (16.6%) participants. Active syphilis infections were less common among 
HIV-negative participants (2.1%) than HIV-positive (9.6%) participants.  
▪ The overall prevalence of hepatitis B in the population of those aged 0-59 years was 3.5%. The 
prevalence of hepatitis B was four times higher among those aged 15-59 years (5.6%) compared to 
those aged 0-14 years (1.3%).  
▪ Among adult people living with HIV, 7.0% of men and 3.5% of women reported having a sexually 
transmitted infection (STI) diagnosed by a medical professional in the past 12 months. Among HIV-
negative adults, 3.4% of men and 1.3% of women reported having an STI diagnosed by a medical 
professional in the last 12 months.  
▪ Among women with HIV aged 30-49 years, the probability of having been screened for cervical 
cancer was 34.5% in urban areas compared to 17.0% in rural areas.  
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1.1 Background 
The Population-based HIV Impact Assessment (PHIA) is a multi-country project funded by the United 
States President’s Emergency Plan for AIDS Relief (PEPFAR) to conduct national HIV-focused surveys that 
describe the status of the HIV epidemic. The surveys measure important national and regional HIV-
related parameters, including progress toward the achievement of the Joint United Nations Programme 
on HIV and AIDS (UNAIDS) 90-90-90 targets (UNAIDS, 2014), and will guide policy and funding priorities. 
 
1.2 Overview of ZAMPHIA 2016 
The Zambia Population-based HIV Impact Assessment (ZAMPHIA), a household-based, national survey, 
was conducted between March and August 2016 to measure the status of Zambia’s national HIV 
response. ZAMPHIA offered HIV counseling and testing with return of results, and collected information 
about uptake of HIV care and treatment services. 
 
This survey is the first in Zambia to measure national HIV incidence, VLS, and pediatric HIV prevalence. 
The results provide information on national and subnational progress toward control of the HIV 
epidemic and Zambia’s progress toward the UNAIDS 90-90-90 treatment targets. ZAMPHIA was led by 
the government of the Republic of Zambia through the Ministry of Health (MOH) and conducted with 
funding from PEPFAR and with technical assistance through the U.S. Centers for Disease Control and 
Prevention (CDC). The survey was implemented by ICAP at Columbia University in collaboration with the 
statistical survey research corporation, Westat, and local partners, including the Central Statistical Office 
(CSO), the Tropical Diseases Research Centre (TDRC), the University of Zambia (UNZA), the University 
Teaching Hospital (UTH), the Zambia National Public Health Institute, and the National HIV/AIDS/STI/TB 
Council. 
 
Multiple HIV-related measures, such as CD4 count distribution, prevalence of detectable ARVs, and HIV 
drug resistance were also assessed to characterize the HIV epidemic in Zambia and provide greater 
clarity on the impact of the national HIV program. In addition, the survey collected information on 
selected behaviors typically associated with HIV acquisition and transmission, and on common HIV 
comorbidities and other health conditions. 
 
1.3 Specific Objectives 
The objective of the survey was to examine the distribution of HIV in Zambia, to assess the coverage and 
impact of HIV services at the population level, and to measure HIV-related risk behaviors using a 
nationally representative sample of adults and children. 
 
Primary Objectives 
▪ To estimate the national rate of new HIV infections (incidence) among adults aged 15-59 years. 
▪ To estimate the provincial level prevalence of HIV VLS, among HIV-positive adults aged 15-59 years. 
 
 
 
1 INTRODUCTION 
17 
 
Secondary Objectives 
▪ To estimate the national and provincial level prevalence of HIV infection for adults aged 15-59 years. 
▪ To estimate the prevalence of HIV-related knowledge and risk behaviors for adults aged 15-59 years. 
▪ To estimate syphilis antibody prevalence among adults aged 15-59 years. 
▪ To estimate the prevalence of hepatitis B among adults and children aged 0-59 years. 
▪ To estimate the national prevalence of HIV infection among children aged 0-14 years. 
▪ To describe the uptake of HIV-related services, especially prevention of mother-to-child 
transmission of HIV (PMTCT) services. 
▪ To determine the distribution of CD4 counts in HIV-positive persons aged 0-59 years. 
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ZAMPHIA 2016 was a nationally representative, cross-sectional, population-based survey of households 
across Zambia. Its target population corresponded to children aged 0-14 years and adults aged 15-59 
years. The survey population excluded institutionalized children and adults. 
 
2.1 Sample Frame and Design 
ZAMPHIA 2016 used a two-stage stratified cluster sample design, where the first stage selected 511 
enumeration areas (EAs) from the 2010 Census of Population and Housing in Zambia, using a probability 
proportional to size method. The second stage randomly selected a sample of households in each EA 
(cluster) using an equal probability method, where the average number of households selected per 
cluster was 27 and the actual number of households selected per cluster ranged from 11 to 48. The 
sampling frame for the second stage was defined based on a household listing exercise conducted from 
August to September 2015, prior to the initiation of data collection. 
 
The sample size of selected households was calculated to provide a representative national estimate of 
HIV incidence among adults aged 15-59 years with a relative standard error less than or equal to 31.2%, 
as well as representative provincial estimates of VLS prevalence among HIV-positive adults aged 15-59 
years with 95% confidence intervals (CIs) ±11.0%. One-half of households were randomly selected for 
inclusion of children aged 0-14 years, which was designed to provide a representative national estimate 
of pediatric HIV prevalence with a relative standard error ≤14.6%. The target sample size was 19,168 for 
adults aged 15-59 years, and 8,974 for children aged 0-14 years. 
 
Table 2.1.A Distribution of sampled enumeration areas and households, by province 
 Enumeration areas  Households 
Province Urban Rural Total   Urban Rural Total 
Central 10 32 42  255 842 1097 
Copperbelt 60 14 74  1621 311 1932 
Eastern 6 43 49  130 1147 1277 
Luapula 6 26 32  159 676 835 
Lusaka 69 16 85  1860 381 2241 
Muchinga 8 42 50  258 1050 1308 
Northern 8 35 43  233 941 1174 
North-Western 9 40 49  297 1008 1305 
Southern 15 40 55  414 1022 1436 
Western 3 29 32  120 716 836 
        
Total 194 317 511  5347 8094 13441 
 
Appendix A. Sample Design and Implementation provides a more detailed explanation of the sampling 
and weighting processes. 
  
2 SURVEY DESIGN, METHODS, AND RESPONSE 
RATES 
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2.2 Eligibility Criteria, Recruitment, and Consent Procedures 
Participants were eligible if they were literate in one of the survey languages or could provide a literate 
witness and were willing and cognitively able to provide consent. The eligible survey population 
included: 
▪ Children aged 0-9 years living in residential households, and child visitors who slept in the household 
the night before the survey, whose parents or guardians were able to provide consent for their 
participation. 
▪ Young people aged 10-17 years living in residential households, and young visitors who slept in the 
household the night before the survey, willing and able to provide assent and whose parents or 
guardians provided permission. 
▪ Women and men aged 18-59 years living in residential households, and visitors who slept in the 
household the night before the survey, who were able to provide consent in one of the eight survey 
languages (English, Bemba, Nyanja, Lozi, Tonga, Lunda, Luvale, or Kaonde). 
 
A designated head of household provided written consent for household members to participate in the 
survey on an electronic informed consent form administered using a tablet (Appendix H). Individual 
members were then rostered during a household interview. Persons aged 15-59 (note that parental 
permission and participant assent were obtained for adolescents 15 to 17 years of age) and 
emancipated minors (minors 15-17 years of age who are married, have children and or living without 
parental/guardian supervision) then provided written consent for an interview on the tablet. After 
completing the interview, they provided written consent for participation in the biomarker component 
of the survey, which included home-based testing and counseling (HBTC) for HIV, hepatitis B, and 
syphilis (for persons 15-59 years of age) with return of HIV test results and CD4 count results for those 
who tested HIV positive, during the household visit. If an individual did not want to receive his or her 
HIV test result, it was considered a refusal and the survey was stopped. Adults were also asked for 
written consent for their blood samples to be stored in a repository for future testing. At each stage of 
the consent process, consent was indicated by signing or making a mark on the consent form on the 
tablet and on a printed copy, which was retained by the participant. 
 
Adolescents aged 10-14 years were asked for assent to the interview and biomarker components after 
permission was granted by their parents or guardians. Parents or guardians provided consent directly for 
minors below the age of assent (ages 0-9 years). In both cases, if a parent or guardian did not want to 
receive his or her HIV test result, this was considered a refusal and the survey was concluded. 
Procedures with non-literate participants, or participants with a sight disability, involved the use of an 
impartial witness, chosen by the potential participant who also signed or made a mark on the consent 
form on the tablet and the printed copy. If no witness could be identified, the potential participant or 
household (if the head of household was illiterate) was deemed ineligible. 
 
Note: only those who slept in the household in the night prior to the survey were included in analysis 
and creation of the dataset. 
 
2.3 Survey Implementation 
 
Training of Field and Laboratory Staff  
Survey staff received training on both the contents of the data collection instruments and tablet use. 
The training curriculum included: 
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▪ Scientific objectives of the survey 
▪ Survey design and methods 
▪ Completion of survey forms 
▪ Data collection 
▪ Staff responsibilities 
▪ Recruitment of participants 
▪ Informed consent procedures, including human subjects’ protection, privacy, and confidentiality 
▪ Blood collection for children and adults, including venipuncture and finger/heel stick 
▪ Home-based HIV testing and counseling (HBTC) 
▪ CD4 count measurement using Point of Care PIMA Analyzer 
▪ Referral of participants to health and social services 
▪ Management and transportation of blood specimens 
▪ Biosafety 
▪ Communication skills 
▪ Protocol deviations, adverse events, and reporting of events  
 
Laboratory staff were trained in specimen management, including sample processing, labeling, and 
quality assurance (QA). Central laboratory staff were trained in viral load (VL) measurement, early infant 
diagnosis (EID), HIV confirmatory testing, and HIV recency testing using the Limiting Antigen (LAg) 
Avidity enzyme immunoassay.  
 
Survey Staff 
Field work started on March 1, 2016 and completed by August 31, 2016. A total of 47 field teams 
conducted the survey; however, at any given time, there were a maximum of 37 teams in the field. Each 
team was composed of one team leader, two interviewers, two nurse counselors, one midwife, and one 
laboratory technician. Survey personnel were selected based on local language proficiency and 
profession. While all survey personnel had the responsibility of obtaining consent and administering the 
interview, nurse counselors, midwives, and laboratory technicians also conducted phlebotomy and 
other duties as needed. In addition, nurse counselors and midwives provided adult and pediatric HIV 
counseling. 
 
Over 40 laboratory staff processed samples and performed additional tests for HIV-1 viral load, infant 
virological testing, and quality control (QC) and QA. Teams were supervised by three or four provincial 
supervisors at a time, along with 40 rotating field monitors who performed spot-checks of teams in the 
field, providing technical support and assistance where needed. National and international monitors 
routinely provided direct observation of field work and QA. 
 
Community Sensitization and Mobilization 
In coordination with the MOH, the Ministry of Community Development and Social Work, CSO, the 
National HIV/AIDS/STI/TB Council, the Network of Zambian People Living with HIV, and the Treatment 
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Advocacy and Literacy Campaign, community mobilization was organized to maximize community 
support and participation rates at the national and subnational levels. The mobilization began with a 
high-level national launch meeting that included key national and regional leaders, mass media, and 
other stakeholders before the survey field work commenced. Community mobilization teams visited 
each enumeration area approximately two to three weeks prior to initiation of data collection and 
partnered with community health workers to meet key gatekeepers in the communities (chiefs, village 
headmen, local government officials, and religious and community leaders). Community mobilizers 
consulted with community leaders and provided them with information about the survey to share with 
their community members. Mobilizers also held community meetings, disseminated written 
informational materials, such as brochures and posters, and held discussions with selected households 
and other community residents. 
 
Questionnaire Data Collection 
Questionnaire and field laboratory data were collected on mobile tablet devices using an application 
programmed in Open Data Kit, an open-source mobile data collection application. The household 
interview collected information on household residents, assets, economic support, recent deaths, and 
orphans and vulnerable children (Appendix E). The adult interview was administered to participants 
aged 15-59 years and included modules on demographic characteristics, sexual and reproductive health, 
marriage, male circumcision, sexual activity, HIV/AIDS knowledge and attitudes, the HIV testing and 
treatment history, TB and other health conditions, alcohol use, and gender norms (see Appendix F). 
Participants who self-reported being HIV positive were asked questions about their HIV care experience. 
Parents also answered questions about their children’s (ages 0-14 years) health and participation in HIV 
testing and care services as a part of the adult interview. In addition, one woman between the ages of 
15-59 years in each household was randomly selected to answer questions about her experiences with 
violence. Participants of any age who reported being victims of violence and minors who reported being 
victims of sexual exploitation were provided with referrals to social services. Female participants were 
interviewed by female staff, and male participants by male staff, whenever possible. The questionnaire 
was administered in the eight languages most commonly used in Zambia. The English, Bemba, Nyanja, 
Lozi, Tonga, Lunda, Luvale, and Kaonde versions of the questionnaires were reviewed and tested 
thoroughly for acceptability, feasibility, and flow of questions.  
 
Adolescents 10-14 years of age participated in an interview that included questions on demographic 
characteristics, HIV stigma, knowledge and risk perception, exposure to HIV prevention interventions, 
sexual behavior, social norms, HIV testing, alcohol and drugs, parental support, and violence (Appendix 
G). 
 
Supervision 
Data-collection teams were regularly supervised by teams of national supervisors/monitors from the 
MOH, CSO, CDC, ICAP, TDRC, and UNZA. All institutions provided national supervisors/monitors, who 
rotated throughout the duration of the survey to perform intensive team monitoring, supervision, 
laboratory, and information technology support based on team metrics and performance. ICAP and CDC 
international staff conducted monitoring visits routinely to ensure adherence to protocol and standard 
operating procedures throughout the duration of the survey. 
 
Regional statisticians from the CSO, who were permanently based in their respective provinces and were 
trained supervisors, assisted with hands-on troubleshooting, replenishment of forms and supplies, and 
community mobilization and entry procedures. 
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These supervision/monitoring teams visited the field teams across the country to deliver survey 
supplies, perform quality checks on data completeness, provide technology support, assess mobilization 
efforts, and help address challenges to data collection. Regular debriefing sessions were held between 
field-based supervisors and monitoring teams. Supervision reports were circulated to principal 
investigator institutions and the ZAMPHIA Technical Working Group to respond to any issues. 
 
Electronic monitoring system 
An electronic dashboard system was established to monitor the progression of the survey. The 
dashboard summarized data uploaded to the PHIA server daily. The dashboard tracked coverage and 
completion of EAs, sampled households, household response, eligible household members providing 
consent to the interview, and biomarker components of the survey, blood draws, response rates (RRs), 
and overall progress towards the achievement of the target sample.  
 
2.4 Field-Based Biomarker Testing 
 
Blood Collection 
Blood was collected by qualified survey staff from consenting participants, including 14 mL of venous 
blood from persons aged 15-59 years; 6 mL from persons aged 2-14 years; and 1 mL of capillary blood 
from children aged 0-23 months (via finger-stick for children aged 6-23 months and heel-stick for 
children under 6 months of age). 
 
Blood samples were labeled with a unique bar-coded participant identification number and stored in 
temperature-controlled cooler boxes. At the end of each day, samples were transported to a satellite 
laboratory for processing into plasma and frozen within 24 hours of blood collection and stored in 
Sarstedt 2.0 mL polypropylene tubes. 
 
HIV Home-Based Testing and Counselling (HBTC) 
HIV HBTC was conducted in each household in accordance with national guidelines (Figure 2.4.A). HIV-
seropositive participants were referred to HIV care and treatment services at a health facility of their 
choice. For children under the age of disclosure (children under 18 years of age), results were provided 
to a parent or guardian. 
 
As per Figure 2.4.A, individuals with a non-reactive result on the screening test (Determine™ HIV-1/2 
[Abbott Molecular Inc., Des Plaines, Illinois, United States]) were reported as HIV negative. Individuals 
with a reactive screening test result underwent confirmatory testing using Uni-Gold™ (Trinity Biotech, 
plc. Wicklow, Ireland). Those with a reactive result on both screening and confirmatory tests were 
classified as HIV positive. Individuals with a reactive screening test result followed by a non-reactive 
confirmatory test result were classified as indeterminate and counseled to attend a facility for a repeat 
test in 4 weeks, per national guidelines. For children less than the age of 18 months, only the screening 
test (Determine) was performed in the household. If the test was reactive, HIV total nucleic acid (TNA) 
polymerase chain reaction (PCR) testing (HIV TNA PCR) for virological testing of HIV infection was 
performed in the central laboratory as described below. The ability of rapid tests to detect HIV 
antibodies among people in the serological window of infection, HIV antibodies in patients on ART, and 
maternal HIV antibodies among infants aged four months or older born to HIV-positive women, is an 
inherent limitation of the study. Participants in the first two categories are not expected to be a 
significant source of bias; further analysis will identify how many infants born to HIV-positive women 
were not identified by a rapid test. 
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Figure 2.4.A Household-based HIV-testing algorithm1, ZAMPHIA 2016 
 
 
 
 
 
 
 
 
 
 
 
 
1 This figure only applies to individuals aged 18 months or older. 
 
Anthropometric Assessment 
Height and weight measurements were obtained for all children aged 0-5 years who tested HIV positive 
during HBTC. Among HIV-negative children, 5.0% were also included for laboratory QC testing. 
 
CD4 Cell Count Measurement 
Participants aged 0-59 years who tested HIV positive during HBTC received a CD4 count measurement in 
the field by qualified survey staff, using the Pima™ CD4 Analyzer (Abbott Molecular Inc., Chicago, Illinois, 
United States, formerly Alere). In addition, a random sample of 5.0% of HIV-negative participants also 
received CD4 count measurement. 
 
Hepatitis B Testing 
Testing for hepatitis B virus infection was conducted in each household for participants of all ages using 
a serological hepatitis B surface antigen rapid diagnostic test, Determine HBsAg (Abbott Molecular Inc., 
Chicago, Illinois, United States, formerly Alere), which is indicative of acute or chronic hepatitis B virus 
infection. 
 
Syphilis Testing 
Testing for syphilis infection was conducted in each household among participants aged 15-59 years 
using the DPP Syphilis Screen and Confirm Assay (Chembio, Medford, NY) for the simultaneous 
detection of antibodies against non-Treponemal and Treponema pallidum antigens, with confirmatory 
testing using the SD BIOLINE Syphilis 3.0 (Abbott Molecular Inc., Chicago, Illinois, United States). SD 
BIOLINE was used for confirmatory testing as it is approved by the Zambian Government. 
 
 
Non-Reactive 
Reactive 
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HIV Negative 
Test 2 (T2)  
Uni-Gold 
Non-Reactive 
Interpretation:  
HIV Positive 
Geenius HIV-1/2 Confirmatory Test 
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Test 1 (T1)  
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2.5 Laboratory-Based Biomarker Testing 
 
Satellite and Central Laboratories 
A total of 22 satellite laboratories for the survey were established in a combination of existing health 
facility laboratories and mobile laboratories. One central referral laboratory was chosen for more 
specialized tests. At each satellite laboratory, trained technicians processed whole blood into plasma 
aliquots and dried blood spot samples for storage at -20°C, HIV confirmatory testing, and QA testing. 
Confirmatory testing, using the Geenius HIV 1/2 Supplemental Assay (Bio-Rad, Bio-Rad, Hercules, 
California, United States), was conducted on all samples that tested HIV positive during HBTC. For QA of 
the HIV rapid-testing conducted in the field, retesting, using the national HIV rapid-testing algorithm, 
was performed in the laboratory upon the first 50 samples tested by each field tester, and subsequently 
all indeterminate samples, along with a random sample of 5.0% of specimens that tested HIV negative 
during HBTC. Central laboratory procedures included VL testing, HIV TNA PCR for infant virological 
testing and for confirmation of status of those who self-reported being HIV positive but tested negative 
in HBTC, HIV recency testing, and long-term storage of samples at -80°C. 
 
Testing of HBTC-Indeterminate Results 
Samples that yielded indeterminate results during HBTC were retested in the laboratory using the 
national HIV rapid-testing algorithm. Those with HIV-positive or indeterminate retesting results 
underwent confirmation with the Geenius HIV 1/2 Supplemental Assay (Bio-Rad). 
 
Viral Load Testing 
HIV-1 VL (HIV RNA copies per mL) of confirmed HIV-positive participants was measured on the Roche 
COBAS AmpliPrep Instrument and COBAS TaqMan 48 Analyzer using the COBAS AmpliPrep/COBAS 
TaqMan HIV-1 Test, v2.0 (Roche Molecular Diagnostics, Branchburg, New Jersey, United States). HIV-1 
VL from dried blood spot specimens, from children and adults with insufficient volume of plasma, was 
measured on the Abbott m2000 RealTime system using the Abbott RealTime HIV-1 Assay (Abbott 
Molecular, Wiesbaden, Germany). 
 
Viral load results were returned within approximately six to eight weeks to the health facility chosen by 
each HIV-positive participant. Additionally, participants were provided with a referral form during HBTC 
for subsequent retrieval of their results. Survey staff also contacted each participant informing them 
that their VL results were available at the chosen facility and further advising them to seek care and 
treatment. 
 
Infant Virological Testing 
For infants under the age of 18 months who screened positive for HIV during HBTC, virological testing 
was conducted via HIV TNA PCR, on the Roche COBAS AmpliPrep Instrument and COBAS TaqMan 48 
Analyzer using the COBAS AmpliPrep/COBAS Taqman HIV-1 Qualitative Test (Roche Molecular 
Diagnostics, Branchburg, New Jersey, United States). Results were returned to a health facility selected 
by the child’s parent or guardian within approximately six to eight weeks, and survey staff also 
contacted the parent or guardian to inform them that the child’s results were available at the facility. 
 
HIV Recency Testing Algorithm 
To distinguish recent from long-term HIV infections, in order to estimate incidence of participants aged 
18 months-59 years, the survey used two different laboratory-based testing algorithms. Each algorithm 
employed a combination of assays: 1) HIV-1 LAg Avidity enzyme immunoassay (EIA) (Sedia Biosciences 
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Corporation, Portland, Oregon, United States) and VL (Figure 2.5.A) and 2) HIV-1 LAg Avidity EIA, VL, and 
ARV detection (Figure 2.5.B), as described in Appendix B. 
 
Specimens with a median normalized optical density (ODn) of ≤ 1.5 were classified as potentially 
recently HIV-infected samples and underwent VL testing for further classification. Specimens with a VL 
of < 1,000 copies/mL were classified as long-term infections, while those with a VL of ≥ 1,000 copies/mL 
were classified as recent infections (Figure 2.5.A). In the ARV-adjusted algorithm, specimens with VL ≥ 
1,000 copies/mL and with detectable ARVs were classified as long-term infections. Specimens with VL ≥ 
1,000 copies/mL and without detectable ARVs were classified as recent infections. 
 
The ZAMPHIA protocol for all procedures described was reviewed and approved by the TDRC Ethical 
Review Committee, the Institutional Review Board at Columbia University, the Zambia National Health 
Research Authority and the CDC.  
 
Figure 2.5.A HIV-1 recent infection testing algorithm (LAg/VL algorithm), ZAMPHIA 2016  
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Figure 2.5.B HIV-1 recent infection testing algorithm (LAg/VL/ARV algorithm), ZAMPHIA 2016 
 
Detection of Antiretroviral Drug Resistance   
HIV resistance to ARVs was assessed for all HIV-positive participants, 18 months of age and older, 
classified as recent HIV infections and a small subset of confirmed long-term infections. In addition, all 
infants less than the age of 18 months with confirmed infection were evaluated to determine vertical 
transmission of ARV-resistant HIV. Mutations in the HIV protease and reverse transcriptase genes that 
confer ARV drug resistance (according to the Stanford drug resistance database) were detected 
simultaneously by use of the CDC in-house multiplex allele-specific drug resistance assay. 
 
Specimens were sent to CDC in the United States where testing was performed at the International 
Laboratory Branch, a World Health Organization (WHO) accredited laboratory for drug resistance 
testing. 
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Detection of Antiretrovirals  
Qualitative screening for detectable concentrations of ARVs was conducted on DBS specimens from all 
HIV-positive adults and children by means of high-resolution liquid chromatography coupled with 
tandem mass spectrometry. The method used for ARV detection was a modified version of the 
methodology described by Koal et al.1 This qualitative assay was highly specific, as it separates the 
parent compound from the fragments, and highly sensitive, with a limit of detection of 0.02 μg/mL for 
each drug, and a signal-to-noise ratio of at least 5:1 for all drugs. As detection of all ARVs in use at the 
time of the survey was cost-prohibitive, three ARVs, efavirenz, atazanavir and lopinavir, were selected as 
markers for the most commonly prescribed first and second line regimens. Samples from participants 
who had suppressed viral loads and/or self-reported on ART, but had no evidence of the first three 
compounds, were tested for nevirapine. These ARVs were also selected based on their relatively long 
half-lives, allowing for a longer period of detection following intake.  
 
Detection of ARVs is considered indicative of participant use of a given drug at the time of blood 
collection. Results below the limit of detection among individuals who self-reported on ART indicate that 
there was no recent exposure to the regimen and that adherence to a prescribed regimen is sub-
optimal, but cannot be interpreted as “not on ART.” In addition, given the limited number of ARVs 
selected for detection, their absence could not rule out the use of other ART regimens that do not 
include them.  
 
ARV detection was performed by the Division of Clinical Pharmacology of the Department of Medicine at 
the University of Cape Town in South Africa. 
 
2.6 Data Processing and Analysis 
Completed household and individual questionnaires and field laboratory data were submitted 
electronically to a cloud server and stored in a secure PostgreSQL database. Data were automatically 
removed from the tablet after secure transmission to the central server. A web-based, automated 
reporting tool drew raw data from the survey server on a weekly basis to generate predefined reports. 
These summarized key statistics for survey monitoring and management, with reports generated for the 
survey team, the government of the Republic of Zambia through the MOH, ICAP at Columbia, the 
University Teaching Hospital, CDC, CSO, TDRC, and UNZA. 
 
Data cleaning was conducted using SAS 9.4. Laboratory data were cleaned and merged with the final 
questionnaire database using unique specimen barcodes and study identification numbers. Sampling 
weights were computed to adjust for probability of selection, nonresponse, and noncoverage. All results 
presented in the report are based on weighted estimates unless otherwise noted. 
 
Analysis weights account for sample selection probabilities and are adjusted for nonresponse and 
noncoverage. Nonresponse adjusted weights were calculated for households, individual interviews, and 
individual blood draws in a hierarchical form. Adjustment for nonresponse for initial individual and 
blood-level weights was based on the development of weighting adjustment cells defined by a 
combination of variables that are potential predictors of response and HIV status. The nonresponse 
adjustment cells were constructed using the Chi-square Automatic Interaction Detector (CHAID) 
algorithm. The cells were defined based on data from the household interview for the adjustment of 
individual-level weights, and from both the household and individual interviews for the adjustment of 
blood sample-level weights. Post-stratification adjustments were implemented to compensate for 
noncoverage in the sampling process. This final adjustment calibrated the nonresponse-adjusted 
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individual and blood weights to make the sum of each set of weights conform to national population 
totals by sex and five-year age groups. 
 
Descriptive analyses of response rates, characteristics of respondents, HIV prevalence, CD4 count 
distribution, HIV testing, self-reported HIV status, self-reported ART, VLS, PMTCT indicators, and sexual 
behavior were conducted using SAS 9.4.  
 
Incidence estimates were based on the number of HIV infections identified as recent with the HIV-1 LAg 
Avidity plus VL algorithm, and obtained using the formula recommended by the WHO Incidence Working 
Group and Consortium for Evaluation and Performance of Incidence Assays, and with assay performance 
characteristics of a mean duration of recent infection (MDRI) = 130 days (95% CI: 118, 142), a time cutoff 
(T) = 1.0 year and percentage false recent (PFR) = 0.00. 
 
2.7 Response Rates 
Of the 13,441 households selected for this survey, 12,193 were occupied, and 89.4% of these completed 
a household interview. The urban and rural weighted household response rates were almost exactly the 
same at 89.5% and 89.2%, respectively (Table 2.7.A). 
 
Table 2.7.A  Household response rates 
Number of households selected, occupied, and interviewed and household 
response rates (unweighted and weighted), by residence, ZAMPHIA 2016 
  Residence 
Total 
Result Urban Rural 
    
Household interviews    
Households selected 5,347 8,094 13,441 
Households occupied 4,989 7,204 12,193 
Households interviewed 4,494 6,463 10,957 
    
Household response rate1 (unweighted) 89.6 88.8 89.1 
Household response rate1 (weighted) 89.5 89.2 89.4 
1Household response rate was calculated using the American Association for Public Opinion Research 
(AAPOR) Response Rate 4 (RR4) method: 
http://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf 
 
Of the 13,317 eligible women and 11,346 eligible men aged 15-59 years, 90.8% of women and 80.4% of 
men were interviewed. The response rate for biomarker testing among those who completed an 
individual interview was 88.5% for males and 90.3% for females (Table 2.7.B). Of the 3,593 eligible 
children aged 10-14 years, 74.6% of males and 79.1% of females completed an interview, while similar 
percentages of males (90.9%) and females (90.6%) completed biomarker testing. Of 8,053 eligible 
children aged 0-9 years, about two-thirds (66.9% for males and 66.7% for females) had their blood 
drawn (Table 2.7.B). 
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Table 2.7.B Interview and blood draw response rates 
Number of eligible individuals and response rates for individual interviews1 and blood draws2 (unweighted and weighted), by 
residence and sex, ZAMPHIA 2016 
 Residence 
   
Result 
Urban  Rural  Total 
Males Females  Males Females  Males Females 
Eligible individuals, age 0-9 years         
Number of eligible individuals 1,399 1,456  2,637 2,561  4,036 4,017 
Blood draw response rate (unweighted) 68.0 68.4  67.8 67.7  67.8 68.0 
Blood draw response rate (weighted) 67.6 68.6  66.5 65.6  66.9 66.7 
         
Eligible individuals, age 10-14 years         
Number of eligible individuals 659 700  1,170 1,064  1,829 1,764 
Interview response rate (unweighted) 78.3 79.0  73.9 80.4  75.5 79.8 
Interview response rate (weighted) 78.3 78.8  72.5 79.2  74.6 79.1 
Blood draw response rate (unweighted) 91.9 92.2  91.2 90.4  91.5 91.1 
Blood draw response rate (weighted) 92.0 92.0  90.2 89.7  90.9 90.6 
         
Eligible individuals, age 15-24 years         
Number of eligible individuals 1,885 2,470  2,452 2,735  4,337 5,205 
Interview response rate (unweighted) 79.6 88.7  81.6 87.6  80.7 88.1 
Interview response rate (weighted) 79.4 88.3  81.4 87.9  80.5 88.1 
Blood draw response rate (unweighted) 90.4 91.9  89.9 89.8  90.1 90.8 
Blood draw response rate (weighted) 90.5 92.0  89.6 89.4  90.0 90.6 
         
Eligible individuals, age 15-49 years         
Number of eligible individuals 4,705 5,660  5,653 6,532  10,358 12,192 
Interview response rate (unweighted) 73.9 89.6  85.4 91.6  80.2 90.7 
Interview response rate (weighted) 73.2 89.3  85.3 91.6  79.8 90.5 
Blood draw response rate (unweighted) 87.6 91.4  89.3 89.9  88.6 90.6 
Blood draw response rate (weighted) 87.5 91.4  89.0 89.4  88.3 90.3 
         
Eligible individuals, age 15-59 years         
Number of eligible individuals 5,093 6,125  6,253 7,192  11,346 13,317 
Interview response rate (unweighted) 74.3 89.7  86.1 92.0  80.8 90.9 
Interview response rate (weighted) 73.6 89.4  86.0 92.0  80.4 90.8 
Blood draw response rate (unweighted) 87.6 91.5  89.6 89.9  88.8 90.6 
Blood draw response rate (weighted) 87.5 91.5  89.4 89.4  88.5 90.3 
1Interview response rate = number of individuals interviewed/number of eligible individuals 
2Blood draw response rate = number of individuals who provided blood/number of individuals interviewed 
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3.1 Key Findings 
 
3.2 Background 
This chapter describes the characteristics of households surveyed in ZAMPHIA 2016. Household 
composition is described in terms of sex of the head of the household, as well as the size of the 
household. The age structure of the de facto household population is described by sex as well as 
urban/rural residence. This chapter also describes the prevalence and composition of households 
impacted by HIV, which are households with one or more HIV-positive member. 
 
3.3 Household Composition 
ZAMPHIA documented 50,859 individuals living in the surveyed households. As is frequently the case in 
southern African countries, the population skews young. In urban areas, 40.6% of the population was 
under the age of 15 years. In rural areas, nearly 50% of the household population was under the age of 
15 years. In rural areas, 10.0% of the household population was over the age of 50 years, whereas in 
urban areas 8.4% of the household population was over the age of 50 years. (Table 3.3.C).  
 
Among the de facto population, 56.3% were under the age of 20 years. Women of childbearing age 
(ages 15-49 years) comprise 24.1% of the population. Those aged 50 years and older comprised 9.4% of 
the population (Figure 3.3.A; Table 3.3.B). 
 
Overall, 74.5% of all households were headed by males. This was the case in both rural (74.2%) and 
urban areas (75.1%). Households had a median size of five members, and the median number of 
children under the age of 18 years per household was two (Table 3.3.A). 
 
  
▪ Among all households, 74.5% were headed by males and 25.5% by females. 
▪ Among female household heads, 31.5% were HIV positive, as compared to 14.0% of male 
household heads. 
▪ Among all households, 21.5% have at least one HIV-positive household member. 
3 SURVEY HOUSEHOLD CHARACTERISTICS 
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Table 3.3.A  Household composition 
Percent distribution of households by sex of head of household; median size of household and median (Q11, Q32) 
number of children under 18 years of age, by residence, ZAMPHIA 2016 
Characteristic 
Residence    
Urban  Rural  Total 
Percent Number  Percent Number  Percent Number 
Household headship         
Male 75.1 3,361  74.2 4,798  74.5 8,159 
Female 24.9 1,133  25.8 1,665  25.5 2,798 
         
Total 100.0 4,494  100.0 6,463  100.0 10,957 
 Residence    
 Urban  Rural  Total 
Characteristic Median Q1, Q3  Median Q1, Q3  Median Q1, Q3 
Size of households 5 (3, 6)  5 (3, 7)  5 (3, 6) 
Number of children under 18 years of age 2 (1, 3)  3 (1, 4)  2 (1, 4) 
1 Q1: quartile one 
2 Q3: quartile three                 
 
Table 3.3.B   Distribution of de facto household population by age and sex 
Percent distribution of the de facto household population, by five-year age groups and sex, ZAMPHIA 2016 
Age 
Males  Females  Total 
Percent Number  Percent Number  Percent Number 
0-4 7.9 4,015  8.1 4,100  16.0 8,115 
5-9 8.0 4,093  8.0 4,045  16.0 8,138 
10-14 6.9 3,566  7.0 3,556  13.9 7,122 
15-19 5.0 2,543  5.5 2,799  10.4 5,342 
20-24 3.6 1,847  4.8 2,447  8.5 4,294 
25-29 2.9 1,494  3.9 1,969  6.8 3,463 
30-34 3.0 1,497  3.5 1,749  6.5 3,246 
35-39 2.4 1,232  2.7 1,388  5.2 2,620 
40-44 2.2 1,099  2.3 1,162  4.4 2,261 
45-49 1.5 768  1.4 745  3.0 1,513 
50-54 1.1 575  1.3 677  2.4 1,252 
55-59 0.8 420  0.9 455  1.7 875 
60-64 0.7 356  1.0 479  1.7 835 
65-69 0.5 277  0.7 360  1.3 637 
70-74 0.4 210  0.6 278  1.0 488 
75-79 0.3 145  0.3 164  0.6 309 
≥80 0.3 169  0.3 180  0.7 349 
         
Total 47.7 24,306  52.3 26,553  100.0 50,859 
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Table 3.3.C  Distribution of de facto household population by age, sex, and residence 
Percent distribution of the de facto household population, by sex, age, and residence, ZAMPHIA 2016 
 Urban 
Age 
Males   Females   Total 
Percent Number   Percent Number   Percent Number 
0-4 14.9 1,417  13.5 1,482  14.1 2,899 
5-14 27.2 2,647  26.0 2,838  26.5 5,485 
15-49 49.8 4,768  52.0 5,691  51.0 10,459 
≥50 8.2 788  8.6 949  8.4 1,737 
         
Total 100.0 9,620  100.0 10,960  100.0 20,580 
 
 Rural 
Age 
Males   Females   Total 
Percent Number   Percent Number   Percent Number 
0-4 17.7 2,598  16.8 2,618  17.2 5,216 
5-14 33.9 5,012  30.6 4,763  32.2 9,775 
15-49 39.1 5,712  41.9 6,568  40.5 12,280 
≥50 9.3 1,364  10.7 1,644  10.0 3,008 
         
Total 100.0 14,686  100.0 15,593  100.0 30,279 
 
Figure 3.3.A Distribution of the de facto population by sex and age, ZAMPHIA 2016 
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Figure 3.3.B Household population by age, sex, and residence, ZAMPHIA 2016 
 
 
3.4 Prevalence of HIV-Affected Households 
Tables 3.4.A, 3.4.B and 3.4.C provide information about the extent to which households in Zambia have 
been affected by the HIV epidemic.  
 
Overall, 21.5% of households had at least one HIV-positive household member, with 29.0% of urban and 
16.0% of rural households being affected (Table 3.4.A). Among those households with any HIV-positive 
members, 74.5% had one HIV-positive person, while 22.3% had two HIV-positive household members 
and 2.8% had three. These percentages were similar for urban and rural households (Table 3.4.B).  
 
Table 3.4.A  Prevalence of HIV-affected households 
Percentage of households with at least one household member who tested HIV positive, by residence, ZAMPHIA 2016 
Residence Percent  Number 
Urban 29.0 3,960 
Rural 16.0 5,419 
   
Total 21.5 9,379 
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Table 3.4.B  HIV-affected households by number of HIV-positive members 
Among households with at least one HIV-positive household member, percent distribution of 
households by number of HIV-positive household members, by residence, ZAMPHIA 2016 
 Residence    
Number of HIV-
positive 
household 
members 
Urban   Rural  Total 
Percent  Number   Percent Number   Percent Number 
1 75.9 874  72.7 619  74.5 1,493 
2 20.7 240  24.4 202  22.3 442 
3 (3.0) 32  * 20  2.8 52 
4 * 4  * 2  * 6 
5 * 0  * 1  * 1 
≥6 * 0  * 0  * 0 
         
Total 100.0 1,150 
 100.0 844  100.0 1,994 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been 
suppressed. 
 
Nationally, the household head was HIV positive for 18.8% of households. This figure differs 
substantially for female-headed and male-headed households, with 31.5% of female household heads 
being HIV positive, compared to 14.0% of male household heads.  
 
 
  
Table 3.4.C  Prevalence of households with an HIV-positive head of household 
Percentage of households with an HIV-positive head of household, by sex of head of household, ZAMPHIA 2016 
Sex of head of household Percent  Number 
Male 14.0 4,564 
Female 31.5 1,707 
 
  
Total 18.8 6,271 
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Figure 3.4.A Prevalence of HIV-affected households by residence, ZAMPHIA 2016 
 
Figure 3.4.B HIV-affected households by number of HIV-positive members and residence, ZAMPHIA 
2016 
 
1The estimate for 3+ HIV in the rural areas has been suppressed because it is based on fewer than 25 
unweighted cases. 
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Figure 3.4.C Prevalence of households with an HIV-positive head of household by sex, ZAMPHIA 2016 
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4.1 Key Findings 
 
4.2 Background 
The ZAMPHIA 2016 survey assessed key indicators and outcomes for children, adolescents, and adults. 
To provide context for these outcomes, this chapter summarizes the basic demographic and 
socioeconomic characteristics of survey respondents. In this report, most key indicators are stratified 
according to these characteristics. 
 
4.3 Demographic Characteristics of the Adult Population 
 
Respondents 
A total of 21,280 persons aged 15-59 years participated in the survey’s individual interviews (9,171 
males and 12,109 females). Slightly more than half of the total population lived in rural areas of the 
country (54.3%) at the time of the survey. The proportion of the population located in Lusaka was 20.1% 
compared to 5.2% located in North-Western Province. The distribution of adults ranged from 3.4% of 
those aged 55-59 years to 22.0% of those aged 15-19 years. Secondary education was the highest level 
of schooling attended for 44.4% of adults. Nearly half (49.4%) of the male population reported 
secondary education as their highest level of schooling attended, compared to 39.6% of the female 
population. The proportion of females with no education (7.1%) was double that of males (3.3%). 
Slightly more than half of the population (53.6%) reported being married or living with a partner, with 
more than a third of the population (37.2%) reporting being single.  
 
  
4 SURVEY RESPONDENT CHARACTERISTICS 
▪ The largest proportion of the population was located in Lusaka (20.1%) and the smallest in North-
Western Province (5.2%). 
▪ Among males, 49.4% reported secondary education as their highest level of schooling attended, 
compared to 39.6% of the female population.  
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Table 4.3.A  Demographic characteristics of the adult population 
Percent distribution of the population age 15-59 years, by sex and other selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Males  Females  Total 
Percent Number  Percent Number  Percent Number 
Residence         
Urban 45.3 3,785  46.1 5,494  45.7 9,279 
Rural 54.7 5,386  53.9 6,615  54.3 12,001 
Province         
Central 9.6 789  9.5 1,001  9.5 1,790 
Copperbelt 16.7 1,565  16.4 2,063  16.6 3,628 
Eastern 10.8 881  11.2 1,147  11.0 2,028 
Luapula 6.4 476  6.9 663  6.6 1,139 
Lusaka 20.2 1,440  20.0 2,207  20.1 3,647 
Muchinga 5.7 846  5.6 1,073  5.6 1,919 
Northern 8.5 771  8.5 959  8.5 1,730 
North-Western 5.2 867  5.2 1,115  5.2 1,982 
Southern 11.8 1,085  11.1 1,288  11.4 2,373 
Western 5.2 451  5.7 593  5.4 1,044 
Marital status         
Never married 44.7 3,779  30.0 3,293  37.2 7,072 
Married or living together 50.7 4,874  56.4 7,010  53.6 11,884 
Divorced or separated 4.0 378  9.1 1,132  6.6 1,510 
Widowed 0.6 64  4.5 585  2.6 649 
Education         
No education 3.3 287  7.1 842  5.2 1,129 
Primary 37.0 3,525  46.3 5,689  41.7 9,214 
Secondary 49.4 4,462  39.6 4,755  44.4 9,217 
More than secondary 10.4 887  7.0 813  8.7 1,700 
Wealth quintile         
Lowest 14.5 1,421  16.1 1,948  15.3 3,369 
Second 18.1 1,776  17.7 2,159  17.9 3,935 
Middle 20.1 1,912  19.4 2,373  19.7 4,285 
Fourth  21.6 1,882  21.8 2,650  21.7 4,532 
Highest 25.7 2,136  25.0 2,930  25.4 5,066 
Age         
15-19 22.3 2,006  21.7 2,331  22.0 4,337 
20-24 19.1 1,496  19.0 2,256  19.1 3,752 
25-29 14.0 1,209  15.4 1,804  14.7 3,013 
30-34 11.9 1,157  13.2 1,614  12.5 2,771 
35-39 10.2 956  9.9 1,299  10.0 2,255 
40-44 8.5 851  7.7 1,071  8.1 1,922 
45-49 6.1 630  5.4 677  5.7 1,307 
50-54 4.5 491  4.3 630  4.4 1,121 
55-59 3.3 375  3.5 427  3.4 802 
Total 15-24 41.4 3,502  40.7 4,587  41.1 8,089 
Total 15-49 92.2 8,305  92.2 11,052  92.2 19,357 
Total 15-59 100.0 9,171  100.0 12,109  100.0 21,280 
Note: Education categories refer to the highest level of education attended, whether or not that level was completed. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
4.4 Demographic Characteristics of the Adolescent Population 
Over 60% of adolescents aged 10-14 years reside in rural areas (63.1% of males, 61.1% of females). 
Copperbelt (15.0%) and Lusaka (14.9%) Provinces have the largest share of the adolescent population, 
followed by the Eastern (13.1%) and Southern (11.7%) Provinces. The vast majority (95.5%) of the 
adolescent population was currently attending school (Table 4.4.A). 
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Table 4.4.A  Demographic characteristics of the adolescent population 
Percent distribution of the population aged 10-14 years, by sex and selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Males  Females  Total 
Percent Number   Percent Number   Percent Number 
Residence         
Urban 36.9 516  38.9 553  37.9 1,069 
Rural 63.1 865  61.1 855  62.1 1,720          
Province         
Central 9.7 117  10.4 140  10.0 257 
Copperbelt 14.3 208  15.6 233  15.0 441 
Eastern 14.2 162  11.9 131  13.1 293 
Luapula 7.2 76  7.9 87  7.6 163 
Lusaka 14.3 184  15.5 196  14.9 380 
Muchinga 7.1 153  6.3 134  6.7 287 
Northern 10.5 116  9.1 112  9.8 228 
North-Western 5.6 136  5.8 147  5.7 283 
Southern 12.0 167  11.4 157  11.7 324 
Western 5.0 62  5.9 71  5.5 133          
Education         
Currently attending  95.4 1,274  95.5 1,313  95.5 2,587 
Not currently attending school 4.6 55  4.5 61  4.5 116 
         
Total 10-14 100.0 1,381  100.0 1,408  100.0 2,789 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
 
4.5 Demographic Characteristics of the Pediatric Population 
Table 4.5.A shows the demographic characteristics of the pediatric population (ages 0-14 years). The 
pediatric population was comprised of 10,208 males and females aged 0-14 years, of which 39.4% were 
under the age of five years. Most children resided in rural areas (63.8%). All provinces were represented 
in the survey’s pediatric population.  
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Table 4.5.A  Demographic characteristics of the pediatric population 
Percent distribution of the population aged 0-14 years, by sex and other selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Males  Females  Total 
Percent Number   Percent Number   Percent Number 
Age         
0-17 months 10.7 510  11.7 569  11.2 1,079 
18-59 months 28.8 1,335  27.6 1,331  28.2 2,666 
5-9 years 33.2 1,880  33.3 1,791  33.2 3,671 
10-14 years 27.3 1,381  27.3 1,408  27.3 2,789          
Residence         
Urban 35.6 1,799  36.7 1,858  36.2 3,657 
Rural 64.4 3,308  63.3 3,243  63.8 6,551          
Province         
Central 10.2 445  10.1 455  10.1 900 
Copperbelt 13.5 712  13.8 731  13.6 1,443 
Eastern 12.4 515  11.7 477  12.1 992 
Luapula 7.7 299  8.2 326  7.9 625 
Lusaka 15.0 697  15.2 704  15.1 1,401 
Muchinga 7.0 575  6.8 549  6.9 1,124 
Northern 10.1 460  9.4 434  9.7 894 
North-Western 5.8 519  5.7 513  5.7 1,032 
Southern 12.1 599  12.0 594  12.1 1,193 
Western 6.3 286  7.1 318  6.7 604          
Wealth quintile         
Lowest 20.9 1,040  19.3 965  20.1 2,005 
Second 21.6 1,110  22.1 1,135  21.9 2,245 
Middle 20.2 1,041  21.5 1,096  20.8 2,137 
Fourth  20.5 1,065  20.1 1,033  20.3 2,098 
Highest 16.8 826  16.9 853  16.9 1,679 
         
Total 0-4 39.5 1,846  39.3 1,902  39.4 3,748 
Total 0-14 100.0 5,107  100.0 5,101  100.0 10,208 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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5.1 Key Findings 
 
5.2 Background 
HIV incidence is the measure of new HIV infections in a population over time. It can provide important 
information on the status of the HIV epidemic and measures impact of HIV prevention programs. HIV 
incidence is useful for effective and targeted HIV prevention planning for vulnerable groups.  
 
While HIV prevalence is a measure of the relative burden of disease in a population, it is not optimal for 
measuring acute changes in an HIV epidemic, including changes in HIV transmission. The survey was 
designed to estimate national-level HIV incidence for the overall population aged 15-59 years. 
Consequently, point estimates disaggregated by age and sex should be interpreted with caution, and 
special attention should be given to CIs presented in Table 5.3.A and Table 5.3.B. In this survey, HIV 
incidence is expressed as the cumulative incidence or risk of new infections in a 12-month period, which 
is a close approximation to the direct incidence rate. It is important to note that ZAMPHIA 2016 was not 
powered to estimate incidence at the provincial level or across different sub-groups. 
 
For ZAMPHIA 2016, a laboratory-based incidence testing algorithm (HIV-1 LAg avidity plus VL) was used 
to distinguish recent from long-term infection, and incidence estimates were obtained using the formula 
recommended by the WHO Incidence Working Group and Consortium for Evaluation and Performance 
of Incidence Assays, with time cutoff (T) = 1.0 year and residual Proportion False Recent (PFR) = 0.00. 
Survey weights are utilized for all estimates. All HIV-positive participants aged 18 months and older were 
tested for recent infection using HIV-1 LAg avidity assay. 
 
Incidence estimation is based on recent/long-term (LT) classification using algorithms with Limiting 
antigen (LAg) avidity.1, 2, 3 The original algorithm incorporated viral load results to mitigate 
misclassification from persons who may be elite controllers or on ART – both groups characterized by 
low VL. As ART coverage has increased, it has become apparent that some individuals on treatment for 
long-periods of time have the potential to be misclassified by the LAg plus VL algorithm as a recent 
infection. Although they may have suppressed VL for years, drug resistance or lack of adherence may 
result in VL ≥ 1000 copies/mL. Based in part on data from multiple PHIA surveys, the updated incidence 
algorithm includes ARV detection as a second exclusion criteria. The addition of ARV detection is 
expected to produce more accurate estimates of both HIV incidence and transmitted HIV drug 
resistance. 
  
5 HIV INCIDENCE  
▪ Annual incidence of HIV among adults aged 15-59 years in Zambia was 0.61% (0.29% among 
males and 0.93% among females). This corresponds to approximately 43,000 new cases of HIV 
annually among adults aged 15-59 years in Zambia.  
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5.3 HIV Incidence among Adults 
 
HIV incidence estimates using LAg Avidity and HIV viral load 
Using the LAg Avidity assay and viral load algorithm, estimated incidence was 0.67% (95% CI: 0.45%-
0.88%) among adults aged 15-59 years (0.32% among males and 1.02% among females). This 
corresponds to 67 new infections per 10,000 uninfected persons in a year, which corresponds to 
approximately 47,000 new cases of HIV infection per year in Zambia (Table 5.3.A). Annual incidence 
peaked among males aged 35-49 years (0.87%), and females aged 25-34 years (1.16%). HIV incidence for 
adults aged 15-49 years was estimated at 0.70% (95% CI: 0.47%-0.93%). HIV incidence was 0.31% among 
males and 1.10% among females aged 15-49 years (Table 5.3.A). 
 
HIV incidence estimates using LAg Avidity, HIV viral load, and ARV detection 
Using the LAg Avidity assay, viral load and ARV algorithm, estimated incidence was 0.61% (95% CI: 
0.40%-0.81%) among adults aged 15-59 years (0.29% among males and 0.93% among females). This 
amounts to approximately 61 new infections per 10,000 persons in a year, which corresponds to 
approximately 43,000 new cases of HIV per year. Annual incidence peaked among males aged 35-49 
years (0.73%) and among females aged 25-34 years (1.07%). HIV incidence for adults aged 15-49 years 
was estimated at 0.64% (95% CI: 0.42%-0.86%; 0.28% among males and 1.00% among females) (Table 
5.3.B). 
 
Table 5.3.A  Annual HIV incidence using LAg/VL1 testing algorithm 
Annual incidence of HIV among persons 15-49 and 15-59 years of age using LAg/VL1 algorithm, by sex and age, ZAMPHIA 
2016 
 Males  Females  Total 
Age 
Percentage 
annual incidence2 
95% CI3   
Percentage 
annual incidence2 
95% CI   
Percentage 
annual incidence2 
95% CI 
15-24 0.08 (0.00, 0.25)  1.07 (0.54, 1.60)  0.57 (0.28, 0.86) 
25-34 0.25 (0.00, 0.62)  1.16 (0.46, 1.86)  0.72 (0.30, 1.13) 
35-49 0.87 (0.13, 1.60)  1.06 (0.30, 1.81)  0.96 (0.43, 1.49) 
15-49 0.31 (0.09, 0.54)  1.10 (0.72, 1.48)  0.70 (0.47, 0.93) 
15-59 0.32 (0.10, 0.54)  1.02 (0.67, 1.37)  0.67 (0.45, 0.88) 
1 LAg/VL: Limiting antigen/viral load. 
2 Relates to Global AIDS Monitoring indicator 1.3: Retention on antiretroviral therapy at 12 months. 
3 CI (confidence interval) indicates the interval that is expected to encompass the true population parameter 95% of the time. 
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Table 5.3.B Annual HIV incidence using LAg/VL/ARV1 testing algorithm 
Annual incidence of HIV among persons 15-49 and 15-64 years of age, by sex and age, using LAg/VL/ARV1 algorithm, 
ZAMPHIA 2016 
 Males  Females  Total 
Age 
Percentage 
annual 
incidence2 
95% CI3  
Percentage 
annual 
incidence2 
95% CI  
Percentage 
annual incidence2 
95% CI 
15-24 0.08 (0.00, 0.25) 
 0.94 (0.44, 1.44)  0.51 (0.23, 0.78) 
25-34 0.25 (0.00, 0.62) 
 1.07 (0.40, 1.73)  0.67 (0.26, 1.07) 
35-49 0.73 (0.05, 1.40) 
 1.06 (0.30, 1.81)  0.89 (0.38, 1.39) 
15-49 0.28 (0.07, 0.49) 
 1.00 (0.64, 1.37)  0.64 (0.42, 0.86) 
15-59 0.29 (0.08, 0.50) 
 0.93 (0.60, 1.26)  0.61 (0.40, 0.81) 
1 LAg/VL/ARV: Limiting antigen/viral load/antiretrovirals 
2 Relates to Global AIDS Monitoring indicator 1.2: Retention on antiretroviral therapy at 12 months 
3 CI: confidence interval indicates the interval that is expected to include the true population parameter 95% of the time 
 
5.4 Gaps and Unmet Needs 
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• About 43,000 new HIV infections occur every year in Zambia among adults 15-59 years, 
according to the LaAg Avidity assay, viral load and ARV algorithm. To reach epidemic control, 
newly infected individuals should be quickly diagnosed and initiated on ART. 
• HIV incidence is higher among women than men in Zambia. This suggests a need for more 
intensive primary prevention among HIV-negative women as well as targeting of secondary 
prevention, including safer sexual behaviors, HIV diagnosis, and treatment among HIV-positive 
individuals. 
• Approaches, such as routine case reporting and case-based surveillance, could provide the data 
needed to describe the demographic profile of those newly infected to allow for targeted 
prevention efforts. 
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6.1 Key Findings 
 
6.2 Background 
This chapter presents representative estimates of prevalence of HIV infection among adults 15-59 years 
of age at the national and provincial levels by selected demographic and behavioral characteristics. HIV 
prevalence testing was conducted in each household using a serological rapid diagnostic testing 
algorithm based on Zambia’s national guidelines, with laboratory confirmation of seropositive samples 
using a supplemental assay. Appendix B further describes the PHIA HIV testing methodology. 
 
6.3 Adult HIV Prevalence by Demographic Characteristics 
The prevalence of HIV among adults 15-59 years of age in Zambia was 12.0%. This corresponds to an 
estimated 960,000 persons aged 15-59 years living with HIV in Zambia. The prevalence was higher 
among females (14.6%) than among males (9.3%) (Table 6.4.A). HIV prevalence was higher among those 
residing in urban areas (15.3%) compared to those living in rural areas (9.2%) (Table 6.3.B).  
 
HIV prevalence ranged from 15.9% in Western province to 5.7% in Muchinga Province. Across all 
provinces, the prevalence for females was higher than males. In Eastern Province, HIV prevalence was 
twice as high among females (10.7%) compared to males (5.2%). By marital status, HIV prevalence 
ranged from 4.7% among never married adults to 48.5% among widowed adults. There was little 
difference in HIV prevalence between participants with different levels of education (Table 6.3.B).  
 
  
6 HIV PREVALENCE 
▪ Prevalence of HIV among adults aged 15-59 years in Zambia is 12.0% (14.6% among females and 
9.3% among males). This corresponds to approximately 960,000 people aged 15-59 years living 
with HIV in Zambia. 
▪ Among those aged 15-49 years, the prevalence was higher among females (14.3%) than among 
males (8.3%), as well as among those residing in urban areas (14.4%) compared to those living in 
rural areas (8.7%). 
▪ HIV prevalence peaked between ages 40-44 years for females (29.6%) and between ages 45-49 
years for males (23.0%). 
▪ HIV prevalence among those aged 20-24 years is four times higher among females (8.3%) than 
among males (2.0%). 
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Table 6.3.A  HIV prevalence by demographic characteristics: Ages 15-49 years 
Prevalence of HIV among persons aged 15-49 years, by sex and selected demographic characteristics, ZAMPHIA 2016 
 Males 
 Females  Total 
Characteristic 
Percentage 
HIV positive 
Number  
Percentage 
HIV positive 
Number  
Percentage 
HIV positive 
Number 
Residence         
Urban 10.4 3,047  18.2 4,636  14.4 7,683 
Rural 6.6 4,311  10.8 5,374  8.7 9,685 
         
Province         
Central 8.5 630  16.2 812  12.4 1,442 
Copperbelt 8.9 1,245  17.3 1,715  13.2 2,960 
Eastern 4.5 736  10.1 965  7.4 1,701 
Luapula 6.8 386  10.9 521  8.9 907 
Lusaka 10.7 1,134  17.9 1,869  14.4 3,003 
Muchinga 2.8 686  7.8 892  5.3 1,578 
Northern 7.7 593  10.9 745  9.4 1,338 
North-Western 4.6 679  8.2 935  6.4 1,614 
Southern 10.7 911  14.4 1,071  12.5 1,982 
Western 12.2 358  18.1 485  15.4 843 
         
Marital status         
Never married 2.7 3,345  7.3 2,959  4.6 6,304 
Married or living together 12.6 3,620  13.6 5,742  13.2 9,362 
Divorced or separated 22.9 293  29.5 895  27.6 1,188 
Widowed (39.0) 40  57.4 336  54.9 376 
         
Education         
No education 6.7 220  11.7 606  10.0 826 
Primary 7.7 2,742  14.0 4,546  11.2 7,288 
Secondary 8.7 3,737  14.8 4,181  11.5 7,918 
More than secondary 9.0 651  15.5 674  11.7 1,325 
         
Wealth quintile         
Lowest 5.6 1,125  8.9 1,547  7.4 2,672 
Second 6.5 1,418  9.8 1,739  8.1 3,157 
Middle 8.2 1,567  15.6 1,966  11.9 3,533 
Fourth 10.7 1,533  18.2 2,255  14.5 3,788 
Highest 9.0 1,678  16.1 2,461  12.6 4,139 
         
Pregnancy status         
Currently pregnant NA NA  9.2 789  NA NA 
Not currently pregnant NA NA  14.8 9,067  NA NA 
Total 15-49 8.3 7,358  14.3 10,010  11.4 17,368 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
 
The prevalence in the population aged 15 to 49 years was 11.4%. The prevalence by sex was 8.3% for 
males and 14.3% for females. In rural areas, the prevalence was 8.7% compared to 14.4% in urban areas. 
The trends in HIV prevalence by other demographic characteristics for persons aged 15-49 years were 
similar to those for persons aged 15-59 years (Tables 6.3.A, 6.3.B). 
 
  
46 
 
 
  
Table 6.3.B  HIV prevalence by demographic characteristics: Ages 15-59 years 
Prevalence of HIV among persons aged 15-59 years, by sex and selected demographic characteristics, ZAMPHIA 2016 
 Males 
 Females  Total 
Characteristic 
Percentage 
HIV positive 
Number  
Percentage 
HIV positive 
Number  
Percentage 
HIV positive 
Number 
Residence         
Urban 11.6 3,315  18.7 5,025  15.3 8,340 
Rural 7.4 4,827  11.1 5,948  9.2 10,775 
         
Province         
Central 9.1 702  16.5 889  12.8 1,591 
Copperbelt 10.0 1,386  17.5 1,898  13.8 3,284 
Eastern 5.2 819  10.7 1,070  8.1 1,889 
Luapula 7.3 426  11.1 590  9.3 1,016 
Lusaka 12.4 1,242  18.8 2,003  15.7 3,245 
Muchinga 3.4 758  7.9 971  5.7 1,729 
Northern 7.9 659  10.5 820  9.2 1,479 
North-Western 4.8 765  8.8 1,012  6.9 1,777 
Southern 11.6 990  15.0 1,186  13.3 2,176 
Western 13.7 395  17.8 534  15.9 929 
         
Marital status         
Never married 2.8 3,368  7.5 2,987  4.7 6,355 
Married or living together 13.4 4,319  13.4 6,333  13.4 10,652 
Divorced or separated 23.9 332  29.4 1,038  27.8 1,370 
Widowed 46.6 60  48.8 536  48.5 596 
         
Education         
No education 7.3 246  12.4 715  10.8 961 
Primary 8.4 3,142  14.3 5,184  11.8 8,326 
Secondary 9.6 4,012  15.2 4,354  12.2 8,366 
More than secondary 11.3 733  15.7 716  13.1 1,449 
         
Wealth quintile         
Lowest 6.3 1,250  9.4 1,712  8.0 2,962 
Second 7.0 1,596  9.7 1,940  8.4 3,536 
Middle 8.9 1,743  15.9 2,174  12.4 3,917 
Fourth 11.5 1,663  18.5 2,431  15.1 4,094 
Highest 10.7 1,849  16.9 2,668  13.9 4,517 
         
Pregnancy status         
Currently pregnant NA NA  9.2 789  NA NA 
Not currently pregnant NA NA  15.1 10,022  NA NA 
         
Total 15-59 9.3 8,142  14.6 10,973  12.0 19,115 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
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Figure 6.3.A HIV prevalence by marital status: Ages 15-59 years, ZAMPHIA 2016 
 
6.4 Adult HIV Prevalence by Age and Sex 
HIV prevalence peaked between ages 40-44 years for females (29.6%) and between ages 45-49 years for 
males (23.0%). HIV prevalence is higher among females than among males in all age groups between 
ages 15-49 years. The disparity in HIV prevalence by sex is most pronounced among young adults: HIV 
prevalence among ages 20-24 years is four times higher among females (8.3%) than among males 
(2.0%); and among ages 25-29 years, prevalence among women is more than twice that of men (13.6% 
for females versus 5.6% for males). (Table 6.4.A, Figure 6.4.A).  
 
  
48 
 
Table 6.4.A  HIV prevalence by age and sex 
Prevalence of HIV among persons age 0-59 years, by sex and age, ZAMPHIA 2016 
 Males 
 Females  Total 
Age 
Percentage 
HIV positive 
Number  
Percentage 
HIV positive 
Number  
Percentage 
HIV positive 
Number 
0-17 months1 1.0 310  0.7 372  0.8 682 
18-59 months 0.9 966  0.7 945  0.8 1,911 
5-9 2.2 1,462  1.3 1,414  1.8 2,876 
10-14 0.7 1,263  1.0 1,283  0.9 2,546 
         
Total 0-4 0.9 1,276  0.7 1,317  0.8 2,593 
Total 0-14 1.3 4,001  1.0 4,014  1.1 8,015 
         
15-19 1.6 1,811  3.3 2,120  2.5 3,931 
20-24 2.0 1,344  8.3 2,045  5.2 3,389 
25-29 5.6 1,053  13.6 1,619  9.8 2,672 
30-34 10.9 1,003  20.2 1,458  15.9 2,461 
35-39 15.1 836  24.7 1,160  19.9 1,996 
40-44 22.2 751  29.6 989  25.8 1,740 
45-49 23.0 560  25.8 619  24.4 1,179 
50-54 22.9 444  20.1 584  21.5 1,028 
55-59 16.9 340  17.7 379  17.3 719 
         
Total 15-24 1.8 3,155  5.7 4,165  3.8 7,320 
Total 15-49 8.3 7,358  14.3 10,010  11.4 17,368 
Total 15-59 9.3 8,142  14.6 10,973  12.0 19,115 
1 This includes only 0-17-month aged infants with confirmed rapid test results. 
 
Figure 6.4.A HIV prevalence by age and sex, ZAMPHIA 2016 
  
49 
 
6.5 Adult HIV Prevalence by Province 
The distribution of HIV infections in the population aged 15-59 years varied geographically across 
Zambia, ranging from 5.7% in Muchinga Province to 15.9% in Western Province and 15.7% in Lusaka 
(Figure 6.5.A, Figure 6.5.B). 
 
Figure 6.5.A HIV prevalence among adults aged 15-59 years, by province, ZAMPHIA 2016 
 
 
  
50 
 
Map 6.5.B HIV prevalence among adults aged 15-59 years, by province, ZAMPHIA 2016 
 
 
6.6 Gaps and Unmet Needs 
 
  
▪ The disparity in HIV prevalence between males and females, particularly in those aged 15-24 
years, suggests an increased focus on early testing and ART initiation for adolescent girls and 
young women as well as the need for preventative services. 
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7.1 Key Findings 
 
7.2 Background 
HIV testing is necessary for awareness of HIV status and is a critical component of HIV epidemic control 
targets. Awareness of HIV-positive status is the first step to engagement with HIV care and treatment 
services, accessing ART, prevention counseling for HIV-positive and HIV-negative individuals to reduce 
risk of HIV transmission or acquisition, and access to screening services for other comorbidities. HIV 
testing is currently one of the key strategies to control the HIV epidemic, since it identifies people living 
with HIV and enables them to link to care. To increase national coverage of testing, the government of 
the Republic of Zambia has instituted guidelines for index case testing, routine provider-initiated testing 
and counselling, peer approach for key populations, self-testing, and implementation of a unique 
identifier for HIV testing and services, among other strategies. 
 
Data presented in this section pertain to adults aged 15-59 years, males and females, who self-reported 
ever receiving an HIV test and receiving the test results. To assess coverage of HIV testing, respondents 
were asked if they had ever been tested for HIV and received their results. Results on HIV testing in the 
last 12 months and receiving the test results are also presented to understand frequent or recent 
testing. 
 
7.3 Self-Reported HIV Testing Among Adults (ages 15-59 years) 
Overall 72.3% of all participants aged 15-59 years reported ever having tested for HIV and receiving their 
results. Among HIV-positive respondents, 90.3% reported they had ever tested and received their 
results (Table 7.3.A). Almost two-thirds of men (65.1%) and more than three quarters (79.2%) of women 
reported ever having been tested for HIV and having received their results. Self-reported HIV ever 
testing peaked at ages 30-34 years for males (83.3%) and ages 25-29 years for females (94.5%). 
Respondents aged 15-19 years had the lowest HIV ever testing coverage estimates for both males 
(27.2%) and females (45.4%) (Tables 7.3.B, 7.3.C).  
 
In the 12 months preceding the survey, 38.4% of all participants aged 15-59 years reported testing for 
HIV (Table 7.3.A). More than a third (34.8%) of men and 42.0% of women reported testing and receiving 
their results in the year preceding the survey (Table 7.3.B, Table 7.3.C, Figure 7.3.C). Among adults who 
tested positive in ZAMPHIA, 5.2% of females and 39.9% of males had received HIV testing and their 
▪ Almost two-thirds of males (65.1%) and 79.2% of females aged 15-59 years reported ever having 
been tested for HIV and having received their results. In this sample, 34.8% of all males and 
42.0% of females in the same age bracket reported receiving an HIV test in the 12 months 
preceding the survey. 
▪ Among males and females aged 15-59 years who tested positive in the survey, 85.9% and 92.9%, 
respectively, reported they had ever been tested for HIV and received their results. 
▪ Among adults in urban areas, 75.9% reported ever testing for HIV while 40.5% reported testing 
for HIV in the 12 months prior to survey, compared 69.3% and 36.7% of adults in rural areas, 
respectively. 
7 HIV TESTING 
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results in the year preceding the survey (Table 7.3.B; Table 7.3.C). The coverage of testing in the year 
preceding the survey peaked at ages 25-29 years at 49.2%, while among those aged 15-19 years, it was 
only 21.9%. (Table 7.3.A). 
 
Testing history varied by marital status for both men and women. Over 80% of widowed (81.0%) and 
married (81.0%) men aged 15-59 years had ever been tested and received their results for HIV, 
compared to 46.5% of males who had never been married. Among those who were married or living 
with a partner, 42.4% had been tested and received their results in the year preceding the survey, while 
one quarter (25.6%) of those who were never married had been tested and received their results in the 
year preceding the survey. Among females aged 15-59 years who were married or living with a partner, 
90.3% had ever been tested and received their results, as compared to 56.2% of females who had never 
been married. The coverage for recent testing (testing in the 12 months preceding the survey) among 
female widows was 29.7%, while among the married, it was 47.6%. (Table 7.3.A and Table 7.3.C) 
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Table 7.3.A  HIV testing: Total 
Percentage of persons aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV testing and 
received their test results in the past 12 months, by result of PHIA survey HIV test and selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Percentage who ever received HIV 
testing and received their results 
Percentage who received HIV testing in 
the past 12 months and received their 
results1 
Number 
Result of PHIA survey HIV test    
HIV positive 90.3 30.7 2,442 
HIV negative 69.8 38.7 16,513 
Not tested 72.5 44.9 2,140 
    
Residence    
Urban 75.9 40.5 9,205 
Rural 69.3 36.7 11,890 
    
Province    
Central 70.0 36.4 1,775 
Copperbelt 71.4 36.4 3,589 
Eastern 75.7 38.6 2,018 
Luapula 64.9 32.6 1,131 
Lusaka 76.7 41.9 3,628 
Muchinga 69.1 34.0 1,907 
Northern 64.1 34.7 1,707 
North-Western 69.7 37.4 1,957 
Southern 75.3 42.6 2,354 
Western 77.6 45.1 1,029 
    
Marital status    
Never married 50.5 28.9 7,026 
Married or living together 86.0 45.2 11,779 
Divorced or separated 82.6 42.0 1,499 
Widowed 84.3 30.6 644 
    
Education    
No education 70.7 35.9 1,118 
Primary 69.7 35.4 9,130 
Secondary 71.9 40.1 9,144 
More than secondary 88.2 46.4 1,690 
    
Wealth quintile    
Lowest 68.1 36.6 3,335 
Second 68.4 35.3 3,892 
Middle 71.6 37.4 4,252 
Fourth 75.8 41.8 4,495 
Highest 75.2 39.8 5,028 
    
Age    
15-19 36.4 21.9 4,302 
20-24 77.2 45.0 3,726 
25-29 87.4 49.2 2,987 
30-34 89.1 47.2 2,747 
35-39 87.2 43.8 2,231 
40-44 83.8 38.8 1,905 
45-49 79.4 35.4 1,298 
50-54 70.4 30.3 1,111 
55-59 69.2 28.3 788 
    
Total 15-24 55.4 32.6 8,028 
Total 15-49 72.5 39.2 19,196 
Total 15-59 72.3 38.4 21,095 
1Relates to PEPFAR HTC_TST 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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Table 7.3.B Self-reported HIV testing: Males 
Percentage of males aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV 
testing and received their test results in the past 12 months, by result of PHIA survey HIV test and selected demographic characteristics, 
ZAMPHIA 2016 
Characteristic 
Percentage who ever received HIV 
testing and received results 
Percentage who received HIV testing 
in the past 12 months and received 
results1 
Number 
Result of PHIA survey HIV test    
HIV positive 85.9 39.9 768 
HIV negative 62.7 33.4 7,284 
Not tested 66.7 40.3 1,019 
        
Residence    
Urban 70.0 37.1 3,742 
Rural 61.0 32.8 5,329 
        
Province    
Central 59.7 32.4 783 
Copperbelt 64.7 33.4 1,538 
Eastern 67.8 33.0 873 
Luapula 57.9 27.6 472 
Lusaka 69.7 37.7 1,430 
Muchinga 61.7 30.3 841 
Northern 58.5 33.0 765 
North-Western 60.9 31.4 851 
Southern 68.9 40.0 1,074 
Western 71.2 44.0 444 
        
Marital status    
Never married 46.5 25.6 3,746 
Married or living together 81.0 42.4 4,817 
Divorced or separated 73.4 41.3 376 
Widowed 81.0 37.6 63 
        
Education    
No education 62.0 32.5 280 
Primary 57.0 29.4 3,486 
Secondary 67.2 37.2 4,416 
More than secondary 84.5 43.3 881 
        
Wealth quintile    
Lowest 59.6 33.9 1,405 
Second 59.4 30.0 1,751 
Middle 63.6 32.9 1,894 
Fourth 68.4 38.2 1,861 
Highest 70.6 37.4 2,116 
        
Age    
15-19 27.2 14.9 1,987 
20-24 65.7 36.4 1,480 
25-29 79.3 45.2 1,193 
30-34 83.3 46.1 1,145 
35-39 82.4 42.8 943 
40-44 79.3 39.8 843 
45-49 77.0 39.5 625 
50-54 72.5 32.4 487 
55-59 68.7 30.5 368 
    
Total 15-24 45.0 24.8 3,467 
Total 15-49 64.6 35.0 8,216 
Total 15-59 65.1 34.8 9,071 
1Relates to PEPFAR HTC_TST 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
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Table 7.3.C Self-reported HIV testing: Females 
Percentage of females aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV testing 
and received their test results in the past 12 months, by result of survey HIV test and selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Percentage who ever received 
HIV testing and received results 
Percentage who received HIV testing in 
the past 12 months and received 
results1 
Number 
Result of PHIA survey HIV test    
HIV positive 92.9 25.2 1,674 
HIV negative 76.8 43.9 9,229 
Not tested 79.2 50.1 1,121 
    
Residence    
Urban 81.4 43.6 5,463 
Rural 77.4 40.6 6,561 
    
Province    
Central 80.0 40.2 992 
Copperbelt 77.9 39.4 2,051 
Eastern 82.9 43.8 1,145 
Luapula 71.0 37.1 659 
Lusaka 83.4 45.9 2,198 
Muchinga 76.3 37.5 1,066 
Northern 69.6 36.4 942 
North-Western 78.0 43.1 1,106 
Southern 81.8 45.1 1,280 
Western 83.2 46.1 585 
    
Marital status    
Never married 56.2 33.4 3,280 
Married or living together 90.3 47.6 6,962 
Divorced or separated 86.5 42.3 1,123 
Widowed 84.7 29.7 581 
    
Education    
No education 74.4 37.3 838 
Primary 79.4 40.0 5,644 
Secondary 77.4 43.6 4,728 
More than secondary 93.4 50.8 809 
    
Wealth quintile    
Lowest 75.5 38.9 1,930 
Second 77.1 40.5 2,141 
Middle 79.6 42.0 2,358 
Fourth 82.8 45.1 2,634 
Highest 79.8 42.2 2,912 
    
Age    
15-19 45.4 28.8 2,315 
20-24 88.3 53.3 2,246 
25-29 94.5 52.7 1,794 
30-34 94.2 48.2 1,602 
35-39 91.9 44.8 1,288 
40-44 88.6 37.7 1,062 
45-49 81.9 30.9 673 
50-54 68.3 28.2 624 
55-59 69.7 26.3 420 
    
Total 15-24 65.5 40.2 4,561 
Total 15-49 80.1 43.2 10,980 
Total 15-59 79.2 42.0 12,024 
1Relates to PEPFAR HTS_TST 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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Figure 7.3.A Proportion of adults who self-reported having received an HIV test in the last 12 months, 
by age and sex, ZAMPHIA 2016 
 
7.4 Gaps and Unmet Needs 
 
  
▪ There is a need for increased testing outreach to males, as less than two-thirds of men (65.1%) 
compared to 79.2% of women had ever been tested and received their results. Promoting 
community-based HIV testing coupled with strengthening linkages to care and treatment can 
help improve HIV testing among males. 
▪ Targeted and strategic testing is required based on the gaps that have been highlighted in 
ZAMPHIA; groups with low rates of ever testing, such as males, those who were never married, 
youths aged 15-19 years, etc. 
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8.1 Key Findings 
 
8.2 Background 
Recent studies have proven that treating people living with HIV at higher CD4 counts improves immune 
recovery, decreases the incidence of non-AIDS events, comorbidities and mortality, and reduces sexual 
and vertical transmission. In 2016, after extensive review of evidence of both the clinical and 
population-level benefits of expanding ART treatment, WHO changed their recommendation to support 
a policy of “Treatment for All,’ regardless of CD4 count.1, 2 By November 2017, almost all countries in 
sub-Saharan Africa had adopted this policy, despite the challenges in ensuring uptake and 
implementation.2 This policy was adopted as “Test and Treat” in Zambia in 2016. 
 
8.3 Self-Reported Diagnosis and Treatment Status among HIV-Positive Adults 
Among HIV-positive adults aged 15-59 years, based on self-report, 33.9% were unaware of their HIV-
positive status, including one-third (37.7%) of the males and 31.6% of the females. Overall, 56.2% of 
HIV-positive adults, including males (53.7%) and females (57.7%), reported awareness of their status and 
ART use (Tables 8.3.A, 8.3.B, 8.3.C).  
 
Among HIV-positive males, the percentage of those who were unaware of their HIV status ranged from 
67.1% among those aged 25-29 years to 20.8% among those aged 50-59 years. Among HIV-positive 
females, the percentage unaware of their HIV status ranged from 70.1% among those aged 15-19 years 
to 20.2% among those aged 40-44 years. The percentage of HIV-positive males who reported being on 
ART ranged from 25.0% among those aged 25-29 years to 76.1% among those aged 50-54 years, while 
the percentage of HIV-positive females who reported being on ART ranged from 26.5% among ages 15-
19 years to 72.5% among ages 55-59 years (Table 8.3.A and Table 8.3.B). 
 
Among married and cohabitating HIV-positive adults aged 15-59 years, 60.4% were aware of their status 
and on ART, 57.2% of males and 63.1% of females, while among those who had never married, 38.8% 
were aware and on ART, including 35.9% of males and 40.4% of females. In the lowest wealth quintile, 
41.4% were unaware while only 25.5% of adults in the highest wealth quintile were unaware of their 
status. (Table 8.3.A, Table 8.3.B and Table 8.3.C). 
8 HIV DIAGNOSIS AND TREATMENT 
▪ Over two-thirds (67.1%) of HIV-positive males aged 25-29 years reported being unaware of their 
HIV status. 
▪ Based on self-report, lack of awareness varied geographically among HIV-positive men and 
women aged 15-59 years, from 26.6% of men unaware of their status in Eastern Province to 
57.1% of men in Luapula, and from 23.5% of women unaware in Southern Province to 42.8% of 
women in Luapula. 
▪ Concordance between self-report of ART and detection of ARVs was high among adults aged 15-
59 years, with 95.3% of those who reported current ART use having detectable ARVs in blood. 
However, self-report of HIV status was less accurate: 15.3% of HIV-positive adults who reported 
that they had not been previously diagnosed with HIV had ARVs detected in their blood.  
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Lack of awareness of HIV status among HIV-positive men aged 15-59 years varied geographically, from 
26.6% unaware in Eastern Province to 57.1% unaware in Luapula Province (Table 8.3.B). As among HIV-
positive men, lack of awareness of HIV status among HIV-positive females varied geographically, from 
23.5% unaware in Southern Province to 42.8% in Luapula Province (Table 8.3.C). ART coverage 
(according to self-report) also varied geographically and peaked in Eastern Province at 64.1%, as 
compared to 36.6% in Northern Province (Table 8.3.A). 
 
 
  
Table 8.3.A HIV treatment status: Males 
Percent distribution of HIV-positive males aged 15-59 years by self-reported antiretroviral therapy (ART) status, by selected demographic 
characteristics, ZAMPHIA 2016 
 
 Aware of HIV status   
Characteristic 
Unaware of HIV 
status 
Not on ART On ART1 Total Number 
Residence      
Urban 32.8 7.8 59.4 100.0 401 
Rural 44.1 9.6 46.3 100.0 365 
Province      
Central 43.9 9.4 46.8 100.0 70 
Copperbelt 33.9 11.5 54.6 100.0 153 
Eastern (26.6) (5.4) (68.0) (100.0) 47 
Luapula (57.1) (4.7) (38.1) (100.0) 34 
Lusaka 31.9 3.2 64.9 100.0 167 
Muchinga (33.8) (8.1) (58.1) (100.0) 28 
Northern 53.2 15.2 31.6 100.0 50 
North-Western (51.2) (4.6) (44.1) (100.0) 39 
Southern 34.8 13.8 51.4 100.0 122 
Western 45.6 10.5 43.9 100.0 56 
Marital status      
Never married 60.8 3.3 35.9 100.0 88 
Married or living together 33.1 9.6 57.2 100.0 573 
Divorced or separated 46.2 7.3 46.5 100.0 75 
Widowed (25.3) (10.4) (64.3) (100.0) 28 
Education      
No education * * * * 20 
Primary 40.1 9.4 50.5 100.0 263 
Secondary 39.6 8.3 52.1 100.0 392 
More than secondary 23.7 6.5 69.9 100.0 90 
Wealth quintile      
Lowest 50.6 10.4 39.1 100.0 81 
Second 41.5 10.0 48.5 100.0 110 
Middle 39.9 12.4 47.7 100.0 163 
Fourth 44.4 7.6 48.0 100.0 198 
Highest 24.2 5.5 70.4 100.0 207 
Age      
15-19 * * * * 24 
20-24 (57.2) (5.5) (37.3) (100.0) 29 
25-29 67.1 7.9 25.0 100.0 57 
30-34 54.8 13.4 31.8 100.0 108 
35-39 39.2 12.3 48.5 100.0 117 
40-44 28.0 8.9 63.1 100.0 162 
45-49 23.5 7.1 69.4 100.0 122 
50-54 20.8 3.2 76.1 100.0 96 
55-59 20.8 4.4 74.8 100.0 51 
Total 15-24 59.4 5.3 35.3 100.0 53 
Total 15-49 41.1 9.6 49.3 100.0 619 
Total 15-59 37.7 8.6 53.7 100.0 766 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy and PEPFAR TX_CURR_NAT / SUBNAT. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. An asterisk 
indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. The sum of the 
sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Table 8.3.B   HIV treatment status: Females 
Percent distribution of HIV-positive females aged 15-59 years by self-reported antiretroviral therapy (ART) status, by selected demographic 
characteristics, ZAMPHIA 2016 
 
 Aware of HIV status   
Characteristic 
Unaware of 
HIV status 
Not on ART On ART1 Total Number 
Residence      
Urban 28.9 10.7 60.4 100.0 997 
Rural 35.6 10.6 53.8 100.0 671 
Province      
Central 31.9 7.9 60.2 100.0 159 
Copperbelt 31.2 11.1 57.7 100.0 352 
Eastern 24.3 13.4 62.3 100.0 129 
Luapula 42.8 6.5 50.7 100.0 71 
Lusaka 29.2 11.9 58.9 100.0 412 
Muchinga 37.9 5.2 56.9 100.0 80 
Northern 40.3 19.5 40.2 100.0 80 
North-Western 42.5 8.0 49.4 100.0 96 
Southern 23.5 7.1 69.3 100.0 185 
Western 40.8 11.2 48.0 100.0 104 
Marital status      
Never married 49.3 10.3 40.4 100.0 235 
Married or living together 26.5 10.4 63.1 100.0 852 
Divorced or separated 37.8 10.4 51.8 100.0 315 
Widowed 22.9 12.4 64.7 100.0 261 
Education      
No education 21.3 16.8 61.8 100.0 88 
Primary 33.0 10.0 57.0 100.0 767 
Secondary 32.2 10.0 57.8 100.0 692 
More than secondary 27.2 13.8 58.9 100.0 121 
Wealth quintile      
Lowest 36.0 14.2 49.8 100.0 163 
Second 37.6 9.1 53.3 100.0 188 
Middle 33.8 7.8 58.4 100.0 358 
Fourth 31.7 13.5 54.8 100.0 469 
Highest 26.3 9.5 64.3 100.0 482 
Age      
15-19 70.1 3.4 26.5 100.0 67 
20-24 55.2 11.4 33.3 100.0 167 
25-29 33.4 12.1 54.5 100.0 222 
30-34 28.4 17.2 54.4 100.0 300 
35-39 23.2 12.2 64.7 100.0 281 
40-44 20.2 8.1 71.6 100.0 291 
45-49 28.1 5.5 66.3 100.0 157 
50-54 24.9 7.9 67.2 100.0 116 
55-59 24.7 2.8 72.5 100.0 67 
Total 15-24 59.9 8.9 31.2 100.0 234 
Total 15-49 32.4 11.2 56.4 100.0 1,485 
Total 15-59 31.6 10.7 57.7 100.0 1,668 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy and PEPFAR TX_CURR_NAT / SUBNAT 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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Table 8.3.C  HIV treatment status: Total 
Percent distribution of HIV-positive persons aged 15-59 years by self-reported HIV diagnosis and antiretroviral therapy (ART) status, by selected 
demographic characteristics, ZAMPHIA 2016 
  Aware of HIV status   
Characteristic Unaware of HIV status Not on ART On ART1 Total Number 
Residence      
Urban 30.3 9.6 60.1 100.0 1,398 
Rural 38.9 10.2 50.9 100.0 1,036 
      
Province      
Central 36.1 8.4 55.5 100.0 229 
Copperbelt 32.2 11.3 56.6 100.0 505 
Eastern 25.0 10.9 64.1 100.0 176 
Luapula 48.1 5.8 46.1 100.0 105 
Lusaka 30.2 8.6 61.2 100.0 579 
Muchinga 36.7 6.1 57.2 100.0 108 
Northern 45.7 17.7 36.6 100.0 130 
North-Western 45.5 6.9 47.6 100.0 135 
Southern 28.6 10.1 61.3 100.0 307 
Western 42.6 10.9 46.5 100.0 160 
      
Marital status      
Never married 53.3 7.9 38.8 100.0 323 
Married or living together 29.6 10.1 60.4 100.0 1,425 
Divorced or separated 39.8 9.7 50.5 100.0 390 
Widowed 23.2 12.2 64.7 100.0 289 
      
Education      
No education 23.4 16.3 60.3 100.0 108 
Primary 35.2 9.8 55.0 100.0 1,030 
Secondary 35.4 9.3 55.3 100.0 1,084 
More than secondary 25.4 10.1 64.5 100.0 211 
      
Wealth quintile      
Lowest 41.4 12.8 45.8 100.0 244 
Second 39.2 9.5 51.3 100.0 298 
Middle 36.0 9.4 54.6 100.0 521 
Fourth  36.4 11.3 52.3 100.0 667 
Highest 25.5 7.9 66.6 100.0 689 
Age      
15-19 67.5 3.9 28.6 100.0 91 
20-24 55.6 10.3 34.1 100.0 196 
25-29 42.4 11.0 46.6 100.0 279 
30-34 36.9 16.0 47.1 100.0 408 
35-39 29.2 12.2 58.6 100.0 398 
40-44 23.7 8.5 67.8 100.0 453 
45-49 25.9 6.3 67.8 100.0 279 
50-54 22.7 5.4 71.9 100.0 212 
55-59 22.9 3.6 73.6 100.0 118 
Total 15-24 59.8 8.0 32.2 100.0 287 
Total 15-49 35.5 10.6 53.9 100.0 2,104 
Total 15-59 33.9 9.9 56.2 100.0 2,434 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy and PEPFAR TX_CURR_NAT / SUBNAT 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Figure 8.3.A Proportion of HIV-positive adults aged 15-59 years self-reporting awareness of HIV status 
and antiretroviral therapy status, by age and sex, ZAMPHIA 2016 
 
*For males in the 15-19 age group, the point estimate has been suppressed because of the limited 
number of observations.  
8.4 Reliability of Self-Reported Treatment Status versus Laboratory ARV Data 
ZAMPHIA determined the presence of four ARVs in blood (atazanavir, efavirenz, lopinavir and 
nevirapine) as markers of first- and second-line regimens prescribed in the country at the time of the 
survey. Overall, 15.3% people living with HIV aged 15-59 years who self-reported they were not aware of 
their status had detectable ARVs in their blood. Of those who self-reported being aware of their HIV-
positive status but not on ART, 6.6% had detectable ARVs in their blood (Table 8.4.C).  
 
Among all HIV-positive persons aged 15-59 years, 95.3% of those who self-reported being aware of their 
HIV-positive status and also being on ART had detectable ARVs in their blood. It is unclear if the 4.7% of 
those self-reporting to be on treatment, but without detectable ARVs, were not adhering to their 
treatment regimen appropriately, or if they were taking a treatment regimen that did not include one of 
the four compounds tested (Table 8.4.C).  
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Table 8.4.A  Concordance of self-reported treatment status versus presence of antiretrovirals (ARVs): Males 
Percent distribution of HIV-positive males aged 15-59 years by presence of detectable ARVs versus self-reported 
antiretroviral therapy (ART) status, ZAMPHIA 2016 
Characteristic 
ARVs1   
Not detectable Detectable Total Number 
Self-reported ART status     
Not previously diagnosed 81.9 18.1 100.0 282 
Previously diagnosed, not on ART 96.6 3.4 100.0 67 
Previously diagnosed, on ART 3.7 96.3 100.0 407 
     
Total 15-24 62.9 37.1 100.0 54 
Total 15-49 45.4 54.6 100.0 614 
Total 15-59 41.0 59.0 100.0 759 
1Antiretroviral detection assay included only atazanavir, efavirenz, and lopinavir. Participants who reported antiretroviral therapy use and/or had 
undetectable viral load but had no evidence of the first three ARVs were tested for nevirapine as well. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
 
Table 8.4.B  Concordance of self-reported treatment status versus presence of antiretrovirals (ARVs): Females 
Percent distribution of HIV-positive females aged 15-59 years by presence of detectable ARVs versus self-reported HIV 
treatment status, ZAMPHIA 2016 
Characteristic 
ARVs1   
Not detectable Detectable Total Number 
Self-reported ART status     
Not previously diagnosed 86.6 13.4 100.0 497 
Previously diagnosed, not on ART2 91.9 8.1 100.0 167 
Previously diagnosed, on ART 5.2 94.8 100.0 988 
 
    
Total 15-24 66.3 33.7 100.0 234 
Total 15-49 41.4 58.6 100.0 1,474 
Total 15-59 40.0 60.0 100.0 1,656 
1Antiretroviral detection assay included only atazanavir, efavirenz, and lopinavir. Participants who reported antiretroviral therapy use and/or had 
undetectable viral load were tested for nevirapine as well. 
2 ART: Antiretroviral therapy 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
 
Table 8.4.C  Concordance of self-reported treatment status versus presence of antiretrovirals (ARVs): Total 
Percent distribution of HIV-positive persons aged 15-59 years by presence of detectable ARVs versus self-reported HIV 
treatment status, ZAMPHIA 2016 
 ARVs1   
Characteristic Not detectable Detectable Total Number 
Self-reported ART status     
Not previously diagnosed 84.7 15.3 100.0 779 
Previously diagnosed, not on ART2 93.4 6.6 100.0 234 
Previously diagnosed, on ART 4.7 95.3 100.0 1,395 
 
    
Total 15-24 65.5 34.5 100.0 288 
Total 15-49 42.8 57.2 100.0 2,088 
Total 15-59 40.4 59.6 100.0 2,415 
1Antiretroviral detection assay included only atazanavir, efavirenz, and lopinavir. Participants who reported antiretroviral therapy use and/or had 
undetectable viral load were tested for nevirapine as well. 
2 ART: Antiretroviral therapy 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable.  
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8.5 Gaps and Unmet Needs 
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▪ The major gap is in reaching and diagnosing those infected with HIV, particularly the substantial 
proportion of men and young people who are unaware of their status. 
▪ Universal routine testing (testing all patients for HIV, regardless of risk when they come in for a 
doctor’s visit) was launched in August 2017. Special targeted HIV testing campaigns are needed 
among those aged 15-24 years, as well as less educated and never married men. Current small-
scale projects aimed at older adolescents (over age 16 years, the age of consent) include school-
based testing and church-based testing. Increased access to self-testing, which was included in 
the National Guidelines in December 2017, could also improve outreach for this age group as 
well as for men in general. 
▪ Other methods for reaching men, especially those who are less educated and never married, 
include HIV testing campaigns in labor or roadside encampments, pubs or bars, and workplaces 
with unskilled laborers (e.g., construction and mining sites). 
▪ In provinces with lower average awareness of HIV status (e.g., Luapula, Northern, North-Western 
and Western Provinces) and lower self-reported ART (e.g., Northern Province), additional 
targeted HIV testing and better ART initiation is also necessary. 
▪ There is also a need to initiate treatment in those who have been diagnosed but are not receiving 
ART. Scaling up Test and Treat and differentiated service delivery (a client-centered approach to 
service delivery for people living with HIV that simplifies and adapts HIV services across the 
cascade) should assist this effort. 
▪ The higher-than-expected lack of concordance of self-reported HIV awareness and treatment 
versus presence of detectable ARVs suggests additional work is needed to provide 
comprehensive HIV education and counseling for those who test positive. National campaigns 
against HIV stigma, particularly targeting self-stigma, could also help address this unmet need. 
Quantifying the amount of detectable ARVs in the ZAMPHIA sample would provide additional 
context on adherence. 
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9.1 Key Findings 
 
9.2 Background 
Viral load suppression (VLS) is a key indicator of treatment success in HIV-positive individuals. For the 
purposes of ZAMPHIA 2016, VLS is defined as VL of less than 1,000 HIV RNA copies per milliliter of 
plasma. This chapter describes VLS among the population of HIV-positive persons aged 15-59 years by 
age, sex, province, and other demographic characteristics. 
 
9.3 Adult Viral Load Suppression by Demographic Characteristics 
Among people living with HIV aged 15-59 years in Zambia, the prevalence of VLS was 59.2% (Table 
9.3.A). Among those who reported being previously diagnosed but not on ART, the prevalence of VLS 
was low: 5.3% for males, and 14.8% for females. 
 
  
9 VIRAL LOAD SUPPRESSION 
▪ Among people living with HIV aged 15-59 years in Zambia, the prevalence of viral load 
suppression (VLS) was 59.2%. 
▪ Prevalence of VLS ranged from 30.7% among HIV-positive individuals aged 15-19 years to 79.0% 
among those aged 55-59 years. 
▪ Among HIV-positive adults aged 15-59 years, the prevalence of VLS varied geographically across 
Zambia, ranging from 47.3% in Western Province to 67.1% in Eastern Province. 
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Table 9.3.A  Viral load suppression prevalence by demographic characteristics 
Percentage of HIV-positive persons aged 15-59 years with viral load suppression by sex, self-reported HIV diagnosis and antiretroviral 
therapy (ART) status, and selected demographic characteristics, ZAMPHIA 2016 
 Males 
 Females  Total 
Characteristic Percentage VLS1 Number  Percentage VLS1 Number  
Percentage 
VLS1 
Number 
Self-reported HIV diagnosis and 
treatment status 
        
Not previously diagnosed 23.2 279  19.8 491  21.2 770 
Previously diagnosed, not on ART 5.3 63  14.8 164  11.8 227 
Previously diagnosed, on ART 87.7 413  90.1 996  89.2 1,409 
Missing * 3  * 4  * 7 
Residence         
Urban 60.5 399  62.5 994  61.8 1,393 
Rural 52.8 359  57.2 661  55.5 1,020 
Province         
Central 56.1 70  60.8 159  59.1 229 
Copperbelt 49.7 152  60.6 352  56.7 504 
Eastern (68.6) 47  66.4 129  67.1 176 
Luapula (45.5) 34  57.6 71  53.1 105 
Lusaka 67.5 167  59.6 412  62.7 579 
Muchinga (65.1) 28  63.2 80  63.7 108 
Northern (50.0) 42  51.0 69  50.6 111 
North-Western (49.8) 39  55.3 97  53.4 136 
Southern 56.0 122  70.0 183  63.7 305 
Western 45.6 57  48.4 103  47.3 160 
Marital status         
Never married 40.5 88  40.2 234  40.3 322 
Married or living together 60.5 565  66.4 843  63.7 1,408 
Divorced or separated 54.2 75  54.2 316  54.2 391 
Widowed (57.6) 28  68.4 257  67.1 285 
Education         
No education * 20  56.3 86  55.2 106 
Primary 52.5 256  60.3 758  57.9 1,014 
Secondary 57.1 392  60.8 689  59.2 1,081 
More than secondary 71.9 89  61.3 122  66.7 211 
Wealth quintile         
Lowest 44.8 79  48.4 160  47.1 239 
Second 52.8 108  56.9 183  55.2 291 
Middle 54.9 162  62.2 353  59.5 515 
Fourth 51.9 198  59.6 469  56.7 667 
Highest 69.9 204  64.6 482  66.6 686 
Total 15-24 36.7 53  33.6 233  34.3 286 
Total 15-49 52.5 611  58.9 1,473  56.6 2,084 
Total 15-59 57.2 758  60.4 1,655  59.2 2,413 
1 Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed viral loads. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
 
9.4 Adult Viral Load Suppression by Age and Sex 
In general, the prevalence of VLS among people living with HIV ranged from 30.7% among those aged 
15-19 years to 79.0% among those aged 55-59 years. Only a third of aged 0-14 years (33.4%) and aged 
15-24 years (34.3%) had suppressed viral loads (Table 9.4.A; Table 9.4.B; Figure 9.4.A).  
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Table 9.4.A  Viral load suppression by age (5-year age groups) 
Percentage of HIV-positive persons from 0-59 years of age with viral load suppression1, by sex and age, ZAMPHIA 2016 
 Males  Females  Total 
Age 
Percentage 
VLS 2 
Number  
Percentage 
VLS2 
Number  
Percentage 
VLS 2 
Number 
0-4 * 13  * 6  * 19 
5-9 (22.4) 30  * 21  22.5 51 
10-14 * 9  * 11  * 20 
15-19 (42.5) 25  25.1 67  30.7 92 
20-24 (31.1) 28  37.5 166  36.3 194 
25-29 36.8 53  57.2 220  52.0 273 
30-34 36.6 107  55.2 295  49.1 402 
35-39 51.9 115  69.7 280  63.1 395 
40-44 66.7 161  70.8 290  69.0 451 
45-49 66.0 122  72.5 155  69.3 277 
50-54 78.3 95  71.6 114  75.1 209 
55-59 82.3 52  76.1 68  79.0 120 
         
Total 15-24 36.7 53  33.6 233  34.3 286 
Total 15-49 52.5 611  58.9 1,473  56.6 2,084 
Total 15-59 57.2 758  60.4 1,655  59.2 2,413 
1Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed viral loads  
2VLS: Viral load suppression 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 9.4.B  Viral load suppression by age (10-to-15-year age groups) 
Percentage of HIV-positive persons from 0-59 years of age with viral load suppression1, by sex and age, ZAMPHIA 2016 
 Males  Females  Total 
Age 
Percentage 
VLS2 
Number  
Percentage 
VLS2 
Number  
Percentage 
VLS2 
Number 
0-14 30.0 52  (38.2) 38  33.4 90 
15-24 36.7 53  33.6 233  34.3 286 
25-34 36.7 160  56.1 515  50.4 675 
35-44 60.1 276  70.3 570  66.1 846 
45-59 73.3 269  73.0 337  73.1 606 
1Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed viral loads 
2 VLS: Viral load suppression 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
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Figure 9.4.A Proportion of viral load suppression (<1,000 copies/mL) among people living with HIV, by 
age and sex, ZAMPHIA 2016 
 
9.5 Adult Viral Load Suppression by Province 
Among HIV-positive adults aged 15-59 years, the prevalence of VLS varies geographically across Zambia, 
ranging from 47.3% in Western Province to 67.1% in Eastern Province. The prevalence of VLS was above 
60% in Muchinga, Lusaka, Southern, and Eastern Provinces. Comparatively, in the remaining six 
provinces, prevalence of VLS was less than 60% (Table 9.3.A; Figure 9.5.A and 9.5.B).  
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Figure 9.5.A Viral load suppression (<1000 copies/mL) among HIV-positive adults aged 15-59, by 
province, ZAMPHIA 2016 
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Map 9.5.B Viral load suppression (<1000 copies/mL) among HIV-positive adults aged 15-59, by 
province, ZAMPHIA 2016 
 
9.6 Gaps and Unmet Needs 
 
  
▪ Western Province has low viral load suppression and high HIV prevalence (15.9%). Test and Treat 
and increased VL testing may help improve viral load suppression. 
▪ Among those who reported being previously diagnosed but not on ART, the prevalence of viral 
load suppression was low: 5.3% for males, and 14.8% for females. Additional analysis is needed 
to explain the suppression of viral load among those who report not being on ART. 
▪ Viral load suppression was particularly low among children, aged 0-14 years (33.4%), and young 
adults, 15-24 years (34.3%), reflecting a need for diagnosis and effective treatment among these 
age groups. 
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10.1 Key Findings 
 
10.2 Background 
In order to bring the HIV epidemic under control, UNAIDS has set the ambitious target referred to as 90-
90-90: By 2020, 90% of all persons living with HIV will know their HIV status; 90% of all persons with 
diagnosed HIV infection will receive sustained ART; and 90% of all persons receiving ART will have viral 
suppression.1 
 
The previous chapters on HIV testing and treatment provide results on coverage of HIV testing and 
treatment services, while VLS among all HIV-positive individuals is a measure of program impact, 
irrespective of knowledge of status or being on treatment. This chapter presents the status of the 90-90-
90 indicators, which provide signals of HIV program performance. Awareness of HIV-positive status and 
treatment status among those aware of being HIV positive are indicators of access to services. Viral load 
suppression among those who are aware of their HIV status and on treatment not only provides an 
indication of access to and retention in care but also when compared to VLS among all HIV-positive 
individuals, provides a measure of program success. Viral load suppression among all HIV-positive 
individuals of 73% (90 x 90 x 90) or greater is an indication of successful testing and treatment services.  
 
The 90-90-90 results in this chapter have been presented in two ways. First, Tables 10.3.A use only self-
reported awareness and ARV status. Individuals are defined as ‘aware ‘of their HIV-positive status if they 
self-reported a positive HIV status before being tested as part of the ZAMPHIA survey. Likewise, 
individuals were defined as ‘on treatment’ if they self-reported that they are taking ART. Second, Table 
10.3.B measures the 90-90-90 indicators using both self-reported and ARV biomarker data. In this table, 
‘aware’ and ‘on treatment’ have been adjusted such that individuals in whom ARVs were detected are 
classified as ‘aware’ and ‘on treatment’ even if they did not self-report. Individuals are classified as 
‘aware’ of their HIV-positive status if they self-reported being HIV positive and/or had detectable ARVs 
in their blood. Likewise, individuals are classified as ‘on treatment’ if they self-reported that they are 
taking ART and/or had detectable ARVs in their blood.  
 
It is important to note that in both cascades, individuals who have suppressed viral loads, but are not 
aware of their HIV-positive status or are not on ARVs, are excluded from the numerator for the third 90 
(viral suppression among those who are aware and on ARVs).  
10 UNAIDS 90-90-90 TARGETS 
▪ Diagnosed: In Zambia, 71.4% of HIV-positive people aged 15-59 years report knowing their HIV 
status and/or had detectable ARVs in their blood (72.6% of females and 69.2% of males). 
▪ On Treatment: Among people living with HIV aged 15-59 years who know their HIV status, 87.1% 
self-reported current use of ART and/or had detectable ARVs in their blood (86.5% of HIV-
positive females and 88.2% of HIV-positive males). 
▪ Suppressed Viral Load: Among people living with HIV aged 15-59 years who report currently 
using ART and/or had detectable ARVs in their blood, 89.2% had suppressed viral loads (90.2% of 
HIV-positive females and 87.7% of HIV-positive males).  
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10.3 Status of the UNAIDS 90-90-90 Targets 
 
90-90-90 cascade based on self-reported awareness of HIV Status and ARV use:  
 
Nearly two-thirds (66.1%) of HIV-positive persons aged 15-59 years reported being aware of their HIV 
status (68.4% of HIV-positive females and 62.3% of HIV-positive males). Among persons who were 
aware of their HIV status, 85.1% self-reported being on ART (84.4% of HIV-positive females and 86.2% of 
HIV-positive males). Among those who self-reported ART, 89.2% had suppressed viral loads (90.1% of 
females and 87.7% of males) (Table 10.3.A).  
 
90-90-90 cascade based on self-reported awareness of HIV Status and ARV use and/or detectable 
ARVs:  
 
When adjusted to include adults who self-reported as HIV positive and/or had detectable ARVs in their 
blood, the proportion of HIV-positive adults who were aware (ARV-adjusted awareness) of their HIV 
status was 71.4% (72.6% among females and 69.2% among males). Among HIV-positive adults who were 
aware of their status, 87.1% self-reported current ARV usage (ARV-adjusted treatment status) or had 
detectable ARVs (86.5% of females and 88.2% of males). Among HIV-positive adults with detectable 
ARVs (ARV-adjusted treatment status), 89.2% had suppressed viral loads (90.2% of females and 87.7% of 
males) (Table 10.3.B, Figure 10.3.A).  
 
Among HIV-positive males aged 35-49 years, 77.0% reported knowledge of their HIV status or had 
detectable ARVs, with 88.4% of them reporting being on ART; among those, 87.3% had suppressed viral 
loads. In contrast, only 47.3% of HIV-positive men aged 25-34 years reported being aware of their status 
or ARVs were detected in their blood; of those, 75.9% reported being on ART, and among them, 90.7% 
had suppressed viral loads (Table 10.3.B). 
 
Among HIV-positive women aged 35-49 years, 81.3% reported awareness of their HIV status or had 
detectable ARVs. In comparison, among those aged 15-24 years, only 45.3% reported knowledge of their 
HIV status. Of HIV-positive women aged 35-49 years, 90.2% reported being on ART or ARVs were 
detected in their blood, and 91.7% of those with detectable ARVs had suppressed viral loads (Table 
10.3.B).  
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Table 10.3.A  Adult 90-90-90 (self-reported antiretroviral therapy (ART) status; conditional percentages) 
90-90-90 targets among people living with HIV aged 15-59 years, by sex and age, ZAMPHIA 2016 
 Diagnosed 
 Males  Females  Total 
Age 
Percentage 
who self-reported 
HIV positive 
Number  
Percentage 
who self-reported 
HIV positive 
Number  
Percentage 
who self-reported 
HIV positive 
Number 
15-24 40.6 53  40.1 234  40.2 287 
25-34 40.6 165  69.4 522  60.8 687 
35-49 69.8 401  76.8 729  73.8 1,130 
15-49 58.9 619  67.6 1,485  64.5 2,104 
15-59 62.3 766  68.4 1,668  66.1 2,434 
 
 On Treatment, among those Diagnosed 
 Males  Females  Total 
Age 
Percentage 
who self-
reported on 
ART 
Number  
Percentage 
who self-
reported on ART 
Number  
Percentage 
who self-
reported on 
ART 
Number 
15-24 * 20  77.9 98  80.0 118 
25-34 72.1 68  78.4 363  77.2 431 
35-49 86.4 279  88.1 566  87.4 845 
15-49 83.7 367  83.4 1,027  83.5 1,394 
15-59 86.2 482  84.4 1,165  85.1 1,647 
 
 Viral Load Suppression among those On Treatment 
 Males  Females  Total 
Age 
Percentage with 
suppressed viral load 
Number  
Percentage with 
suppressed viral 
load 
Number  
Percentage with 
suppressed viral 
load 
Number 
15-24 * 17  78.1 76  71.3 93 
25-34 (90.7) 47  88.3 289  88.7 336 
35-49 87.7 240  91.2 504  89.8 744 
15-49 85.6 304  88.9 869  87.8 1,173 
15-59 87.7 413  90.1 996  89.2 1,409 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 10.3.B  Adult 90-90-90 (self-reported antiretroviral therapy (ART) status and/or laboratory antiretroviral (ARV) data; conditional 
percentages) 
90-90-90 targets among people living with HIV age 15-59 years, by sex and age, ZAMPHIA 2016 
 Diagnosed1 
 Males  Females  Total 
Age 
Percentage 
who self-reported 
HIV positive AND/ OR 
with detectable ARVs 
Number   
Percentage 
who self-reported 
HIV positive 
AND/OR with 
detectable ARVs 
Number   
Percentage 
who self-reported 
HIV positive AND/OR  
with detectable ARVs 
Number 
15-24 48.3 54  45.3 234  46.0 288 
25-34 47.3 164  73.1 522  65.4 686 
35-49 77.0 401  81.3 732  79.4 1,133 
15-49 66.0 619  72.0 1,488  69.8 2,107 
15-59 69.2 767  72.6 1,672  71.4 2,439 
 
 On Treatment2, among those Diagnosed 
 Males  Females  Total 
Age 
Percentage 
with detectable ARVs 
AND/OR who self-
reported being on 
ART 
Number   
Percentage 
with detectable ARVs 
AND/OR who self-
reported being on ART 
Number   
Percentage 
with detectable ARVs 
AND/OR who self-
reported being on ART 
Number 
15-24 (89.2) 25  81.4 110  83.3 135 
25-34 75.9 78  80.8 383  79.8 461 
35-49 88.4 306  90.2 603  89.4 909 
15-49 86.0 409  85.8 1,096  85.8 1,505 
15-59 88.2 535  86.5 1,242  87.1 1,777 
 
 Viral Load Suppression among those On Treatment3 
 Males  Females  Total 
Age 
Percentage with 
suppressed viral load 
Number  
Percentage with 
suppressed viral 
load 
Number  
Percentage with 
suppressed viral 
load 
Number 
15-24 * 22  76.9 89  72.6 111 
25-34 90.7 57  88.7 314  89.1 371 
35-49 87.3 269  91.7 549  89.9 818 
15-49 85.9 348  89.1 952  88.0 1,300 
15-59 87.7 469  90.2 1,087  89.2 1,556 
1Relates to Global AIDS Monitoring indicator (GAM) 1.1: People living with HIV who know their HIV status, and PEPFAR Indicator 
DIAGNOSED_NAT. 
2Relates to GAM 1.2: People living with HIV on antiretroviral therapy, and PEPFAR TX_CURR_NAT / SUBNAT. 
3Relates to GAM 1.4: People living with HIV who have suppressed viral loads, and PEPFAR VL_SUPPRESSION_NAT. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Figure 10.3.A Adult 90-90-90 (adjusted for laboratory antiretroviral data1 among adults aged 15-59 
years), ZAMPHIA 2016 
 
 
10.4 Gaps and Unmet Needs 
 
 
10.5 References 
1. Joint United Nations Programme on HIV/AIDS. 90-90-90. An ambitious treatment target to help end 
the AIDS epidemic. Geneva: UNAIDS; 2014. 
http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed December 17, 
2018. 
▪ The major gap is in diagnosis of those individuals, especially among males and young adults, who 
are unaware of their HIV-positive status.  
▪ A gap persists in the initiation of ART, especially among young adults aged 25-34 years, among 
whom 20% of those already diagnosed were not receiving ART based on ARV-adjusted measures.  
▪ Although VLS is high among those on ARVs, further attention could be focused upon those who 
are undiagnosed and those who are not on ARVs so that additional gaps that remain continue to 
be addressed. 
1In the antiretroviral (ARV)-adjusted 90-90-90 participants are classified as ‘Aware’ or ‘Diagnosed’ if they self-
reported as HIV positive before testing HIV positive in ZAMPHIA and/or had detectable ARVs in their blood. 
Participants are classified as ‘On Treatment’ if they self-reported that they were on treatment and/or if they had 
detectable ARVs in their blood.  
*Inset numbers are conditional proportions.  
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11.1 Key Findings 
 
 
11.2 Background 
The quality of HIV care is based on key principles of accessibility, efficiency, and safety. As countries 
implement treatment for all people living with HIV, ensuring a sustainable health system that is people-
centered and innovative requires diligent monitoring and responsiveness.1 Indicators such as CD4 count 
at diagnosis and retention on ART can provide evidence of program coverage, the ability to reach 
vulnerable populations, and quality of care. The distribution of CD4 counts also reflects population 
health, and the potential impact of HIV on mortality. Finally, the measurement of primary (transmitted) 
and secondary drug resistance allows optimization of national ART guidelines including second- and 
third-line therapies. ZAMPHIA, therefore, provides a unique opportunity to gauge progress in the 
expansion of HIV clinical services in Zambia, as well as identify gaps and future challenges. 
 
11.3 CD4 Counts and Immunosuppression 
The median CD4 count among all HIV-positive adults aged 15-59 years was 421 cells/μL. Nearly two-
thirds (64.3%) of those within this age group were immunosuppressed (defined as CD4 count < 500 
cells/μL). Prevalence of immunosuppression was lower in HIV-positive females (58.9%) than in males 
(73.2%) aged 15-59 years. Among HIV-positive participants who reported not being aware of their status 
(that is, not being previously diagnosed with HIV), the median CD4 count was 388 cells/μL. The median 
CD4 count was 451 cells/μL among those who reported being previously diagnosed and on ART, 
compared to 330 cells/μL among those who reported that they had been previously diagnosed but were 
not on ART (Table 11.3.A, Figure 11.3.A). Among those on ART, the median CD4 count was 397 cells/μL 
among men and 485 cells/μL among women (Table 11.3.A). 
 
The proportion of immunosuppression (CD4 count of less than 500 cells/μL) among HIV-positive persons 
who reported having been previously diagnosed and on ART was 59.2%, compared to 76.0% among 
those who reported having been previously diagnosed but not on ART, and 69.8% among those 
reporting not being previously diagnosed. Among those aged 15-59 years who were previously 
diagnosed and on ART, approximately half (53.2%) of the females were immunosuppressed compared to 
70.0% of the males. By age, the proportion of immunosuppression ranged from 53.2% among those 
aged 15-19 years to 73.2% among those aged 55-59 years. By province, the median CD4 count in HIV-
positive persons ranged from 369 cells/μL for those residing in North-Western Province to 457 cells/μL 
among those residing in Luapula (Table 11.3.A).  
11 CLINICAL PERSPECTIVES ON PEOPLE LIVING WITH 
HIV 
▪ The median CD4 count among all HIV-positive participants aged 15-59 years was 421 cells/μL. 
Nearly two-thirds (64.3%) of those within this age group had CD4 counts < 500 cells/µL. The 
proportion of immunosuppression (defined as CD4 count < 500 cells/μL) among HIV-positive 
persons who reported having been previously diagnosed and on ART was 59.2%, compared to 
76.0% among those who reported having been previously diagnosed but not on ART. 
▪ Prevalence of immunosuppression was 58.9% in HIV-positive females compared to 73.2% in 
males aged 15-59 years. 
▪ Overall, among people newly with HIV aged 15-59 years, 45.5% had a CD4 count less than 350 
cells/µL and 17.7% had a CD4 count less than 200 cells/µL.  
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Table 11.3.A Median CD4 count and prevalence of immunosuppression 
Among HIV-positive persons aged 15-59 years, median (Q1, Q3) CD4 count and percentage with immunosuppression (< 500 cells/μL), by sex, self-reported diagnosis and antiretroviral therapy (ART) 
status, and selected demographic characteristics, ZAMPHIA 2016 
 Males 
 Females  Total 
Characteristic 
Median 
(Q1, Q3) 
Percentage 
< 500 
cells/μL 
Number  
Median 
(Q1, Q3) 
Percentage 
< 500 
cells/μL 
Number  
Median 
(Q1, Q3) 
Percentage 
< 500 
cells/μL 
Number 
Self-reported diagnosis and treatment status            
Not previously diagnosed 360 (223, 501) 74.8 274  414 (276, 569) 66.2 499  388 (254, 539) 69.8 773 
Previously diagnosed, not on ART 248 (142, 412) 88.1 68  365 (257, 525) 70.2 168  330 (213, 488) 76.0 236 
Previously diagnosed, on ART 397 (260, 529) 70.0 411  485 (345, 666) 53.2 993  451 (303, 615) 59.2 1,404 
Missing * * 13  * * 20  464 (290, 618) (54.6) 33 
            
Residence            
Urban 368 (227, 509) 72.7 403  450 (303, 614) 59.8 1,004  423 (277, 574) 64.5 1,407 
Rural 364 (240, 511) 73.8 363  449 (302, 645) 57.8 676  418 (273, 581) 64.0 1,039 
            
Province            
Central 326 (246, 450) 83.8 69  432 (274, 616) 60.7 159  377 (267, 545) 68.8 228 
Copperbelt 382 (242, 540) 68.3 153  444 (315, 616) 59.4 353  418 (279, 580) 62.6 506 
Eastern 445 (247, 554) (63.4) 45  440 (308, 615) 60.4 129  441 (286, 593) 61.3 174 
Luapula 318 (207, 559) (69.0) 32  475 (332, 716) 56.0 69  457 (277, 631) 60.8 101 
Lusaka 381 (228, 511) 71.3 167  465 (318, 628) 57.3 414  435 (279, 578) 62.7 581 
Muchinga 308 (189, 453) (82.4) 27  470 (327, 596) 55.4 80  437 (277, 575) 63.4 107 
Northern 427 (206, 536) 66.7 54  376 (280, 611) 60.5 91  399 (263, 583) 63.0 145 
North-Western 335 (202, 472) (82.4) 38  387 (265, 567) 68.4 97  369 (238, 523) 73.1 135 
Southern 355 (238, 488) 76.8 123  479 (324, 633) 54.1 186  413 (274, 560) 64.3 309 
Western 338 (169, 442) 81.8 58  416 (274, 671) 65.2 102  378 (235, 537) 71.8 160 
            
Marital status            
Never married 425 (285, 576) 65.7 85  438 (298, 616) 60.9 236  431 (293, 612) 62.5 321 
Married or living together 362 (227, 508) 73.1 574  471 (324, 642) 55.3 861  427 (277, 573) 63.6 1,435 
Divorced or separated 342 (220, 474) 79.2 77  420 (282, 562) 65.6 315  402 (269, 544) 69.0 392 
Widowed 259 (170, 467) (82.5) 28  424 (270, 657) 60.8 262  413 (253, 635) 63.4 290 
            
Education            
No education * * 20  417 (299, 561) 67.4 88  417 (279, 539) 69.5 108 
Primary 364 (230, 526) 70.8 263  452 (301, 646) 57.6 768  432 (280, 607) 61.7 1,031 
Secondary 370 (240, 508) 73.5 390  452 (301, 616) 59.4 699  417 (274, 562) 65.4 1,089 
More than secondary 344 (221, 486) 78.5 92  471 (343, 619) 58.0 125  410 (254, 552) 68.4 217 
            
Wealth quintile            
Lowest 294 (175, 491) 75.2 80  407 (264, 623) 58.1 161  363 (226, 562) 64.5 241 
Second 371 (262, 522) 72.5 111  448 (303, 652) 58.8 191  429 (280, 604) 64.4 302 
Middle 369 (208, 485) 77.4 160  445 (296, 624) 58.6 360  416 (273, 569) 65.3 520 
Fourth 362 (247, 500) 74.9 201  442 (297, 609) 59.2 474  414 (274, 569) 65.0 675 
Highest 396 (234, 532) 69.4 208  462 (333, 628) 59.4 486  437 (290, 583) 63.2 694 
            
Age            
15-19 * * 23  475 (345, 629) 56.4 65  492 (345, 655) 53.2 88 
20-24 381 (270, 459) (79.6) 27  475 (320, 665) 54.1 169  449 (314, 620) 58.8 196 
25-29 383 (247, 543) 64.9 57  475 (307, 662) 54.2 223  456 (289, 630) 57.1 280 
30-34 330 (205, 466) 78.2 106  444 (296, 612) 58.2 301  401 (249, 559) 64.5 407 
35-39 357 (217, 488) 75.8 116  439 (302, 574) 62.7 286  412 (276, 536) 67.5 402 
40-44 382 (210, 531) 67.7 162  457 (284, 622) 58.0 292  425 (249, 574) 62.3 454 
45-49 351 (227, 471) 78.8 125  428 (291, 624) 64.4 159  400 (269, 548) 71.5 284 
50-54 326 (259, 489) 76.2 97  427 (307, 606) 59.2 117  394 (280, 560) 68.2 214 
55-59 352 (225, 474) 77.3 53  400 (269, 596) 69.6 68  384 (250, 555) 73.2 121 
            
Total 15-24 437 (311, 604) 63.7 50  476 (337, 654) 54.8 234  458 (331, 643) 56.8 284 
Total 15-49 372 (228, 512) 72.5 616  453 (303, 629) 58.4 1,495  429 (276, 578) 63.4 2,111 
Total 15-59 365 (231, 510) 73.2 766  450 (303, 623) 58.9 1,680  421 (275, 576) 64.3 2,446 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed.  
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable.  
The interquartile range (IQR) is a measure of variability, based on dividing a data set into quartiles. Quartiles divide a rank-ordered data set into four equal parts. The values that divide each part are 
called the first, second, and third quartiles; and they are denoted by Q1, Q2, and Q3, respectively. 
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Figure 11.3.A CD4 count distribution among HIV-positive adults aged 15-59 years, by antiretroviral 
therapy status, ZAMPHIA 2016 
 
11.4 Late HIV Diagnosis 
Late HIV diagnosis can be assessed by considering the CD4 counts among persons discovered to be HIV 
positive at the time of the survey but who had reported themselves to be HIV negative during the 
interview portion of the survey (that is, they self-reported as HIV negative and had no detectable 
antiretrovirals). Overall, among these people newly diagnosed with HIV aged 15-59 years, 45.5% had a 
CD4 count less than 350 cells/μL and 17.7% had a CD4 count less than 200 cells/μL. There were no 
notable differences between urban and rural areas or by education level. (Table 11.4.A)  
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Table 11.4.A Late HIV diagnosis 
Among persons aged 15-59 years who tested HIV positive in the PHIA survey but self-reported as HIV negative and with no detectable antiretrovirals, 
percentage who had a CD4 cell count < 200 cells/μL and < 350 cells/μL, by sex and selected demographic characteristics, ZAMPHIA 2016 
 Males  Females  Total 
Characteristic 
Percentage 
< 200 
cells/μL1 
Percentage 
< 350 
cells/μL1 
Number  
Percentage 
< 200 
cells/μL1 
Percentage 
< 350 
cells/μL1 
Number  
Percentage 
< 200 
cells/μL1 
Percentage 
< 350 
cells/μL1 
Number 
Residence            
Urban 23.4 51.5 103  14.0 41.6 228  17.5 45.3 331 
Rural 22.4 48.6 119  14.6 43.6 198  17.9 45.7 317             
Province            
Central * * 21  (15.8) (35.2) 40  13.9 38.6 61 
Copperbelt (21.7) (54.7) 42  13.3 47.4 87  16.4 50.1 129 
Eastern * * 11  * * 23  (12.5) (42.9) 34 
Luapula * * 15  * * 22  (14.0) (47.6) 37 
Lusaka (29.0) (53.8) 39  14.4 35.5 101  19.6 42.0 140 
Muchinga * * 7  (11.2) (44.0) 27  (20.1) (53.7) 34 
Northern * * 18  (21.3) (59.9) 27  (20.2) (53.6) 45 
North-Western * * 15  (16.6) (60.7) 28  (14.9) (45.4) 43 
Southern (24.8) (46.4) 32  (8.5) (42.8) 34  17.4 44.8 66 
Western * * 22  (18.5) (38.8) 37  23.4 44.5 59             
Marital status            
Never married (11.7) (37.5) 42  9.0 32.3 100  9.9 34.1 142 
Married or living together 25.6 51.9 151  12.9 45.3 185  19.3 48.6 336 
Divorced or separated * * 24  16.3 41.0 96  19.0 46.8 120 
Widowed * * 5  (29.1) (58.7) 44  (28.7) (56.6) 49             
Education            
No education * * 4  * * 17  * * 21 
Primary 26.0 54.0 88  15.3 44.6 203  19.0 47.8 291 
Secondary 21.9 46.8 114  13.3 38.3 182  17.2 42.1 296 
More than secondary * * 15  * * 24  (16.2) (51.4) 39             
Wealth quintile            
Lowest (24.0) (64.3) 32  (15.6) (45.4) 47  19.4 53.8 79 
Second (13.2) (38.7) 36  13.4 40.0 57  13.3 39.4 93 
Middle (36.4) (49.8) 48  12.2 40.8 102  20.9 44.1 150 
Fourth  18.1 51.6 63  15.7 42.7 124  16.7 46.5 187 
Highest (25.6) (49.8) 41  14.4 44.2 96  18.2 46.1 137             
Age            
15-19 * * 9  (4.6) (29.3) 44  5.9 27.3 53 
20-24 * * 16  2.8 25.9 79  3.8 30.3 95 
25-29 (17.3) (48.5) 32  6.3 40.7 64  10.9 44.0 96 
30-34 30.6 55.5 52  17.0 47.9 73  23.5 51.6 125 
35-39 (7.3) (38.9) 40  (41.0) (63.0) 48  23.3 50.4 88 
40-44 (26.4) (52.5) 29  (27.4) (55.3) 45  27.0 54.0 74 
45-49 * * 23  (14.2) (47.0) 35  27.6 55.0 58 
50-54 * * 12  * * 24  (10.2) (52.7) 36 
55-59 * * 9  * * 14  * * 23 
Total 15-24 (8.9) (36.1) 25  3.5 27.2 123  4.6 29.1 148 
Total 15-49 21.6 49.0 201  14.1 42.0 388  17.1 44.8 589 
Total 15-59 22.9 50.0 222  14.3 42.5 426  17.7 45.5 648 
1Relates to Global AIDS Monitoring indicator 1.5: Late HIV diagnosis. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
 
11.5 Retention on Antiretroviral Therapy 
Tables 11.5.A and 11.5.B provide the percentages of HIV-positive persons who are still on treatment 
among those who say they had initiated ART less than 12 months (Table 11.5.A) and 12 months or 
longer (Table 11.5.B) before the survey. Among people living with HIV aged 15-59 years who initiated 
ART less than 12 months prior to the survey, 98.9% (100% of men and 98.1% of women) reported that 
they were still taking ART at the time of the survey (Table 11.5.A). Among those aged 15-59 year who 
initiated ART 12 months or more prior to the survey, 97.9 reported that they were still taking ART at the 
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time of the survey. This was similar between men and women (98.7% and 97.6% respectively) (Table 
11.5.B). There was little variation by socio-demographic characteristics aside from marital status.  
 
 
Table 11.5.A Retention on antiretroviral therapy (ART): People initiating antiretroviral therapy less than 12 months prior to the survey 
Among HIV-positive persons aged 15-59 years who reported initiating ART less than 12 months prior to the survey, percentage who reported still 
receiving ART, by sex and selected demographic characteristics, ZAMPHIA 2016 
 Males  Females  Total 
Characteristic 
Percentage 
still receiving ART1 
Number   
Percentage 
still receiving ART1 
Number   
Percentage 
still receiving ART1 
Number 
Presence of detectable ARVs2         
    Detectable             100.0  79  99.1 162  99.4 241 
    Not detectable                * 6   * 11  * 17 
Residence         
Urban (100.0) 48  98.5 106  99.1 154 
Rural (100.0) 37  97.5 68  98.5 105 
Province         
Central * 11  * 17  (100.0) 28 
Copperbelt (100.0) 25  (97.4) 35  98.7 60 
Eastern * 0  * 14  * 14 
Luapula * 3  * 4  * 7 
Lusaka * 14  (98.0) 45  98.7 59 
Muchinga * 7  * 7  * 14 
Northern * 6  * 10  * 16 
North-Western * 4  * 9  * 13 
Southern * 9  * 24  (100.0) 33 
Western * 6  * 9  * 15 
Marital status         
Never married * 8  (100.0) 28  (100.0) 36 
Married or living together 100.0 63  97.4 95  98.6 158 
Divorced or separated * 11  (100.0) 28  (100.0) 39 
Widowed * 2  * 21  * 23 
Education         
No education * 3  * 11  * 14 
Primary * 23  97.4 71  98.2 94 
Secondary 100.0 51  98.9 78  99.4 129 
More than secondary * 8  * 14  * 22 
Wealth quintile         
Lowest * 7  * 15  * 22 
Second * 14  * 20  (100.0) 34 
Middle * 14  (97.3) 35  (98.3) 49 
Fourth  (100.0) 29  96.9 57  98.1 86 
Highest * 21  (98.7) 46  99.2 67 
Age         
15-19 * 0  * 5  * 5 
20-24 * 2  * 20  * 22 
25-29 * 9  (98.5) 38  (98.8) 47 
30-34 * 9  (97.3) 32  (98.0) 41 
35-39 * 18  (97.1) 31  (98.4) 49 
40-44 * 24  * 22  (100.0) 46 
45-49 * 15  * 17  (100.0) 32 
50-54 * 6  * 5  * 11 
55-59 * 2  * 4  * 6 
Total 15-24 * 2  (96.5) 25  (97.0) 27 
Total 15-49 100.0 77  98.0 165  98.8 242 
Total 15-59 100.0 85  98.1 174  98.9 259 
1Relates to Global AIDS Monitoring indicator 1.3: Retention on antiretroviral therapy at 12 months; 2Antiretroviral (ARV) detection assay included only atazanavir, 
efavirenz, and lopinavir. Participants who reported antiretroviral therapy use and/or had undetectable viral load but had no evidence of the first three ARVs were 
tested for nevirapine as well. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution; an asterisk indicates that an estimate is 
based on a very small number (less than 25) of unweighted cases and has been suppressed. The sum of the sample sizes for a given classification may be less than the 
total sample size because of missing responses to the classification variable 
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Table 11.5.B Retention on antiretroviral therapy (ART): People initiating antiretroviral therapy more than 12 months prior to the survey 
Among HIV-positive persons aged 15-59 years who self-reported initiating ART 12 months or more prior to the survey, percentage who self-reported 
still receiving ART, by sex and selected demographic characteristics, ZAMPHIA 2016 
 Males  Females  Total 
Characteristic 
Percentage 
still receiving ART1 
Number 
 
Percentage 
still receiving ART1 
Number  
Percentage 
still receiving ART1 
Number 
Presence of detectable ARVs2         
   Detectable 99.7 308  100.0 771  99.9 1,079 
   Not detectable * 12  67.1 59  67.8 71 
Residence         
Urban 99.4 182  97.1 523  97.9 705 
Rural 97.6 144  98.3 314  98.1 458 
Province         
Central (87.1) 25  98.6 81  95.4 106 
Copperbelt 100.0 58  98.3 177  98.8 235 
Eastern (100.0) 31  96.9 63  98.0 94 
Luapula * 8  (95.1) 33  (96.2) 41 
Lusaka 99.2 90  97.6 208  98.3 298 
Muchinga * 9  (96.5) 37  (97.3) 46 
Northern * 17  (96.3) 37  97.6 54 
North-Western * 13  (97.8) 43  98.5 56 
Southern 100.0 55  98.3 111  98.9 166 
Western * 20  (95.4) 47  97.0 67 
Marital status         
Never married * 19  98.4 71  98.9 90 
Married or living together 99.1 263  97.3 469  98.1 732 
Divorced or separated (100.0) 25  97.0 142  97.6 167 
Widowed * 18  98.3 154  97.1 172 
Education         
No education * 9  (89.6) 48  89.0 57 
Primary 100.0 106  99.2 384  99.4 490 
Secondary 98.0 157  96.9 342  97.3 499 
More than secondary 100.0 54  98.0 63  99.1 117 
Wealth quintile         
Lowest (100) 26  97.3 70  98.1 96 
Second (95.1) 46  96.8 91  96.1 137 
Middle 97.7 63  99.2 178  98.8 241 
Fourth  98.8 71  94.5 219  95.8 290 
Highest 100.0 116  99.2 274  99.5 390 
Age         
15-19 * 6  * 10  * 16 
20-24 * 6  (91.5) 42  (93.2) 48 
25-29 * 6  97.6 83  96.1 89 
30-34 * 22  94.3 143  94.5 165 
35-39 (100.0) 36  97.7 161  98.3 197 
40-44 100.0 75  99.4 190  99.6 265 
45-49 98.7 73  100.0 90  99.3 163 
50-54 98.5 67  98.6 74  98.6 141 
55-59 (100.0) 35  (100.0) 44  100.0 79 
Total 15-24 * 12  93.3 52  95.0 64 
Total 15-49 98.5 224  97.3 719  97.7 943 
Total 15-59 98.7 326  97.6 837  97.9 1,163 
1Relates to Global AIDS Monitoring indicator 1.3: Retention on antiretroviral therapy at 12 months; 2Antiretroviral detection assay included only 
atazanavir, efavirenz, and lopinavir. Participants who reported antiretroviral therapy use and/or had undetectable viral load but had no evidence of 
the first three ARVs were tested for nevirapine as well. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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11.6 Transmitted Resistance to Antiretroviral Therapy 
As indicated in section 1.3 the objective of ZAMPHIA was to estimate the prevalence of resistance to 
ARVs, using samples from HIV-positive participants who were identified as recent HIV infections using 
the Recent Infection Testing Algorithm (Figure 2.5.A). 
 
Among 38 successfully amplified samples from recently infected HIV-positive adults identified in 
ZAMPHIA, four (10.5%) had evidence of resistance to ARVs. Three had mutations associated with 
resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) only, one had mutations 
associated with resistance to nucleoside reverse transcriptase inhibitors (NRTI) only (Table 11.6.A).  
 
Table 11.6.A Resistance to antiretrovirals  
Among persons aged 15-59 years who were recently infected with HIV, percentage with resistance to antiretrovirals, 
by class of ARV, ZAMPHIA 2016 
  Percent Number DR Mutations Detected1 
Successfully amplified2 (92.7) 38  
Any * 4 G190A, K103N, K65KR  
NRTI * 1 K65KR 
NNRTI * 3 G190A,K103N 
PI * 0  
NRTI & NNRTI * 0  
NRTI, NNRTI & PI * 0  
1Based on Stanford Database for HIV Drug Resistance Mutation. https://hivdb.stanford.edu/assets/media/resistance-mutation-handout-
Dec2017.b8f72e32.pdf  
2Unweighted figures, from a total of 38 cases. 
NRTI: Nucleoside Reverse Transcriptase Inhibitors; NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitors; PI: Protease inhibitor 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
* Commonly used ARVs by class include: NNRTIs nevirapine (NVP) and efavirenz (EFV); NRTIs tenofovir (TDF), lamivudine (3TC), zidovudine (AZT), 
emtricitabine (FTC) and PIs lopinavir/ritonavir (LPV/r) and atazanavir (ATV). 
 
Table 11.6.B shows the distribution of HIV-subtypes among HIV-positive adults who underwent HIV 
genotyping. Of the 141 adults living with HIV who underwent HIV genotyping, 135 (95.7% were infected 
with subtype C; 5 were infected with a recombinant subtype; 1 was infected with subtype A. No one 
sampled presented with subtypes B, D, or G. 
 
Table 11.6.B HIV Subtype 
Percent distribution of HIV-positive persons age 15-59 years that that 
underwent genotyping, by HIV Subtype, ZAMPHIA 2016 
  Total 
  Percent Number 
Subtype A * 1 
Subtype B 0 0 
Subtype C 95.7 135 
Subtype D 0 0 
Subtype G 0 0 
Recombinant * 5 
   
Total 100.0 141 
Unweighted figures     
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11.7 Viral Load Suppression and Severe Immunosuppression  
Among HIV-positive adults aged 15-59 years, those who reported ART use had high levels of VLS 
irrespective of the reported duration of therapy, however, with very different percentages of VLS among 
those who reported ART use versus those who were not on ART; 90.5% VLS for those on ART for 12 
months or more, 84.7% among those on ART for less than 12 months and 19.1% VLS for those not on 
ART. In contrast, the prevalence of severe immunosuppression (CD4 count less than 200 cells/μL) was 
quite similar for those on 12 months or less of ART use (16.9%) and those who self-reported not using 
ART (17.5%) as compared to adults on 12 months or more of ART use (10.2%) (Table 11.7.A).  
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Table 11.7.A Viral load suppression and severe immunosuppression 
Among HIV-positive persons aged 15-59 years, percentage with viral load suppression (< 1,000 copies/mL) and percentage with severe immunosuppression (CD4 count < 200 cells/μL) by self-
reported antiretroviral therapy (ART) status, by selected demographic characteristics, ZAMPHIA 2016 15-59 years, percentage with viral load suppression (< 1,000 copies/mL) and percentage with 
severe immunosuppression (CD4 count < 200 cells/μL) by ART status, by selected demographic characteristics, ZAMPHIA 2016 
 
On ART ≥ 12 months On ART < 12 months Not on ART   On ART ≥ 12 months On ART < 12 months Not on ART   
Characteristic With viral 
load 
suppression 
Number With viral 
load 
suppression 
Number With viral 
load 
suppression 
Number Total1 With 
severe 
immuno-
suppression 
Number With 
severe 
immuno-
suppression 
Number With 
severe 
immuno-
suppression 
Number Total2 
Sex 
              
Male 90.9  316  78.0  82  20.1  342   740  14.4  320  27.3  85  23.4  342   747  
Female 90.3  806  89.0  167  18.5  655  1,628  7.9  817  10.1  169  13.7  667  1,653                 
Residence 
              
Urban 89.2  681  86.7  150  20.4  532  1,363  11.0  690  13.8  152  16.4  535  1,377  
Rural 92.6  441  81.5  99  17.7  465  1,005  8.7  447  21.8  102  18.7  474  1,023                 
Age 
              
15–24 74.2  58  (61.6)  26  16.2  192   276  16.5  60  (7.7)  25  6.2  189   274  
25–59 91.5  1,064  87.4  223  19.9  805  2,092  9.7  1,077  17.9  229  20.3  820  2,126                 
Total 15–59 90.5  1,122  84.7  249  19.1  997  2,368  10.2  1,137  16.9  254  17.5  1,009  2,400  
1 Number of HIV+ who had viral load values. 
2 Number of HIV+ who had CD4 values. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
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11.8 Gaps and Unmet Needs 
 
11.9 References 
1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection. Geneva: World Health Organization; 2016. 
Http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed December 17, 2018. 
 
  
• Late diagnosis, or CD4 counts less than 350 cells/μL among adults at the time of HIV diagnosis, is 
common (45.5%) particularly among HIV-positive people aged 30-49 years. In order to achieve 
epidemic control, there is a need to reach this high-risk population of undiagnosed people living 
with HIV. 
• In light of the findings of high prevalence of late diagnosis, especially among men, several 
policies and guidelines are in place to address this gap in HIV diagnosis and treatment.  
o The National ART Guidelines (2018) promotes the use of index testing and other modalities 
to improve early case identification. The guidelines also present guidance on enhanced 
screening and the use of prophylaxis for opportunistic infections among patients presenting 
with severe immunosuppression defined as CD4 count <100 cells/µl. This is a response to late 
diagnosis. 
o In 2017, the Government of the Republic of Zambia implemented universal routine provider-
initiated testing during all patient interactions with the healthcare system. A remaining gap is 
the measurement of HIV-associated mortality, particularly as it relates to late diagnosis and 
non-adherence to treatment regimens.  
• Upcoming drug resistance studies will shed more light on primary and secondary drug 
resistance in the country. 
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12.1 Key Findings 
 
 
12.2 Background 
Pregnant women living with HIV are at high risk of transmitting HIV to their infants during pregnancy, 
during labor and delivery, or through breastfeeding. Over 90% of new infections among infants and 
young children occur through mother-to-child transmission. Without any interventions, between 20% 
and 45% of infants may become infected, with an estimated risk of 5-10% during pregnancy, 10-20% 
during labor and delivery, and 5-20% through breastfeeding.1 In 2010, global targets were set to 
decrease new HIV infections in children and reduce mortality among mothers living with HIV, including a 
90% reduction in child HIV infections, a 50% reduction in AIDS-related maternal deaths, and virtual 
elimination of mother-to-child transmission.2 
 
To prevent MTCT, the United Nations recommends a comprehensive four-pronged approach including: 
(1) primary prevention of HIV infection among women of childbearing age; (2) preventing unintended 
pregnancies among women living with HIV; (3) preventing HIV transmission from women living with HIV 
to their infants; and (4) providing appropriate treatment, care, and support to mothers living with HIV 
and their children and families.2 
 
This chapter describes ANC attendance, breastfeeding practices, awareness of a woman’s HIV status 
prior to or during pregnancy, use of ART during pregnancy in women who were aware of their HIV-
positive status during pregnancy, and infant HIV testing to confirm HIV infection though self-report by 
the mother and through biomarker testing during the survey. 
 
12.3 Antenatal Care Attendance 
Almost all (99.0%) women aged 15-49 years who delivered in the three years preceding the survey, 
attended at least one ANC visit for their most recent birth. Attending at least one ANC visit is almost 
universal, regardless of urban/rural residence, province, marital status, education, and age (Table 12.3.A 
Antenatal care). 
 
  
12 PREVENTION OF MOTHER-TO-CHILD TRANSMISSION 
▪ In Zambia, 99.0% of women aged 15-49 years who delivered in the three years preceding the 
survey, attended at least one ANC visit for their most recent birth. 
▪ Prevention of mother-to-child transmission: Among women aged 15-49 years who delivered in the 
12 months preceding the survey, 93.1% knew their HIV status; while 98.9% of HIV-positive women 
who gave birth in the 12 months preceding the survey received ARVs.  
▪ Among infants born in the previous 17 months to HIV-positive mothers who reported ever 
breastfeeding, 9.3% were confirmed to be HIV positive. 
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Table 12.3.A  Antenatal care 
Among women aged 15-49 years who delivered in the three years preceding the survey, percentage who attended at least one antenatal 
care visit for her most recent birth, by selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Percentage who attended at least one 
antenatal visit 
Number 
Residence   
Urban 99.5 1,540 
Rural 98.8 2,624 
   
Province   
Central 98.9 350 
Copperbelt 99.1 641 
Eastern 99.3 401 
Luapula 98.3 262 
Lusaka 99.4 589 
Muchinga 97.2 462 
Northern 99.7 368 
North-Western 99.8 389 
Southern 99.6 458 
Western 98.0 244 
   
Marital status   
Never married 98.9 512 
Married or living together 99.1 3,260 
Divorced or separated 98.4 314 
Widowed 98.5 69 
   
Education   
No education 97.8 296 
Primary 98.7 2,153 
Secondary 99.6 1,505 
More than secondary 100.0 209 
   
Wealth quintile   
Lowest 98.0 879 
Second 98.8 910 
Middle 99.5 857 
Fourth 99.5 834 
Highest 99.4 668 
   
Age   
15-19 99.2 439 
20-24 99.3 1,152 
25-29 99.1 976 
30-34 98.6 808 
35-39 98.9 508 
40-44 98.9 234 
45-49 (100.0) 47 
   
Total 15-24 99.2 1,591 
Total 15-49 99.0 4,164 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
12.4 Breastfeeding 
More than half (59.0%) of women aged 15-49 years who gave birth during the three years preceding the 
survey were breastfeeding their last-born child at the time of the survey. Over 90% were currently 
breastfeeding their last-born children younger than the age of 12 months. Current breastfeeding 
decreased to 81.6% among last born children aged 12-17 months and to 32.9% among last-born children 
aged 18-23 months. Among last-born children over 2 years of age (24-36 months), only 6.2% were 
currently breastfed.   
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For children last-born to women aged 15-49 years in the three years preceding the survey, less than half 
(44.9%) of HIV-positive women were breastfeeding at the time of the survey, compared to 60.2% of HIV-
negative women. Among HIV-positive women, 5.5% had never breastfed their last-born child, as 
compared to 0.6% of HIV-negative women (Table 12.4.A). 
 
Table 12.4.A Breastfeeding status by child's age and mother's HIV status 
Percent distribution of last-born children born to women aged 15-49 years in the three years preceding the survey by 
breastfeeding status, by child's age and mother's HIV status, ZAMPHIA 2016 
Characteristic Never breastfed 
Ever breastfed, but not 
currently breastfeeding 
Currently breast-
feeding 
Total Number 
Child's age (months)      
0-1 0.5 0.0 99.5 100.0 238 
2-3 0.9 0.4 98.7 100.0 265 
4-5 0.4 1.3 98.3 100.0 231 
6-8 0.0 2.9 97.1 100.0 418 
9-11 1.6 4.0 94.3 100.0 401 
12-17 1.2 16.0 82.8 100.0 725 
18-23 1.4 65.2 33.3 100.0 719 
24-36 1.5 92.2 6.3 100.0 1,091 
      
Result of mother's PHIA 
survey HIV test 
     
HIV positive 5.7 47.9 47.9 100.0 405 
HIV negative 0.6 38.6 38.6 100.0 3,306 
Not tested 0.5 34.0 34.0 100.0 398 
      
Total 1.1 39.1 59.8 100.0 4,109 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable.  
 
12.5 Awareness of Mother’s HIV Status 
Among women aged 15-49 years who gave birth during the 12 months preceding the survey, 93.1% 
reported that they knew their HIV status (98.6% in urban areas and 89.9% in rural areas). 
 
In urban areas, 8.5% of women who delivered within the past 12 months already knew that they were 
HIV positive when they were offered an HIV test in ANC, and 2.5% tested positive during ANC (87.6% 
tested negative). In contrast, in rural areas, 2.6% already knew that they were HIV positive and 1.8% 
tested positive during ANC (85.5% tested negative). A higher percentage of women over the age of 30 
years already knew that they were HIV positive (11.4% among ages 35-39 years and 8.0% among ages 
40-44-years), compared to women in younger age groups (0.4% among ages 15-19 years and 4.9% 
among ages 25-29 years).There was geographical variation in the proportion of women who knew their 
HIV status, ranging from 83.5% in Luapula to 97.9% in Central and Lusaka Provinces among women aged 
15-49 years who delivered within the 12 months preceding the survey (Table 12.5.A).  
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Table 12.5.A  Prevention of mother-to-child transmission, known HIV status 
Among women aged 15-49 years who gave birth within the past 12 months, percentage who were tested for HIV during antenatal care and 
received their results or who already knew they were HIV positive, by selected demographic characteristics, ZAMPHIA 2016 
  Tested for HIV and received result1 
   
Characteristic 
Percentage who 
tested HIV 
positive 
Percentage who 
tested HIV 
negative 
Percentage who 
already knew 
they were HIV 
positive 
Total 
percentage with 
known HIV 
status 
Number of women who 
delivered within the 
past 12 months 
Residence      
Urban 2.5 87.6 8.5 98.6 560 
Rural 1.8 85.5 2.6 89.9 998 
Province      
Central 1.3 90.5 6.2 97.9 138 
Copperbelt 2.7 86.4 8.0 97.1 232 
Eastern 2.0 93.5 2.3 97.7 165 
Luapula 0.8 81.1 1.5 83.5 107 
Lusaka 3.0 87.3 7.6 97.9 210 
Muchinga 0.8 81.5 1.7 84.0 161 
Northern 0.6 82.4 3.7 86.7 157 
North-Western 1.2 84.3 2.1 87.6 135 
Southern 4.3 86.9 5.4 96.5 175 
Western 2.6 81.4 2.9 86.9 78 
Marital status      
Never married 1.8 86.9 2.3 91.0 210 
Married or living together 2.1 87.1 4.3 93.5 1,233 
Divorced or separated 1.5 80.0 9.9 91.4 90 
Widowed * * * * 20 
Education      
No education 2.0 80.4 4.9 87.2 98 
Primary 1.5 86.0 3.2 90.7 793 
Secondary 3.2 87.6 5.7 96.5 580 
More than secondary 0.0 88.2 11.8 100.0 86 
Wealth quintile      
Lowest 1.4 84.0 1.4 86.9 344 
Second 1.6 85.1 2.2 88.9 349 
Middle 1.9 85.9 6.7 94.4 321 
Fourth 4.4 86.9 6.8 98.1 281 
Highest 1.6 90.5 7.6 99.7 258 
Age      
15-19 0.5 83.9 0.4 84.8 216 
20-24 1.6 89.0 3.3 94.0 475 
25-29 2.9 86.3 4.9 94.2 325 
30-34 3.7 85.9 6.2 95.7 286 
35-39 1.0 83.3 11.4 95.7 173 
40-44 3.9 82.8 8.0 94.8 73 
45-49 * * * * 10 
Total 15-24 1.2 87.3 2.4 90.9 691 
Total 15-49 2.1 86.3 4.7 93.1 1,558 
1Relates to PEPFAR PMTCT_STAT_NAT / SUBNAT. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
12.6 Antiretroviral Therapy among HIV-Positive Pregnant Women 
Among HIV-positive women aged 15-49 years who delivered in the 12 months preceding the survey, 
98.9% reported receiving ARVs (55.8% were already taking ARVS at the time of their first ANC visit, while 
43.1% were newly initiated on ARVs during pregnancy or labor and delivery). ARV use varied between 
rural and urban areas among HIV-positive women aged 15-49 years who delivered in the 12 months 
preceding the survey; 64.3% of women in urban areas were already taking ARVs at their first ANC visit, 
as compared to 43.2% of women in rural areas. Further, 35.7% of women in urban areas were newly 
initiated on ART during pregnancy or labor and delivery as compared to 54.0% of women in rural areas 
(Table 12.6.A).  
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Table 12.6.A  Prevention of mother-to-child transmission: HIV-positive pregnant women who received antiretrovirals (ARVs) 
Among HIV-positive women aged 15-49 years who gave birth within the past 12 months, percentage who received antiretrovirals during 
pregnancy to reduce the risk of mother-to-child transmission, by selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Percentage who 
were already on 
ARVs prior to 
pregnancy 
Percentage who were newly 
initiated on ARVs during 
pregnancy or labor and 
delivery 
Total percentage 
who received 
ARVs1 
Number of HIV-positive 
women who gave birth 
within the past 12 months 
Residence     
Urban 64.3 35.7 100.0 66 
Rural (43.2) (54.0) (97.3) 41 
Province     
Central * * * 10 
Copperbelt (67.6) (32.4) (100.0) 25 
Eastern * * * 7 
Luapula * * * 3 
Lusaka (59.2) (36.1) (95.3) 25 
Muchinga * * * 4 
Northern * * * 7 
North-Western * * * 5 
Southern * * * 17 
Western * * * 4 
Marital status     
Never married * * * 9 
Married or living together 52.9 45.6 98.5 78 
Divorced or separated * * * 11 
Widowed * * * 9 
Education     
No education * * * 6 
Primary (48.1) (48.8) (96.9) 39 
Secondary 56.7 43.3 100.0 53 
More than secondary * * * 9 
Wealth Quintile     
Lowest * * * 9 
Second * * * 12 
Middle (60.5) (39.5) (100.0) 28 
Fourth (51.2) (45.0) (96.2) 32 
Highest (66.9) (33.1) (100.0) 25 
Age     
15-19 * * * 2 
20-24 * * * 22 
25-29 (44.8) (55.2) (100.0) 25 
30-34 (54.8) (45.2) (100.0) 29 
35-39 * * * 21 
40-44 * * * 8 
45-49 * * * 0 
Total 15-24 * * * 24 
Total 15-49 55.8 43.1 98.9 107 
1Relates to Global AIDS Monitoring indicator 2.3: Preventing the mother-to- child transmission of HIV and PMTCT_ARV_NAT / SUBNAT.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
12.7 Early Infant Diagnosis 
Among infants born in the three years preceding the survey to women 15-49 years who self-reported 
being HIV positive during the corresponding pregnancy (diagnosed before or at any time during it), by 
HIV-positive women aged 15-49 years, more than half (58.4%) of them were tested for HIV within two 
months of birth, while 25.6% were tested between two to 12 months of birth (Table 12.7.A). 
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Table 12.7.A  Prevention of mother-to-child transmission, early infant testing 
Among HIV-positive women aged 15-49 years who delivered within the past 36 months, percentage whose last-born 
infant had an HIV test done within 2 months of birth and within 12 months of birth, by result of HIV test, ZAMPHIA 
2016 
Characteristic 
Percentage of infants 
who had an HIV test 
done within 2 months of 
birth1 
Percentage of infants who 
had an HIV test done 
between 2 to 12 months of 
birth2,3 
Number of last-born 
infants of HIV-positive 
women who delivered 
within the past 36 
months 
Result of infant's HIV test    
HIV positive * * 9 
HIV negative 66.2 32.4 183 
Don't know/other (78.7) (19.4) 49 
    
Total 58.4 25.6 284 
1Relates to Global AIDS Monitoring indicator 2.1: Early infant diagnosis and PEPFAR PMTCT_EID; 2Relates to PEPFAR PMTCT_EID; 3Includes only 
last-born infants. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
 
12.8 Mother-to-Child Transmission 
Among all infants born 17 months preceding the survey to HIV-positive mothers aged 15-49, 7.7% were 
confirmed through the survey to be HIV positive regardless of breastfeeding status. Among infants born 
in the previous 17 months to HIV-positive mothers who reported ever breastfeeding, 9.3% were 
confirmed to be HIV positive (Table 12.8.A).  
 
Table 12.8.A  Mother-to-child transmission of HIV 
Among infants born in the last 17 months to HIV-positive women aged 15-49 years, percentage confirmed positive for HIV 
infection, by mother's self-reported antiretroviral therapy (ART) and breastfeeding status ZAMPHIA 2016 
Characteristic 
Percentage of infants 
confirmed HIV positive1 
Number of infants born to 
HIV-positive women2 
Mother's self-reported ART status   
Mother unaware of HIV status during pregnancy * 10 
Already on ART at first antenatal visit (3.4) 25 
Newly initiated on ART during pregnancy or labor and delivery * 20 
Did not receive ARTs during pregnancy * 3 
Missing self-reported ART status during pregnancy * 16 
 
  
Mother's self-reported breastfeeding status   
Ever breastfed the infant 9.3 63 
Never breastfed the infant * 2 
Missing breastfeeding status * 9 
 
  
Total 0-11 months (7.5) 47 
Total 0-17 months 7.7 74 
1Relates to Global AIDS Monitoring indicator 2.2: Mother-to-child transmission of HIV; 2Includes only infants who were tested for HIV during the PHIA survey. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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12.9 Gaps and Unmet Needs 
 
12.10 References 
1. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-
poor countries: Translating research into policy and practice. JAMA, 2000, 283:1175–1182. 
doi:10.1001/jama.283.9.1175. 
 
2. World Health Organization. Towards the elimination of mother-to-child transmission of HIV: Report of 
a WHO technical consultation. Geneva: World Health Organization; 2011. 
Http://apps.who.int/iris/bitstream/handle/10665/44638/9789241501910_eng.pdf;jsessionid=CD35DAE
3C3D00349A9B149BCFF9262C4?sequence=1 Accessed December 17, 2018. 
 
  
▪ According to self-report from mothers, nearly half of infants born to HIV-positive women did not 
receive a virological test for HIV infection in the first two months of life. It is essential to ensure 
early testing of HIV-exposed children and the return of results to parents. Further studies are 
necessary to pinpoint the reasons for this gap and guide interventions to improve early infant 
diagnosis. 
▪ Despite large scale roll-out of PMTCT, about one in 13 children born to HIV-positive mothers 
(tested by ZAMPHIA) were still found to be HIV positive, indicating that diagnosis, treatment 
initiation, and treatment monitoring among pregnant women all require further improvement. 
▪ Further progress is needed to put Zambia on the path to elimination of MTCT. 
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13.1 Key Findings 
 
13.2 Background 
One-third of the population of sub-Saharan Africa is between the ages of 10-24 years.1 Adolescents and 
young adults, ages 15-24 years, are more likely to engage in risky sexual behaviors than older adults and 
have less frequent contact with the healthcare system.1 Control of HIV in this demographic is critical for 
long-term epidemic control, but is also particularly challenging.  
 
This chapter presents the prevalence of early sexual debut before the age of 15 years among men and 
women, by marital status, province, socio-economic, and demographic characteristics. Knowledge of HIV 
prevention among men and women aged 15-24 years is described. Incidence, prevalence, and the 90-
90-90 cascade are also described for those aged 15-24 years. 
 
13.3 Sex Before the Age of 15 Years 
Among persons aged 15-24 years, nearly twice the proportion of males (17.1%) compared to females 
(9.5%) reported having sexual intercourse before the age of 15 years. Sexual debut before the age of 15 
years among those aged 15-24 years was also twice as high in rural areas (17.3%) compared to urban 
areas (8.6%). Geographically, early sexual debut ranged from 7.4% in Copperbelt Province to 29.4% in 
North-Western Province. The percentage who reported early sexual debut was 17.9% among those with 
only primary education compared to 4.1% among those with more than a secondary education (Table 
13.3.A). 
 
  
13 ADOLESCENTS AND YOUNG ADULTS 
▪ Nearly twice the proportion of males (17.1%) as compared to females (9.5%) aged 15-24 years 
reported having sexual intercourse before the age of 15 years.  
▪ The percentage of young people, aged 15-24 years, who had sex before the age of 15 years, was 
nearly twice as high in rural areas (17.3%) compared to urban areas (8.6%). 
▪ Less than half of people aged 15-24 years in both urban (46.7%) and rural (32.4%) areas had 
comprehensive knowledge on HIV transmission and prevention. 
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Table 13.3.A  Sex before the age of 15 years 
Percentage of males and females age 15–24 years who have had sexual intercourse before the age of 15; by sex and selected 
demographic characteristics, ZAMPHIA 2016 
 Males  Females  Total 
Characteristic 
Percentage 
who had sex 
before age 15 
Number  
Percentage 
who had sex 
before age 15 
Number  
Percentage who 
had sex before 
age 15 
Number 
Residence         
Urban 11.7 1,469  5.8 2,150  8.6 3,619 
Rural 21.7 1,938  12.9 2,313  17.3 4,251 
Province         
Central 16.3 297  8.0 360  12.3 657 
Copperbelt 10.9 578  4.1 799  7.4 1,377 
Eastern 22.5 306  13.2 378  17.8 684 
Luapula 26.2 177  10.9 248  18.1 425 
Lusaka 11.5 575  5.2 857  8.3 1,432 
Muchinga 14.2 309  8.3 353  11.4 662 
Northern 10.9 287  10.4 357  10.6 644 
North-Western 38.1 339  20.5 416  29.4 755 
Southern 16.5 398  12.0 501  14.2 899 
Western 34.1 141  20.7 194  26.8 335 
Marital status         
Never married 17.1 2,973  7.3 2,705  13.0 5,678 
Married or living together 17.6 347  12.9 1,503  14.0 1,850 
Divorced or separated (11.2) 40  14.9 191  14.1 231 
Widowed * 0  * 9  * 9 
Education         
No education 10.5 52  11.5 149  11.2 201 
Primary 21.8 1,165  14.4 1,578  17.9 2,743 
Secondary 15.5 2,058  6.9 2,556  11.3 4,614 
More than secondary 7.4 130  0.5 179  4.1 309 
Wealth quintile         
Lowest 24.5 488  14.4 655  19.2 1,143 
Second 22.2 626  14.8 753  18.5 1,379 
Middle 18.7 683  10.8 854  14.8 1,537 
Fourth 14.8 735  7.2 1,010  10.9 1,745 
Highest 10.8 860  4.4 1,178  7.6 2,038 
Age         
15-19 19.7 1,962  10.6 2,285  15.2 4,247 
20-24 14.0 1,445  8.2 2,178  11.0 3,623 
Total 15-24 17.1 3,407  9.5 4,463  13.3 7,870 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
13.4 Knowledge about HIV Prevention 
ZAMPHIA collected information on knowledge of HIV prevention, by asking two questions about 
prevention of sexual transmission of HIV and three questions related to common misconceptions about 
contracting HIV. Table 13.4.A and 13.4.B shows knowledge about HIV transmission and prevention 
among males and females, respectively, ages 15-24 years, by selected demographic characteristics. The 
following questions were asked: 
▪ Can the risk of HIV transmission be reduced by having sex with only one uninfected partner who has 
no other partners? 
▪ Can a person reduce the risk of getting HIV by using a condom every time they have sex? 
▪ Can a healthy-looking person have HIV? 
▪ Can a person get HIV from mosquito bites? 
▪ Can a person get HIV by sharing food with someone who is infected? 
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Overall, 41.3% of male and 36.8% female participants responded correctly to all 5 questions. Knowledge 
scores on individual questions among male participants varied, ranging from 68.5% of participants 
responding correctly to the question, “Can a person get HIV from mosquito bites?” to 85.9% responding 
correctly to the question, “Can the risk of HIV transmission be reduced by having sex with only one 
uninfected partner who has no other partners?” Knowledge scores varied among female participants as 
well. Among the female participants, 83.9% responded correctly to the question “Can a person get HIV 
by sharing food with someone who is infected?” as compared to 68.7% of female participants 
responding correctly to the question, “Can a person get HIV from mosquito bites?” Among male 
participants living in urban areas, 50.4% responded correctly to all five questions compared to 33.9% of 
those living in rural areas (Table 13.4.A and Table 13.4.B).  
 
Knowledge about HIV transmission and prevention also varied by education and wealth quintile. Among 
males with no formal education, 15.7% correctly responded to all five questions, in contrast to 75.3% 
among those with more than a secondary education who had correct responses to all five questions. 
Knowledge scores also ranged from 30.7% of those in the lowest wealth quintile responding correctly to 
all questions compared to 57.3% among those in the highest quintile. Similar patterns were observed 
across both genders (Table 13.4.A and Table 13.4.B).  
 
Among males and females aged 15-24 years residing in urban areas, 46.7% correctly responded to all 
five questions in contrast to 32.4% of young people residing in rural areas (Table 13.4.C). 
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Table 13.4.A  Young people, knowledge about HIV prevention: Males1 
Among males aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission of HIV and reject major 
misconceptions about HIV transmission, by selected demographic characteristics, ZAMPHIA 2016 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of HIV 
transmission be 
reduced by having sex 
with only one 
uninfected partner who 
has no other partners? 
Can a person 
reduce the risk 
of getting HIV by 
using a condom 
every time they 
have sex? 
Can a 
healthy-
looking 
person 
have 
HIV? 
Can a 
person get 
HIV from 
mosquito 
bites? 
Can a person 
get HIV by 
sharing food 
with someone 
who is 
infected? 
All five 
questions 
Number2 
Residence        
Urban 89.9 86.4 86.3 75.9 87.9 50.4 757 
Rural 82.6 81.6 77.5 62.5 80.9 33.9 1,021 
Province        
Central 85.1 80.5 88.8 64.5 88.0 42.1 149 
Copperbelt 90.2 86.0 85.7 76.9 84.9 49.5 293 
Eastern 84.5 78.5 79.8 55.6 77.6 30.0 159 
Luapula 89.5 90.4 81.9 66.1 85.3 47.1 94 
Lusaka 89.3 83.7 83.8 72.6 87.9 46.7 281 
Muchinga 85.6 86.7 82.8 69.6 83.7 49.0 171 
Northern 83.0 89.4 79.5 73.2 89.8 41.3 164 
North-Western 80.2 81.9 84.2 63.3 81.4 37.2 181 
Southern 81.1 77.9 71.5 62.9 76.5 30.0 208 
Western 81.5 86.2 69.2 70.9 81.0 29.5 78 
Marital status        
Never married 85.4 83.8 81.1 69.1 83.9 41.7 1,538 
Married or living together 91.6 86.0 83.6 64.0 86.7 39.3 190 
Divorced or separated * * * * * * 23 
Widowed * * * * * * - 
Education        
No education (51.8) (54.9) (61.2) (63.6) (56.7) (15.7) 29 
Primary 80.0 78.5 73.6 54.7 73.9 26.9 622 
Secondary 89.3 86.9 85.8 74.7 89.7 47.8 1,057 
More than secondary 98.1 93.0 91.6 92.7 98.1 75.3 70 
Wealth quintile        
Lowest 82.8 82.4 73.0 61.2 74.5 30.7 276 
Second 80.3 77.0 79.8 59.2 83.1 32.2 324 
Middle 83.3 84.1 79.4 64.9 82.3 34.9 355 
Fourth  89.5 84.9 82.1 70.3 84.0 42.2 383 
Highest 90.2 87.9 88.1 79.8 91.4 57.3 433 
Age        
15-19 82.4 80.7 79.3 67.1 81.3 37.4 995 
20-24 89.9 87.2 83.9 70.1 87.2 45.9 783 
        
Total 15-24 85.9 83.7 81.4 68.5 84.1 41.3 1,778 
1Relates to Global AIDS Monitoring indicator 5.1: Young people: Knowledge about HIV prevention. 2Includes only participants who answered 
all five questions.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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Table 13.4.B  Young people, knowledge about HIV prevention: Females1 
Among females aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission of HIV and reject major 
misconceptions about HIV transmission, by selected demographic characteristics, ZAMPHIA 2016 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of HIV 
transmission be 
reduced by having 
sex with only one 
uninfected partner 
who has no other 
partners? 
Can a person 
reduce the risk 
of getting HIV 
by using a 
condom every 
time they 
have sex? 
Can a 
healthy-
looking 
person have 
HIV? 
Can a 
person get 
HIV from 
mosquito 
bites? 
Can a 
person get 
HIV by 
sharing 
food with 
someone 
who is 
infected? 
All five 
questions 
Number2 
Residence        
Urban 84.0 77.2 85.7 72.6 89.8 43.3 1,100 
Rural 77.7 74.6 75.0 65.1 78.6 30.9 1,218 
Province        
Central 77.0 75.1 80.5 73.5 86.1 37.5 192 
Copperbelt 85.5 78.5 81.2 74.2 90.6 43.8 388 
Eastern 69.0 73.0 82.5 59.6 77.5 29.8 197 
Luapula 82.0 76.8 78.5 68.3 77.7 34.2 137 
Lusaka 83.8 78.3 87.9 69.7 85.8 40.5 425 
Muchinga 78.5 70.3 74.3 68.3 84.1 29.9 189 
Northern 82.3 70.2 76.8 68.0 84.6 34.8 190 
North-Western 83.2 74.7 78.0 71.4 87.5 38.6 218 
Southern 81.2 77.1 74.6 67.8 81.5 36.9 273 
Western 77.1 76.8 70.3 58.3 75.1 26.2 109 
Marital status        
Never married 78.6 74.7 78.2 72.0 86.2 38.4 1,401 
Married or living together 84.3 76.6 82.5 62.4 79.7 33.0 774 
Divorced or separated 87.5 88.3 87.3 69.5 86.1 46.5 101 
Widowed * * * * * * 4 
Education        
No education 77.0 64.5 69.4 57.8 66.6 18.1 100 
Primary 75.8 72.9 72.9 59.2 75.5 26.6 798 
Secondary 83.3 77.7 84.4 74.5 89.8 43.0 1,327 
More than secondary 90.7 89.4 94.1 82.4 96.8 61.4 93 
Wealth quintile        
Lowest 78.6 70.6 75.5 56.7 70.7 27.0 348 
Second 76.0 73.6 72.1 62.7 76.7 29.7 404 
Middle 81.0 77.5 78.4 71.5 87.2 36.5 462 
Fourth  80.4 76.1 82.8 67.8 85.4 35.5 507 
Highest 84.9 78.9 87.5 78.3 92.8 49.1 591 
Age        
15-19 76.2 72.5 75.1 69.3 83.6 33.4 1,212 
20-24 85.8 79.7 85.7 68.0 84.3 40.7 1,106 
Total 15-24 80.7 75.8 80.1 68.7 83.9 36.8 2,318 
1Relates to Global AIDS Monitoring indicator 5.1: Young people: Knowledge about HIV prevention. 2Includes only participants who answered 
all five questions. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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Table 13.4.C  Young people, knowledge about HIV prevention: Total1 
Among males and females aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission of HIV and reject major misconceptions about HIV transmission, by selected demographic 
characteristics, ZAMPHIA 2016 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of HIV transmission be reduced 
by having sex with only one uninfected 
partner who has no other partners? 
Can a person reduce the risk of 
getting HIV by using a condom 
every time they have sex? 
Can a healthy-
looking person 
have HIV? 
Can a person get 
HIV from 
mosquito bites? 
Can a person get HIV by 
sharing food with someone 
who is infected? 
All five 
questions 
Number2 
Residence        
Urban 86.8 81.6 86.0 74.2 88.9 46.7 1,857 
Rural 80.2 78.2 76.2 63.8 79.8 32.4 2,239 
Province        
Central 81.0 77.8 84.6 69.0 87.1 39.8 341 
Copperbelt 87.8 82.2 83.5 75.5 87.8 46.6 681 
Eastern 76.7 75.7 81.2 57.6 77.6 29.9 356 
Luapula 85.5 83.1 80.1 67.3 81.2 40.2 231 
Lusaka 86.5 80.9 85.9 71.2 86.8 43.6 706 
Muchinga 82.4 79.2 78.9 69.0 83.9 40.3 360 
Northern 82.7 80.1 78.2 70.7 87.3 38.2 354 
North-Western 81.7 78.4 81.1 67.3 84.4 37.9 399 
Southern 81.2 77.5 73.1 65.4 79.1 33.5 481 
Western 79.2 81.2 69.8 64.2 77.8 27.7 187 
Marital status        
Never married 82.6 80.0 79.9 70.3 84.8 40.3 2,939 
Married or living together 86.0 78.8 82.8 62.8 81.4 34.5 964 
Divorced or separated 87.5 87.6 88.0 69.2 86.8 47.2 124 
Widowed * * * * * * 4 
Education        
No education 70.8 62.1 67.3 59.3 64.2 17.5 129 
Primary 77.9 75.6 73.2 57.0 74.7 26.8 1,420 
Secondary 86.3 82.4 85.1 74.6 89.7 45.4 2,384 
More than secondary 94.5 91.2 92.9 87.6 97.4 68.5 163 
Wealth quintile        
Lowest 80.6 76.4 74.3 58.9 72.5 28.8 624 
Second 78.1 75.2 75.9 60.9 79.9 31.0 728 
Middle 82.1 80.8 78.9 68.2 84.7 35.7 817 
Fourth  84.9 80.5 82.4 69.0 84.7 38.8 890 
Highest 87.5 83.3 87.8 79.1 92.1 53.2 1,024 
Age        
15-19 79.3 76.6 77.2 68.2 82.5 35.4 2,207 
20-24 87.8 83.4 84.8 69.1 85.8 43.3 1,889 
Total 15-24 83.2 79.7 80.7 68.6 84.0 39.0 4,096 
1Relates to Global AIDS Monitoring indicator 5.1: Young people: Knowledge about HIV prevention. 2Includes only participants who answered all five questions. Estimates in parentheses are based on a small number (25 to 49) 
of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. The sum of the sample sizes for a given classification may be less than the total sample size 
because of missing responses to the classification variable. 
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13.5 HIV Incidence and Prevalence 
Annual HIV incidence among persons aged 15-24 years in Zambia was 0.57% (0.08% among males and 
1.07% among females) (Table 5.3.A). The prevalence of HIV among adults aged 15-24 in Zambia was 
3.8% (5.7% females and 1.8% males) (Table 6.4.A). 
 
13.6 HIV Testing, Treatment, and Viral Load Suppression 
Among those 15-24 years of age, 55.4% had ever been tested and received their result and 32.6% had 
been tested and received their result in the last 12 months (Table 7.3.A).  
 
Among HIV-positive males, 40.6% were aware of their HIV-positive status while 35.3% reported they 
were receiving ART (Table 8.3.A). Among HIV-positive females aged 15-24 years, 40.1% were aware of 
their HIV-positive status, while 31.2% reported they were receiving ART (Table 8.3.B). Among people 
living with HIV aged 15-24 years in Zambia, the prevalence of VLS was 34.3% (Table 9.4.A). 
 
13.7 Status of the UNAIDS 90-90-90 Targets 
Based on self-report and/or detection of ARVs in blood, it is estimated that 46.0% of people living with 
HIV aged 15-24 years had been diagnosed with HIV (48.3% of males and 45.3% of females), and that 
among those who had been previously diagnosed, 83.3% were on ART and/or had ARVs in their blood. 
Among those on treatment, 72.6% had suppressed viral loads (Table 10.3.A, Figure 13.7.A). 
 
Figure 13.7.A Young adults 90-90-90 (laboratory ARV-adjusted data¥ among young adults aged 15-24 
years), ZAMPHIA 2016 
 
 
                                                      
¥In the antiretroviral (ARV)-adjusted 90-90-90, participants are classified as ‘Aware’ or ‘Diagnosed’ if they self-reported as being 
HIV positive before testing HIV positive in ZAMPHIA and/or had detectable ARVs in their blood. Participants are classified as ‘On 
Treatment’ if they self-reported that they were on treatment and/or if they had detectable ARVs in their blood.  
*Inset numbers are conditional proportions. 
1 Estimates are suppressed due to less than 25 observations.  
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13.8 Gaps and Unmet Needs 
 
13.9 References 
1. Hervish A, Clifton D. The Status Report on Adolescents and Young People in Sub-Saharan Africa: 
Opportunities and Challenges. Johannesburg and Washington, DC: Population Reference Bureau; 2012. 
  
▪ Among adolescents and young adults aged 15-24 years, about six in ten lack correct knowledge 
about HIV transmission and prevention. More complete and accurate knowledge is urgently 
required among this age group so as to increase awareness.  
▪ Nearly three-fifths of those aged 15-24 years living with HIV have not been diagnosed. Among 
those on treatment, more than a quarter do not have VLS, indicating that diagnosis, treatment 
initiation, and treatment monitoring among this group all require further improvement. 
▪ Scale up of interventions to delay sexual debut are planned to reach all schooling levels and 
those out of school. The ZAMPHIA survey results suggest that special attention should be paid to 
North-Western and Western Provinces, as well as rural areas. Some planned interventions aim to 
address cultural values that promote early sexual debut. 
▪ Healthcare providers should be trained to interact with adolescents and young people seeking 
sexual and reproductive health services. 
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14.1 Key Findings 
 
 
14.2 Background 
Estimates of prevalence of HIV in children, estimates of the number of children living with HIV, and VLS 
among HIV-positive children are most commonly derived indirectly from clinic-based data or 
epidemiologic models. ZAMPHIA 2016 provides direct measurements of these estimates among children 
aged 0-14 years, which are critical for meeting the needs of pediatric HIV treatment, planning for HIV 
prevention, care, and treatment services for children, evaluating PMTCT programs and addressing 
specific needs of children aged 10-14 years. 
 
This chapter presents results on the UNAIDS 90-90-90 cascade in children aged 0-14 years, using both 
parent/guardian-reported data (on awareness of child’s HIV status and ARV use) and data on detectable 
ARVs. Analyses for the 90-90-90 tables for children were similar to that described for adults in chapter 
10. Parents or guardians were asked about a child’s HIV infection status and ART use. Children with 
parent/guardian-reported awareness of HIV-positive status should also have ARV and viral suppression 
data. Data on detectable ARVs were used in combination with self-reported ARV use to define 
awareness of HIV-positive status and ARV status of a child. Presence of detectable ARVs in children with 
parent/guardian-reported unawareness of HIV-positive status were reclassified as aware of HIV-positive 
status. Children who had VLS, but whose parents reported them as not diagnosed with HIV or not on 
ARVs (parent/guardian-reported data or based on ARV detection) were not included in the numerator 
for the third 90 (viral suppression among those who are aware of their HIV-positive status and on ARVs). 
 
This chapter also presents results on the nutrition status of HIV-positive and a sub-sample of HIV-
negative children using two indices: Height-for-age and weight-for-age. Stunting, or low height-for-age, 
reflects inadequate nutrition over a long period of time. Children whose height-for-age z score is below 
minus two standard deviations (-2 SD) from the WHO Child Growth Standards median are considered 
stunted or chronically undernourished. Children who are below minus three standard deviations (-3 SD) 
are considered severely stunted.  
 
Underweight, or low weight-for-age captures both inadequate nutrition in the period immediately 
before the survey as well as and long-term undernutrition. Underweight is therefore an indicator of 
overall undernutrition. Children whose weight-for-age z score is below minus two standard deviations (-
2 SD) from the WHO Child Growth Standards median are classified as underweight. Children whose 
weight-for-age z score is below minus three standard deviations (-3 SD) from the WHO Child Growth 
Standards median are considered severely underweight 
 
14 CHILDREN 
▪ The prevalence of HIV among children aged 0-14 years in Zambia was 1.1%. 
▪ Only 50.6% of HIV-positive children aged 0-14 years were previously diagnosed. Of the previously 
diagnosed, 92.3% were on treatment. However, of those on treatment, only 54.3% had 
suppressed viral loads. 
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The means of the z scores are presented as summary statistics representing the nutrition status of all 
children in the population. The farther away the mean z scores are from 0, the higher the prevalence of 
undernutrition. 
 
These indicators are presented for all HIV-positive children and 5% of HIV-negative children based on 
the child’s HIV exposure (mother is HIV negative or mother is HIV positive, unknown or dead) and HIV 
infection status. The HIV status of the mother and child is based on the HIV testing conducted in 
ZAMPHIA. 
 
14.3 HIV Prevalence 
The prevalence of HIV among children aged 0-14 years in Zambia was 1.1%. HIV prevalence among 
females was 1.0% and 1.3% among males. Ages 5-9 years had the highest HIV prevalence at 1.8% (2.2% 
for males, 1.3% and females) (Table 6.4.A). 
 
14.4 Viral Load Suppression 
Among children aged 0-14 years in Zambia, the prevalence of VLS was 33.4% (38.2% for females and 
30.0% for males) (Table 9.4.B). 
 
14.5 Status of the UNAIDS 90-90-90 Targets 
Table 14.5.A shows progress towards the 90-90-90 targets among children living with HIV (CLHIV) aged 
0-14 years, based on parent-reported ART use. Among all children who tested HIV positive in ZAMPHIA 
aged 0-14 years, 47.0% were reported by their parents as HIV positive, 89.6% were reported by their 
parent/guardian as receiving antiretroviral therapy, and 53.1% had suppressed viral loads (Table 14.5.A).  
 
Table 14.5.B shows progress towards the 90-90-90 targets among children living with HIV aged 0-14 
years, based on parent-reported ART use and/or detectable ARVs. Overall, the combined parent-
reported and ARV-adjusted data shows that 50.6% of HIV-positive Zambian children aged 0-14 years 
knew their status. Of children aged 0-14 years, who were previously diagnosed, 92.3% were on 
treatment. Of those on treatment, only 54.3% had suppressed viral loads (Table 14.5.B). 
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Table 14.5.A Pediatric 90-90-90 (parent-reported antiretroviral therapy (ART) data; conditional 
percentages) 
90-90-90 targets among people living with HIV aged 0-14 years, by age ZAMPHIA 2016 
 Diagnosed 
 Total 
Age 
Percentage 
whose parent reported 
 that the child is HIV positive 
Number 
0-17 months * 6 
18-59 months * 16 
0-4 years * 22 
5-9 years (59.1) 47 
10-14 years * 19 
0-14 years 47.0 88 
 
On Treatment  VLS 
Among children whose parent reported that  
the child is HIV positive 
 Among children whose parent reported 
that the child is on ART 
Percentage whose parent reported that  
the child is on ART 
Number  
Percentage with 
VLS 
Number 
* 0  * 0 
* 7  * 7 
* 7  * 7 
(86.8) 27  * 24 
* 7  * 6 
(89.6) 41  (53.1) 37 
 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution.  An 
asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 14.5.B  Pediatric 90-90-90 (parent-reported antiretroviral therapy (ART) data and laboratory antiretroviral 
(ARV) data; conditional percentages) 
90-90-90 targets among people living with HIV aged 0-14 years, by age ZAMPHIA 2016 
 Diagnosed 
 Total 
Age 
Percentage 
whose parent reported that the child is 
HIV positive AND/OR with detectable ARVs 
Number 
0-17 months * 6 
18-59 months * 16 
0-4 years * 22 
5-9 years (61.8) 48 
10-14 years * 20 
0-14 years 50.6 90 
 
On Treatment  VLS 
Among children whose parent reported that the child 
is HIV positive AND/OR with detectable ARVs 
 Among children whose parent reported the child was 
on ART AND/OR with detectable ARVs 
Percentage whose parent reported the 
child was on ART AND/OR with detectable 
ARVs 
Number  
Percentage with 
VLS 
Number 
* 0  * 0 
* 7  * 7 
* 7  * 7 
(87.6) 29  (40.4) 26 
* 10  * 10 
(92.3) 46  (54.3) 43 
 
1Relates to Global AIDS Monitoring indicator 1.1: People living with HIV who know their HIV status, and PEPFAR DIAGNOSED_NAT; 2Relates to 
Global AIDS Monitoring indicator 1.2: People living with HIV on Antiretroviral Therapy, and PEPFAR TX_CURR_NAT / SUBNAT; 3Relates to Global 
AIDS Monitoring indicator 1.4: People living with HIV who have suppressed viral loads and PEPFAR VL_SUPPRESSION_NAT 
Figures in parentheses are based on 25 to 49 unweighted cases. An asterisk indicates that a figure is based on fewer than 25 unweighted cases 
and has been suppressed. 
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Figure 14.5.A Pediatric 90-90-90 (laboratory ARV-adjusted data1), ZAMPHIA 2016 
 
 
1 In the antiretroviral (ARV)-adjusted 90-90-90 participants are classified as ‘Aware’ or ‘Diagnosed’ if they 
self-reported as being HIV positive before testing HIV positive in ZAMPHIA and/or had detectable ARVs 
in their blood. Participants are classified as ‘On Treatment’ if they self-reported that they were on 
treatment and/or if they had detectable ARVs in their blood.  
*Inset numbers are conditional proportions. 
 
14.6 Nutrition Status  
Among HIV-unexposed children (i.e., children born to an HIV-negative mother), 17.0% were stunted and 
11.5% were severely stunted. Among HIV-exposed and uninfected children (i.e., HIV-negative children 
born to HIV-positive mothers), 21.4% were stunted and 26.3% were severely stunted (Table 14.6.A). 
 
Among HIV-unexposed children, 5.6% were underweight while 4.9% of HIV-exposed and uninfected 
children were underweight (Table 14.6.A).  
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14.6.A Nutritional status of children aged 0-59 months 
Prevalence of malnourishment among HIV-positive1 and HIV-negative children aged 0-59 months by mother's 
HIV status, according to two anthropometric indices of nutritional status: Height-for-age and weight-for-age2, 
ZAMPHIA 2016 
  Height-for-age 
Mother's HIV Status Child's Status 
Percentage 
below -3 SD 
Percentage 
below -2 SD3 
Mean z score 
(SD) 
Number of 
children 
HIV positive, unknown, dead 
HIV positive * * *  17  
HIV negative (26.3) (21.4) (-1.5)  41  
Total 26.9 20.7 -1.6  58  
HIV negative HIV positive * * *  0  
 HIV negative 11.5 17.0 -1.1  103  
 Total 11.5 17.0 -1.1  103  
 
Weight-for-age 
Percentage 
below -3 SD 
Percentage 
below -2 SD3 
Mean z score 
(SD) 
Number of 
children 
* * *  19  
(0.1) (4.9) (-0.1)  45  
0.6 5.6 -0.2  64  
* * *  0  
0.0 5.6 -0.6  113  
0.0 5.6 -0.6  113  
 
1Child's HIV status as defined by the result of the child's ZAMPHIA HIV test result. 
2Each index is expressed in standard deviation units (SD) from the median of the WHO Child Growth Standards. 
3Includes children who are below -3 standard deviations (SD) from the WHO Child Growth Standards. 
Figures in parentheses are based on 25 to 49 unweighted cases. An asterisk indicates that a figure is based on fewer than 25 unweighted cases and 
has been suppressed. 
 
14.7 Gaps and Unmet Needs 
  
▪ Approximately half of children living with HIV have not been diagnosed. Though widespread 
community HIV testing is not recommended for children, it is critical to identify undiagnosed HIV-
positive children. Targeted community testing (e.g., OVC, index, etc.) could help increase HIV 
diagnosis among children. 
▪ Additionally, just over half of the children who were reported to be on treatment had suppressed 
viral loads, indicating a need for improved adherence, retention, and treatment monitoring. 
More effective cohort tracking (using tracking tools to track each child’s health and 
development) from PMTCT, ensuring availability and supply of preferred pediatric ARV 
formulations, interventions to reduce loss-to-follow-up and promote medication adherence, 
routine VL monitoring, are among the interventions that are needed to promote pediatric 
adherence, retention and treatment.  
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15.1 Key Findings 
 
15.2 Background 
This chapter describes the prevalence of sexual behaviors that elevate risk of HIV infection. ZAMPHIA 
2016 asked questions about high-risk behaviors, including early sexual debut, recent engagement 
(during the last 12 months preceding the survey) in multiple sexual partnerships, condom use at last 
sexual intercourse, recent engagement in paid sexual intercourse, and condom use at last sexual 
intercourse with a non-marital, non-cohabitating partner. With this information, programs can target 
those individuals most in need of information and most at risk for HIV infection. 
 
Since 2007, WHO and UNAIDS have recommended voluntary medical male circumcision (VMMC) as a 
cost-effective strategy to reduce female-to-male sexual transmission of HIV. To inform VMMC programs, 
males aged 15-59 years were asked if they had undergone medical or traditional circumcision. 
 
15.3 HIV Prevalence by Sexual Behavior 
Among participants who reported sexual debut before the age of 15 years, the proportion of those who 
were HIV positive was 11.9%. Of those participants who used condoms at last sexual intercourse in the 
12 months preceding the survey, 15.0% of males and 28.2% of females were HIV positive, as compared 
to 9.7% of men and 12.4% of women who reported they did not use a condom at last sexual intercourse 
(Table 15.3.A). This may reflect uptake of positive prevention strategies. 
 
The prevalence of HIV was 31.9% among females aged 15-59 years who reported having had two or 
more sexual partners in the 12 months preceding the survey, compared to 12.5% among their male 
counterparts. HIV prevalence among males who did not have a sexual partner during the 12 months 
preceding the survey was lower (8.9%) than that of females reporting the same sexual behavior (22.6%), 
while HIV prevalence was estimated at 10.4% among males and 14.2% among females who had one 
partner. HIV prevalence was twice as high among women who reported paid sexual intercourse in the 
previous 12 months (32.2%) as among those who did not (14.7%) (Table 15.3.A). 
 
  
15 HIV RISK FACTORS 
▪ HIV prevalence was twice as high among women who reported paid sexual intercourse in the 
previous 12 months (32.2%) as among those who did not (14.7%). 
▪ Only two in 10 (21.2%) of males aged 15-59 years report having been medically circumcised. 
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Table 15.3.A HIV prevalence by sexual behavior 
Prevalence of  HIV among persons aged 15-59 years, by sex and sexual behavior characteristics, ZAMPHIA 2016 
 Males 
 Females  Total 
Characteristic 
Percentage 
HIV 
positive 
Number  
Percentage 
HIV 
positive 
Number  
Percentage 
HIV 
positive 
Number 
Age at first sexual intercourse         
<15 8.4 1,188  16.8 1,051  11.9 2,239 
15-19 10.3 3,554  15.7 6,209  13.3 9,763 
20-24 11.3 1,313  17.2 1,650  14.2 2,963 
≥25 15.3 474  26.2 286  18.8 760 
         
Number of sexual partners in the past 12 months         
0 8.9 1,409  22.6 1,806  15.6 3,215 
1 10.4 3,925  14.2 7,091  12.6 11,016 
≥2 12.5 1,121  31.9 266  15.6 1,387 
         
Condom use at last sexual intercourse 
in the past 12 months 
        
Used condom 15.0 1,072  28.2 1,125  20.8 2,197 
Did not use condom 9.7 3,967  12.4 6,216  11.2 10,183 
No sexual intercourse in the past 12 months 8.9 1,409  22.6 1,806  15.6 3,215 
         
Paid sexual intercourse in the past 12 months         
Yes1 15.0 365  32.2 74  17.4 439 
Used condom at last paid sexual intercourse 15.0 178  (51.1) 32  19.7 210 
Did not use condom at last paid sexual intercourse 14.5 184  (17.2) 41  14.9 225 
No2 10.3 4,544  14.7 7,200  12.7 11,744 
         
Total 15-24 1.8 3,155  5.7 4,165  3.8 7,320 
Total 15-49 8.3 7,358  14.3 10,010  11.4 17,368 
Total 15-59 9.3 8,142  14.6 10,973  12.0 19,115 
1Includes persons who paid or received money for sexual intercourse. 
2No paid sexual intercourse or no sexual intercourse in the past 12 months 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
 
The prevalence of sexual debut before the age of 15 years among persons aged 15-24 years was higher 
in rural areas (17.3%) than in urban areas (8.6%). By province, the prevalence was highest in North-
Western Province (29.4%) and Western Province (26.8%). The prevalence of sexual debut before age 15 
years was 19.2% in the lowest wealth quintile and 7.6% in the highest wealth quintile (Table 13.3.A). 
 
15.4 Condom Use at Last Sex with a Non-marital, Non-Cohabitating Partner 
Among all persons aged 15-59 years who reported having sex in the past 12 months, 33.8% reported 
having sex with a non-marital, non-cohabitating partner. Among participants aged 15-24 years, 60.5% 
reported having sex with a non-marital, non-cohabitating partner (Table 15.4.C). 
 
Of those who reported having sex in the past 12 months with a non-marital, non-cohabitating partner, 
condom use at last intercourse was reported by 37.6% for those aged 15-59 (Table 15.4.C).  
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Among males aged 15-59 years who reported having had sexual intercourse in the 12 months preceding 
the survey, 42.8% reported having a non-marital, non-cohabitating partner during that time. Of these 
men, 40.4% used a condom during their last sexual intercourse with a non-marital, non-cohabitating 
partner. For this risk group, condom use in urban areas was 45.4%, compared to 35.7% in rural areas. 
Condom use the last time males had sex with a non-marital, non-cohabitating partner during the 12 
months preceding the survey varied geographically, from 29.8% in Western Province to 50.2% in 
Copperbelt Province. More than half (59.7%) of those who had more than secondary education reported 
condom use the last time they had sex with a non-marital, non-cohabitating partner in the past year, as 
compared to 32.1% of those with no education (Table 15.4.A). 
 
Among females aged 15-59 who reported having had sexual intercourse in the 12 months preceding the 
survey, 25.8% reported having a non-marital, non-cohabitating partner during that time. Of these 
women, 33.5% reported using a condom during their last sexual intercourse with such a partner. Similar 
to men, the percentage of condom use at last sex with non-marital, non-cohabitating partners among 
females in this group was higher in urban (39.4%) than in rural areas (27.2%). Condom use among this 
group of females ranged from 15.0% among those with no education to 54.5% among those with more 
than secondary education (Table 15.4.B). 
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Table 15.4.A Condom use at last sex with a non-marital, non-cohabitating partner: Males 
Among males age 15-59 years who reported having sex in the past 12 months, percentage who reported having a non-marital, non-cohabitating partner in 
the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 months, percentage who reported 
using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected demographic characteristics, ZAMPHIA 2016 
 
Among males who reported having sex 
in the past 12 months 
 
Among males who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported having sex with a 
non-marital, non-cohabitating partner in the 
past 12 months 
Number  
Percentage who reported using a condom the 
last time they had sex with a non-marital, non-
cohabitating partner1 
Number 
Residence      
Urban 48.3 2,163  45.4 994 
Rural 38.7 3,457  35.7 1,228 
Province      
Central 36.9 469  35.8 162 
Copperbelt 40.3 903  50.2 342 
Eastern 36.0 550  46.4 189 
Luapula 36.8 289  37.3 104 
Lusaka 54.8 800  43.1 415 
Muchinga 29.6 502  41.8 130 
Northern 33.0 513  35.8 157 
North-Western 48.3 558  31.0 251 
Southern 45.2 722  37.1 306 
Western 55.9 314  29.8 166 
Marital status      
Never married 98.5 1,424  41.8 1,393 
Married or living together 15.9 3,929  37.4 586 
Divorced or separated 90.6 210  35.9 190 
Widowed (91.9) 32  (47.8) 30 
Education      
No education 35.1 176  32.1 57 
Primary 34.0 2,202  26.7 684 
Secondary 49.8 2,592  43.7 1,207 
More than secondary 45.0 648  59.7 273 
Wealth quintile      
Lowest 34.4 936  26.5 300 
Second 34.0 1,141  30.5 362 
Middle 40.8 1,202  41.5 453 
Fourth 48.6 1,152  38.1 524 
Highest 52.2 1,159  52.8 574 
Age      
15-19 96.7 510  34.2 489 
20-24 75.0 903  43.5 654 
25-29 45.8 872  44.9 389 
30-34 29.1 860  41.4 243 
35-39 22.2 721  37.8 154 
40-44 20.4 661  35.8 131 
45-49 20.3 476  38.2 94 
50-54 13.7 348  (40.0) 42 
55-59 9.7 269  (28.6) 26 
Total 15-24 82.3 1,413  39.9 1,143 
Total 15-49 45.9 5,003  40.5 2,154 
Total 15-59 42.8 5,620  40.4 2,222 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Table 15.4.B Condom use at last sex with a non-marital, non-cohabitating partner: Females 
Among females age 15-59 years who reported having sex in the past 12 months, percentage who reported having a non-marital, non-cohabitating partner in 
the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 months, percentage who reported 
using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected demographic characteristics, ZAMPHIA 2016 
 Among females who reported having sex 
in the past 12 months 
 
Among females who reported having sex 
with a non-marital, non-cohabitating partner in the past 12 
months 
Characteristic 
Percentage who reported having sex with a 
non-marital, non-cohabitating partner in 
the past 12 months 
Number  
Percentage who reported using a condom the 
last time they had sex with a non-marital, non-
cohabitating partner1 
Number 
Residence      
Urban 30.2 3,476  39.4 1,016 
Rural 22.3 4,569  27.2 945       
Province      
Central 22.6 691  33.3 148 
Copperbelt 27.2 1,313  38.4 333 
Eastern 21.4 800  30.6 162 
Luapula 22.1 434  19.5 91 
Lusaka 29.8 1,357  41.3 402 
Muchinga 14.8 747  30.9 100 
Northern 18.2 621  24.9 109 
North-Western 32.1 751  25.0 227 
Southern 25.8 923  36.9 224 
Western 43.7 408  27.0 165       
Marital status      
Never married 95.9 1,160  39.4 1,106 
Married or living together 3.1 6,141  19.0 184 
Divorced or separated 90.9 545  25.4 493 
Widowed 88.9 174  30.9 153       
Education      
No education 16.9 533  15.0 82 
Primary 19.0 4,038  21.9 711 
Secondary 34.8 2,895  39.4 964 
More than secondary 35.7 575  54.5 202       
Wealth quintile      
Lowest 23.7 1,303  22.5 278 
Second 20.9 1,518  23.2 297 
Middle 24.1 1,637  27.7 374 
Fourth 26.7 1,777  36.2 461 
Highest 32.1 1,775  46.7 547       
Age      
15-19 63.2 791  37.1 495 
20-24 33.4 1,661  36.5 538 
25-29 21.5 1,446  38.8 303 
30-34 16.1 1,322  23.5 209 
35-39 15.7 1,020  28.5 156 
40-44 18.9 772  26.1 139 
45-49 14.8 433  23.3 61 
50-54 11.4 375  (13.3) 41 
55-59 9.3 225  * 19       
Total 15-24 43.7 2,452  36.8 1,033 
Total 15-49 26.9 7,445  34.0 1,901 
Total 15-59 25.8 8,045  33.5 1,961 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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Table 15.4.C Condom use at last sex with a non-marital, non-cohabitating partner: Total 
Among persons age 15-59 years who reported having sex in the past 12 months, percentage who reported having a non-marital, non-cohabitating 
partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 months, percentage 
who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected demographic characteristics, 
ZAMPHIA 2016 
 Among persons who reported having sex 
in the past 12 months 
 
Among persons who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported having sex with a 
non-marital, non-cohabitating partner in the 
past 12 months 
Number  
Percentage who reported using a condom the 
last time they had sex with a non-marital, non-
cohabitating partner1 
Number 
Residence      
Urban 38.6 5,639  42.9 2,010 
Rural 30.1 8,026  32.4 2,173 
Province      
Central 29.1 1,160  34.8 310 
Copperbelt 33.5 2,216  45.1 675 
Eastern 28.0 1,350  39.8 351 
Luapula 28.8 723  29.9 195 
Lusaka 41.6 2,157  42.4 817 
Muchinga 21.4 1,249  37.6 230 
Northern 25.5 1,134  31.8 266 
North-Western 39.8 1,309  28.5 478 
Southern 35.3 1,645  37.0 530 
Western 49.5 722  28.5 331 
Marital status      
Never married 97.5 2,584  40.9 2,499 
Married or living together 8.8 10,070  33.8 770 
Divorced or separated 90.8 755  28.8 683 
Widowed 89.5 206  34.3 183 
Education      
No education 22.3 709  23.0 139 
Primary 25.0 6,240  24.6 1,395 
Secondary 42.8 5,487  42.1 2,171 
More than secondary 41.2 1,223  57.8 475 
Wealth quintile      
Lowest 28.6 2,239  24.7 578 
Second 27.1 2,659  27.5 659 
Middle 32.0 2,839  36.0 827 
Fourth  37.0 2,929  37.4 985 
Highest 41.6 2,934  50.3 1,121 
Age      
15-19 77.6 1,301  35.6 984 
20-24 51.7 2,564  40.9 1,192 
25-29 32.2 2,318  42.6 692 
30-34 21.8 2,182  34.0 452 
35-39 18.9 1,741  33.8 310 
40-44 19.7 1,433  31.5 270 
45-49 17.9 909  32.9 155 
50-54 12.7 723  29.0 83 
55-59 9.5 494  (23.6) 45 
Total 15-24 60.5 3,865  38.6 2,176 
Total 15-49 35.7 12,448  37.9 4,055 
Total 15-59 33.8 13,665  37.6 4,183 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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15.5 Male Circumcision 
Table 15.5.A provides information about the extent of male circumcision in Zambia, differentiating 
between medical and non-medical circumcision.  
 
Overall, 21.2% of males age 15-59 report having been medically circumcised and an additional 5.9% 
report non-medical circumcision. Medical circumcision varied by age from 28.2% among men 20-24 to 
9.1% among men 55-59. Coverage of circumcision varied by education with 9.9% of those with no 
education reporting medical circumcision compared to 37.8% of those with more than secondary 
education. By wealth quintile, coverage of circumcision also varied with 12.1% of those in the lowest 
wealth quintile reporting medical circumcision compared to 35.3% of those in the highest wealth 
quintile. In urban areas, coverage of male circumcision was higher in urban areas (29.2%) than in rural 
areas (14.6%). By province coverage of male circumcision ranged from 39.0% in the North-Western 
Province to 8.3% in the Eastern Province. By age, coverage of male circumcision is higher in young ages. 
 
  
Table 15.5.A Male circumcision 
Percent distribution of males aged 15-59 years by self-reported circumcision status, by result of PHIA survey HIV test and selected demographic 
characteristics, ZAMPHIA 2016 
 Circumcised1 
Uncircumcised Unknown Total Number 
Characteristic Medical circumcision 
Non-medical 
circumcision 
Result of PHIA survey HIV test       
HIV positive 12.7 4.6 80.9 1.8 100.0 779 
HIV negative 21.9 6.1 70.4 1.6 100.0 7,363 
Not tested 22.7 6.0 69.6 1.6 100.0 1,029 
Residence 
     
 
Urban 29.2 4.5 64.3 2.0 100.0 3,785 
Rural 14.6 7.2 77.0 1.3 100.0 5,386 
Province 
     
 
Central 15.0 2.6 80.8 1.6 100.0 789 
Copperbelt 29.4 5.7 62.7 2.2 100.0 1,565 
Eastern 8.3 0.8 90.0 0.9 100.0 881 
Luapula 16.4 6.2 75.0 2.4 100.0 476 
Lusaka 27.8 3.0 67.0 2.3 100.0 1,440 
Muchinga 12.6 1.2 85.3 0.9 100.0 846 
Northern 10.3 2.1 86.1 1.5 100.0 771 
North-Western 39.0 40.9 19.1 1.0 100.0 867 
Southern 16.2 1.9 80.7 1.1 100.0 1,085 
Western 33.8 20.7 44.6 1.0 100.0 451 
Marital status 
     
 
Never married 28.3 4.9 65.6 1.2 100.0 3,779 
Married or living together 15.2 6.6 76.6 1.7 100.0 4,874 
Divorced or separated 17.4 8.2 71.0 3.3 100.0 378 
Widowed 16.2 15.3 64.3 4.2 100.0 64 
Education 
     
 
No education 9.9 6.4 81.7 2.0 100.0 287 
Primary 12.6 6.6 79.2 1.5 100.0 3,525 
Secondary 24.9 5.7 68.0 1.4 100.0 4,462 
More than secondary 37.8 4.4 55.1 2.7 100.0 887 
Wealth quintile 
     
 
Lowest 12.1 7.5 79.2 1.2 100.0 1,421 
Second 12.3 8.4 77.9 1.5 100.0 1,776 
Middle 14.8 6.0 78.2 1.0 100.0 1,912 
Fourth  24.2 5.1 68.6 2.1 100.0 1,882 
Highest 35.3 4.0 58.6 2.1 100.0 2,136 
 113 
 
 
 
Table 15.5.A Male circumcision (continued) 
Percent distribution of males aged 15-59 years by self-reported circumcision status, by result of PHIA survey HIV test and selected demographic 
characteristics, ZAMPHIA 2016 
 Circumcised1 
Uncircumcised Unknown Total Number 
Characteristic Medical circumcision 
Non-medical 
circumcision 
Age       
15-19 26.3 4.4 68.0 1.3 100.0 2,006 
20-24 28.2 4.9 65.7 1.2 100.0 1,496 
25-29 24.3 6.0 68.2 1.5 100.0 1,209 
30-34 18.7 4.7 74.7 1.9 100.0 1,157 
35-39 16.4 6.2 75.5 1.8 100.0 956 
40-44 13.4 7.6 75.7 3.2 100.0 851 
45-49 11.8 9.5 77.4 1.3 100.0 630 
50-54 10.4 11.4 76.7 1.6 100.0 491 
55-59 9.1 7.6 81.1 2.2 100.0 375 
Total 15-24 27.2 4.6 66.9 1.3 100.0 3,502 
Total 15-49 22.2 5.6 70.6 1.6 100.0 8,305 
Total 15-59 21.2 5.9 71.2 1.6 100.0 9,171  
1Relates to Global AIDS Monitoring indicator 3.16: Prevalence of male circumcision and PEPFAR VMMC_TOTALCIRC NAT / SUBNAT. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
 
15.6 Gaps and Unmet Needs 
 
  
▪ Among sexually active adults aged 15-59, who reported sexual intercourse with a non-marital, 
non-cohabitating partner in the 12 months preceding the survey, nearly two-thirds reported not 
using a condom at last sexual intercourse with such partner. Widespread condom distribution with 
targeted messaging should be scaled up. 
▪ More than seven out of ten men in Zambia reported being uncircumcised. Significant further scale 
up is required to meet programmatic targets of 80% coverage of male circumcision laid out in the 
Country Operational Plan for the Scale-up of VMMC in Zambia. 
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16.1 Background 
Intimate partner violence (IPV) is defined as physical violence, sexual violence, stalking and psychological 
aggression (including coercive tactics) by a current or former intimate partner (i.e., spouse, 
boyfriend/girlfriend, dating partner, or ongoing sexual partner).1 Exposure to IPV has been implicated in 
increased risk of a woman contracting HIV, through mechanisms such as forced sex with an HIV-positive 
partner, an increase in risky sexual behaviors, and reduced ability to negotiate forms of safe sex (e.g., 
condom use).2 Data from ZAMPHIA 2016 will fill gaps in information on subnational prevalence 
estimates and demographic characteristics of women who experienced different forms of IPV. This 
chapter provides data on the nature of violence in this population, which can assist in the development 
of violence prevention programs. 
 
This chapter reports the prevalence of experiencing sexual or physical violence perpetrated by a live-in 
partner in the last 12 months among ever married or partnered women. Here, sexual violence is defined 
as being physically forced or pressured to have sex. Physical violence is defined as being punched, 
kicked, whipped, beaten, slapped, pushed, shoved, choked, smothered, drowned or burned. Having an 
object thrown at you or being hurt or threatened with a knife, gun or other weapon is also physical 
violence. Prevalence numbers are broken down by HIV status and socio-economic and demographic 
characteristics. Violence markers are measured against a woman’s HIV status, as well as demographic 
characteristics. 
 
Violence questionnaires were administered to women aged 15-59 years who have ever been in an 
intimate relationship. Questions were adapted from the Demographic and Health Survey as well as 
Violence Against Children Survey, which measures physical, emotional, and sexual violence in childhood, 
adolescence, and young adulthood (up to the age of 24 years). Women were asked if they had 
experienced physical or sexual violence from a live-in intimate partner in the past 12 months. Women 
reporting violence were offered referral to social services. 
 
16.2 Prevalence of Recent Intimate Partner Violence 
Prevalence of IPV in the last 12 months was reported in similar proportions among HIV-positive (4.4%) 
and HIV-negative women (4.3%). There was also little geographic differentiation in physical or sexual 
violence, with reported levels being similar in urban and rural areas. By age, the prevalence of self-
reported physical or sexual violence in the last 12 months ranged from 7.9% among women aged 15-19 
years to 1.4% among women aged 50-54 years. Experience of physical and sexual violence did not differ 
by education level or wealth quintile (Table 16.2.A).  
 
IPV is likely under-reported in the survey; the finding that 7.0% of respondents aged 15-24 years 
experienced sexual or physical violence in the last 12 months was low compared to previous data on IPV 
in Zambia.   
16 INTIMATE PARTNER VIOLENCE  
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Table 16.2.A  Prevalence of recent intimate partner violence 
Among ever-married or partnered women aged 15-59 years, percentage who experienced physical or sexual violence from a live-in  partner 
in the past 12 months1, by woman's HIV status and selected demographic characteristics, ZAMPHIA 2016 
Characteristic 
Physical 
violence 
Sexual 
violence 
Physical and 
sexual 
violence 
Physical or 
sexual 
violence2 
Number of ever-
married or 
partnered women 
Result of PHIA survey HIV test      
HIV positive 3.9 0.9 0.4 4.4 1,060 
HIV negative 3.6 0.9 0.2 4.3 4,884 
Not tested 1.5 0.6 0.0 2.0 645 
Residence      
Urban 3.5 1.0 0.3 4.2 2,568 
Rural 3.4 0.8 0.2 4.0 4,021 
Province      
Central 3.7 1.2 0.3 4.7 553 
Copperbelt 2.1 0.7 0.2 2.7 991 
Eastern 3.4 1.0 0.3 4.1 764 
Luapula 1.0 0.5 0.0 1.5 381 
Lusaka 3.6 0.5 0.1 4.0 1,015 
Muchinga 3.4 1.4 0.6 4.2 700 
Northern 4.4 1.1 0.0 5.5 585 
North-Western 3.2 2.3 0.5 5.1 549 
Southern 5.1 0.4 0.1 5.3 728 
Western 4.4 0.8 0.8 4.2 323 
Marital status      
Never married * * * * - 
Married or living together 3.6 0.8 0.2 4.2 5,473 
Divorced or separated 3.7 0.9 0.3 4.3 735 
Widowed 1.0 1.6 0.6 2.0 372 
Education      
No education 3.1 1.1 0.6 3.6 567 
Primary 3.2 0.7 0.1 3.8 3,693 
Secondary 4.2 1.0 0.3 4.9 1,986 
More than secondary 2.1 1.8 0.7 3.2 342 
Wealth quintile      
Lowest 3.5 0.6 0.1 3.9 1,321 
Second 3.7 1.0 0.4 4.4 1,406 
Middle 4.0 0.7 0.2 4.5 1,366 
Fourth  3.5 0.3 0.1 3.7 1,380 
Highest 2.4 1.9 0.5 3.9 1,092 
Age      
15-19 5.6 2.4 0.4 7.9 280 
20-24 5.9 1.0 0.2 6.7 1,164 
25-29 4.4 0.9 0.6 4.6 1,260 
30-34 3.3 0.7 0.2 3.9 1,177 
35-39 2.5 0.6 0.0 3.1 909 
40-44 2.1 0.5 0.1 2.5 709 
45-49 1.3 1.4 0.4 2.3 434 
50-54 1.3 0.1 0.0 1.4 388 
55-59 0.4 1.2 0.0 1.6 268 
Total 15-24 5.9 1.3 0.3 7.0 1,444 
Total 15-49 3.7 0.9 0.3 4.4 5,933 
Total 15-59 3.4 0.9 0.2 4.1 6,589 
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Table 16.2.A  Prevalence of recent intimate partner violence (continued) 
1Based on the following variables and questionnaire wording: 
 frcsx12mopt: "In the past 12 months, did a partner physically force you to have sex?" 
 prssx12mopt: "In the past 12 months, did a partner pressure you to have sex and did succeed?" 
 vlnc12moptnr: "In the past 12 months, did a partner do any of these things to you? 
   -Punched, kicked, whipped, or beat you with an object 
   -Slapped you, threw something at you that could hurt you, pushed you or shoved you 
   -Choked smothered, tried to drown you, or burned you intentionally 
   -Used or threatened you with a knife, gun or other weapon?" 
 
All questions include the definition "By partner, I mean a live-in partner, whether or not you were married at the time." 
 
Women who did not answer vlnc12moptnr because they were never a victim of physical violence (vlnc = 0) nor a victim of violence in the 
past 12 months (vlnc12motimes = 0) are included as not having experienced physical violence from a partner in the past 12 months. 
 
Women who did not answer frcsx12mopt and/or prssx12mopt because they were never forced or pressured to have sex (frcsxtimes = 0, 
prssxtimes = 0) and/or were never forced or pressured to have sex in the past 12 months (prssx12mo = 2, frcsx12mo=2) are included as not 
having experienced sexual violence from a partner in the past 12 months. 
2Relates to Global AIDS Monitoring indicator 4.3: Prevalence of recent intimate partner violence. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed.  
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
16.3 Gaps and Unmet Needs 
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▪ While IPV is likely under-reported in face-to-face interviews, 7.0% of women aged 15-24 years 
reported sexual or physical violence by a live-in partner in the last 12 months. Violence 
prevention interventions should target partners of young women while social support services 
should target the affected women themselves. 
▪ Future studies should also address IPV experienced by men. 
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17.1 Key Findings 
 
17.2 Background 
Attitudes toward and perceptions of people living with HIV play an important role in the HIV epidemic. 
Misconceptions about HIV have resulted in people developing numerous false beliefs, such as HIV/AIDS 
always entails death, is associated with depraved and immoral behaviors, results from irresponsibility, 
and is only spread through sex.1 Fears arising from these beliefs can lead to marginalization of particular 
populations, rendering them more vulnerable to HIV. Furthermore, discrimination against HIV/AIDS 
continues to act as a barrier to prevention and treatment, undermining programmatic attempts to help 
people living with HIV, and may even result in the denial of health services.1 
 
This chapter focuses on HIV-related stigma and discrimination. The prevalence of discriminatory 
attitudes among adults aged 15-59 years is reported by province, age, and other socio-economic and 
demographic characteristics. Prevalence was assessed by asking participants whether they agree or 
disagree with common discriminatory statements: “Would you buy fresh vegetables from a shopkeeper 
or vendor if you knew that this person had HIV?” and “Do you think that children living with HIV should 
be able to attend school with children who are HIV negative?”  Table 17.3.A summarizes the response to 
each question individually and together by reporting the percentage of respondents who replied “No” to 
either question. This data can help to explain how HIV-related stigma may negatively impact efforts 
aimed at HIV prevention, HIV testing, and access to HIV treatment and care. 
 
17.3 Discriminatory Attitudes Toward People Living with HIV 
Overall, 15.9% of respondents aged 15-59 years who have heard of HIV said they would not buy 
vegetables from an HIV-positive vendor and 11.4% said that HIV-positive children should not attend 
school with HIV-negative children, while 20.3% expressed agreement with at least one of the 
discriminatory attitudes. One in four people (25.3%) in rural areas held at least one discriminatory 
attitude compared to 14.5% of people in urban areas. Among young people aged 15-19 years, 28.7% 
held a discriminatory attitude compared to 14.9% of those aged 40-44 years. Among those who had no 
education, 34.3% held at least one discriminatory attitude, in comparison to 5.7% of those who have 
had some education past secondary (Table 17.3.A). 
 
  
17 DISCRIMINATORY ATTITUDES TOWARD PEOPLE 
LIVING WITH HIV 
▪ In rural areas, 25.3% of people held discriminatory attitudes toward people living with HIV 
compared to 14.5% in urban areas. 
▪ Discriminatory attitudes toward people living with HIV are more common in those with less 
education, ranging from 34.3% among those with no education to 5.7% among those with more 
than secondary education. 
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Table 17.3.A Discriminatory attitudes toward people living with HIV 
Among persons aged 15-59 years who have heard of HIV, percentage who report discriminatory attitudes towards people living with HIV, by 
selected demographic characteristics, ZAMPHIA 2016 
 
Would you buy fresh 
vegetables from a shopkeeper 
or vendor if you knew that this 
person had HIV? 
 
Do you think that children 
living with HIV should be able 
to attend school with children 
who are HIV negative? 
 Both questions   
Characteristic 
Percentage who responded 
"No" 
 Percentage who responded 
"No" 
 
Percentage who 
responded "No" to 
either of the two 
questions1 
 Number2 
Residence        
Urban 11.1  7.9  14.5  4,516 
Rural 20.1  14.5  25.3  5,722         
Province        
Central 14.5  11.1  19.6  855 
Copperbelt 11.0  8.4  15.1  1,765 
Eastern 21.7  13.0  24.9  970 
Luapula 21.9  18.9  28.5  538 
Lusaka 11.3  7.7  14.2  1,753 
Muchinga 20.1  15.3  25.2  916 
Northern 19.1  15.6  25.8  857 
North-Western 16.7  12.2  22.2  959 
Southern 16.5  12.0  21.6  1,141 
Western 20.9  10.5  23.9  484         
Marital status        
Never married 18.7  12.8  23.0  3,461 
Married or living together 14.4  10.7  19.0  5,689 
Divorced or separated 12.5  8.8  16.6  708 
Widowed 11.7  9.3  15.0  298         
Education        
No education 27.9  18.6  34.3  526 
Primary 22.1  17.0  27.7  4,321 
Secondary 11.3  7.4  15.0  4,559 
More than secondary 3.8  2.4  5.7  827         
Wealth quintile        
Lowest 25.8  19.6  32.0  1,587 
Second 22.4  16.9  28.3  1,893 
Middle 16.3  10.2  20.1  2,071 
Fourth  11.9  9.8  16.4  2,177 
Highest 8.9  5.2  11.6  2,465         
Age        
15-19 23.3  17.0  28.7  2,108 
20-24 17.4  11.4  21.6  1,835 
25-29 13.7  9.7  17.5  1,442 
30-34 12.5  9.7  17.2  1,315 
35-39 11.6  9.3  16.6  1,067 
40-44 10.9  9.0  14.9  963 
45-49 12.2  8.0  16.0  640 
50-54 15.5  10.1  18.6  503 
55-59 14.2  9.7  17.7  365 
Total 15-24 20.5  14.3  25.4  3,943 
Total 15-49 16.0  11.6  20.5  9,370 
Total 15-59 15.9  11.4  20.3  10,238 
1Relates to Global AIDS Monitoring indicator 4.1: Discriminatory attitudes towards people living with HIV.  
2IIncludes only participants who answered both questions.  
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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17.4 Gaps and Unmet Needs 
 
17.5 References 
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Monitoring 2017. Indicators for 
monitoring the 2016 United Nations Political Declaration on HIV and AIDS. Geneva, Switzerland: UNAIDS; 
2016. http://www.unaids.org/sites/default/files/media_asset/2017-Global-AIDS-Monitoring_en.pdf.  
Accessed December 17, 2018. 
  
▪ Discriminatory attitudes were more common among adolescents aged 15-19 years (28.7%) 
followed by those aged 20-24 years (21.6%). Interventions to reduce discrimination should target 
venues where these young people congregate, including schools and youth groups. Age-
appropriate, sexual and reproductive health education at all levels of schooling would help 
combat false beliefs and HIV stigma. Open access to sexual and reproductive health services, 
including HIV prevention in schools, could also help reduce stigma.  
▪ Discriminatory attitudes towards people living with HIV were more common in rural areas 
(25.3%) as compared to urban areas (14.5%). Education and community interventions to 
decrease stigma could improve the lives of people living with HIV in these areas. Involvement of 
local stakeholders and traditional leaders is crucial for effective change. 
▪ Further investigation of institutional and community discrimination is necessary to fully address 
discriminatory attitudes and stigma against HIV and people living with HIV.  
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18.1 Key Findings 
 
18.2 Background 
People living with HIV are at risk for acquiring other diseases, including TB, hepatitis B, syphilis, and 
other STIs. TB is the leading causes of death for people living with HIV. HIV infection predisposes a 
person to TB infection and progression to active disease. Information regarding health seeking behavior, 
particularly for TB health services, is therefore very important. A UNAIDS model estimates there were 
38,000 (95%  CI 24,000-55,000) incident TB cases among HIV-positive persons in Zambia in 2015.1 This 
chapter describes the TB clinical care cascade for HIV-positive individuals: Receipt of care at a TB clinic, 
TB diagnoses among those receiving care, and treatment among those diagnosed with TB. 
 
Women living with HIV are at greater risk of developing cervical cancer because their weakened immune 
systems are not able to clear human papilloma virus (HPV) infections. WHO recommends HPV screening 
and treatment for all sexually active HIV-positive women.2 ZAMPHIA 2016 provides population-based 
rates of screening not available from routine clinic data, which does not capture women not in care. This 
chapter presents cervical cancer screening rates by age and socio-demographic characteristics.  
 
18 TUBERCULOSIS, SYPHILIS, HBV, STI SYMPTOMS, 
AND CERVICAL CANCER SCREENING 
▪ Based on self-report, 60.9% of adults aged 15-59 years who visited a TB clinic were tested for HIV 
during a TB clinic visit; however, 30.7% did not test for HIV during the visit and did not know their 
HIV status. 
▪ Among adult PLHIV who had ever visited a TB clinic, 54.3% were diagnosed with TB and of these, 
98.4% were treated for TB. 
▪ Overall, 39.4% of HIV-positive persons were screened for TB at their last HIV clinic visit. 
▪ The prevalence of having ever been infected with syphilis among those aged 15-59 years was 
6.8% (7.2% among females and 6.3% among males). 
▪ The overall prevalence of active syphilis infection was 3.0% (3.4% among females and 2.7% 
among males). 
▪ The prevalence of ever having been infected with syphilis was lower among HIV-negative (5.5%) 
than among HIV-positive (16.6%) participants. Active syphilis infections were less common 
among HIV-negative participants (2.1%) than HIV-positive (9.6%) participants.  
▪ The overall prevalence of hepatitis B in the population aged 0-59 years was 3.5%. The prevalence 
of hepatitis B was four times higher among those aged 15-59 years (5.6%) compared to those 
aged 0-14 years (1.3%).  
▪ Among adult PLHIV, 7.0% of men and 3.5% of women reported having a sexually transmitted 
infection (STI) diagnosed by a medical professional in the past 12 months. Among HIV-negative 
adults, 3.4% of men and 1.3% of women reported having an STI diagnosed by a medical 
professional in the last 12 months. 
▪ Among women with HIV aged 30-49 years, the probability of having been screened for cervical 
cancer was 34.5% in urban areas compared to 17.0% in rural areas. 
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HIV and HBV have similar transmission routes and concurrent infection with both viruses often results in 
more rapid progression of HBV to cirrhosis and higher liver-disease mortality. ZAMPHIA 2016 provides 
population-based HBV prevalence among HIV-positive individuals, which can support actionable policy 
recommendations for screening and treatment. It may also potentially provide an estimate of the 
impact of national HBV vaccination programs. This chapter describes the prevalence of HBV in 
individuals aged 0 to 59 years, by province, sex, age, and socio-economic and demographic 
characteristics. 
 
Syphilis is a relatively common STI, and untreated syphilis can result in severe morbidity in adults as well 
as in infants. Providing a syphilis diagnosis in a timely manner also allows patients to get treated, 
thereby reducing morbidity and transmission to sexual partners or vertically to newborn infants. As 
syphilis has been implicated in increasing transmission and acquisition of HIV, describing syphilis in HIV-
positive individuals adds to the understanding of the epidemiology of HIV. This chapter describes syphilis 
prevalence in adults aged 15 to 59 years, by HIV status, age, sex, and socio-economic and demographic 
characteristics. This chapter also describes prior screening for STIs in both adult men and women. 
 
18.3 Tuberculosis 
Table 18.3.A shows the prevalence of self-reported HIV testing during a TB clinic visit among adults by 
knowledge of HIV status and sex. Overall, 60.9% of adults aged 15-59 years tested for HIV during a TB 
clinic visit, and 8.4% did not test because already knew their HIV status. More than 3 in 10 (30.7%) 
adults 15-59 who visited a TB clinic were not tested for HIV and did not know their HIV status. 
 
Table 18.3.A  HIV testing in tuberculosis clinics 
Percent distribution of persons aged 15-59 years who had ever visited a tuberculosis (TB) clinic by whether 
they were tested for HIV during a TB clinic visit, by sex, ZAMPHIA 2016 
  
Tested for HIV during 
a TB clinic visit 
Not Tested for HIV during a TB clinic 
visit 
  
Characteristic 
Already knew they 
were HIV positive 
Did not know 
their status 
Total Number 
Sex      
Male 62.4 5.3 32.3 100.0 653 
Female 59.2 11.9 28.9 100.0 761 
      
Total 15-59 60.9 8.4 30.7 100.0 1,414 
 
Table 18.3.B presents information on the percentage of HIV-positive persons who visited a TB clinic, 
were diagnosed for TB, and received treatment. Among self-reported HIV-positive persons, 29.9% had 
ever visited a TB clinic, with 36.6% of males having ever visited a TB clinic compared to 26.2% of females 
(Table 18.3.B). Among adult people living with HIV who had ever visited a TB clinic, 54.3% were 
diagnosed with TB. Among those HIV-positive adults diagnosed with TB at a TB clinic, 98.4% were 
treated for TB (Table 18.3.B).  
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Table 18.3.B  Tuberculosis clinic attendance and services among HIV-positive adults 
Among self-reported HIV-positive persons aged 15-59 years, percentage who ever visited a tuberculosis (TB) clinic; among those who had 
ever visited a TB clinic, percentage who were diagnosed for TB; and among those diagnosed with TB, percentage who were treated for TB, 
by sex, ZAMPHIA 2016 
  Among HIV-positive persons  
Among HIV-positive persons 
 who ever visited a TB clinic 
 Among HIV-positive persons who 
were diagnosed with TB 
Characteristic 
Percentage who ever 
visited a TB clinic 
Number  
Percentage who were 
diagnosed with TB 
Number  
Percentage who were 
treated for TB 
Number 
Sex 
        
Male 36.6 521 
 56.7 190  98.8 110 
Female 26.2 1,220 
 52.4 332  98.1 174 
 
        
Total 15-59 29.9 1,741 
 54.3 522  98.4 284 
 
Table 18.3.C shows that among self-reported HIV-positive persons, 39.4% were screened for TB at their 
last HIV clinic visit (41.9% among males and 38.0% among females).  
 
Table 18.3.C  Tuberculosis symptom screening in HIV clinics 
Among self-reported HIV-positive persons in HIV care aged 15-59 years, percentage who were screened 
for tuberculosis symptoms during their last HIV clinic visit, by sex, ZAMPHIA 2016 
Characteristic 
Percentage who were screened 
for TB symptoms 
Number 
Sex   
Male 41.9 477 
Female 38.0 1,125 
 
  
Total 15-59 39.4 1,602 
 
18.4 Syphilis 
 
Syphilis Prevalence 
Overall, the prevalence of having ever been infected with syphilis among those aged 15-59 years was 
6.8% (7.2% among females and 6.3% among males). The prevalence of ever having been infected with 
syphilis was lower among HIV-negative (5.5%) than among HIV-positive (16.6%) participants. The overall 
prevalence of active syphilis infection was 3.0% (3.4% among females and 2.7% among males). The 
prevalence of active infection was lower among HIV-negative (2.1%) than HIV-positive (9.6%) 
participants. 
 
The prevalence of having ever been infected with syphilis ranged 2.9% in Eastern Province to 10.9% in 
Western Province. The prevalence of active infection ranged from 1.2% in Eastern to 5.2% in Western 
Province. Prevalence of active syphilis in the never married was 1.6%, compared to 6.8% among those 
widowed. Prevalence of having ever been infected with syphilis ranged from 2.7% among those aged 15-
19 years to more than 11% among those aged 40-59 years (Table 18.4.A). 
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Table 18.4.A  Syphilis prevalence 
Prevalence of syphilis (ever infected and active infection) among persons age 15-59 years, by sex, result of PHIA survey HIV test, and selected demographic characteristics, 
ZAMPHIA 2016 
 Males  Females  Total 
Characteristic 
Percentage 
ever infected 
Percentage 
active 
infection 
Number  
Percentage 
ever 
infected 
Percentage 
active 
infection 
Number  
Percentage 
ever 
infected 
Percentage 
active infection 
Number 
Result of PHIA survey HIV test            
HIV positive 18.2 11.3 779  15.6 8.5 1,688  16.6 9.6 2,467 
HIV negative 5.1 1.8 7,363  5.8 2.5 9,284  5.5 2.1 16,647             
Residence            
Urban 6.8 2.9 3,315  7.7 3.6 5,025  7.2 3.2 8,340 
Rural 6.0 2.5 4,827  6.9 3.2 5,947  6.4 2.8 10,774             
Province            
Central 8.6 3.8 702  8.1 3.8 889  8.3 3.8 1,591 
Copperbelt 8.2 2.7 1,386  9.6 3.6 1,898  8.9 3.2 3,284 
Eastern 1.9 0.7 819  3.9 1.7 1,070  2.9 1.2 1,889 
Luapula 7.3 3.4 426  8.6 5.1 590  8.0 4.3 1,016 
Lusaka 5.2 2.5 1,242  7.0 3.9 2,003  6.1 3.2 3,245 
Muchinga 5.8 2.3 758  4.7 2.7 971  5.2 2.5 1,729 
Northern 7.5 3.0 659  7.0 2.9 819  7.3 3.0 1,478 
North-Western 4.2 1.3 765  6.6 2.0 1,012  5.4 1.7 1,777 
Southern 5.1 2.3 990  6.6 3.2 1,186  5.9 2.8 2,176 
Western 12.6 6.3 395  9.4 4.1 534  10.9 5.2 929             
Marital status            
Never married 3.5 1.4 3,368  3.8 2.0 2,987  3.6 1.6 6,355 
Married or living together 8.1 3.3 4,319  7.7 3.5 6,332  7.9 3.4 10,651 
Divorced or separated 14.6 7.2 332  12.6 6.1 1,038  13.2 6.4 1,370 
Widowed 20.2 12.1 60  14.3 6.0 536  15.0 6.8 596             
Education            
No education 5.4 0.7 246  8.0 4.1 715  7.2 3.1 961 
Primary 7.0 3.1 3,142  8.9 4.1 5,183  8.1 3.7 8,325 
Secondary 6.4 2.6 4,012  5.8 2.8 4,354  6.1 2.7 8,366 
More than secondary 4.2 1.7 733  3.7 0.8 716  4.0 1.3 1,449             
Wealth quintile            
Lowest 6.2 2.4 1,250  7.1 2.8 1,712  6.7 2.6 2,962 
Second 6.5 2.6 1,596  7.2 3.3 1,940  6.9 3.0 3,536 
Middle 6.8 2.9 1,743  8.2 4.2 2,173  7.5 3.6 3,916 
Fourth  8.0 3.8 1,663  8.0 3.9 2,431  8.0 3.8 4,094 
Highest 4.5 1.8 1,849  6.0 2.7 2,668  5.3 2.2 4,517             
Pregnancy status            
Currently pregnant1 NA NA NA  6.3 3.0 789  NA NA NA 
Not currently pregnant NA NA NA  7.4 3.4 10,021  NA NA NA 
Age            
15-19 2.1 0.6 1,811  3.3 1.6 2,120  2.7 1.1 3,931 
20-24 3.9 1.8 1,344  5.5 2.9 2,045  4.7 2.4 3,389 
25-29 5.8 3.0 1,053  7.7 4.0 1,619  6.8 3.5 2,672 
30-34 8.2 3.9 1,003  7.2 3.3 1,458  7.7 3.5 2,461 
35-39 7.1 3.4 836  9.5 4.0 1,160  8.3 3.7 1,996 
40-44 11.9 5.3 751  11.9 5.8 988  11.9 5.5 1,739 
45-49 11.9 5.3 560  11.7 5.0 619  11.8 5.2 1,179 
50-54 9.8 2.4 444  12.1 3.6 584  11.0 3.0 1,028 
55-59 12.4 2.6 340  10.2 4.2 379  11.3 3.4 719 
Total 15-24 3.0 1.1 3,155  4.3 2.2 4,165  3.6 1.7 7,320 
Total 15-49 6.0 2.7 7,358  6.9 3.3 10,009  6.4 3.0 17,367 
Total 15-59 6.3 2.7 8,142  7.2 3.4 10,972  6.8 3.0 19,114 
1Relates to Global AIDS Monitoring indicator 2.4: Syphilis among pregnant women  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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18.5 Hepatitis B   
The prevalence of hepatitis B was four times higher among those aged 15-59 years (5.6%) as compared 
to those aged 0-14 years (1.3%). In the population aged 0-59 years, the overall prevalence was 3.5% 
(Table 18.5). 
 
The prevalence of hepatitis B among HIV-negative participants aged 15-59 years was 5.4% (6.9% among 
males, 3.9% among females). Prevalence among HIV-positive participants in the same age group was 
7.1% (nearly double among males, at 10.2%, when compared with females, at 5.2%). Among those aged 
0-14 years, the prevalence of hepatitis B was nearly five times higher in those who were HIV positive 
(5.9%) than in those who were HIV negative (1.2%). 
 
 
18.6 Self-Reported Symptoms and Diagnosis of Sexually Transmitted Infection 
Among all men aged 15-59 years, 4.9% reported abnormal penile discharge, 6.4% reported a penile sore 
and 3.5% reported being diagnosed with an STI by a medical professional in the past 12 months. Among 
HIV-positive men aged 15-59 years, 9.8% reported abnormal discharge, and 14.3% reported a sore or 
ulcer while 7.0% reported they had been diagnosed with a STI in the past 12 months by a medical 
professional (Table 18.6.A). 
 
For females aged 15-59 years, 4.6% self-reported abnormal vaginal discharge in the past 12 months and 
3.7% self-reported an ulcer or sore on or near the vagina. Overall 1.5% were diagnosed with an STI in the 
past 12 months by a doctor, clinical officer, or nurse. Among HIV-positive females, 6.8% reported 
abnormal discharge, while 7.9% reported a sore or ulcer and 3.5% reported being medically diagnosed 
with an STI in the 12 months preceding the survey (Table 18.6.B).  
 
  
Table 18.5 Hepatitis B prevalence by HIV status 
Prevalence of hepatitis B among persons age 0-59 years, by sex, HIV status, and age, ZAMPHIA 2016 
 Males 
 Females  Total 
Characteristic 
Percentage 
HBsAg1 
positive 
Number  
Percentage 
HBsAg 
positive 
Number  
Percentage 
HBsAg 
positive 
Number 
HIV Positive         
0-14 3.4 53  (9.2) 42  5.9 95 
15-59 10.2 779  5.2 1,688  7.1 2,467 
0-59 9.4 832  5.4 1,730  7.0 2,562 
         
HIV Negative         
0-14 1.3 3,948  1.1 3,972  1.2 7,920 
15-59 6.9 7,363  3.9 9,285  5.4 16,648 
0-59 4.1 11,311  2.5 13,257  3.3 24,568 
         
Total         
0-14 1.4 4,001  1.2 4,014  1.3 8,015 
15-59 7.2 8,142  4.1 10,973  5.6 19,115 
0-59 4.4 12,143  2.7 14,987  3.5 27,130 
1HBsAg is the hepatitis B surface antigen (positivity indicates acute or chronic hepatitis B infection) 
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Table 18.6.A  Other sexually transmitted infections: Males 
Among males aged 15-59 years, percentage who self-reported symptoms of a sexually transmitted infection and percentage who reported 
clinical diagnosis of a sexually transmitted infection in the 12 months preceding the survey; by HIV status and selected demographic 
characteristics, ZAMPHIA 2016 
 Self-reported symptoms in the past 12 months  
Percentage who were 
diagnosed with an STI in the 
past 12 months by a doctor, 
clinical officer, or nurse 
 
Characteristic 
Percentage who 
had abnormal 
discharge from the 
penis1 
Percentage who 
had an ulcer or 
sore on or near the 
penis 
Number  Number 
Result of PHIA survey HIV test       
HIV positive 9.8 14.3 708  7.0 712 
HIV negative 4.7 5.9 5,891  3.4 5,923 
Not tested 1.9 3.1 786  1.4 790 
       
Residence       
Urban 5.2 5.8 2,941  3.6 2,968 
Rural 4.6 6.9 4,444  3.4 4,457 
       
Province       
Central 5.1 8.1 616  3.4 615 
Copperbelt 2.8 5.1 1,197  2.8 1,208 
Eastern 5.5 6.9 714  4.4 715 
Luapula 3.8 4.9 370  1.8 373 
Lusaka 7.0 6.9 1,140  4.4 1,152 
Muchinga 2.0 4.3 681  2.5 684 
Northern 4.8 6.3 645  1.9 646 
North-Western 5.1 4.4 731  4.2 733 
Southern 4.2 6.0 904  3.4 911 
Western 7.1 11.2 387  5.2 388 
       
Marital status       
Never married 5.3 5.2 2,451  3.5 2,463 
Married or living together 4.2 6.7 4,484  3.1 4,506 
Divorced or separated 9.4 14.0 349  8.7 353 
Widowed 4.4 5.3 55  3.0 57 
       
Education       
No education 7.7 10.5 227  5.1 229 
Primary 4.9 6.9 2,819  3.6 2,842 
Secondary 5.0 6.4 3,538  3.6 3,548 
More than secondary 3.5 4.0 796  2.3 801 
       
Wealth quintile       
Lowest 4.1 7.1 1,182  3.5 1,187 
Second 5.1 5.8 1,442  2.8 1,450 
Middle 4.9 7.7 1,583  4.6 1,589 
Fourth  5.4 6.8 1,505  2.9 1,512 
Highest 4.6 4.8 1,638  3.5 1,652 
       
Age       
15-19 3.9 3.6 974  1.6 977 
20-24 5.5 6.6 1,257  3.7 1,265 
25-29 6.6 7.9 1,104  5.2 1,110 
30-34 5.4 6.9 1,051  4.2 1,055 
35-39 5.5 8.1 882  3.7 887 
40-44 3.8 7.2 764  3.8 775 
45-49 2.9 6.0 575  3.0 576 
50-54 2.3 2.9 439  0.7 440 
55-59 3.7 5.2 339  1.6 340 
 
Total 15-24 
 
4.9 
 
5.4 
 
2,231 
  
2.9 
 
2,242 
Total 15-49 5.1 6.7 6,607  3.7 6,645 
Total 15-59 4.9 6.4 7,385  3.5 7,425 
1Relates to Global AIDS Monitoring indicator 10.4: Men with urethral discharge 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. 
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Table  18.6.B Other sexually transmitted infections: Females 
Among females aged 15-59 years, percentage who self-reported symptoms of a sexually transmitted infection and percentage who reported clinical diagnosis 
of a sexually transmitted infection in the 12 months preceding the survey; by HIV status and selected demographic characteristics, ZAMPHIA 2016 
 Self-reported symptoms in the past 12 months 
 Percentage who were 
diagnosed with an STI in 
the past 12 months by a 
doctor, clinical officer, or 
nurse 
 
Characteristic 
Percentage who had abnormal 
discharge from the vagina 
Percentage who had an 
ulcer or sore on or near the 
vagina 
Number  Number 
Result of PHIA survey HIV test       
HIV positive 6.8 7.9 1,570  3.5 1,573 
HIV negative 4.4 3.1 7,885  1.3 7,911 
Not tested 2.9 1.2 926  0.5 928 
       
Residence       
Urban 5.5 4.2 4,638  1.8 4,657 
Rural 3.9 3.2 5,743  1.2 5,755 
       
Province       
Central 3.5 3.4 866  1.3 869 
Copperbelt 4.3 3.7 1,729  1.5 1,735 
Eastern 3.0 2.3 1,018  2.0 1,023 
Luapula 2.5 2.8 568  0.5 567 
Lusaka 6.1 4.5 1,871  1.8 1,879 
Muchinga 4.3 3.9 928  1.8 929 
Northern 4.9 3.5 816  1.3 819 
North-Western 3.6 2.2 972  1.2 971 
Southern 6.6 3.5 1,099  1.4 1,103 
Western 5.0 6.5 514  2.0 517 
       
Marital status       
Never married 5.0 4.5 2,082  1.5 2,095 
Married or living together 4.3 2.9 6,635  1.2 6,652 
Divorced or separated 6.3 5.6 1,062  2.8 1,063 
Widowed 3.4 5.2 551  2.8 551 
       
Education       
No education 4.3 2.9 705  1.4 706 
Primary 4.2 3.6 5,040  1.5 5,046 
Secondary 4.5 3.8 3,884  1.6 3,904 
More than secondary 8.1 4.1 747  1.6 751 
       
Wealth quintile       
Lowest 3.4 3.0 1,691  1.0 1,693 
Second 3.2 2.5 1,876  0.9 1,884 
Middle 4.4 4.0 2,075  2.0 2,077 
Fourth  5.5 4.8 2,322  1.9 2,328 
Highest 5.7 3.5 2,378  1.6 2,391 
       
Age       
15-19 3.6 2.8 1,315  1.1 1,323 
20-24 5.6 4.1 2,021  1.8 2,029 
25-29 4.2 3.8 1,706  1.7 1,710 
30-34 5.6 3.9 1,517  1.7 1,518 
35-39 4.7 2.7 1,214  1.6 1,220 
40-44 4.8 4.8 1,001  1.6 1,003 
45-49 4.2 3.1 632  0.6 632 
50-54 4.0 4.7 581  1.8 584 
55-59 2.3 2.9 394  0.3 393 
 
Total 15-24 
 
4.7 
 
3.5 
 
3,336 
  
1.5 
 
3,352 
Total 15-49 4.7 3.6 9,406  1.6 9,435 
Total 15-59 4.6 3.7 10,381  1.5 10,412 
Figures in parentheses are based on 25 to 49 unweighted cases. An asterisk indicates that a figure is based on fewer than 25 unweighted cases and has been 
suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
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18.7 Cervical Cancer Screening Among HIV-Positive Women 
Among HIV-positive women aged 30-49 years, 27.3% report being screened for cervical cancer. The 
proportion of women screened in urban areas (34.5%) was roughly twice the proportion screened in 
rural areas (17.0%). By province, self-reported screening ranged from 43.6% in Lusaka to 7.1% in 
Luapula. Among HIV-positive women who have secondary education, 32.1% have been screened for 
cervical cancer compared to 11.2% of women with no education. Similarly, 40.7% of women in the 
highest wealth quintile have been screened, while only 10.6% of women in the lowest wealth quintile 
have been screened (Table 18.7.A).  
 
Table 18.7.A  Cervical cancer screening among women living with HIV1 
Among HIV-positive women aged 30-49 years, percentage who report being screened for cervical cancer, by selected demographic 
characteristics, ZAMPHIA 2016 
Characteristic 
Percentage who report ever having had a 
screening test for cervical cancer 
Number 
Residence   
Urban 34.5 613 
Rural 17.0 426 
   
Province   
Central 31.6 98 
Copperbelt 20.0 212 
Eastern 19.0 83 
Luapula (7.1) 42 
Lusaka 43.6 257 
Muchinga 14.6 50 
Northern 17.1 60 
North-Western 16.7 62 
Southern 24.6 112 
Western 29.0 63 
   
Marital status   
Never married 24.8 78 
Married or living together 28.3 581 
Divorced or separated 24.8 202 
Widowed 27.1 174 
   
Education   
No education 11.2 58 
Primary 23.2 490 
Secondary 32.1 410 
More than secondary 39.5 81 
   
Wealth quintile   
Lowest 10.6 105 
Second 11.4 126 
Middle 24.7 221 
Fourth  28.1 282 
Highest 40.7 303 
   
Age   
30-34 25.3 302 
35-39 28.9 284 
40-44 31.3 294 
45-49 21.5 159 
   
Total 30-49 27.3 1,039 
1Relates to Global AIDS Monitoring indicator 10.10: Cervical cancer screening among women living with HIV. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
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18.8 Gaps and Unmet Needs 
 
18.9 References 
1. Joint United Nations Programme on HIV/AIDS. UNAIDS data tables, 2017. Accessed on December 17, 
2018 at http://aidsinfo.unaids.org/. 
  
▪ Linkages between TB and HIV care should be improved. Roughly 60% of HIV-positive adults aged 
15-59 years were not screened for TB symptoms during their last HIV clinic visit. This finding is 
not consistent with programmatic data which shows lower estimates of unscreened people living 
with HIV. Among adults aged 15-59 years who ever visited a TB clinic, nearly a third were not 
tested for HIV although they did not know their HIV status. 
▪ Hepatitis B prevalence was higher among HIV-positive children compared to HIV-negative 
children. Coverage and efficacy of immunization programs, among HIV-positive children in 
particular, should be further investigated.  
▪ A targeted HBV immunization program for at-risk adults, like health-care workers and PLHIV, 
should also be considered.  
▪ Nearly three quarters of HIV-positive women aged 30-49 years reported that they had never 
been screened for cervical cancer. Coverage of screening for this common co-morbidity should 
be expanded, particularly in rural areas. 
▪ More information about the prevalence, transmission, and treatment of human papillomavirus is 
needed for the general population and among people living with HIV.  
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▪ ZAMPHIA estimated that approximately 43,000 new HIV infections are occurring annually among 
adults aged 15-59 years (HIV incidence: 0.61% [95% CI: 0.40-0.81%]). Relative to males, HIV 
incidence among women remains unacceptably high (HIV incidence: 0.29% males, 0.93% females). 
▪ There has been remarkable progress toward the achievement of the UNAIDS 90-90-90 targets in 
adults, with 71.4% of people living with HIV aged 15-59 years diagnosed, 87.1% of those diagnosed 
receiving ART, and 89.2% of those on treatment with suppressed viral loads. However, diagnosis of 
younger adolescents and children living with HIV continues to be a concern, with only 50.6% of 
those aged 0-14 years actually diagnosed. Viral load suppression also continues to be an area of 
concern in the younger populations living with HIV, with only half (54.3%) of those aged 0-14 who 
were on treatment achieving a suppressed viral load, and 72.6% of those aged 15-24 years who 
were on treatment having a suppressed viral load. Further, the percentage with viral load 
suppression among all HIV-positive individuals aged 15-24 years was only 34.3%. With the goal set 
by UNAIDS to end the AIDS epidemic by 2030, continued expansion of HIV testing and treatment, 
especially for men and young women, will play a central role.  
▪ Health care during pregnancy, delivery, and soon after delivery is important for the survival and 
well-being of mothers and children. Zambia has achieved high coverage of the key intervention to 
reduce vertical transmission of HIV, with 98.9% of HIV-positive women aged 15-49 years who gave 
birth during the 12 months preceding the survey reporting that they received ARVs during 
pregnancy, labor or delivery. 
▪ However, there is an important gap in early diagnosis of HIV infection in infants, which is essential to 
ensure their survival. The current programmatic target for virological testing of HIV in infants in 
Zambia is to test at least 71% of children born to HIV-positive women within two months of birth. 
However, ZAMPHIA indicates that only 58.4% of last-born children of HIV-positive mothers who 
delivered in the past 36 months had HIV testing performed within 2 months of birth, and an 
additional 25.6% had it performed between two and 12 months of age. It is essential to increase the 
coverage of virological testing for HIV. Several system-level interventions can be useful, for example, 
in the laboratory, facilitating access to testing with the potential use of point-of-care technologies, 
and, in the facilities, through service quality improvement initiatives, training of health care 
personnel, and additional points of entry to testing. 
▪ Among reproductive-aged women (ages 15-49 years), the findings that 6.9% had past syphilis 
infection and 3.3% had active syphilis infections suggests that routine ANC syphilis, as well as HIV, 
testing, with prompt treatment of women testing positive, could further limit preventable perinatal 
mortality. 
 
  
DISCUSSION AND CONCLUSIONS 
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Appendix A provides a high-level overview of sampling and weighting procedures for ZAMPHIA (Zambia 
Population-based HIV Impact Assessment) 2016. In-depth details are provided in the Zambia PHIA 
(ZAMPHIA) Technical Report, which may be found on the PHIA project website. 
 
A.1 Sample Design 
Overview 
The sample design for ZAMPHIA is a stratified multistage probability sample design, with strata defined 
by the 10 provinces of the country, first-stage sampling units defined by enumeration areas (EAs) within 
strata, second-stage sampling units defined by households within EAs, and finally eligible persons within 
households. Within each province, the first-stage sampling units (also referred to as primary sampling 
units or PSUs) were selected with probabilities proportionate to the number of households in the PSU 
based on the 2010 census. The allocation of the sample PSUs to the 10 provinces was made in a manner 
designed to achieve specified precision levels for (1) a national estimate of the HIV incidence rate and 
(2) provincial estimates of viral load suppression (VLS). 
 
The second-stage sampling units were selected from lists of dwelling units/households compiled by 
trained staff for each of the sampled PSUs. Upon completion of the listing process, a random systematic 
sample of dwelling units/households was selected from each PSU at rates designed to yield self-
weighting (i.e., equal probability) samples within each province to the extent feasible. 
 
Within the sampled households, all eligible adolescents and adults aged 15 to 59 years were included in 
the study sample for data collection. All eligible children aged 0 to 14 years in every other household of 
the sampled households were included in the study for data collection. 
 
Population of Inference 
The population of inference for ZAMPHIA is comprised of the de facto household population. The de 
facto population is comprised of individuals who were present in households (i.e., slept in the 
household) on the night prior to the household interview. In contrast, the de jure population is 
comprised of individuals who are usual residents of the household, irrespective of whether or not they 
slept in the household on the night prior to the household interview.  
 
Precision Specifications and Assumptions 
The following specifications were used to develop the sample design for ZAMPHIA. 
▪ The relative standard error of the national estimate of HIV incidence among persons aged 15-49 
should be 30% or less.  
▪ 95% confidence bounds around the estimated VLS rate among HIV-positive persons aged 15-49 for 
each of the 10 strata (provinces) should be  10% or less. 
 
The following assumptions were used to develop the sample design for ZAMPHIA. 
APPENDIX A SAMPLE DESIGN AND IMPLEMENTATION 
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▪ An overall HIV prevalence rate of 0.103 (10.3%) that varies by province. Source: 2013-14 Zambia 
Demographic and Household Survey (Preliminary Report). 
▪ An annual HIV incidence rate for adults aged 15-49 of 𝑃𝑎 = 0.0060 (0.60%). Source: UNAIDS 
estimate for 2012 and 2013-14 Zambia Demographic and Household Survey (Preliminary Report). 
▪ A mean duration of recent infection (MDRI) of 130 days, yielding an annualization rate of 365/130= 
2.8077. Hence, the estimated incidence rate for MDRI = 130 days is 𝑃𝑚 = 0.0060/2.8077=0.0021 
(0.21%). 
▪ A VLS rate among HIV-positive adults aged 15-49 in each province h of Pvh = 50%. This is a 
conservative assumption because it will overstate the actual variance of the VLS rate. 
▪ An intra-cluster correlation (ICC) of = 0.05 for both prevalence and incidence. The ICC provides an 
average measure of the homogeneity of responses within the first-stage sampling units. 
▪ An occupancy rate of 91.9% for sampled dwelling units. Note that this is not included in the 
calculation of the overall survey response rate, but does determine the initial numbers of dwelling 
units to be sampled. A sample of 16,806 dwelling units will yield a sample of about 15,000 occupied 
dwelling units (households). Source: Central Statistical Office (CSO) [Zambia], Ministry of Health 
(MOH) [Zambia], and ICF International. 2014. Zambia Demographic and Health Survey 2013-14. 
Rockville, Maryland, USA: Central Statistical Office, Ministry of Health, and ICF International 
▪ An overall household response rate of 97.9% among the occupied dwelling units. Source: 2013-14 
Zambia Demographic and Household Survey (DHS). 
▪ The average number of persons aged 15 to 49 in a household is 1.89. Source: 2013-14 Zambia 
Demographic and Household Survey (DHS). 
▪ The percentage of persons in households who are 0-14 is 49.6%. Source: 2013-14 Zambia 
Demographic and Household Survey (DHS). 
▪ The percentage of persons in households who are 50-59 is 4.0%. Source: 2013-14 Zambia 
Demographic and Household Survey (DHS). 
▪ Among the individuals 15-59 years of age in eligible responding households, a biomarker response 
rate of 68.9%. This corresponds to an overall biomarker response rate of 67.5%. This is a 
conservative estimate derived from response rates in the 2013-14 Zambia Demographic and 
Household Survey (DHS). 
▪ Among the children 0-14 years of age in eligible responding households, a biomarker response rate 
of 62.1%. 
▪ The assumed values of response rates and number of participating persons per household is based 
on data from the 2013-14 Zambia DHS as well as recent AIDS indicator surveys conducted in other 
sub-Saharan African countries. 
 
Selection of the Primary Sampling Units 
The PSUs for ZAMPHIA are defined to be the EAs created for the census 2010. The sampling frame 
consisted of 25,631 EAs containing 2.8 million households and 13.1 million persons as of the 2010 
census. The EAs vary widely in size, with 97 EAs containing less than 30 households, and 149 containing 
more than 300 households. An attempt was made to combine the small EAs with an adjacent large EA 
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for sampling purposes, but this was found to be impracticable, and a decision was made to exclude 
these EAs from the sampling frame. Thus, the final sampling frame contained 25,534 EAs. The total 
deletions accounted for approximately 0.08 percent of the 2010 population. 
 
A stratified sample of 511 EAs was selected from the sampling frame. The 10 strata specified for 
sampling were the 10 provinces of Zambia. The EA samples were selected systematically and with 
probabilities proportionate to a measure of size (MOS) equal to the number of households in the EA 
based on the 2010 census. Prior to selection, the EAs were sorted by type of EA, including urban/rural. 
The sorting of the EAs prior to sample selection induces an implicit geographic stratification. To select 
the sample from a particular stratum, the cumulative MOS was determined for each EA in the ordered 
list of EAs, and the sample selections were designated using a sampling interval equal to the total MOS 
of the EAs in the stratum divided by the number of EAs to be selected and a random starting point. The 
resulting sample has the property that the probability of selecting an EA within a particular stratum is 
proportional to the MOS of the EA in the stratum. 
 
Details regarding EA substitution and segmentation may be found in the ZAMPHIA Technical Report. 
 
Selection of Households 
For both sampling and analysis purposes, a household is defined to be a group of individuals who reside 
in a physical structure such as a house, apartment, compound, or homestead, and share in 
housekeeping arrangements. The physical structure in which people reside is referred to as the dwelling 
unit, which may contain more than one household meeting the above definition. Households are eligible 
for participation in the study if they are located within the sampled EA. 
 
The selection of households for ZAMPHIA involved the following steps: (1) listing the dwelling 
units/households within the sampled EAs; (2) assigning eligibility codes to the listed dwelling 
unit/household records; (3) selecting the samples of dwelling units/households; and (4) designating a 
subsample of households for data collection for children. 
 
A description of the household listing process as well as a summary of household eligibility may be 
found in the ZAMPHIA Technical Report. 
 
Selection of households utilized an equal probability design. In order to achieve equal probability 
samples of households within each of the 10 provinces of Zambia, the sampling rates required to select 
dwelling units/households within an EA will depend on the difference between the MOS used in 
sampling and the actual number of dwelling units/households found at the time of listing. Thus, 
application of these within-EA sampling rates can yield more or less than the desired 12,100 households 
in EAs where the sampling MOS differs from the actual listing count. The ZAMPHIA Technical Report 
provides an in-depth description of the equal probability sample design, as well as a detailed summary 
of the results of the household selection. 
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Table A.1 Number of sampled dwelling units/households and expected unequal weighting design 
effects by stratum 
Stratum 
(Province) 
No. 
sample 
PSUs 
(clusters) 
Number of 
sampled 
dwelling 
units/house-
holds  
Number of 
dwelling 
units/households 
flagged for child 
data collection 
Minimum 
PSU 
sample 
size 
Maximum 
PSU 
sample 
size 
UEW 
DEFF for 
PHIA 
sample 
after 
capping 
Central 42 1,371 686 19 60 1.01 
Copperbelt 74 2,415 1,207 15 60 1.02 
Eastern 49 1,599 800 15 60 1.03 
Luapula 32 1,044 522 15 60 1.01 
Lusaka 85 2,800 1400 15 60 1.04 
Muchinga 50 1,632 816 15 61 1.04 
Northern 43 1,468 734 16 60 1.01 
North-Western 49 1,632 816 15 60 1.01 
Southern 55 1,795 897 15 60 1.00 
Western 32 1,044 522 17 60 1.00 
Total 511 16,800 8,400  15 61 1.07* 
*Reflects variation in weights within and across strata. 
PSU: Primary sampling unit 
UEW: Unequal weighting 
DEFF: Design effect  
 
Selection of Individuals 
The selection of individuals for ZAMPHIA involved the following steps: (1) compiling a list of all 
individuals known to reside in the household or who slept in the household during the night prior to 
data collection; (2) identifying those rostered individuals who are eligible for data collection; and (3) 
selecting for the study those individuals meeting the age and residency requirements of the study. 
However, only those individuals who slept in the household the night before the household interview 
(i.e., the de facto population) were retained for subsequent weighting and analysis. 
 
The ZAMPHIA Technical Report provides a brief description of the process for listing and selecting 
individuals for participation in ZAMPHIA and presents detailed summaries of the distributions of eligible 
individuals and participants in individual interviews and HIV testing by strata and age. 
 
A.2 Weighting 
Overview 
In general, the purpose of weighting survey data from a complex sample design is to (1) compensate for 
variable probabilities of selection, (2) account for differential nonresponse rates within relevant subsets 
of the sample, and (3) adjust for possible undercoverage of certain population groups. Weighting is 
accomplished by assigning an appropriate sampling weight to each responding sampled unit (e.g., a 
household or person), and using that weight to calculate weighted estimates from the sample. The 
critical component of the sampling weight is the base weight that is defined to be the reciprocal of the 
probability of including a household or person in the sample. The base weights are used to inflate the 
responses of the sampled units to population levels and are generally unbiased (or consistent) if there is 
no nonresponse or noncoverage in the sample. When nonresponse or noncoverage occurs in the survey, 
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weighting adjustments are applied to the base weights to compensate for both types of sample 
omissions. 
 
Nonresponse is unavoidable in virtually all surveys of human populations. For ZAMPHIA, nonresponse 
can occur at different stages of data collection, for example, (1) before the enumeration of individuals in 
the household, (2) after household enumeration and selection of persons but before completion of the 
individual interview, and (3) after completion of the interview but before collection of a viable blood 
sample. 
 
Noncoverage arises when some members of the survey population have no chance of being selected for 
the sample. For example, noncoverage can occur if the field operations fail to enumerate all dwelling 
units during the listing process, or if certain household members are omitted from the household 
rosters. To compensate for such omissions, the post-stratification procedures are used to calibrate the 
weighted sample counts to available population projections. 
 
Methods 
The overall weighting approach for ZAMPHIA includes several steps. Methods and results for each of the 
steps below are detailed in the ZAMPHIA Technical Report. 
 
Initial checks: Checks of the data files are carried out as part of the survey and data quality control, and 
the probabilities of selection for PSUs and households are calculated and checked. 
 
Creation of jackknife replicates: The variables needed to create the jackknife replicates for variance 
estimation are established at this point. This step can be implemented immediately after the PSU 
sample has been selected. All of the subsequent weighting steps described below are applied to the full 
sample, and to each of the jackknife replicates. 
 
Calculation of PSU base weights: The weighting process begins with the calculation and checking of the 
sample PSU (EA) base weights as the reciprocals of the overall PSU probabilities of selection. 
 
Calculation of household weights: The next step is to calculate household weights. The household base 
weights are calculated as the PSU weights times the reciprocal of the within-PSU household selection 
probabilities. The household base weights are adjusted first to account for dwelling units for which it 
could not be determined whether the dwelling unit contained an eligible household and then the 
responding households have their weights adjusted to account for non-responding eligible households. 
This adjustment is made based on the EA the households are in, and the resulting weight is the final 
household weight. 
 
Calculation of person-level interview weights: Once the household weights are determined, they are 
used to calculate the individual base weights. The individual base weights are then adjusted for 
nonresponse among the eligible individuals, with a final adjustment for the individual weights to 
compensate for undercoverage in the sampling process by post-stratifying (i.e., weighting up) to 2016 
population projections. 
 
Calculation of person-level HIV testing weights: The individual weights adjusted for nonresponse are in 
turn the initial weights for the HIV testing data sample, with a further adjustment for nonresponse to 
HIV testing, and a final post-stratification adjustment to compensate for undercoverage. 
 
Application of weighting adjustments to jackknife replicates: All of the adjustment processes are 
applied to the full sample and the replicate samples so that the final set of full sample and replicate 
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weights can be used for variance estimation that takes into account the complex sample design and 
every step of the weighting process. 
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B.1 Specimen Collection and Handling 
Blood was collected by qualified survey staff from consenting participants. Fourteen milliliters (mL) of 
venous blood was collected from persons aged 15 years and older, while six mL was collected from 
persons aged 2-14 years. One mL of capillary blood was collected from children aged 0-2 years using 
finger-stick for children aged 6-24 months and heel-stick for children less than age six months. 
 
Blood samples were labeled with a unique bar-coded participant identification number and stored in 
temperature-controlled cooler boxes. At the end of each day, samples were transported to a satellite 
laboratory for registration in a laboratory information management system, processing into plasma and 
dried blood spots (DBS), and storage at -20°C within 24 hours of blood collection. Approximately weekly, 
samples were transported to Tropical Diseases Research Centre (TDRC) for additional testing and long-
term storage at -80°C. 
 
B.2 Household-Based Procedures 
HIV Rapid Testing 
HIV rapid testing was conducted in each household in accordance with Zambia’s national guidelines 
(Figure B.2.A). HIV-positive and HIV-indeterminate samples underwent additional testing at a satellite 
laboratory, as described in Section B.3. For participants who self-reported an HIV=positive status but 
tested HIV negative during the survey, additional testing was conducted at TDRC, as described in Section 
B.3. For children less than the age of 18 months, only the initial rapid test was performed. If the test was 
reactive, the sample underwent additional testing at TDRC, as described in Section B.3. 
 
Figure B.2.A Household-based HIV testing algorithm1, ZAMPHIA 2016 
  
1This figure applies to individuals aged 18 months or older.  
APPENDIX B HIV TESTING METHODOLOGY 
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CD4 Testing  
All participants who tested HIV positive and a random sample of five percent of participants who tested 
HIV negative received a CD4 T-cell count measurement in the field by qualified survey staff. The 
measurement was performed using a Pima™ Analyzer and Pima™ CD4 Cartridge (Abbott Molecular Inc., 
Chicago, Illinois, United States, formerly Alere). 
 
Counseling, Referral to Care, and Active Linkage to Care 
Pre- and post-test counseling were conducted in each household in accordance with Zambia’s national 
guidelines. For participants age 15 years or older, results were communicated directly to the participant, 
while for participants aged 15-17 years, results were communicated to the participant’s parent or 
guardian. All participants who consented to HIV testing were asked to share contact information and to 
select a referral health facility prior to testing. Participants with an HIV-positive test result were referred 
to HIV care and treatment at the health facility of their choice, while participants with an HIV-
indeterminate test result were advised to seek repeated testing at the health facility of their choice in 
four weeks. Further, HIV-positive participants were asked to consent to be contacted by qualified health 
care personnel, in order to facilitate active linkage to HIV care and treatment in Zambia’s healthcare 
system. 
 
In rare cases where participants were provided an incorrect HIV test result, self-reported being HIV 
positive but tested HIV negative during the survey, or required additional collection of blood to 
complete testing, households were revisited by qualified personnel to provide participants with correct 
information and guidance on appropriate actions. 
 
Quality Assurance and Control 
To control the quality of the performance of HIV rapid tests, field staff conducted testing of a panel of 
HIV-positive and HIV-negative dried tube specimens on a weekly basis. To assure the quality of the 
performance of field staff conducting HIV testing, proficiency testing using a panel of blinded HIV-
positive and HIV-negative dried tube specimens was evaluated twice during the course of fieldwork. 
Additionally, sample re-testing was conducted at a satellite lab for (1) the first 50 samples tested by each 
field staff member, (2) a random sample of five percent of HIV-negative specimens, and (3) all HIV-
indeterminate specimens. 
 
A limitation of this survey is the limitation of rapid tests to detect HIV antibodies among people in the 
serological window of infection, in HIV-positive people on antiretroviral therapy (ART), and maternal 
antibodies in infants four months and older. Participants in the first two categories are not expected to 
be a significant source of bias. Further analysis will identify how many infants born to HIV-positive 
women were not identified by a rapid test. 
 
B.3 Laboratory-Based Procedures 
Twenty-five survey satellite laboratories were established in existing health facility laboratories across 
the country. An additional three mobile satellite labs were also utilized. One central laboratory was 
established at TDRC in Ndola, Zambia. 
 
Geenius Testing  
All HIV-positive samples, as well as samples with discrepant or indeterminate results, were tested using 
the Geenius™ HIV 1/2 Supplemental Assay (Bio-Rad, Hercules, California, United States) (Figure B.3.A). 
Testing was conducted at TDRC in accordance with the manufacturer’s protocol. 
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HIV TNA Polymerase Chain Reaction 
HIV total nucleic acid (TNA) polymerase chain reaction (PCR) was conducted for children aged less than 
18 months who had a reactive HIV test result during household-based testing (Figure B.3.A). 
Additionally, HIV TNA PCR was evaluated for participants who self-reported an HIV-positive status, but 
tested HIV negative during the survey, as well as for samples that were HIV positive by the rapid testing 
algorithm but were HIV negative or indeterminate by Geenius testing (Figure B.3.B). HIV TNA PCR was 
conducted on the Roche COBAS AmpliPrep Instrument and COBAS TagMan 48 Analyzer using the COBAS 
AmpliPrep/COBAS TaqMan HIV-1 qualitative test (Roche Molecular Diagnostics, Branchburg, New Jersey, 
United States). 
 
Classification of Final HIV Status 
For participants aged 18 months or older, the algorithm for classification of final HIV status included 
results from HIV rapid testing, Geenius testing, and HIV TNA PCR (Figure B.3.A). For participants of ages 
less than 18 months, the algorithm for classification of final HIV status included results from HIV rapid 
testing and HIV TNA PCR (Figure B.3.B). Classification of final HIV status was used to determine 
estimates for HIV prevalence and to inform estimates for HIV incidence.  
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Figure B.3.A Final HIV Status Classification Algorithm (18 months), ZAMPHIA 2016 
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Figure B.3.B Final HIV Status Classification Algorithm (<18 months), ZAMPHIA 2016 
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Viral Load Testing 
HIV-1 VL (HIV ribonucleic acid (RNA) copies per ml) from confirmed HIV-positive participants was 
measured using the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 (v2.0) instrument 
(Roche Molecular Systems, Branchburg, New Jersey, United States). The COBAS® AmpliPrep instrument 
(Roche Molecular Systems) was used to prepare plasma samples for amplification and detection using 
the COBAS® TaqMan® Analyser (Roche Molecular Systems, Branchburg, New Jersey, United States). The 
Abbott RT-PCR m2000rt system (Abbott Molecular Inc., Chicago, Illinois, United States) was used to 
measure VL from DBS samples from children and from adults with insufficient volume of plasma. 
 
VL results were returned to the health facility chosen by each HIV-positive participant. Participants were 
provided with a referral form during home-based testing and counseling for subsequent retrieval of 
their results. Survey staff also contacted participants who provided contact information, informing them 
that their VL results were available at the chosen facility and further advising them to seek care and 
treatment. 
 
HIV Recency Testing 
Estimation of HIV incidence was based on the classification of confirmed HIV-positive cases as recent or 
long-term HIV infections. The survey used two laboratory-based testing algorithms to estimate 
incidence. The first estimate used an algorithm that employed a combination of the HIV-1 Limiting 
Antigen (LAg) Avidity enzyme immunoassay (Sedia Biosciences Corporation, Portland, Oregon, United 
States) and VL results (Figure B.3.C). Antiretroviral (ARV) detection results were added to that algorithm 
for the second estimate (Figure B.3.D). The HIV recent infection testing algorithms were applied to 
repository specimens from all confirmed HIV-positive participants ages 18 months and older. 
 
LAg testing was performed twice, with an initial screening test followed by a confirmatory process: 
specimens with a normalized optical density (ODn) > 2.0 during initial testing were classified as long-term 
infections, while those with ODn ≤ 2.0 underwent further testing of the specimen in triplicate. Specimens 
with median ODn > 1.5 in confirmatory testing were classified as long-term infections. Specimens with 
median ODn < 0.4 were retested using the HIV diagnostic testing algorithm to confirm HIV-1 
seropositivity, and samples identified as HIV-1 seronegative were excluded from the total number of HIV 
positives and incorporated into the total number of negative specimens for incidence estimation. 
 
Specimens with median ODn ≤ 1.5 were classified as potential HIV-recent infections, and their VL results 
were assessed. For the first incidence testing algorithm, specimens with VL < 1,000 copies/ml were 
classified as long-term infections, while those with VL ≥ 1,000 copies/ml were classified as recent 
infections. For the updated incidence algorithm, those classified as recent infections by the first 
algorithm were reclassified using ARV detection data.  Those specimens in which efavirenz (EFV), 
atazanavir (ATV), lopinavir (LPV), and nevirapine (NVP) were detected were classified as long-term 
infections and those in which no ARVs were detected remained classified as recent infections.  
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Figure B.3.C  HIV-1 Recent Infection Testing Algorithm (Algorithm (LAg/VL algorithm),ZAMPHIA 2016 
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Figure B.3.D  HIV-1 recent infection testing algorithm (LAg/VL/ARV algorithm), ZAMPHIA 2016 
 
 
 
HIV Incidence Estimation 
 
Incidence estimates were obtained using the formula recommended by the World Health Organization 
Incidence Working Group and Consortium for Evaluation and Performance of Incidence Assays. 
Weighted counts for HIV-negative persons (N); HIV-positive persons (P); numbers tested on the LAg 
assay (Q); and numbers HIV recent (R) are provided for use in incidence calculations or the United 
Nations Joint Programme on HIV/AIDS Spectrum models (Tables B.3.A, B.3.B). Incidence estimates were 
calculated using the following parameters: mean duration recent infection (MDRI) = 130 days (95% CI: 
118-142 days); proportion false recent (PFR) = 0.00; time cutoff (T) = 1 year. In-depth details are 
provided in the ZAMPHIA Technical Report. 
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Table B.3.A:  Annual HIV incidence auxiliary data: N, P, Q, R (LAg/VL algorithm) 
Table B.3.A:  Annual HIV incidence auxiliary data: N, P, Q, R, (LAg/VL1 algorithm) 
Annual incidence of HIV among persons ages 15-49 and 15-64 years, by sex and age, ZAMPHIA 2016 
 
Males 
 
Females 
 
Total 
Age Number 
HIV 
negative
2 
(N) 
Number 
HIV 
positive2 
(P) 
Number 
tested on 
LAg assay2 
(Q) 
Number 
HIV 
recent2 
(R) 
  Number 
HIV 
negative2 
(N) 
Number 
HIV 
positive2 
(P) 
Number 
tested on 
LAg assay2 
(Q) 
Number 
HIV 
recent2 
(R) 
  Number 
HIV 
negative2 
(N) 
Number 
HIV 
positive2 
(P) 
Number 
tested on 
LAg assay2 
(Q) 
Number 
HIV 
recent2 
(R) 
15-24 3097.75 57.25 57.25 0.86  3928.62 236.38 236.38 15.09  7044.15 275.85 275.85 14.41 
25-34 1890.75 165.25 165.25 1.68  2566.03 510.97 508.96 10.64  4485.51 647.49 645.70 11.43 
35-49 1728.73 418.27 416.19 5.34  2032.25 735.75 731.97 7.68  3786.16 1128.84 1123.11 12.92 
15-49 6745.80 612.20 610.28 7.52  8582.37 1427.63 1422.20 33.65  15396.15 1971.85 1964.82 38.49 
15-59 7388.65 753.35 750.38 8.43  9367.07 1605.93 1600.44 34.02  16821.20 2293.80 2285.51 39.94 
1 LAg/VL: limiting antigen/viral load 
2 Weighted number 
Note: mean duration recent infection (MDRI) = 130 days (95% CI: 118-142 days); proportion false recent (PFR) = 0.00; time cutoff (T) = 1 year 
 
Table B.3.B:  Annual HIV incidence auxiliary data: N, P, Q, R (LAg/VL/ARV algorithm) 
Table B.3.B:  Annual HIV incidence auxiliary data: N, P, Q, R (LAg/VL/ARV1 algorithm) 
Annual incidence of HIV among persons ages 15-49 and 15-64 years, by sex and age, using LAg/VL/ARVs algorithm, by sex and age, ZAMPHIA 2016 
 
Males 
 
Females 
 
Total 
Age Number 
HIV 
negative2 
(N) 
Number 
HIV 
positive2 
(P) 
Number 
tested on 
LAg assay2 
(Q) 
Number 
HIV 
recent2 
(R) 
  Number 
HIV 
negative2 
(N) 
Number 
HIV 
positive2 
(P) 
Number 
tested on 
LAg assay2 
(Q) 
Number 
HIV 
recent2 
(R) 
  Number 
HIV 
negative2 
(N) 
Number 
HIV 
positive2 
(P) 
Number 
tested on 
LAg assay2 
(Q) 
Number 
HIV 
recent2 
(R) 
15-24 3097.75 57.25 57.25 0.86 
 
3928.62 236.38 236.38 13.20 
 
7044.15 275.85 275.85 12.73 
25-34 1890.75 165.25 165.25 1.68 
 
2566.03 510.97 508.96 9.76 
 
4485.51 647.49 645.70 10.65 
35-49 1728.73 418.27 416.19 4.49 
 
2032.25 735.75 731.97 7.68 
 
3786.16 1128.84 1123.11 11.93 
15-49 6745.80 612.20 610.28 6.74 
 
8582.37 1427.63 1422.20 30.75 
 
15396.15 1971.85 1964.82 35.02 
15-59 7388.65 753.35 750.38 7.63 
 
9367.07 1605.93 1600.44 31.10 
 
16821.20 2293.80 2285.51 36.42 
1 LAg/VL/ARV: Limiting antigen/viral load/antiretroviral  
2 Weighted number 
Note: mean duration recent infection (MDRI) = 130 days (95% CI: 118-142 days); proportion false recent (PFR) = 0.00; time cutoff (T) = 1 year 
 145 
 
 
Detection of Antiretrovirals 
To understand recent exposure to ARVs and hence level of ART coverage, samples from all confirmed 
HIV-positive participants were evaluated for the presence of selected ARVs, using high-resolution liquid 
chromatography coupled with tandem mass spectrometry to detect ARVs from DBS specimens.1 Three 
ARVs, one non-nucleoside reverse transcriptase inhibitors (NNRTIs), EFV, and two protease inhibitors 
(PIs), ATV and LPV, were used as markers for both first- and second-line regimens, based on Zambia’s 
national treatment guidelines. Samples from participants who were virally suppressed and/or self-
reported on ART but had no evidence of the first three compounds were tested for an additional NNRTI, 
NVP. The ARVs were selected based on their long half-lives, allowing for longer window period from 
drug exposure to detection. 
 
 
To qualitatively detect ARVs, a single DBS was eluted, and chromatographic separation carried out on a 
Luna 5μm PFP column (110 Å, 50 x 2 mm) (Phenomonex, Torrance, CA). Each ARV was detected using an 
API 4000 LC/MS/MS instrument (Applied Biosystems, Foster City, CA). Internal standards and in-house 
quality control cut-off samples including negative controls were utilized in each run. This qualitative 
method used a limit of detection (LOD) of 0.02 μg/ml for each ARV, with a signal-to-noise ratio of at 
least 5:1 for all ARVs. Samples with concentrations above 0.02 μg/ml were considered positive for each 
ARV. Testing was conducted at University of Cape Town in South Africa. 
 
Genotyping for Detection of Antiretroviral Drug Resistance and HIV Subtyping 
To determine the extent of transmitted HIV-1 drug resistance mutations among participants in the 
ZAMPHIA, samples from confirmed HIV-positive participants aged less than 18 months and HIV-positive 
participants aged 18 months or older who were classified as recent infections as well as an equal or 
greater number of who were classified as long-term infections were evaluated using a TaqMan® SNP 
Genotyping Assay (Applied Biosystems) to identify mutations within the HIV-1 pol gene region, which 
encodes amino acid substitutions known to be responsible for resistance to specific ARVs. 
 
Viral RNA or TNA from plasma or DBS was extracted using the NucliSENS® easyMAG® (bioMérieux, 
France) platform. The HIV pol gene was amplified by one-step RT-PCR, which was followed by nested 
PCR. Sequencing of the approximately one-kilobase amplicons was performed on the ABI 3730 DNA 
Analyzer (Applied Biosystems)7,8,9. 
 
The customized ReCALL software program was used to edit raw sequences and generate consensus 
sequences.5 Mutations in the protease and reverse transcriptase genes were classified as potentially 
associated with drug resistance, according to the Stanford University HIV Drug Resistance Database.6 
Sequences with >98% homology were flagged for potential cross-contamination or possible 
epidemiological links. Internal quality assurance measures and in-house quality control standards were 
included in each run, to validate results. The assay’s sensitivity has been established at 1000 copies/ml 
for plasma and DBS.7 Sequences were also analyzed for potential cross-contamination by phylogenetic 
analysis from code 6 of the protease gene to code 251 of the reverse transcriptase gene. 
 
Subtyping of each sample was performed using the REGA HIV-1 & 2 Automated Subtyping Tool8,9. This 
BioAfrica viral subtyping tool is designed to use phylogenetic methods in order to identify the HIV-1 
subtype of a specific sequence. The sequence is analyzed for recombination using boot-scanning 
methods. 
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Estimates from sample surveys are affected by two types of errors: non-sampling errors and sampling 
errors. Non-sampling errors result from mistakes made during data collection (e.g., misinterpretation of 
an HIV test result) and data management (e.g., transcription errors in data entry). While ZAMPHIA 
implemented numerous quality assurance and control measures minimize non-sampling errors, these 
errors are impossible to avoid and difficult to evaluate statistically. 
 
In contrast, sampling errors can be evaluated statistically. The sample of respondents selected for 
ZAMPHIA is only one of many samples that could have been selected from the same population, using 
the same design and expected size. Each of these samples would yield results that differ somewhat from 
the results of the actual sample selected. Sampling errors are a measure of the variability between all 
possible samples. Although the degree of variability is not known exactly, it can be estimated from the 
survey results. 
 
The standard error, which is the square root of the variance, is the usual measurement of sampling error 
for a particular statistic (e.g., proportion, mean, rate, count). In turn, the standard error can be used to 
calculate confidence intervals within which the true value for the population can reasonably be assumed 
to fall. For example, for any given statistic calculated from a sample survey, the value of that statistic will 
fall within a range of approximately plus or minus two times the standard error of that statistic in 95 
percent of all possible samples of identical size and design. 
 
ZAMPHIA utilized a multi-stage stratified sample design, which requires complex calculations to obtain 
sampling errors. Specifically, a variant of the jackknife replication method was implemented in SAS (SAS 
Institute, North Carolina) to estimate variance for proportions (e.g., HIV prevalence), rates (e.g., annual 
HIV incidence), and counts (e.g., numbers of people living with HIV). Each replication considers all but 
one cluster in the calculation of the estimates. Pseudo-independent replications are thus created. In 
ZAMPHIA a jackknife replicate is created by randomly deleting one cluster from each variance-
estimation stratum and retaining all of the clusters in the remaining strata A total of 253 variance-
estimation strata were created by pairing (or occasionally tripling) the sample clusters in the systematic 
order in which they had been selected. Hence, 253 replications were created. The variance of a sample-
based statistic, y, is calculated as follows: 
 
var(y) = ∑  𝐾𝑘=1 (yk - y)
2 
 
where y is the full-sample estimate, and yk is the corresponding estimate for jackknife replicate k (k = 1, 
2, ..., K).  
 
In addition to the standard error, the design effect for each estimate is also calculated. The design effect 
is defined as the ratio of the standard error using the given sample design to the standard error that 
would result if a simple random sample had been used. A design effect of 1.0 indicates that the sample 
design is as efficient as a simple random sample, while a value greater than 1.0 indicates the increase in 
APPENDIX C ESTIMATES OF SAMPLING ERRORS 
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the sampling error due to the use of a more complex and less statistically efficient design. Confidence 
limits for the estimates, which are calculated as  
 
y  ±  t(0.975; K) √𝑣𝑎𝑟(𝑦) , 
 
where t(0.975; K) is the 97.5th percentile of a t-distribution with K degrees of freedom, are also 
computed. 
 
Sampling errors for selected variables from ZAMPHIA are presented in Tables C.1 through C.8. For most 
variables, sampling error tables include the weighted estimate, unweighted denominator, standard 
error, design effect, and lower and upper 95 percent confidence limits. 
 
  
 149 
 
 
 Table C.1:  Sampling errors: Annual HIV incidence using LAg/VL/ARV testing algorithm, by 
age, ZAMPHIA 2016 
Age (years) 
Weighted 
estimate (%)  
Design 
effect 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
15-24 0.51 0.86 0.23 0.78 
25-34 0.67 0.91 0.26 1.07 
35-49 0.89 0.99 0.38 1.39 
15-49 0.64 0.88 0.42 0.86 
15-59 0.61 0.90 0.40 0.81 
MALES 
15-24 0.08 1.07 0 0.24 
25-34 0.25 0.88 0 0.62 
35-49 0.73 0.97 0.05 1.40 
15-49 0.28 0.93 0.07 0.49 
15-59 0.29 0.93 0.08 0.50 
FEMALES 
15-24 0.94 0.94 0.44 1.44 
25-34 1.07 1.00 0.40 1.73 
35-49 1.06 1.01 0.31 1.81 
15-49 1.00 0.90 0.64 1.37 
15-59 0.93 0.91 0.60 1.26 
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Table C.2:  Sampling errors: HIV prevalence by age, ZAMPHIA 2016 
Age 
Weighted 
estimate (%)  
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
0-17 months 0.838 682 0.256 0.309 1.366 
18-59 months 0.797 1,911 0.208 0.369 1.225 
5-9 1.768 2,876 0.260 1.233 2.303 
10-14 0.880 2,546 0.207 0.453 1.308 
Total 0-4 0.808 2,593 0.173 0.451 1.165 
Total 0-14 1.147 8,015 0.125 0.889 1.404 
15-19 2.489 3,931 0.264 1.944 3.033 
20-24 5.244 3,389 0.394 4.434 6.055 
25-29 9.843 2,672 0.627 8.552 11.134 
30-34 15.868 2,461 0.821 14.177 17.559 
35-39 19.896 1,996 1.003 17.831 21.962 
40-44 25.769 1,740 1.306 23.08 28.459 
45-49 24.382 1,179 1.410 21.479 27.286 
50-54 21.496 1,028 1.450 18.509 24.483 
55-59 17.322 719 1.624 13.977 20.666 
Total 15-24 3.768 7,320 0.239 3.276 4.261 
Total 15-49 11.353 17,368 0.316 10.702 12.004 
Total 15-59 
 
12.000 
19,115 0.320 11.342 12.658 
MALES 
0-17 months 0.994 310 0.292 0.392 1.595 
18-59 months 0.920 966 0.317 0.267 1.573 
5-9 2.199 1,462 0.427 1.321 3.078 
10-14 0.716 1,263 0.251 0.199 1.234 
Total 0-4 0.938 1,276 0.248 0.427 1.449 
Total 0-14 1.296 4,001 0.176 0.934 1.658 
15-19 1.618 1,811 0.304 0.992 2.244 
20-24 2.044 1,344 0.395 1.231 2.857 
25-29 5.586 1,053 0.769 4.003 7.169 
30-34 10.927 1,003 1.095 8.672 13.182 
35-39 15.064 836 1.325 12.336 17.792 
40-44 22.194 751 1.675 18.744 25.644 
45-49 23.043 560 1.975 18.976 27.11 
50-54 22.859 444 2.121 18.49 27.227 
55-59 16.857 340 2.069 12.596 21.118 
Total 15-24 1.815 3,155 0.238 1.325 2.305 
Total 15-49 8.320 7,358 0.337 7.626 9.015 
Total 15-59 9.253 8,142 0.346 8.541 9.965 
FEMALES 
0-17 months 0.707 372 0.408 0.000 1.547 
18-59 months 0.663 945 0.274 0.099 1.227 
5-9 1.333 1,414 0.307 0.700 1.966 
10-14 1.046 1,283 0.309 0.410 1.683 
Total 0-4 0.676 1,317 0.226 0.210 1.141 
Total 0-14 0.996 4,014 0.153 0.682 1.311 
15-19 3.347 2,120 0.411 2.500 4.194 
20-24 8.335 2,045 0.64 7.016 9.654 
25-29 13.568 1,619 0.974 11.563 15.574 
30-34 20.162 1,458 1.155 17.783 22.54 
35-39 24.650 1,160 1.415 21.736 27.564 
40-44 29.577 989 1.67 26.137 33.017 
45-49 25.848 619 1.809 22.123 29.574 
50-54 20.138 584 1.736 16.564 23.713 
55-59 17.748 379 2.276 13.061 22.436 
Total 15-24 5.675 4,165 0.398 4.856 6.495 
Total 15-49 14.262 10,010 0.421 13.396 15.128 
Total 15-59 14.635 10,973 0.414 13.782 15.489 
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Table C.3:  Sampling errors: HIV prevalence by residence and province, ages 15-59 years, ZAMPHIA 2016 
Characteristic 
Weighted 
estimate (%)  
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
Residence      
Urban 15.3 8,340 0.5 14.2 16.3 
Rural 9.2 10,775 0.4 8.4 10.1 
Province      
Central 12.8 1,591 1.2 10.4 15.2 
Copperbelt 13.8 3,284 0.7 12.3 15.3 
Eastern 8.1 1,889 1.1 5.9 10.3 
Luapula 9.3 1,016 1.3 6.7 11.9 
Lusaka 15.7 3,245 0.8 14.1 17.3 
Muchinga 5.7 1,729 0.9 3.9 7.5 
Northern 9.2 1,479 1.0 7.2 11.2 
North-Western 6.9 1,777 0.6 5.6 8.1 
Southern 13.3 2,176 0.9 11.5 15.0 
Western 15.9 929 1.9 11.9 19.9 
MALES 
Residence      
Urban 11.6 3,315 0.6 10.3 12.8 
Rural 7.4 4,827 0.4 6.5 8.2 
Province      
Central 9.1 702 1.0 6.9 11.3 
Copperbelt 10.0 1,386 0.8 8.3 11.7 
Eastern 5.2 819 0.9 3.3 7.1 
Luapula 7.3 426 1.6 4.0 10.5 
Lusaka 12.4 1,242 1.1 10.2 14.7 
Muchinga 3.4 758 0.6 2.3 4.6 
Northern 7.9 659 1.1 5.7 10.1 
North-Western 4.8 765 0.7 3.3 6.3 
Southern 11.6 990 0.9 9.8 13.4 
Western 13.7 395 1.9 9.8 17.5 
FEMALES 
Residence      
Urban 18.7 5,025 0.7 17.4 20.1 
Rural 11.1 5,948 0.5 10.0 12.2 
Province      
Central 16.5 889 1.6 13.3 19.7 
Copperbelt 17.5 1,898 0.9 15.5 19.4 
Eastern 10.7 1,070 1.4 7.9 13.5 
Luapula 11.1 590 1.7 7.7 14.6 
Lusaka 18.8 2,003 0.9 16.9 20.7 
Muchinga 7.9 971 1.4 5.1 10.7 
Northern 10.5 820 1.2 8.0 12.9 
North-Western 8.8 1,012 0.8 7.1 10.6 
Southern 15.0 1,186 1.2 12.6 17.5 
Western 17.8 534 2.5 12.6 23.1 
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Table C.4:  Sampling errors: Viral load suppression by age, ZAMPHIA 2016 
Age (years) 
Weighted 
estimate (%)  
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
0-14 33.4 90 5.4 22.3 44.4 
15-24 34.3 286 3.1 28.0 40.6 
25-34 50.4 675 2.0 46.2 54.5 
35-44 66.1 846 1.9 62.2 70.1 
45-59 73.1 606 1.9 69.3 77.0 
      
Total 15-24 34.3 286 3.1 28.0 40.6 
Total 15-49 56.6 2,084 1.3 53.9 59.4 
Total 15-59 59.2 2,413 1.2 56.6 61.7 
MALES 
0-14 30.0 52 6.9 15.7 44.2 
15-24 36.7 53 7.5 21.3 52.0 
25-34 36.7 160 4.7 27.1 46.2 
35-44 60.1 276 2.9 54.2 66.1 
45-59 73.3 269 2.8 67.6 78.9 
      
Total 15-24 36.7 53 7.5 21.3 52.0 
Total 15-49 52.5 611 2.2 47.9 57.1 
Total 15-59 57.2 758 2.0 53.1 61.3 
FEMALES 
0-14 38.2 38 8.9 19.8 56.5 
15-24 33.6 233 3.1 27.2 39.9 
25-34 56.1 515 2.2 51.6 60.6 
35-44 70.3 570 2.1 65.9 74.6 
45-59 73.0 337 2.6 67.7 78.4 
      
Total 15-24 33.6 233 3.1 27.2 39.9 
Total 15-49 58.9 1,473 1.4 55.9 61.9 
Total 15-59 60.4 1,655 1.3 57.6 63.2 
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Table C.5:  Sampling errors: Viral load suppression by residence and province, ages 15-59 years, ZAMPHIA 2016 
Characteristic 
Weighted 
estimate (%)  
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
Residence      
Urban 61.8 1,393 1.5 58.7 64.9 
Rural 55.5 1,020 2.1 51.1 59.8 
Province      
Central 59.1 229 3.5 52.0 66.3 
Copperbelt 56.7 504 2.4 51.7 61.7 
Eastern 67.1 176 4.0 58.8 75.4 
Luapula 53.1 105 7.4 37.9 68.2 
Lusaka 62.7 579 2.3 58.0 67.3 
Muchinga 63.7 108 4.2 55.0 72.5 
Northern 50.6 111 8.8 32.5 68.6 
North-Western 53.4 136 3.3 46.7 60.2 
Southern 63.7 305 3.6 56.3 71.1 
Western 47.3 160 5.9 35.2 59.5 
MALES 
Residence      
Urban 60.5 399 2.6 55.2 65.8 
Rural 52.8 359 3.1 46.4 59.1 
Province      
Central 56.1 70 4.8 46.1 66.0 
Copperbelt 49.7 152 4.5 40.5 58.9 
Eastern 68.6 47 5.8 56.6 80.5 
Luapula 45.5 34 14.0 16.7 74.3 
Lusaka 67.5 167 3.9 59.5 75.5 
Muchinga 65.1 28 9.8 44.9 85.2 
Northern 50.0 42 8.2 33.1 66.9 
North-Western 49.8 39 5.6 38.2 61.4 
Southern 56.0 122 5.3 45.1 67.0 
Western 45.6 57 7.4 30.4 60.9 
FEMALES 
Residence      
Urban 62.5 994 1.7 59.1 66.0 
Rural 57.2 661 2.3 52.5 62.0 
Province      
Central 60.8 159 4.1 52.4 69.2 
Copperbelt 60.6 352 2.6 55.1 66.0 
Eastern 66.4 129 4.4 57.3 75.5 
Luapula 57.6 71 5.6 46.0 69.1 
Lusaka 59.6 412 2.5 54.4 64.9 
Muchinga 63.2 80 5.4 52.0 74.3 
Northern 51.0 69 10.5 29.4 72.5 
North-Western 55.3 97 4.5 46.1 64.5 
Southern 70.0 183 4.3 61.1 78.9 
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Western 48.4 103 6.0 36.1 60.7 
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Table C.6:  Sampling errors: Self-reported ARV data 90-90-90 by age (conditional percentages), ZAMPHIA 2016 
 Diagnosed  On Treatment  Suppressed Viral Load 
Age (years) 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
15-24 40.2 287 2.9 34.1 46.2  80.0 118 3.6 72.7 87.4  71.3 93 5.1 60.7 81.8 
25-34 60.8 687 2.1 56.4 65.1  77.2 431 2.4 72.2 82.1  88.7 336 1.8 85.1 92.4 
35-49 73.8 1,130 1.6 70.4 77.1  87.4 845 1.3 84.7 90.0  89.8 744 1.2 87.4 92.2 
15-49 64.5 2,104 1.3 61.8 67.2  83.5 1,394 1.1 81.3 85.8  87.8 1,173 1.1 85.6 90.1 
15-59 66.1 2,434 1.2 63.6 68.6  85.1 1,647 1.0 83.0 87.1  89.2 1,409 0.9 87.3 91.2 
MALES 
15-24 40.6 53 7.5 25.2 56.1  * 20 7.1 72.3 100.0  * 17 12.5 25.9 77.5 
25-34 40.6 165 4.2 31.9 49.2  72.1 68 6.0 59.7 84.4  90.7 47 4.2 82.0 99.4 
35-49 69.8 401 2.4 64.8 74.7  86.4 279 2.0 82.4 90.4  87.7 240 2.2 83.2 92.2 
15-49 58.9 619 2.3 54.1 63.6  83.7 367 1.8 80.0 87.4  85.6 304 2.1 81.3 90.0 
15-59 62.3 766 2.1 58.0 66.6  86.2 482 1.5 83.1 89.3  87.7 413 1.7 84.3 91.1 
FEMALES 
15-24 40.1 234 3.1 33.6 46.5  77.9 98 4.2 69.3 86.4  78.1 76 5.1 67.5 88.7 
25-34 69.4 522 2.2 64.9 73.9  78.4 363 2.5 73.3 83.6  88.3 289 1.9 84.3 92.2 
35-49 76.8 729 1.8 73.1 80.5  88.1 566 1.6 84.8 91.4  91.2 504 1.2 88.8 93.6 
15-49 67.6 1,485 1.4 64.8 70.5  83.4 1,027 1.4 80.6 86.3  88.9 869 1.1 86.6 91.3 
15-59 68.4 1,668 1.3 65.7 71.1  84.4 1,165 1.2 81.9 87.0  90.1 996 1.0 87.9 92.2 
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Table C.7:  Sampling errors: ARV-adjusted 90-90-90 by age (unconditional percentages), ZAMPHIA 2016 
 Diagnosed  On Treatment  Suppressed Viral Load 
Age (years) 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
15-24 46.0 288 3.0 39.8 52.3  38.4 288 3.0 32.2 44.5  27.8 288 2.9 22.0 33.7 
25-34 65.4 686 2.0 61.2 69.6  52.1 686 2.2 47.7 56.6  46.5 686 2.1 42.1 50.8 
35-49 79.4 1,133 1.5 76.4 82.5  71.0 1,133 1.7 67.5 74.5  63.8 1,133 1.7 60.3 67.4 
15-49 69.8 2,107 1.3 67.2 72.4  59.9 2,107 1.4 57.1 62.8  52.8 2,107 1.3 50.0 55.5 
15-59 71.4 2,439 1.2 69.0 73.7  62.2 2,439 1.3 59.6 64.8  55.5 2,439 1.2 52.9 58.1 
MALES 
15-24 48.3          54  8.0 31.8 64.8  43.1          54  8.0 26.6 59.6  26.3          54  6.9 12.0 40.6 
25-34 47.3        164  4.4 38.3 56.2  35.8        164  4.5 26.6 45.1  32.5        164  4.4 23.4 41.6 
35-49 77.0        401  2.2 72.4 81.6  68.0        401  2.4 63.2 72.9  59.4        401  2.4 54.5 64.3 
15-49 66.0        619  2.2 61.5 70.4  56.7        619  2.2 52.1 61.3  48.7        619  2.2 44.3 53.2 
15-59 69.2        767  1.9 65.3 73.2  61.1        767  2.0 57.0 65.1  53.6        767  1.9 49.6 57.5 
FEMALES 
15-24 45.3        234  3.1 39.0 51.6  36.9        234  3.0 30.6 43.1  28.3        234  3.0 22.2 34.5 
25-34 73.1        522  2.1 68.6 77.5  59.0        522  2.3 54.3 63.8  52.4        522  2.3 47.7 57.1 
35-49 81.3        732  1.6 77.9 84.6  73.3        732  1.9 69.2 77.3  67.2        732  2.1 63.0 71.4 
15-49 72.0      1,488  1.4 69.1 74.8  61.7      1,488  1.6 58.5 64.9  55.0      1,488  1.6 51.8 58.2 
15-59 72.6      1,672  1.3 70.1 75.2  62.9      1,672  1.4 59.9 65.8  56.7      1,672  1.4 53.7 59.6 
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Table C.8:  Sampling errors: Number of new infections annually and number of PLHIV, ages 15-59 years, ZAMPHIA 2016 
  
Weighted 
estimate  
Standard 
error 
Lower 
confidence limit 
Upper 
confidence limit 
Number of new infections annually 42855 7050 28307 57402 
Number of PLHIV 960665 25579 907983 1013346 
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Obert Siazilemu Male Interviewer 
Clymore Kalyangile Team Lead 
Daniel Siakavuba Lab Technician 
Rosemary Chuza Nurse Counselor 
Nancy Mulamfwu Midwife 
Catherine Maliko Nurse Counselor 
Sandra Mushukulumbwe Female Interviewer 
Fielder Shampile Male Interviewer 
John Sambambi Team Lead 
Chabota Miyoba Lab Technician 
Nowanga Mabuku Nurse Counselor 
Annie Mutale Nurse Counselor 
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Laura b. Winga Midwife 
Cleopatra Mwanalushi Female Interviewer 
Sebby Nyanga Male Interviewer 
Liywali Simuyunyi Team Lead 
Sainedi Phiri Lab Technician 
Esnelly C. Ngoma  Nurse Counselor 
Mervis Bwalya Nurse Counselor 
Vinace Chingobe Midwife 
Pamela Hampwili Female Interviewer 
Webster Muyabi Male Interviewer 
Peter Kamangu Team Lead 
Chawela Nyondo Lab Technician 
Linda Chilongo Nurse Counselor 
Sharon Phiri Nurse Counselor 
Bibian Banda Midwife 
Patra Hamwanza Female Interviewer 
Alfred Mbewe Male Interviewer 
Webster Sikalumbi Team Lead 
Choolwe Hangoma Lab Technician 
Precious M. Kasewenta Nurse Counselor 
Tumelo Mshanga Nurse Counselor 
Elizabeth Kamanya Midwife 
Susan Siavwapa Female Interviewer 
Jeremiah Tembo Male Interviewer 
Somili Kalombo Team Lead 
Collins Litwayi Lab Technician 
Lusa Kitengwe Nurse Counselor 
Mbashila Muzhinga Nurse Counselor 
Eness Katanya Midwife 
Pungwa M. Mateo Female Interviewer 
Samuel Kapandula Male Interviewer 
Cyrus Nkumba Team Lead 
Patience Luneta Lab Technician 
Kambenjah Stellia Malenji Female Interviewer 
Susana Helasi Nurse Counselor 
Annie Kasongo Mumba Nurse Counselor 
Rachael Kamalamba Midwife 
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Innocent Musonda Male Interviewer 
Morgan Salimbunda Male Interviewer 
John Sambambi Team Lead 
Michael Muyutu Lab Technician 
Constance Mayondi Nurse Counselor 
Sombo Mundanya Nurse Counselor 
Prisca Phiri Midwife 
Mercy Kalungu Female Interviewer 
Prince Chilongu Male Interviewer 
Mutombu Kanganja Team Lead 
Gerald Musonda Lab Technician 
Stella Yamba Nurse Counselor 
Maureen Fubisha Female Interviewer 
Lovely Soneka Midwife 
Boombwe Mwale Female Interviewer 
Cletus Kaluwa Male Interviewer 
Begger Beenzu Team Lead 
Samuel Kimbambi Lab. Tech 
Ruth Katambi Nurse Counselor 
Beauty Mushala Nyikosa Female Interviewer 
Bupe Kiyekyaya Midwife/Counselor  
Sombo Chinyama Female Interviewer 
Makubanda Kabondo Male Interviewer 
Chris Lunzi Lubinda Team Lead 
Kapalu Dilema Lab Technician 
Grace Kapitango Nurse Counselor 
Loveness Womba Manengu Female Interviewer 
Sheila Makungu Midwife 
Martha Kazoko Muluka Female Interviewer 
Nasilele Kozi Male Interviewer 
Pelebo Hambulo Team Lead 
Florence Mushitala Lab Technician 
Jessica Sweta Nurse Counselor 
Catherine Kambita Female Interviewer 
Joan Mtonga Midwife/ Counselor 
Milton Chilongu Male Interviewer 
Isiyombo Sooka Male Interviewer 
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Jinix Kanyanga Team Lead 
Chiyesu Kang'ombi Lab Technician 
Fridah Kusaloka Nurse Counselor 
Sandra Kuchaya Female Interviewer 
Nama Felistus Lingwavo Female Interviewer 
Gladys K Machona Midwife/Counselor 
Shadreck Chileya Male Interviewer 
Sikundu Mwanalushi Team Lead 
Sandra Kamalamba Lab. Tech 
Susan Kayuka Nurse Counselor 
Mary Kozi Chama Midwife 
Florence Kaluwaji Female Interviewer 
Innocent Wema Male Nurse counsellor 
Victor Litia Liswaniso Male Interviewer 
Joseph Mashilipa Team Lead 
George Kamau Lab Technician 
Ella Simawu Nurse Counselor 
Kakuhu Mwezeh Nurse Counselor 
Ngambo Masumba Female Interviewer 
Given Kutela Female Interviewer 
Geoffrey Motoka Male Interviewer 
Clymore Kalyangile Team Lead 
Ferdinand Kanyanda Lab Technician 
Ngambo Kawilila Nurse Counselor 
Joseph Samukuwe Male Counselor 
Charity Mkanza Female Interviewer 
Patricia Funjika Female Interviewer 
Emmanuel Kanyoka Male Interviewer 
Jonathan Lutangu Team Leader 
Evans Mulyata Male Nurse/Interviewer 
Joyce Kamwana Nurse Counselor 
Edmond Kutela Male Counselor 
Catherine Kasabula Female Interviewer 
Carol Kachongo Female Interviewer 
Jedo Ndumba Male Interviewer 
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ENGLISH 
 
 
 
CONFIDENTIAL 
ZAMBIA MINISTRY OF HEALTH  
HIV IMPACT ASSESSMENT 
HOUSEHOLD QUESTIONNAIRE 
TICK IF HOUSEHOLD  
SELECTED FOR        
CHILDREN’S SURVEY 
HOUSEHOLD IDENTIFICATION 
PROVINCE NAME:   ______________________________________________ 
 
PROVINCE CODE  
 
REGION CODE 
 
DISTRICT CODE 
 
CLUSTER NUMBER 
 
HH NUMBER 
 
REGION NAME:  _______________________________________________ 
DISTRICT NAME: 
 _______________________________________________
_ 
CLUSTER NAME: _______________________________________________ 
NAME OF HOUSEHOLD HEAD: ______________________________________________ 
 
TOTAL PERSONS 
IN HOUSEHOLD: 
 
 
TOTAL ELIGIBLE 
WOMEN: 
 
 
TOTAL 
ELIGIBLE  
MEN: 
TOTAL 
ELIGIBLE 
ADOLESCENTS: 
 
TOTAL 
ELIGIBLE 
CHILDREN: 
 
 
LINE NO. OF RESPONDENT TO 
HOUSEHOLD QUESTIONNAIRE 
LANGUAGE OF INTERVIEW:  
 
LANGUAGE CODES: 
(01) ENGLISH 
(02) BEMBA 
(03) KAONDE   
(04) LOZI 
(05) LUNDA 
(06) LUVALE 
(07) NYANJA 
(08) TONGA 
 
SUPERVISOR:  ______________________________ 
 
              DATE:  ______________________________ 
 
SUPERVISOR CODE: 
 
FIELD 
EDITOR: 
OFFICE 
EDITOR: 
 
KEYED BY: 
* RESULTS CODES: 
(1) COMPLETED 
(2) NO HOUSEHOLD MEMBER AT HOME OR NO COMPETENT 
RESPONDENT AT HOME AT TIME OF VISIT 
(3) ENTIRE HOUSEHOLD ABSENT FOR EXTENDED PERIOD OF    
TIME 
(4) POSTPONED 
 
(5) REFUSED 
(6) DWELLING VACANT OR ADDRESS NOT A DWELLING 
(7) DWELLING DESTROYED 
(8) DWELLING NOT FOUND 
(9) PARTLY COMPLETED 
(10) OTHER (SPECIFY) 
START TIME 
 
START 
 
Record the start time.  
 
USE 24 HOUR TIME.  
 
IF START TIME IS 3:12 PM, RECORD 15 
HOURS, 12 MINUTES, NOT 03 HOURS, 12 
MINUTES.  
 
HOUR:  
 
MINUTES:   
 
APPENDIX E HOUSEHOLD QUESTIONNAIRE 
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LI
NE 
NO
. 
USUAL RESIDENTS AND 
VISITORS 
RELATIONSHIP 
TO HEAD OF 
HOUSEHOLD SEX RESIDENCE AGE 
  
Please give me the names of the 
persons who usually live in your 
household and guests of the 
household who stayed here last 
night, starting with the head of the 
household. 
 
AFTER LISTING THE NAME AND 
RECORDING THE RELATIONSHIP 
AND SEX FOR EACH PERSON 
ASK QUESTIONS 2-3 BELOW TO 
BE SURE THAT THE SCHEDULE 
IS COMPLETE. 
 
THEN ASK APPROPRIATE 
QUESTIONS IN COLUMNS 5-28c 
FOR EACH PERSON. 
What is the 
relationship of 
(NAME) to the 
head of the 
household? 
 
SEE CODES 
BELOW 
Is (NAME) 
Male or 
Female? 
Does 
(NAME) 
usually live 
here? 
Did (NAME) 
sleep here 
last night? 
IF LESS THAN 2 YEARS, 
RECORD IN MONTHS. 
 
 
How old is 
(NAME)? 
Is age of 
(NAME) 
recorded in 
MONTHS/ 
YEARS? 
(1) (2) (3) (4) (5) (6) (7) (8) 
1  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
2  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
3  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
4  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
5  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
6  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
7  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
8  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
9  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
10  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
  CODES FOR COLUMN 3: RELATIONSHIP TO HOUSEHOLD HEAD 
YES    NO 01 = HEAD 
02 = 
WIFE/HUSBAND/PARTN
ER 
03 = SON OR 
DAUGHTER 
04 = SON-IN-LAW/ 
        DAUGHTER-IN-LAW 
05 = GRANDCHILD 
06 = PARENT 
07 = PARENT-IN-LAW 
08 = BROTHER/SISTER 
09 = CO-WIFE 
10 = OTHER RELATIVE 
11 = ADOPTED/ 
        FOSTER/STEPCHILD 
12 =  NOT RELATED 
98 = DON’T KNOW 
YES    NO 
YES 
 
ADD TO 
SCHED
ULE 
   NO 
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HOUSEHOLD SCHEDULE 
LINE 
NO. 
IF (NAME) is 18-
64 years 
IF (NAME) IS 15 
OR OLDER IF (NAME) IS 0-17 YEARS 
SICK PERSON MARITAL STATUS SURVIVORSHIP AND RESIDENCE OF BIOLOGICAL PARENTS 
 
CHECK COLUMNS 
7 AND 8, IF 
UNDER 18 
➔ 10 
 
IF 18 YEARS OR 
MORE: 
 
Has (NAME) been 
very sick for at least 
3 months during the 
past 12 months, 
that is (NAME) was 
too sick to work or 
do normal 
activities? 
What is (NAME)’s 
current marital 
status? 
 
1=MARRIED/COHA
BITATING/LIVING 
TOGETHER 
2=DIVORCED 
3=SEPARATED 
4=WIDOWED 
5=NEVER-
MARRIED 
Is (NAME)’s 
natural 
mother 
alive? 
Does (NAME)’s 
natural mother 
usually live in this 
household or 
was she a guest 
last night? 
 
IF YES: What is 
her name? 
RECORD 
MOTHER’S LINE 
NUMBER. 
 
IF NO: 
RECORD 
FEMALE 
GUARDIAN’S 
LINE NUMBER 
OR ‘00’ IF 
FEMALE 
PARENT OR 
GUARDIAN NOT 
PRESENT IN 
HH. 
Is (NAME)’s 
natural 
father alive? 
Does (NAME)’s natural father 
usually live in this household or 
was he a guest last night? 
 
IF YES: What is his name? 
RECORD FATHER’S LINE 
NUMBER. 
 
IF NO: 
RECORD MALE GUARDIAN’S 
LINE NUMBER OR ‘00’ IF MALE 
PARENT OR GUARDIAN NOT 
PRESENT IN HH. 
(1) (9) (10) (11) (12) (13) (14) 
1 
 
Y       N 
 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
2 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
3 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
4 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
5 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
6 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      14 
 
7 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
8 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
9 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
 
10 
 
Y       N 
 
Y     N     DK 
        
      13 
 
Y     N     DK 
        
      15 
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HOUSEHOLD SCHEDULE 
LINE 
NO. 
IF (NAME) is 0-17 years 
 SICKNESS AND RESIDENCE OF BIOLOGICAL 
PARENTS 
MOTHER 
DEAD OR 
SICK 
FATHER DEAD 
OR SICK 
 
RECORD LIN 
E NUMBER OF 
PARENT/GUARDIAN WHO WILL 
FILL OUT CHILDREN’S MODULE 
FOR (NAME) 
CHECK COLUMN  11, IF 
COLUMN 11 ‘N’ ➔ 18 
 
IF COLUMN 11 ‘Y’: 
 
Has (NAME)’s natural mother 
been very sick for at least 3 
months during the past 12 
months, that is she was too 
sick to work or do normal 
activities? 
CHECK COLUMN 12, IF 
COLUMN 12 ‘N’ ➔ 19 
 
 
IF COLUMN 13 ‘Y’: 
 
Has (NAME)’s natural 
father been very sick for at 
least 3 months during the 
past 12 months, that is he 
was too sick to work or do 
normal activities? 
 
IF CHILD’S 
NATURAL 
MOTHER 
HAS DIED 
(COLUMN 11 
‘N’) OR BEEN 
SICK 
(COLUMN 16 
‘Y’), SELECT 
Y. 
 
IF CHILD’S 
NATURAL 
FATHER HAS 
DIED (COLUMN 
13‘N’) OR BEEN 
SICK (COLUMN 
17 ‘Y’), SELECT 
Y. 
(1) (15) (16) (17) (18) (19) 
1 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
2 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
3 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
4 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
5 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
6 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
7 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
8 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
9 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
 
10 
 
 
Y         N 
                        
                  
 
Y         N 
                        
                 
 
Y       N 
 
 
Y       N 
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 HOUSEHOLD SCHEDULE 
LINE NO. 
IF (NAME) IS 5 YEARS OR OLDER IF (NAME) IS 5-24 YEARS 
IF (NAME) IS 0-4 
YEARS 
EVER ATTENDED SCHOOL 
CURRENT/RECENT SCHOOL ATTENDANCE 
BIRTH 
REGISTRATION 
 
Has (NAME) 
ever 
attended 
school? 
What is the highest level of school 
(NAME) has attended? 
 
SEE CODES BELOW. 
 
What is the highest grade 
(NAME) completed at that level? 
 
SEE CODES BELOW. 
Did (NAME) 
attend school 
at any time 
during the 
2015 school 
year? 
During this/that school year, 
what level and grade [is/was] 
(NAME) attending? 
 
SEE CODES BELOW. 
Does (NAME) have a 
birth certificate? 
 
IF NO, PROBE: Has 
(NAME)’s birth ever 
been registered with 
the civil authority? 
 
1=HAS CERTIFICATE 
2=REGISTERED 
3=NEITHER 
4=DON’T KNOW 
(1) (20) (21) (22) (23) (24) 
1 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE  
2 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
3 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
4 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
5 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
6 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
7 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
8 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
9 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
10 Y       N 
 LEVEL      GRADE 
Y       N 
 LEVEL      GRADE 
 
 
CODES FOR Q21 AND Q23 (EDUCATION): 
 
LEVEL 
0=NURSERY/KINDERGARTEN 
1=PRIMARY 
2=SECONDARY 
3=HIGHER 
8=DON’T KNOW 
 
GRADE 
00=LESS THAN 1 YEAR COMPLETED 
98=DON’T KNOW 
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 HOUSEHOLD SCHEDULE 
LINE 
NO. 
ELIGIBILITY 
 
DO NOT READ: 
 
IS (NAME) ELIGIBLE 
FOR SURVEY? 
   
(1) (25)    
1 Y               N    
2 Y               N    
3 Y               N    
4 Y               N    
5 Y               N    
6 Y               N    
7 Y               N    
8 Y               N    
9 Y               N    
10 Y               N    
 
 
TOTAL ELIGIBLE MEN (ADULTS 15-59 YEARS) 
TOTAL ELIGIBLE WOMEN (ADULTS 15 -59 YEARS) 
TOTAL ELIGIBLE ADOLESCENT (10 TO 14 YEARS) 
TOTAL ELIGIBLE CHILDREN (0 MONTHS TO 9 YEARS) 
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 HOUSEHOLD SCHEDULE 
LINE NO. 
SPOUSES AND CO-HABITATING PARTNERS 
 
Record the LINE 
NUMBER (NAME)’s 
of spouse or partner. 
If no spouse or 
partner leave blank. 
Record the LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If no 
spouse or partner 
leave blank. 
Record the LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If no 
spouse or 
partner leave 
blank. 
Record the LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If no 
spouse or 
partner leave 
blank. 
Record the LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If no 
spouse or 
partner leave 
blank. 
Record the LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If no 
spouse or 
partner leave 
blank. 
(1) (26a) (26b) (26c) (26d) (26e) (26f) 
1 
      
2 
      
3 
      
4 
      
5 
      
6 
      
7 
      
8 
      
9 
      
10 
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SUPPORT FOR ORPHANS AND VULNERABLE CHILDREN  
 
101 
 
DO NOT READ:  CHECK COLUMN 7 IN THE 
HOUSEHOLD SCHEDULE. 
 
ANY CHILD AGE 0-17 YEARS? 
 
 
NUMBER OF  
CHILDREN 
0-17 YRS:   
 
NONE
→114 
 
102 
 
DO NOT READ:  CHECK COLUMN 9 IN THE 
HOUSEHOLD SCHEDULE. 
 
ANY SICK ADULT AGE 18-64 YEARS? 
 
YES………………………………………..……1 
NO………………………………………………2 
 
YES →     
105 
 
103 
 
DO NOT READ:  CHECK COLUMN 18 IN THE 
HOUSEHOLD SCHEDULE. 
 
ANY CHILD WHOSE MOTHER HAS DIED OR 
IS VERY SICK? 
 
 
 
YES………………………………………..……1 
NO………………………………………………2 
 
YES→     
105 
      
 
104 
 
DO NOT READ:  CHECK COLUMN 19 IN THE 
HOUSEHOLD SCHEDULE. 
 
ANY CHILD WHOSE FATHER HAS DIED OR 
IS VERY SICK? 
 
 
 
YES………………………………………..……1 
NO………………………………………………2 
 
NO→114  
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105 
 
Record names, line numbers, and ages of all children 0-17 who are identified in columns 11, 13, 
16 and 17 as having a sick adult in their household or having a mother and/or father who has 
died or has been very sick. 
  
 
 
NAME (FROM COLUMN 2) 
 
CHILD (1) 
 
________________ 
 
CHILD (2) 
 
________________ 
 
CHILD (3) 
 
________________ 
 
 
 
 
LINE NUMER (FROM COLUMN 1) 
   
  
 
AGE (FROM COLUMN 7) 
 
   
 
➢ INTERVIEWER SAY:  “I would like to ask you about any formal, organized help or 
support for children that your household may have received for which you did not 
have to pay. By formal, organized support, I mean help provided by someone 
working for a program. This program could be government, private, religious, 
charity, or community-based.” 
 
106 
 
Now I would like to ask you about 
the support your household received 
for (NAME). 
 
In the last 12 months, has your 
household received any medical 
support for (NAME), such as medical 
care, supplies, or medicine, for which 
you did not have to pay? 
 
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
  
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
 
107 
 
In the last 12 months, has your 
household received any emotional or 
psychological support for (NAME), 
such as companionship, counseling 
from a trained counselor, or spiritual 
support, which you received at home 
and for which you did not have to 
pay? 
 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8 
 
       
NO, DK→ 109 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8 
 
       
  NO, DK→ 109 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8 
 
       
NO, DK→ 109 
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108 
 
Did your household receive any of 
this emotional or psychological 
support for (NAME) in the past 3 
months? 
 
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
  
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
 
109 
 
In the last 12 months, has your 
household received any material 
support for (NAME), such as 
clothing, food, or financial support, 
for which you did not have to pay? 
 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8 
 
NO, DK → 111 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8        
 
NO, DK→ 111 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8        
 
NO, DK→ 111 
 
110 
 
Did your household receive any of 
this material support for (NAME) in 
the past 3 months? 
 
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
  
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
 
 
111 
 
In the last 12 months, has your 
household received any social 
support for (NAME) such as help in 
household work, training for a 
caregiver, or legal services, for which 
you did not have to pay? 
 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8 
 
NO, DK → 113 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8 
 
NO, DK → 113 
 
 
YES…………………1 
NO…………………..2 
DON’T KNOW……..8 
 
NO, DK → 113 
 
 
112 
 
Did your household receive any of 
this social support for (NAME) in the 
past 3 months? 
 
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
  
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
 
YES…………………1 
NO…………………..2 
  DON’T KNOW……..8  
113  
In the last 12 months, has your 
household received any support for 
(NAME)’s schooling, such as 
allowance, free admission, books, or 
supplies, for which you did not have 
to pay? 
 
 
YES…………………1 
NO, DID NOT 
RECEIVE 
SUPPORT...………..2 
NO, CHILD DOES 
NOT ATTEND 
SCHOOL…………...3 
  DON’T KNOW……..8 
 
SKIP IF CHILD<5 
YEARS 
 
YES…………………1 
NO, DID NOT 
RECEIVE 
SUPPORT...………..2 
NO, CHILD DOES 
NOT ATTEND 
SCHOOL…………...3 
  DON’T KNOW……..8 
 
SKIP IF CHILD<5 
YEARS 
 
YES…………………1 
NO, DID NOT 
RECEIVE 
SUPPORT...………..2 
NO, CHILD DOES 
NOT ATTEND 
SCHOOL…………...3 
  DON’T KNOW……..8 
 
SKIP IF CHILD<5 
YEARS 
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MATRIX END 
INTERVIEWER SAYS: “Thank you for the information regarding (NAME).” 
 
IF THERE IS ANOTHER CHILD 0-17 YEARS IN THE HOUSEHOLD WHO HAS BEEN IDENTIFIED IN 105 AS 
HAVING A MOTHER/FATHER WHO HAS DIED OR IS VERY SICK BESIDES (NAME) → CONTINUE TO 106 AND 
ASK ABOUT THE NEXT CHILD. 
 
INTERVIEWER SAYS: “Next, I would like to ask you about (NAME)”.  
 
         TICK IF CONTINUATION SHEET REQUIRED. 
 
IF NO OTHER CHILDREN, CONTINUE HOUSEHOLD INTERVIEW. 
 
HOUSEHOLD DEATHS  
114  
Now I would like to ask you more questions 
about your household. Has any usual resident of 
your household died since 2013? 
 
YES………………………………………..……1 
NO………………………………………………2 
 
NO → 201 
 
115  
How many usual household residents died since 
2013?   
 
NUMBER OF DEATHS…………. 
 
      
 
 
 
ASK 116-119 AS APPROPRIATE FOR EACH PERSON WHO DIED. IF THERE WERE MORE THAN 3 
DEATHS USE ADDITIONAL QUESTIONNAIRES. 
116  
What was the name of the person 
who died (most recently/before 
him/her)? 
 
 
NAME 1ST DEATH  
 
__________________ 
  
NAME 2ND DEATH  
 
__________________ 
 
NAME 3RD DEATH  
 
__________________ 
117  
When did (NAME) die? Please give 
your best guess. 
 
DAY 
 
 
MONTH 
 
 
YEAR 
 
DAY 
 
 
MONTH 
 
 
YEAR 
 
DAY 
 
 
MONTH 
 
 
YEAR 
118  
Was (NAME) male or female? 
 
 
MALE ……………….1 
 
FEMALE…………….2 
 
 
MALE ……………….1 
 
FEMALE…………….2 
 
 
MALE ……………….1 
 
FEMALE…………….2 
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119  
How old was (NAME) when (he/she) 
died? 
 
RECORD DAYS IF LESS THAN 1 
MONTH, MONTHS IF LESS THAN 1 
YEAR, AND COMPLETED YEARS 
IF 1 YEAR OR MORE. 
 
DAYS 
 
 
MONTHS 
 
 
YEARS 
 
DAYS 
 
 
MONTHS 
 
 
YEARS 
 
DAYS 
 
 
MONTHS 
 
 
YEARS 
  
CONTINUE TO NEXT DEATH ACCORDING UP TO THE NUMBER REPORTED FROM 115. 
 
         TICK IF CONTINUATION SHEET REQUIRED. 
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HOUSEHOLD CHARACTERISTICS 
 
201 
 
What is the main source of drinking water for 
members of your household? 
 
PIPED WATER 
PIPED INTO DWELLING………………11 
PIPED TO YARD/PLOT………………...12 
PUBLIC TAP/STANDPIPE……………..13 
TUBE WELL OR BOREHOLE……………21 
DUG WELL 
   PROTECTED WELL…………………….31 
   UNPROTECTED WELL………………...32 
WATER FROM SPRING 
   PROTECTED SPRING………………….41 
   UNPROTECTED SPRING……………...42 
RAINWATER………………………………..51 
TANKER TRUCK…………………………...61 
CART WITH SMALL TANK……………….71 
SURFACE WATER (RIVER/DAM/LAKE/ 
POND/STREAM/CANAL/IRRIGATION 
CHANNEL)………………...........................81 
BOTTLED WATER………………………...91 
OTHER……………………………………...96 
___________________________________ 
(SPECIFY) 
 
 
11, 12, 51 
→  204 
 
201a Where is that water source located? IN OWN DWELLING…………………………..1 
IN OWN YARD/PLOT………………………....2 
ELSEWHERE………………………………….3 
1,2 → 203 
201b How long does it take to go there, get water, and 
come back? 
 
MINUTES    
 
ON PREMISES……………………………...996 
DON’T KNOW……………………………….998 
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202  
 
What do you usually do to make your water safer 
to drink? 
 
Anything else? 
 
RECORD ALL MENTIONED. 
 
BOIL……………………………………………A 
ADD BLEACH/CHLORINE/CLORIN…….....B 
STRAIN THROUGH A CLOTH……………..C 
USE WATER FILTER 
(CERAMIC/SAND/COMPOSITE/ETC.)..…...D 
SOLAR DISINFECTION……..……………....E 
LET IT STAND AND SETTLE..……………..F 
OTHER………………………………………..X 
___________________________________ 
(SPECIFY) 
DON’T KNOW ………………………………..Z 
 
 
203 
 
What kind of toilet facility do members of your 
household usually use? 
 
FLUSH OR POUR FLUSH TOILET 
     FLUSH TO PIPED SEWER 
        SYSTEM…………………………….…..11 
     FLUSH TO SEPTIC TANK………………12 
     FLUSH TO PIT LATRINE……….……….13 
     FLUSH TO SOMEWHERE ELSE……....14 
     FLUSH, DON’T KNOW WHERE………..15  
PIT LATRINE 
     VENTILATED IMPROVED 
        PIT LATRINE …..21 
     PIT LATRINE WITH SLAB………………22 
     PIT LATRINE WITHOUT SLAB/ 
        OPEN PIT…………………………...…..23 
COMPOSTING TOILET……………………..31 
BUCKET TOILET………………………...….41 
HANGING TOILET/HANGING LATRINE…51 
NO FACILITY/BUSH/FIELD…………......…61 
  
OTHER……………………………………….96 
 
___________________________________ 
(SPECIFY) 
 
 
NO 
FACILITY/
BUSH/FIEL
D → 206 
 
204 
 
Do you share this toilet facility with other 
households? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
NO → 206 
 
205 
 
How many households use this toilet facility? 
 
NO. OF HOUSEHOLDS IF LESS THAN 10 
________(1 DIGIT) 
10 OR MORE HOUSEHOLDS …………….95 
DON’T KNOW ……………………………….98 
 
PREFACE BEFORE QUESTIONS 206-212r:  
Does your household have: 
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206 
 
 
Electricity? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
207 
 
A radio? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
208 
 
A television? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
 209 
 
A mobile telephone?  
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
  
210 
 
A non-mobile telephone? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
211 
 
A refrigerator?  
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
212a A bed? YES………………………………………....…1 
NO…………………………………………..…2 
 
212b A chair? YES………………………………………....…1 
NO…………………………………………..…2 
 
212c A table? YES………………………………………....…1 
NO…………………………………………..…2 
 
212d A cupboard? YES………………………………………....…1 
NO…………………………………………..…2 
 
212e A sofa? YES………………………………………....…1 
NO…………………………………………..…2 
 
212f A clock? YES………………………………………....…1 
NO…………………………………………..…2 
 
212g A fan? YES………………………………………....…1 
NO…………………………………………..…2 
 
212h A sewing machine? YES………………………………………....…1 
NO…………………………………………..…2 
 
212i A cassette player? YES………………………………………....…1 
NO…………………………………………..…2 
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212j A plough? YES………………………………………....…1 
NO…………………………………………..…2 
 
212k A grain grinder? YES………………………………………....…1 
NO…………………………………………..…2 
 
212l A VCR/DVD? YES………………………………………....…1 
NO…………………………………………..…2 
 
212m A tractor? YES………………………………………....…1 
NO…………………………………………..…2 
 
212n A hammer mill? YES………………………………………....…1 
NO…………………………………………..…2 
 
212o A computer? YES………………………………………....…1 
NO…………………………………………..…2 
 
212p Internet? YES………………………………………....…1 
NO…………………………………………..…2 
 
212q A microwave? YES………………………………………....…1 
NO…………………………………………..…2 
 
212r Does your household have any mosquito nets that 
can be used while sleeping? 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
213 
 
What type of fuel does your household mainly use 
for cooking? 
 
ELECTRICITY…………………………………1 
LIQUID PRONAME GAS (LPG) …………….2 
NATURAL GAS ………………………….……3 
BIOGAS…………………………….…………..4 
KEROSENE                     …………….………5 
COAL, LIGNITE……………………….……….7 
CHARCOAL  …………………………….…….8  
WOOD…………………………………………..9 
STRAW/SHRUBS/GRASS…………....…….10 
AGRICULTURAL CROP                           …11 
ANIMAL DUNG……………………………….12 
SOLAR POWER………………………….…..13 
NO FOOD COOKED IN HOUSEHOLD…  ...95 
OTHER………………………………….……..96 
___________________________________ 
(SPECIFY) 
 
 185 
 
 
214 
 
MAIN MATERIAL OF FLOOR 
 
RECORD OBSERVATION. 
 
NATURAL FLOOR 
   EARTH / SAND…………………………………11 
   DUNG……………………………………………12 
RUDIMENTARY FLOOR 
   WOOD PLANKS………………………………..21 
   PALM/BAMBOO/LEEDS………………………22 
FINISHED FLOOR 
PARQUET OR POLISHED WOOD………….31 
VINYL (PVC) OR ASPHALT STRIPS…………32 
CERAMIC/TERRAZZO TILES……………….33 
CONCRETE CEMENT ………………….……34 
CARPET………………………………………..35 
OTHER…………………………………………….96 
___________________________________ 
(SPECIFY) 
 
 
215 
 
MAIN MATERIAL OF THE ROOF 
 
RECORD OBSERVATION. 
 
NATURAL ROOFING 
   NO ROOF……………………………………….…11 
   THATCH/PALM LEAF …………………………...12 
  
RUDIMENTARY ROOFING 
     RUSTIC MAT……………………………..…..….21 
     PALM/BAMBOO…………………………………22 
    WOOD PLANKS……………………….…….…..23   
   CARDBOARD………………..……………………24 
 
FINISHED ROOFING 
     METAL/IRON 
SHEETS………………………...31WOOD……………
…………………….….......…….32  
     CALAMINE/CEMENT/FIBRE (ASBESTOS)….33  
     CERAMIC TILES/HARVEY TILES……...……..34 
     CEMENT………………………………...……….35  
 ROOFING SHINGLES…………………………….36 
MUD TILES………………………………………….37 
OTHER……………………….……………………...96 
___________________________________ 
(SPECIFY)    
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216 
 
MAIN MATERIAL OF THE EXTERIOR WALLS 
 
RECORD OBSERVATION. 
 
NATURAL WALLS 
NO WALLS…………………………………………11      
CANE/PALM/TRUNKS………….………………...12 
     MUD………………………………………….…..13 
  
RUDIMENTARY WALLS 
    BAMBOO/POLE WITH MUD……………………21 
   STONE WITH MUD……………….……..……….22 
   PLYWOOD …………..…………………….…….24 
   CARDBOARD…………………….…....25 
   REUSED WOOD………….………………...……26 
FINISHED WALLS 
CEMENT…………………………………….…….…31 
STONE WITH LIME/CEMENT………………….….32 
BRICKS……………………………………..……....33 
CEMENT BLOCKS…………………………………34 
WOOD PLANKS ……………...………35 
OTHER………………………………………….…...96 
___________________________________ 
(SPECIFY) 
 
 
  
217 
 
How many rooms in this household are used for 
sleeping? 
 
NUMBER OF ROOMS: 
 
PREFACE BEFORE QUESTIONS 218-224a:  
Does any member of your household own: 
 
 
218 
 
A bicycle? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
  
219 
 
A motorcycle or motor scooter? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
  
220 
 
A car or truck? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
 
221  
 
A boat with a motor? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
222 
 
A watch? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
223 
 
An animal-drawn cart? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
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224a A banana boat? 
YES………………………………………....…1 
NO…………………………………………..…2 
 
224b 
Does any member of this household own any 
agricultural land? 
YES………………………………………....…1 
NO…………………………………………..…2 
NO → 
224d 
224c 
How many lima, acres, or hectares of agricultural 
land do members of this household own? 
LIMA 
                                         
ACRES 
 
HECTARES 
 
95 OR MORE HECTARES………………..995 
DON’T KNOW………………………………998 
 
224d 
Does this household own any livestock, herds, 
other farm animals, or poultry? 
YES………………………………………....…1 
NO…………………………………………..…2 
NO→227 
PREFACE BEFORE QUESTIONS   225-226i:  
How many of [INSERT ANIMAL] does this household own? 
 
IF NONE, ENTER ‘00’. 
IF MORE THAN 95, ENTER ‘95’. 
IF UNKNOWN, ENTER ’98’. 
 
 
  
225 
 
Traditional cattle? 
 
 
 
 
 
 
226a Dairy cattle? 
  
226b Beef cattle? 
  
 
226c 
 
Goats? 
 
 
 
 
 
  
226d 
 
Sheep? 
  
. 
. 
. 
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226e 
 
Chicken or other poultry?   
 
 
 
 
 
 
  
226f 
 
  
Horses/donkeys/mules? 
 
 
 
 
 
 
226g 
 
Rabbits? 
 
 
 
 
 
 
226h 
 
Pigs? 
 
 
 
 
 
226i Other livestock? 
  
227 
Does any member of this household have a bank 
account? 
YES………………………………………....…1 
NO…………………………………………..…2 
 
228 
In the past 4 weeks, was there ever no food to eat 
of any kind in your household because of lack of 
resources to get food? 
YES………………………………………....…1 
NO…………………………………………..…2 
DON’T KNOW………………………………..8 
NO, DON’T 
KNOW → 
230 
229 How often did this happen in the past 4 weeks? 
RARELY (1-2 TIMES).…………………....…1 
SOMETIMES (3-10 TIMES)………………...2 
OFTEN (MORE THAN 10 TIMES)..………..3 
 
230 
In the past 4 weeks, did you or any household 
member go to sleep at night hungry because there 
was not enough food? 
YES………………………………………....…1 
NO…………………………………………..…2 
DON’T KNOW………………………………..8 
NO, DON’T 
KNOW → 
232 
231 How often did this happen in the past 4 weeks? 
RARELY (1-2 TIMES).…………………....…1 
SOMETIMES (3-10 TIMES)………………...2 
OFTEN (MORE THAN 10 TIMES)..………..3 
 
232 
In the past 4 weeks, did you or any household 
member go a whole day and night without eating 
anything because there was not enough food? 
YES………………………………………....…1 
NO…………………………………………..…2 
DON’T KNOW………………………………..8 
 
233 How often did this happen in the past 4 weeks? 
RARELY (1-2 TIMES).…………………....…1 
SOMETIMES (3-10 TIMES)………………...2 
OFTEN (MORE THAN 10 TIMES)..………..3 
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ECONOMIC SUPPORT 
 
301 
 
Has your household received any of the following 
forms of external economic support in the last 12 
months? 
 
SELECT ALL THAT APPLY. 
 
NOTHING ……………………………………..A 
CASH TRANSFER (E.G., PENSIONS, 
DISABILITY GRANTS, CHILD 
GRANT)…..……………………………………B 
ASSISTANCE FOR SCHOOL FEES…….....C 
MATERIAL SUPPORT FOR EDUCATION 
(E.G., UNIFORMS, SCHOOL BOOKS, 
EDUCATION, TUITION SUPPORT, 
BURSARIES)…………………………………..D 
INCOME GENERATION SUPPORT IN CASH 
OR KIND (E.G., AGRIGULTURAL 
INPUTS)………………..……………………...E 
FOOD ASSISTANCE PROVIDED AT THE 
HOUSEHOLD OR EXTERNAL 
INSTITUTION………….……..…………….....F 
MATERIAL OR FINANCIAL SUPPORT FOR 
SHELTER……………………....……………..G 
SOCIAL 
PENSION……………………....……………..H 
OTHER………………………………………..X 
___________________________________ 
(SPECIFY) 
DON’T KNOW ………………………………..Z 
 
NOTHING 
→END OF 
SECTION 
 
302 
 
Has your household received any of the following 
forms of external economic support in the last 3 
months? 
 
SELECT ALL THAT APPLY. 
 
NOTHING ……………………………………..A 
CASH TRANSFER (E.G., PENSIONS, 
DISABILITY GRANTS, CHILD 
GRANT)…..……………………………………B 
ASSISTANCE FOR SCHOOL FEES…….....C 
MATERIAL SUPPORT FOR EDUCATION 
(E.G., UNIFORMS, SCHOOL BOOKS, 
EDUCATION, TUITION SUPPORT, 
BURSARIES)…………………………………..D 
INCOME GENERATION SUPPORT IN CASH 
OR KIND (E.G., AGRIGULTURAL 
INPUTS)………………..……………………...E 
FOOD ASSISTANCE PROVIDED AT THE 
HOUSEHOLD OR EXTERNAL 
INSTITUTION………….……..…………….....F 
MATERIAL OR FINANCIAL SUPPORT FOR 
SHELTER……………………....……………..G 
SOCIAL 
PENSION……………………....……………..H 
OTHER………………………………………..X 
___________________________________ 
(SPECIFY) 
DON’T KNOW ………………………………..Z 
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END OF HOUSEHOLD INTERVIEW 
➢ INTERVIEWER SAY: “This is the end of the household survey. Thank you very much for your time 
and for your responses.” 
END TIME 
 
END 
 
Record the end time.  
 
USE 24 HOUR TIME.  
 
IF START TIME IS 3:12 PM, RECORD 15 
HOURS, 12 MINUTES, NOT 03 HOURS, 12 
MINUTES.  
 
 
 
HOUR:  
 
MINUTES:   
 
 
INTERVIEWER OBSERVATIONS: 
TO BE COMPLETED AFTER THE INTERVIEW: 
 
COMMENTS ABOUT RESPONDENT:  
 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________ 
 
COMMENTS ABOUT SPECIFIC QUESTIONS:  
 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________ 
 
GENERAL QUESTIONS:  
 
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________ 
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MODULE 1: RESPONDENT BACKGROUND  
 
L1 
 
 
 
 
 
 
 
 
LANGUAGE OF QUESTIONNAIRE 
  
 
ENGLISH =1 
BEMBA =2 
KAONDE =3 
LOZI =4 
LUNDA =5 
LUVALE =6 
NYANJA =7 
TONGA =8 
  
  
 
L2 
 
 
 
 
 
 
  
 
LANGUAGE OF INTERVIEW 
  
 
ENGLISH =1 
BEMBA  =2 
KAONDE =3 
LOZI =4 
LUNDA =5 
LUVALE =6 
NYANJA =7 
TONGA =8 
OTHER =9 
  
  
 
L3 
 
 
 
 
 
 
  
 
NATIVE LANGUAGE OF PARTICIPANT 
 
ENGLISH =1 
BEMBA =2 
KAONDE =3 
LOZI =4 
LUNDA =5  
LUVALE =6 
NYANJA =7  
 
APPENDIX F ADULT QUESTIONNAIRE 
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TONGA =8 
OTHER =9 
L4 
  
TRANSLATOR USED 
  YES =1 
NO =2  
  
  
 
Interviewer says: “Thank you for agreeing to participate in this survey. The first set of questions is about your life in general. 
Afterwards, we will move on to other topics.” 
  
  
101 
  
IS THE RESPONDENT MALE OR FEMALE? 
  
 
MALE =1 
FEMALE =2 
 
  
  
103 
  
  
  
 
Have you ever attended school? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 103 = 2,-8,-9 
 
SKIP TO 106 
104 
  
  
  
Are you enrolled in school? 
  
 
YES =-1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 104 = -8, -9 
  
SKIP TO 106 
105 
 
 
  
What is the highest level of school you 
attended: primary, secondary, or higher? 
  
 
PRIMARY =1 
SECONDARY =2 
HIGHER =3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
106 
  
  
What is the highest [class/form/year] you 
completed at that level? 
  
 
CLASS/FORM/YEAR =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
 
106a 
 
 
  
 
How long have you been living continuously in 
[NAME OF CURRENT PLACE OF 
RESIDENCE- HOUSEHOLD]? 
 
 
NUMBER OF YEARS =integer 
ALWAYS =95 
VISITOR =96 
DON'T KNOW =-8 
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IF LESS THAN ONE YEAR, RECORD '00' 
YEARS. 
REFUSED =-9 
107 
  
  
In the last 12 months, on how many separate 
occasions have you been away from home for 
one or more nights?  
CODE ‘00’ IF NONE. 
  
 
NUMBER OF TRIPS =integer 
DON’T KNOW =-8 
REFUSED =-9 
IF 107 = 0,-8,-9 
SKIP TO 109 
  
108 
 
 
 
In the last 12 months, have you been away 
from your home for more than one month at a 
time? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
109 
  
  
  
Have you done any work in the last 12 months 
for which you received a salary, cash or in 
kind as payment? 
  
 
YES =1 
NO  =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 109= 2,-8,-9 
SKIP TO 109b 
  
109a 
  
  
  
Have you done any work in the last 7 days for 
which you received a salary, cash or in kind as 
payment? 
 
YES =1 
NO =2 
DON’T KNOW  =-8 
REFUSED =-9 
 
 
109b 
 
 
 
 
 
 
 
 
 
 
  
 
What is your ethnic group/tribe? 
 
BEMBA =1 
TONGA =2 
KAONDE =3 
LOZI =4 
LUNDA =5 
LUVALE =6 
MAMBWE =7 
NGONI =8 
NYANJA =9 
TUMBUKA=10 
OTHER =96 
DON'T KNOW =-8 
REFUSED =-9 
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110 
  
  
  
  
  
What is your religion? 
 
CATHOLIC =1 
PROTESTANT =2 
MUSLIM =3 
NONE =4 
OTHER =96 
DON'T KNOW =-8 
REFUSED =-9  
  
 
 
 
 
MODULE 2: MARRIAGE  
 
Interviewer says: “Now I would like to ask you about your current and previous relationships and/or marriages.  
  
  
     201       
  
  
  
Have you ever been married or lived together 
with a [man/woman] as if married? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 201 = 2,-8,-9 
SKIP TO 301 
  
     202       
  
  
 
How old were you the first time you married or 
started living with a [man/woman] as if married? 
  
 
AGE IN YEARS =integer 
DON’T KNOW  =-8 
REFUSED =-9 
  
  
     203       
  
  
  
 
Have you ever been widowed? That is, did a 
spouse ever die while you were still married or 
living with them? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSE TO ANSWER =-9 
  
  
     204       
  
  
  
  
  
  
 
What is your marital status now: are you married, 
living together with someone as if married, 
widowed, divorced, or separated? 
MARRIED =1 
LIVING TOGETHER =2 
WIDOWED =3 
DIVORCED =4 
SEPARATED =5 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 204 = 3,4,5,-8,-9 
SKIP TO 301 
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Interviewer says: “The next several questions are about your current spouse or partner(s).” 
  
  
208 
  
  
Altogether, how many wives or partners do you 
have?  
  
 
NUMBER OF WIVES OR PARTNERS 
=integer 
DON’T KNOW =-8 
REFUSED =-9 
IF 208 = -8,-9 
SKIP Q IF 101=2 
SKIP TO 301 
  
 
M2B 
 
  
 
The Household schedule listed [count] household 
members as your wives/partners. Please review 
the list below. Are all of the listed household 
members your wives/partners who live in the 
household?   
[List of partners] 
  
 
YES =1 
NO =2 
DON'T KNOW =-8 
REFUSED =-9 
IF M2B= 1 
SKIP TO Q3 
IF M2B= -8,-9 
SKIP TO 301 
SKIP Q IF 101=2 
SKP TO 301 
209.2 
  
  
  
 
Is [NAME] your wife/partner? 
 
YES =1 
NO =2 
DON'T KNOW =-8 
REFUSED =-9 
  
SKIP Q IF 101=2 
 
209.3 
  
  
  
 
Does [NAME] live in the household? 
 
YES =1 
NO =2 
DON'T KNOW =-8 
REFUSED =-9 
After loop 
SKIP Q IF 101=2 
SKIP TO Q3 
Q3 
  
  
  
Do you have additional spouse(s)/partner(s) that 
live with you? 
 
YES =1 
NO=2 
DON'T KNOW =-8 
REFUSED =-9 
IF Q3= 2,-8,-9 
SKIP Q IF 101=2 
SKIP TO 301 
Q4 
  
 
How many additional spouses(s)/partner(s) live 
with you? 
 
NUMBER OF ADDITIONAL 
SPOUSE(S)/PARTNER(S) =integer 
DON'T KNOW =-8 
REFUSED =-9 
 
IF Q4= -8,-9 
SKIP TO 301 
IF integer 
SKIP Q IF 101=2 
SKIP TO A1-2 
A1-1 
Please select the spouse/partner that lives with 
you.   
SKIP Q IF 101=2 
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A1-2 
  
 
Please enter name of your spouse/partner that 
lives with you. 
 
NAME OF SPOUSE/PARTNER =text 
DON'T KNOW =-8 
REFUSED =-9 
 
AKIP Q IF 101=2 
     206       
  
  
 
How many wives/partners do you have who live 
elsewhere? 
  
 
NUMBER OF WIVES/PARTNERS LIVING 
ELSEWHERE =1 
DON’T KNOW  =-8 
REFUSE TO ANSWER =-9 
 
ALL RESPONSES 
SKIP TO 301 
SKIP Q IF 101=2 
  
210 
 
  
 
Is your husband or partner living with you now or 
is he staying elsewhere? 
  
 
LIVING TOGETHER =1 
STAYING ELSEWHERE =2 
DON’T KNOW =-8 
REFUSE TO ANSWER =-9 
 
IF 210 = 2, -8, -9 
SKIP TO 212 
SKIP Q IF 101=1 
  
     211       
  
  
 
The Household schedule listed [NAME OF 
HUSBAND/PARTNER] as your husband/partner 
who is living here. Is that correct? 
 
YES =1 
NO =2 
DON'T KNOW=-8 
REFUSED =-9 
  
 
SKIP Q IF 101=1 
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F1-1 
Please select the spouse/partner that lives with 
you.   
SKIP Q IF 101=1 
F1-2 
  
Please enter the name of your spouse/partner 
that lives with you. 
  
 
NAME OF SPOUSE/PARTNER =text 
DON'T KNOW =-8 
REFUSED =-9 
  
SKIP Q IF 101=1 
     212       
  
  
  
 
Does your husband or partner have other wives 
or does he live with other women as if married? 
 
YES =1 
IF 212 = 2, -8, -9 
SKIP TO 301 
NO =2  
DON’T KNOW =-8  
REFUSED =-9 SKIP Q IF 101=1 
     213       
  
  
 
Including yourself, in total, how many wives or 
live-in partners does your husband or partner 
have? 
  
 
NUMBER OF WIVES OR LIVE-IN 
PARTNERS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
 
SKIP Q IF 101=1 
 
 
 
 
MODULE 3: REPRODUCTION 
 
Interviewer says: “Now I would like to ask you questions about your pregnancies and your children.” 
  
     301       
  
  
 
How many times have you been pregnant 
including a current pregnancy? 
CODE ‘00’ IF NONE. 
  
 
NUMBER OF TIME(S) =integer 
DON’T KNOW =-8 
REFUSED =-9 
IF 301 = 0, -8, -9 
SKIP TO 351 
  
     302       
  
  
  
 
Have you ever had a pregnancy that resulted 
in a live birth? 
A live birth is when the baby shows signs of 
life, such as breathing, beating of the heart or 
movement. 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 302 = 2, -8, -9 
SKIP TO 349 
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302a 
  
  
  
 
In total, how many children have you given 
birth to who were born alive? 
These include children who were born alive 
but later died and children who live with you 
and do not live with you. 
 
NUMBER OF CHILDREN =integer 
DON'T KNOW =-8 
REFUSED =-9 
 
303 
  
  
 
How many children have you given birth to 
since 2012? 
CODE ‘00’ IF NONE. 
These include children who were born alive 
but later died. They could have been children 
who have lived with you or have not lived with 
you.  
 
NUMBER OF CHILDREN =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 303 = 0, -8, -9 
SKIP TO 349 
  
 
Interview says: “Now I would like to ask you some questions about the last pregnancy that resulted in a live birth since 2012.” 
  
304 
  
  
  
Did your last pregnancy result in birth to twins 
or more? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
305 
  
  
 
What is the name of the child from your last 
pregnancy that resulted in a live birth?  
A live birth is when the baby shows signs of 
life, such as breathing, beating of the heart or 
movement. 
IF MULTIPLE BIRTH, LIST ALL NAMES. IF 
THE CHILD WAS NOT NAMED BEFORE 
DEATH, INPUT BIRTH 1. 
 
NAME =text 
  
  
  
305a 
  
  
  
 
When you were pregnant with [NAME], did 
you plan to get pregnant at that time? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 305a = 1,-8,-9 
SKIP TO 306 
  
305b 
  
  
  
Did you plan to have a baby later or did you 
not plan to have any (more) children? 
  
 
LATER =1 
NO MORE =2 
DON'T KNOW =-8 
REFUSED =9 
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306 
  
  
  
 
When you were pregnant with [NAME], did 
you visit a health facility for antenatal care? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 306 = 1 
SKIP TO 307a 
IF 306 = -8, -9 
SKIP TO 323 
  
307 
  
  
  
  
  
  
  
  
  
  
  
 
What is the main reason you did not visit a 
clinic for antenatal care when you were 
pregnant with [NAME]? 
  
 
CLINIC WAS TOO FAR AWAY =1 
COULD NOT TAKE TIME OFF WORK/TOO 
BUSY =2 
COULD NOT AFFORD TO PAY FOR THE 
VISIT =3 
DID NOT TRUST THE CLINIC STAFF =4 
RECEIVED CARE AT HOME =5 
DID NOT WANT AN HIV TEST DONE =6 
HUSBAND/FAMILY WOULD NOT LET ME 
GO =7 
USED TRADITIONAL BIRTH 
ATTENDANT/HEALER =8 
COST OF TRANSPORT =9 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 323 
  
307a 
  
  
  
  
 
At what months in your pregnancy did you 
attend the antenatal clinic? 
SELECT ALL THAT APPLY. 
  
 
0-3 MONTHS/1st TRIMESTER=A 
4-6 MONTHS/2nd TRIMESTER =B 
7-9 MONTHS/3rd TRIMESTER=C 
DON'T KNOW=Y 
REFUSED =Z 
  
  
 
Interviewer says: “I will now be asking you questions on HIV testing. Please remember that your responses will be kept 
confidential and will not be shared with anyone else.” 
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308 
  
  
  
 
Have you ever tested for HIV before your 
pregnancy with [NAME]? 
  
YES =1 
NO  =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 308 = 2, -8, -9 
SKIP TO 311 
  
309 
  
  
  
 
Did you test positive for HIV before your 
pregnancy with [NAME]? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 309 = 2,-8,-9 
SKIP TO 311 
  
 
310 
  
  
  
 
At the time of your first antenatal care visit 
when you were pregnant with [NAME], were 
you taking ARVs, that is, antiretroviral 
medications, to treat HIV?  
ARVs are antiretroviral medications or 
medications to treat HIV. 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 310 = 1 
SKIP TO 319 
IF 310 = 2,-8,-9 
SKIP TO 316 
  
311 
  
  
  
During any of your visits to the antenatal care 
clinic when you were pregnant with [NAME], 
were you offered an HIV test? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
312 
  
  
  
 
Were you tested for HIV during any of your 
antenatal care clinic visits when you were 
pregnant with [NAME]? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 312 = 1 
SKIP TO 314 
IF 312 = -8,-9 
SKIP TO 319 
  
313 
  
  
  
  
  
  
 
What is the main reason you were not tested 
for HIV during antenatal care with [NAME]? 
  
 
DID NOT WANT AN HIV TEST DONE / DID 
NOT WANT TO KNOW MY STATUS =1  
DID NOT RECEIVE PERMISSION FROM 
SPOUSE/FAMILY =2 
AFRAID OTHERS WOULD KNOW ABOUT 
TEST RESULTS =3 
DID NOT NEED TEST/LOW RISK =4 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 319 
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314 
  
  
How many times did you test for HIV during 
your pregnancy with [NAME]? 
  
NUMBER OF TIMES = integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
315 
  
  
  
  
  
 
What was the result of your last HIV test 
during your pregnancy with [NAME]? 
  
 
POSITIVE =1 
NEGATIVE =2 
UNKNOWN/INDETERMINATE =3 
DID NOT RECEIVE RESULTS =4 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 315 = 2,3,4,-8,-9 
SKIP TO 319 
  
316 
  
  
  
 
Did you take ARVs during your pregnancy 
with [NAME] to stop [NAME] from getting HIV? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 316 = 1 
SKIP TO 318 
IF 316 = -8,-9 
SKIP TO 319 
  
317 
  
  
  
  
  
  
  
  
  
  
  
  
 
What was the main reason you did not take 
ARVs while you were pregnant with [NAME]? 
  
 
HEALTH CARE PROVIDER DID NOT 
PRESCRIBE =1 
I FELT HEALTHY/NOT SICK =2 
COST OF MEDICATIONS =3 
COST OF TRANSPORT =4=5 
RELIGIOUS REASONS  
WAS TAKING TRADITIONAL 
MEDICATIONS =6 
MEDICATIONS OUT OF STOCK =7 
DID NOT WANT PEOPLE TO KNOW HIV 
STATUS =8 
DID NOT RECEIVE PERMISSION FROM 
SPOUSE/FAMILY =9 
NOT ELIGIBLE FOR TREATMENT=10 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
  
318 
  
  
  
  
 
How many months pregnant were you when 
you started taking ARVs? 
  
 
MONTHS 1-3/1ST TRIMESTER =1 
MONTHS 4-6/2ND TRIMESTER =2 
MONTHS 7-9/3RD TRIMESTER =3 
DON’T KNOW =-8 
REFUSED =-9 
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319 
  
  
  
 
When you were pregnant with [NAME], were 
you offered a test for syphilis? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
320 
  
  
  
When you were pregnant with [NAME], were 
you tested for syphilis? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 320 = 2,-8,-9 
SKIP TO 323 
  
321 
  
  
  
  
Did you test positive for syphilis during your 
pregnancy with [NAME]? 
  
YES =1 
NO =2 
DID NOT GET RESULT =3 
DON’T KNOW =-8 
REFUSED =-9 
IF 321 = 2,3,-8,-9 
SKIP TO 323 
  
322 
  
  
  
 
Did you get treatment for syphilis during your 
pregnancy with [NAME]? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
323 
  
  
  
  
  
 
Where did you give birth to [NAME]? 
  
 
AT HOME =1 
AT A HEALTH FACILITY =2 
IN TRANSIT =3 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 323 = 1,3,96,-8,-9 
SKIP TO 329 
  
 
324 
  
  
  
 
Were you offered an HIV test during labor? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
325 
  
  
  
 
Did you test for HIV during labor? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 325 = 2,-8.-9 
SKIP TO 329 
SKIP Q IF 309 = 1 OR 
315 = 1 
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326 
  
  
  
  
  
 
What was the result of that test? 
  
 
POSITIVE =1 
NEGATIVE =2 
UNKNOWN/INDETERMINATE =3 
DID NOT RECEIVE RESULTS =4 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 326 = 2,3,4,-8,-9 
SKIP TO 329 
SKIP Q IF 309 = 1 OR 
315 = 1 
  
327 
  
  
  
  
 
During labor, did you take ARVs to protect 
[NAME] against HIV? 
  
YES =1 
NO, OFFERED BUT DID NOT TAKE =2 
NO, NOT OFFERED =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 327 = 2,3,-8.-9 
SKIP TO 329 
  
328 
  
  
  
Did you continue to take the ARVs after 
delivery? 
  
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
329 
  
  
  
  
  
  
  
  
 
When did you give birth to [NAME]? Please 
give your best guess. 
  
DAY =date 
DON’T KNOW DAY =-8 
REFUSED DAY =-9 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH=-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
  
  
330 
  
  
  
 
Is [NAME] still alive? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 330 = 1,-8,-9 
SKIP TO 332 
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331 
  
  
  
  
  
  
  
  
 
When did [NAME] die?  
  
DAY =date 
DON’T KNOW DAY =-8 
REFUSED DAY =-9 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
 
ALL RESPONSES 
SKIP TO 334 
  
332 
  
Is [NAME] living with you? 
  YES =1 
NO =2 
 
IF 332 = 2 
SKIP TO 334 
  
333 
  
RECORD HOUSEHOLD LINE NUMBER OF 
CHILD 
RECORD ‘00’ IF CHILD NOT LISTED IN 
HOUSEHOLD 
HOUSEHOLD LINE NUMBER =integer 
  
  
  
334 
  
  
  
  
 
Did [NAME] take any ARVs to stop him/her 
from getting HIV infection? This would be 
before [NAME]’s first HIV test. 
  
 
YES =1 
NO, DID NOT TAKE ARVS =2 
NO, CHILD NOT ALIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 334 = 2,3,-8,-9 
SKIP TO 336 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
  
335 
  
  
  
  
  
For how long did [NAME] take the ARVs to 
stop him/her from getting HIV? 
CODE ‘00’ IF LESS THAN ONE WEEK. 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN WEEKS 
OR IN MONTHS. 
  
 
WEEKS =integer 
MONTHS =integer 
ARVS TAKEN ONCE =96 
STILL TAKING ARVS =97 
DON’T KNOW  =-8 
REFUSED =-9 
 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
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336 
  
  
  
  
 
Did [NAME] take Septrin or cotrimoxazole? 
This would be before [NAME]’s first HIV test. 
Septrin or cotrimoxazole is a medicine 
recommended for people with HIV, even if 
they have not started treatment for HIV. It 
helps prevent certain infections but it is not 
treatment for HIV. 
  
 
YES =1 
NO, DID NOT TAKE COTRIM =2 
NO, CHILD NOT ALIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 336 = 2,3,-8,-9 
SKIP TO 338 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
  
337 
  
  
  
  
 
For how long did [NAME] take Septrin or 
cotrimoxazole? 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN WEEKS 
OR IN MONTHS. 
CODE ‘00’ IF LESS THAN ONE WEEK. 
  
 
WEEKS =integer 
MONTHS =integer 
STILL TAKING COTRIMOXOZOLE =97 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
  
338 
  
  
  
  
 
Did you ever breastfeed [NAME]? 
  
 
YES =1 
NO, NEVER BREASTFED =2 
NO, CHILD NOT ALIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 338 = 2,3,-8,-9 
SKIP TO 342 
  
339 
  
  
  
 
Are you still breastfeeding [NAME]? 
  
 
YES =1 
NO =2 
DON 'T KNOW =-8 
REFUSED =-9 
 
IF 339=1 
SKIP TO 341 
IF 339 = -8,-9 
SKIP TO 342 
  
340 
  
  
  
 
For how long did you breastfeed [NAME]? 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN WEEKS 
OR IN MONTHS. 
CODE ‘00” WEEKS IF LESS THAN 1 WEEK. 
  
 
WEEKS =integer 
MONTHS =integer 
DON’T KNOW =-8 
REFUSED  =-9 
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341 
  
  
  
  
 
How old was [NAME] when you started giving 
[NAME] cow’s/goat’s milk, powdered milk, 
water, or any other foods or liquid? 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN 
MONTHS OR IN YEARS. 
CODE '00' IF LESS THAN 1 MONTH. 
  
 
MONTHS =integer 
YEARS =integer 
NEVER =96 
DON'T KNOW =-8 
REFUSED =-9 
  
  
341a 
  
  
  
 
Did you continue taking ARVs while you were 
breastfeeding [NAME]? 
  
 
YES =1 
NO =2 
DON 'T KNOW =-8 
REFUSED =-9 
  
  
342 
  
  
  
  
 
After [NAME] was born, was he/she tested for 
HIV?  
  
 
YES =1 
NO, NOT TESTED FOR HIV =2 
NO, CHILD NOT ALIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 342 = 1 
SKIP TO 344 
IF 342 = 2,3,-8,-9 
SKIP TO 348 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
SKIP Q IF 339=1 OR 2 
  
343 
  
  
  
  
 
While you were breastfeeding, was [NAME] 
tested for HIV? 
  
 
YES =1 
NO, NOT TESTED FOR HIV =2 
NO, CHILD NOT ALIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 343 = 2,3,-8,-9 
SKIP TO 346 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
  
344 
  
  
  
  
 
How old was [NAME] when he/she first tested 
for HIV? 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN WEEKS, 
MONTHS OR IN YEARS. 
CODE ‘00’ IF LESS THAN 1 WEEK. 
  
 
WEEKS =integer 
MONTHS =integer 
YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
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345 
  
  
  
  
  
 
What was the result of [NAME]’s first HIV test? 
  
 
POSITIVE,CHILD HAS  HIV =1 
NEGATIVE, CHILD DOES NOT HAVE HIV 
=2 
UNKNOWN/INDETERMINATE =3 
DID NOT RECEIVE RESULTS =4 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
  
346 
  
  
  
  
 
After you stopped breastfeeding, was [NAME] 
tested for HIV? 
  
  
 
YES =1 
NO, NOT TESTED FOR HIV =2  
NO, CHILD NOT ALIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 346 = 2,3,-8,-9 
SKIP TO 348 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
SKIP Q IF 345 = 1 
SKIP Q IF 338 = 2,3,-8,-9 
OR 339=1 
  
347 
 
 
 
 
 
 
What was the result of [NAME]’s HIV test? 
  
 
POSITIVE, CHILD HAS  HIV =1 
NEGATIVE, CHILD DOES NOT HAVE HIV 
=2 
UNKNOWN/INDETERMINATE =3 
DID NOT RECEIVE RESULTS =4 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 309!=1 & 
315!=1 & 326!=1 
SKIP Q IF 345 = 1 
SKIP Q IF 338 = 2,3,-8,-9 
OR 339=1 
  
348 
 
 
Thank you for the information regarding 
[NAME]. 
DID THE RESPONDENT HAVE MORE THAN 
ONE CHILD (I.E. TWINS, TRIPLETS)? 
 
YES =1 
NO =2 
 
IF 348 = 1 
SKIPTO 330 
 
Interviewer says: “I will now ask about current pregnancies.” 
 
IF 101 = 1 
SKIP TO 351 
349 
  
  
  
 
Are you pregnant now? 
  
 
YES =1 
NO =2 
DON’T KNOW/UNSURE =-8 
REFUSED =-9 
 
IF 349 = 2,-8,-9 
SKIP TO 351 
  
 
350 
 
 
 
How many months pregnant are you? 
  
 
MONTHS = integer 
DON’T KNOW / UNSURE =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 3001 
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Interviewer says: “I will now ask you about family planning.” 
  
351 
  
  
  
 
Are you or your partner currently doing 
something or using any method to delay or 
avoid getting pregnant? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 351 = 2  
SKIP TO 353 
IF 351= -8,-9 
SKIP TO 3001 
  
352 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Which method are you or your partner using? 
SELECT ALL THAT APPLY. 
  
 
FEMALE STERILIZATION =A 
MALE STERILIZATION =B 
PILL =C 
IUD/”COIL” =D 
INJECTIONS =E 
IMPLANT =F 
CONDOM =G 
FEMALE CONDOM =H 
RHYTHM/NATURAL METHODS =I 
WITHDRAWAL =J 
NOT HAVING SEX =K 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
 
IF 352_Y=1 OR 352_Z=1 
SKIP TO 3001 
  
353 
  
  
  
 
Would you like to have a/another child? 
  
 
YES =1 
NO =2 
UNDECIDED/DON'T KNOW=-8 
REFUSED =-9 
 
IF 353= 2 
SKIP TP 355 
IF 353= -8,-9 
SKIP TO 3001 
  
354 
  
  
  
  
 
How long would you like to wait before the 
birth of a/another child? 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN 
MONTHS OR IN YEARS. 
CODE ‘96’ IF LESS THAN 1 MONTH. 
  
 
MONTHS =integer 
YEARS =integer 
NOW/SOON =96 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 354= 96,-8,-9 
SKIP TO 3001 
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355 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Can you tell me why you are not using a 
method to prevent pregnancy? 
SELECT ALL THAT APPLY. 
  
 
NOT MARRIED/NO PARTNER =A 
NOT HAVING SEX =B 
INFREQUENT SEX=C 
MENOPAUSAL/HYSTERECTOMY=D 
(PARTNER) CANNOT GET PREGNANT =E 
NOT MENSTRUATED SINCE LAST BIRTH 
=F 
BREASTFEEDING =G 
KNOWS NO METHOD =H 
KNOWS NO SOURCE =I 
SIDE EFFECTS/HEALTH CONCERNS =J 
LACK OF ACCESS/TOO FAR =K 
COSTS TOO MUCH =L 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
  
  
 
 
MODULE 3A CHILDREN 
    3001      
The HOUSEHOLD SCHEDULE noted that 
[Name of Respondent] will fill out the 
children’s module for [Number of children]. 
Please read this statement:  
I am going to ask you a number of questions 
about your child/children regarding their health 
and where they get their health services. We 
will ask you about these children: 
[list of children] 
[LINE NUMBER]    [CHILD’S NAME] 
NUMBER OF CHILDREN 
 
Integer  
 3001=0 
    3003      
Now I am going to ask you questions for 
[NAME]. NAME =text 
  
     
3004      
  
  
  
How old was [NAME] at his/her last birthday? 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN YEARS 
OR IN MONTHS. 
CODE ‘00’ IF LESS THAN ONE MONTH. 
 
MONTHS =integer 
YEARS =integer 
DON'T KNOW =-8 
REFUSED=-9 
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3005      
  
  
  
 
Is [NAME] a boy or girl? 
  
 
BOY =1 
GIRL =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
     
3006      
  
  
  
  
 
Is [NAME] currently enrolled in school? 
  YES =1 
NO, CURRENTLY NOT IN SCHOOL =2 
NO, TOO YOUNG TO BE IN SCHOOL =3 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 3006=2 
SKIP TO 3010 
IF 3006 =3,-8,-9 
SKIP TO 3013 
  
    3007      
  
  
  
During the last school week, did [NAME] miss 
any school days for any reason? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 3007= 2,-8,-9 
SKIP TO 3009 
  
3008 
  
  
  
  
  
  
  
  
  
 
Why did [NAME] miss school? 
SELECT ALL THAT APPLY. 
 
NO MONEY FOR SCHOOL, MATERIALS, 
TRANSPORT=A 
CHILD WAS TOO SICK TO ATTEND 
SCHOOL =B 
SCHOOL IS TOO FAR AWAY/NO SCHOOL 
=C 
CHILD HAS TO WORK =D 
CHILD HAS TO CARE FOR HOUSEHOLD 
MEMBERS =E 
CHILD DOES NOT LIKE/WANT TO GO TO 
SCHOOL =F 
SCHOOL WAS NOT IN SESSION =G 
OTHER =X 
DON'T KNOW =Y 
REFUSED =Z 
 
 
3009 
  
  
 
What class/form/year is [NAME] in now? 
  
 
CLASS/FORM/YEAR integer 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 3013 
  
3010 
  
  
Was [NAME] enrolled in school during the 
previous school year? 
  
 
YES =1 
NO =2 
 
IF 3010 = 2,-8,-9 
SKIP TO 3013 
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  DON’T KNOW =-8 
REFUSED =-9 
  
3011 
  
  
What class/form/year was [NAME] during the 
previous school year? 
  
 
CLASS/FORM/YEAR =integer 
DON’T KNOW =-8 
REFUSED =-9 
ALL RESPONSES 
SKIP TO 3013 
  
Interviewer says: “I will now ask you about your child's circumcision history.” 
3013 
  
  
  
Is [NAME] circumcised? 
Circumcision is the complete removal of the 
foreskin from the penis. I have a picture to 
show you what a completely circumcised 
penis looks like. 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 3013 = 2 
SKIP TO 3016 
IF 3013 = -8,-9 
SKIP TO 3017 
SKIP Q IF 3005=2 
  
 
3014 
  
  
  
 
How old was [NAME] when he was 
circumcised? Please give your best guess 
ONLY ONE OPTION MAY BE SELECTED. 
FOR EXAMPLE, ANSWER ONLY IN YEARS 
OR IN MONTHS. 
CODE ‘00’ IF LESS THAN ONE MONTH. 
 
MONTHS=integer 
YEARS =integer 
DON'T KNOW =-8 
REFUSED=-9 
 
SKIP Q IF 3005=2 
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3015 
  
  
  
  
  
 
Who circumcised [NAME]? 
  
 
DOCTOR, CLINICAL OFFICER, OR NURSE 
=1 
TRADITIONAL PRACTITIONER / 
CIRCUMCISER =2 
MIDWIFE =3 
OTHER =96 
DON’T KNOW =-8 
REFUSE TO ANSWER =-9 
 
ALL RESPONSES 
SKIP TO 3017 
SKIP Q IF 3005=2 
  
3016 
  
  
  
 
Are you planning to have [NAME] circumcised 
in the future? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 3005=2 
  
3017 
  
  
  
 
Has [NAME] ever been tested for HIV? 
 
YES  
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 3017 = 1 
SKIP TO 3019 
IF 3017 = -8,-9 
SKIP TO 3040a 
3018 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Why has [NAME] never been tested for HIV? 
SELECT ALL THAT APPLY. 
  
 
DON'T KNOW WHERE TO TEST  =A 
TEST COSTS TOO MUCH =B 
TRANSPORT  COSTS TOO MUCH =C 
TOO FAR AWAY =D 
AFRAID OTHERS WILL KNOW ABOUT 
TEST RESULTS =E 
DON'T NEED TEST/LOW RISK =F 
DID NOT RECEIVE PERMISSION FROM 
SPOUSE/FAMILY =G 
AFRAID SPOUSE/PARTNER/FAMILY  WILL 
KNOW RESULTS =H 
DON’T WANT TO KNOW CHILD HAS HIV =I 
CANNOT GET TREATMENT FOR HIV =J 
TEST KITS NOT AVAILABLE =K 
RELIGIOUS REASONS =L 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
 
ALL RESPONSE 
SKIP TO 3040a 
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3019 
  
  
  
 
You said earlier that [NAME] had been 
tested for HIV. Was that the last time 
(NAME) was tested for HIV? 
 
YES =1 
NO=2 
DON'T KNOW=-8 
REFUSED=-9 
 
IF 3019 = 2,-8,-9 
SKIP TO 3022 
SKIP Q IF 342!=1 OR 
343!=1 OR 346!=1 
 
3020 
  
  
  
  
  
 
What month and year was [NAME]’s most 
recent HIV test done?  
  
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH=-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED  YEAR =-9 
  
SKIP Q IF 342!=1 OR 
343!=1 OR 346!=1 
  
3021 
  
  
  
  
  
 
You mentioned earlier that (NAME) 
received an HIV-positive result.  
What was the month and year of 
[NAME]'s first HIV-positive test result? 
Please give your best guess. 
This will be the very first HIV-positive test 
result that [NAME] had received. 
PROBE TO VERIFY DATE. 
  
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR  =-8 
REFUSED  YEAR=-9 
 
ALL RESPONSES SKIP 
TO 3024 
SKIP Q IF 342!=1 OR 
343!=1 OR 346!=1 
SKIP Q IF 345!=1 OR 
347!=1 
  
3022 
  
  
  
  
  
 
What month and year was [NAME]’s most 
recent HIV test done?  
  
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED  YEAR =-9 
  
3023 
  
  
  
  
  
 
What was [NAME]’s last HIV test result? 
  
POSITIVE =1 
NEGATIVE =2 
UNKNOWN/INDETERMINATE =3 
DID NOT RECEIVE RESULTS =4 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 3023 = 2,3,4,-8,-9 
SKIP TO 3040a 
SKIP Q IF (333=3002) & 
(345 = 1 OR 347 = 1) 
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3024 
  
  
  
 
Has [NAME] ever received HIV medical care 
from a doctor, clinical officer or nurse? 
 
YES =1 
NO =2 
DON’T KNOW  =-8 
REFUSED =-9 
 
IF 3024= 1 
SKIP TO 3026 
IF 3024 = -8,-9 
SKIP TO 3029 
 
3025 
  
  
  
  
  
  
  
  
  
  
 
What is the main reason why [NAME] has 
never seen a doctor, clinical officer or nurse 
for HIV medical care? 
  
 
FACILITY IS TOO FAR AWAY =1 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE FOR CHILD =2 
COST OF CARE =3 
COST OF TRANSPORT =4 
I DON’T THINK CHILD NEEDS IT, HE/SHE 
IS NOT SICK=5 
I FEAR PEOPLE WILL KNOW THAT CHILD 
HAS HIV IF I TAKE HIM/HER TO A 
CLINIC=6 
RELIGIOUS REASONS =7 
CHILD IS TAKING TRADITIONAL 
MEDICINE =8 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 3029 
  
3026 
  
  
  
  
  
 
What month and year did [NAME] first see a 
doctor, clinical officer or nurse for HIV medical 
care? 
PROBE TO VERIFY DATE. 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH=-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED =-9 
 
3027 
  
  
  
  
  
 
What month and year did [NAME] last see a 
doctor or nurse for HIV medical care? 
  
 
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED =-9 
FACILITY IS TOO FAR AWAY =1 
 
IF currentdate-3027<7 
MONTHS,-8,-9 
SKIP TO 3029 
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3028  
  
  
  
  
  
  
  
  
  
  
 
What is the main reason for [NAME] not 
seeing a doctor, clinical officer or nurse for 
HIV medical care for more than 6 months? 
 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE FOR CHILD =2 
COST OF CARE =3 
COST OF TRANSPORT =4 
I DON’T THINK CHILD NEEDS IT, HE/SHE 
IS NOT SICK =5 
I FEAR PEOPLE WILL KNOW THAT CHILD 
HAS HIV IF I TAKE HIM/HER TO A CLINIC 
=6 
RELIGIOUS REASONS =7 
CHILD IS TAKING TRADITIONAL 
MEDICINE =8 
NO APPOINTMENT SCHEDULED/DID NOT 
MISS MOST RECENT APPOINTMENT =9 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
3029 
  
  
  
Has [NAME] ever had a CD4 count test? 
The CD4 count tells you how sick you are with 
HIV and if you need to take ARVs or other HIV 
medications. 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 3029 = 2,-8,-9 SKIP 
TO 3031 
IF 3029= (2,-8, OR -9) & 
(3024 = 2,-8 OR -9) 
SKIP TO 3040a 
  
3030 
  
  
  
  
  
 
What month and year was [NAME] last tested 
for his/her CD4 count? 
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
 
IF 3024 = 2,-8,-9 
SKIP TO 3040a 
3031 
  
  
  
Has [NAME] ever taken ARVs, that is, 
antiretroviral medications, to treat his/her HIV 
infection? 
  
 
YES -1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 3031 = 1 
SKIP TO 3033 
IF 3031 = -8,-9 
SKIP TO 3038 
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3032 
  
  
  
  
  
  
  
  
  
  
 
What is the main reason [NAME] has never 
taken ARVs? 
 
CHILD IS NOT ELIGIBLE FOR 
TREATMENT=1 
HEALTH CARE PROVIDER DID NOT 
PRESCRIBE =2 
HIV MEDICINES NOT AVAILABLE =3 
DO NOT THINK CHILD NEEDS IT, HE/SHE 
IS NOT SICK=4 
COST OF MEDICATIONS =5 
COST OF TRANSPORT =6 
 RELIGIOUS REASONS =7 
CHILD IS TAKING TRADITIONAL 
MEDICATIONS =8 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 3038 
3033 
  
  
  
  
  
 
What month and year did [NAME] first start 
taking ARVs? 
PROBE TO VERIFY DATE. 
  
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
  
  
3034 
  
  
  
  
  
 
What month and year did [NAME] last receive 
ARVs? 
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
 
3035 
  
  
  
 
Is [NAME] currently taking ARVs, that is, 
antiretroviral medications? 
By currently, I mean that [NAME] may have 
missed some doses but [NAME] is still taking 
ARVs. 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 3035 = 1 
SKIP TO 3037 
IF 3035 =-8,-9 
SKIP TO 3038 
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3036 
  
  
  
  
  
  
  
  
  
  
  
 
Can you tell me the main reason why [NAME] 
is not currently taking ARVs? 
 
I HAVE TROUBLE GIVING CHILD A 
TABLET EVERYDAY=1 
CHILD HAD SIDE EFFECTS/RASH =2 
FACILITY/PHARMACY TOO FAR AWAY TO 
GET MEDICATION REGULARLY =3 
COST OF MEDICATIONS =4 
COST OF TRANSPORT =5 
CHILD IS HEALTHY, HE/SHE IS NOT SICK 
=6 
FACILITY WAS OUT OF STOCK=7 
RELIGIOUS REASONS=8 
CHILD IS TAKING TRADITIONAL 
MEDICATIONS =9 
OTHER =96 
DON’T KNOW =8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 3038 
3037 
  
  
 
People sometimes forget to take all of their 
ARVs every day. In the past 30 days, how 
many days has [NAME] missed taking any 
ARV pills? 
CODE ‘00’ FOR NONE. 
  
 
DAYS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
3038 
  
  
  
 
Is [NAME] currently taking Septrin or 
cotrimoxazole?  
Septrin or cotrimoxazole is a medicine 
recommended for people with HIV, even if 
they have not started treatment for HIV. It 
helps prevent certain infections but it is not 
treatment for HIV. 
By currently, I mean that [NAME] may have 
missed some doses but is still taking Septrin. 
 
YES =1 
NO =2 
I DON’T KNOW WHAT IT IS =3 
REFUSED =-9 
 
IF 3038 = 1,3,-9 SKIP TO 
3040a 
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3039 
  
  
  
  
  
  
  
  
  
  
  
  
 
Can you tell me the main reason why [NAME] 
is not currently taking Septrin or 
Cotrimoxazole daily? 
  
 
WAS NOT PRESCRIBED =1 
I HAVE TROUBLE GIVING CHILD A 
TABLET EVERYDAY =2 
CHILD HAD SIDE EFFECTS/RASH =3 
FACILITY/PHARMACY TOO FAR AWAY TO 
GET Septrin/COTRIMOXOZOLE 
REGULARLY =4 
CHILD DOES NOT NEED IT, HE/SHE IS 
NOT SICK =5 
PHARMACY/ FACILITY WAS OUT OF 
STOCK =6 
COST OF MEDICATIONS =7 
COST OF TRANSPORT =8 
DOCTOR SAID NO LONGER NEEDED =9 
RELIGIOUS REASONS =10 
OTHER =96 
I DON’T KNOW =-8 
REFUSED =-9 
  
  
3040a 
  
  
  
In the last 12 months, were you told by a 
doctor, clinical officer or nurse that [NAME] 
was underweight or had a low weight? 
  
YES=1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 3040a = 2,-8,-9 SKIP 
TO 3041 
  
3040b 
  
  
  
  
  
 
Was [NAME] given a nutritional supplement or 
referred for a nutritional consult or both? 
 
NO, NEVER GIVEN 
SUPPLEMENT/REFERRED =1 
YES, GIVEN SUPPLEMENT =2 
YES, REFERRED =3 
BOTH GIVEN SUPPLEMENT AND 
REFERRED =4 
DON'T KNOW =-8 
REFUSED =-9 
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3041 
  
  
  
 
At the last HIV medical care visit, did a doctor, 
clinical officer or nurse ask if: 
-        [NAME] had any of the following 
tuberculosis or TB symptoms: cough, fever, 
night sweats, and weight loss OR  
-       [NAME] had contact with someone who 
had tuberculosis or TB? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 3024 = 2,-8,-9  
  
3042 
  
  
  
In the last 12 months, has [NAME] 
experienced these TB symptoms or had 
contact with someone with TB? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 3042 = 2,-8,-9 
SKIP TO 3044 
SKIP Q IF 3024 = 2,-8,-9 
  
3043 
  
  
  
  
In the last 12 months, did [NAME] receive a 
chest x-ray or sputum test to look for TB?   
A sputum test is when the patient has to 
cough and collect the sample in a cup. 
SELECT ALL THAT APPLY. 
CHEST X-RAY =A 
SPUTUM TEST =B 
NONE OF THESE =C 
DON’T KNOW =Y 
REFUSED =Z 
 
SKIP Q IF 3024 = 2,-8,-9 
3044 
  
  
  
 
Has [NAME] ever visited a tuberculosis or TB 
clinic for TB diagnosis or treatment? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =9 
IF 3044 = 2,-8,-9 
SKIP TO 3049a 
  
 
3045 
  
  
  
  
 
Was [NAME] tested for HIV at the TB clinic? 
  
 
YES =1 
NO, WAS NOT TESTED FOR HIV =2  
NO, WAS ALREADY HIV POSITIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
3046 
  
  
  
 
Have you ever been told by a doctor, clinical 
officer or nurse that [NAME] had TB? 
  
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 3046 = 2,-8,-9 
SKIP TO 3049a 
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3047    
  
  
  
  
  
 
What month and year did a doctor, clinical 
officer or nurse diagnose [NAME] with TB? 
RECORD THE MOST RECENT TIME IF 
DIAGNOSED WITH TB MORE THAN ONCE. 
  
MONTH =DATE 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
  
  
3048 
  
  
  
 
Was [NAME] ever treated for TB? 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 3048 = 2,-8,-9 
SKIP TO 3049a 
3049 
  
  
  
  
 
Has [NAME] completed at least 6 months of 
treatment for TB?  
  
 
YES =1 
NO, THE MEDICINE WAS STOPPED IN  
LESS THAN 6 MONTHS =2 
NO, CHILD IS STILL ON TREATMENT =3 
DON’T KNOW =-8 
REFUSED =-9 
  
3049a 
  
  
  
 
And now my last question about [NAME] is on 
Hepatitis B: 
Has your child ever been vaccinated for 
Hepatitis B? 
Please show us his/her under 5 vaccination 
card. 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
3050 
  
 
Thank you for the information about [NAME].  
DOES THE RESPONDENT HAVE ANOTHER 
CHILD AGED 0-14 YEARS? 
 
YES =1 
NO =2 
IF 3050= 1 
SKIP TO 3003 
  
 
MODULE 4: MALE CIRCUMCISION 
Interviewer says: “I will be asking a few questions about your own experience with circumcision. Circumcision is the complete 
removal of the foreskin from the penis. I have a picture to show you what a completely circumcised penis looks like.” 
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404       
  
  
  
Many men do not want to talk about 
circumcision, but it is important for us to have 
this information. Some men are circumcised. 
Are you circumcised? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED=-9 
 
IF 404=1 
SKIP TO 406 
IF 404 = -8,-9 
SKIP TO 1001 
     405       
  
  
  
 
Are you planning to get circumcised?  
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 1001 
  
     406       
  
  
How old were you when you were 
circumcised? Please give your best guess. 
IF LESS THAN ONE YEAR, CODE ‘00’.  
 
AGE IN YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
     407       
  
  
  
  
  
 
Who did the circumcision? 
 
 
DOCTOR, CLINICAL OFFICER, OR NURSE 
=1 
TRADITIONAL PRACTITIONER / 
CIRCUMCISER =2 
MIDWIFE =3 
OTHER =96 
DON’T KNOW =-8 
REFUSED=-9 
  
  
 
MODULE 10:  ALCOHOL USE 
 
Interviewer says: “The next few questions will be on your use of alcohol. Remember, all the answers you provide will be kept 
confidential.” 
  
1001 
  
  
  
  
  
  
 
How often do you have a drink containing 
alcohol? 
 
NEVER =0 
MONTHLY OR LESS =1 
2-4 TIMES A MONTH =2 
2-3 TIMES A WEEK =3 
4 OR MORE TIMES A WEEK =4 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 1001 = 0,-8,-9 
SKIP TO 501 
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 1002      
  
  
  
  
  
  
 
How many drinks containing alcohol do you 
have on a typical day? 
  
1 OR 2 =0 
3 OR 4 =1 
5 OR 6 =2 
7 TO 9 =3 
10 OR MORE =4 
DON’T KNOW=-8 
REFUSED =-9 
  
  
    1003      
  
  
  
  
  
  
 
How often do you have six or more drinks on 
one occasion? 
 
NEVER =0 
LESS THAN MONTHLY =1 
MONTHLY =2 
WEEKLY =3 
DAILY OR ALMOST DAILY =4 
DON’T KNOW =-8 
REFUSED =-9 
 
 
MODULE 5: SEXUAL ACTIVITY 
 
Interviewer says: “In this part of the interview, I will be asking questions about your sexual relationships and practices. These 
questions will help us have a better understanding of how they may affect your life and risk for HIV.” 
502 
 
 
 
 
How old were you when you had vaginal sex 
for the very first time? 
Vaginal sex is when a penis enters a vagina. 
  
 
AGE IN YEARS =integer 
NEVER HAD VAGINAL SEX =96 
DON’T KNOW =-8 
REFUSED =-9 
 
  
502a 
 
People have sex in different ways. Some have 
vaginal sex. Some have anal sex. Anal sex is 
when a penis enters a person's anus. Have 
you ever had anal sex? 
  
 
YES =1 
NO =1 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 502a= 2,-8,-9 
SKIP TO 503 
IF 502a=2,-8,-9 & 
502=96,-8,-9 
SKIP TO 601 
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502b 
 
How old were you when you had anal sex for 
the very first time? 
  
 
AGE IN YEARS=integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
503 
 
The first time you had vaginal or anal sex, was 
a condom used? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
503a 
 
How old was the person you first had vaginal 
or anal sex with? Please give your best guess. 
  
 
AGE IN YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
504 
 
The first time you had vaginal or anal sex, was 
it because you wanted to or because you were 
forced to? 
 
WANTED TO =1 
FORCED TO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 504 = 1,-8,-9 
SKIP TO 505a 
505 
 
The first time you had vaginal or anal sex, 
were you physically forced or were you 
pressured into having sex through 
harassment, threats or tricks? 
  
 
PHYSICALLY FORCED =1 
PRESSURED =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
505a 
 
People often have sex with different partners 
over their lifetime. In total, with how many 
different people have you had sex in your 
lifetime? Please give your best guess. 
IF NUMBER OF SEXUAL PARTNERS IS 
GREATER THAN 100, CODE '100' 
 
NUMBER OF PARTNERS IN LIFETIME __ 
__ __ 
DON’T KNOW =-8 
REFUSED =-9 
  
  
506 
 
In total, with how many different people have 
you had sex in the last 12 months? 
IF NONE CODE ‘00’. 
IF NUMBER OF SEXUAL PARTNERS IS 
GREATER THAN 100, CODE '100' 
 
NUMBER OF SEXUAL PARTNERS IN LAST 
12 MONTHS __ __ __ 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 506= 0,-8,-9 
SKIP TO 601 
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Interviewer says: “Now I would like to ask you some questions about the partners you have had sex with in the last 12 months. 
Let me assure you again that your answers are completely confidential and will not be told to anyone. I will first ask you about 
your most recent partner.” 
  
507 
 
I would like to ask you for the initials of your 
partner so I can keep track. They do not have 
to be the actual initials of your partner. 
 
INITIALS =text 
  
508 
 
Does [INITIALS] live in this household? 
 
YES =1 
NO =2 
IF 508 = 2 
SKIP TO 510 
509 
 
HOUSEHOLD LINE NO. for [INITIALS] 
CODE ‘00’ IF NOT LISTED IN HOUSEHOLD 
ROSTER. 
 
LINE NO=integer 
  
  
510 
 
What is your relationship with [INITIALS]? 
  
 
HUSBAND/WIFE =1 
LIVE-IN PARTNER =2 
PARTNER, NOT LIVING WITH 
RESPONDENT =3 
EX-SPOUSE/PARTNER =4 
FRIEND/ACQUAINTANCE =5 
SEX WORKER =6 
SEX WORKER CLIENT =7 
STRANGER =8 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
  
  
511 
 
How long has it been since you last had sex 
with [INITIALS]? 
IF LESS THAN ONE WEEK RECORD IN 
DAYS, IF LESS THAN ONE MONTH, 
RECORD IN WEEKS, OTHERWISE 
RECORD IN MONTHS. 
  
 
DAYS =integer 
WEEKS=integer 
MONTHS=integer 
DON’T KNOW =-8 
REFUSED =-9 
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512 
 
How long has it been since you first had sex 
with [INITIALS]? 
IF LESS THAN ONE WEEK RECORD IN 
DAYS, IF LESS THAN ONE MONTH, 
RECORD IN WEEKS. IF LESS THAN ONE 
YEAR, RECORD IN MONTHS. OTHERWISE, 
RECORD IN YEARS. 
  
 
DAYS =integer 
WEEKS =integer 
MONTHS =integer 
YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
513 
 
Is [INITIALS] male or female? 
  
 
MALE =1 
FEMALE =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
514 
 
How old is [INITIALS]? Please give your best 
guess. 
  
 
AGE IN YEARS=integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
514a 
 
The last time you had sex with [INITIALS], did 
you have vaginal sex, anal sex or both? 
  
 
VAGINAL=1 
ANAL=2 
BOTH =3 
DON'T KNOW=-8 
REFUSED =-9 
  
515 
 
The last time you had sex with [INITIALS] was 
a condom used? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
516 
 
The last time you had sex with [INITIALS] 
were either of you drinking alcohol?  
  
 
ONLY I WAS DRINKING =1 
ONLY PARTNER WAS DRINKING=2 
BOTH WERE DRINKING=3 
NEITHER =4 
DON’T KNOW =-8 
REFUSED =-9 
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517 
 
Did you enter into a sexual relationship with 
[INITIALS] because [INITIALS] provided you 
or expected that [INITIALS] would provide you 
with material support in other ways?  
Material support means helping you to pay for 
things, or giving you gifts or other items you 
needed or requested.  
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 517 = 2,-8,-9 
SKIP TO 519 
SKIP Q IF 510 = 6,7 
  
518 
 
In the last 12 months, what all did you 
receive? 
SELECT ALL THAT APPLY. 
 
DID NOT RECEIVE ANYTHING =A 
MONEY =B 
FOOD =C 
SCHOOL FEES =D 
EMPLOYMENT =E 
GIFTS/FAVORS =F 
TRANSPORT =G 
SHELTER/RENT =H 
PROTECTION =I 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
 
SKIP Q IF 510 = 1,2,6,7 
519 
 
Was [INITIALS] circumcised? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 513 = 2,-8,-9 
  
520 
 
Do you expect to have sex with [INITIALS] 
again? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
521 
 
Have you ever taken an HIV test with 
[INITIALS]?  
  
 
YES=1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 521 = 1,-8,-9 
SKIP TO 523 
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522 
 
What is the main reason you haven't tested for 
HIV with (INITIALS) as a couple? 
READ RESPONSES ALOUD. 
 
NOT A PARTNER/COUPLE=1 
NEVER DISCUSSED =2 
WE ARE NOT AT RISK FOR HIV =3 
PARTNER REFUSED =4 
I REFUSED =5 
WE KNOW OUR STATUS =6 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
523 
 
Does [INITIALS] know your HIV status? HIV 
status could mean you are HIV negative or 
HIV positive. 
  
 
YES =1 
NO =1 
DON’T KNOW =-8 
REFUSED =-9 
  
  
524 
 
What is the HIV status of [INITIALS]?  
READ RESPONSES ALOUD. 
 
THINK (INITIALS) IS POSITIVE =4 
(INTIALS) TOLD ME HE/SHE IS POSITIVE 
=3 
POSITIVE, TESTED TOGETHER =1 
THINK (INITIALS) IS NEGATIVE =4 
(INITIALS) TOLD ME HE/SHE IS NEGATIVE 
=5 
NEGATIVE, TESTED TOGETHER=2 
DON’T KNOW STATUS =3 
REFUSED =-9 
 
525 
 
DID THE RESPONDENT HAVE ANOTHER 
PARTNER IN THE LAST 12 MONTHS? 
  
 
YES =1 
NO =2 
 
IF 525 = 1 
SKIP TO 507 
  
 
Interviewer says: “Now I am going to ask you some additional questions about your sexual activities. Again, I am asking that 
you answer these questions honestly. Let me assure you again that your answers are completely confidential and will not be 
shared with anyone.  
525a 
 
Have you ever sold sex for money? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 525a = 2,-8,-9 
SKIP TO 527a 
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526 
 
In the last 12 months, have you sold sex for 
money? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 526 = 2,-8,-9 
SKIP TO 527a 
527 
 
The last time you sold sex for money, was a 
condom used?  
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
527a 
 
Have you ever paid money for sex? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8  
REFUSED =-9 
 
IF 527a = 2,-8,-9 
SKIP TO 601 
  
528 
 
In the last 12 months, have you paid money 
for sex? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 528 = 2,-8,-9 
SKIP TO 601 
  
529 
 
The last time you paid money for sex, was a 
condom used?  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
 
MODULE 6: HIV/AIDS KNOWLEDGE AND ATTITUDES 
Interviewer says: “Now I will ask you questions on your knowledge of HIV.” 
601 
 
Can the risk of HIV transmission be reduced 
by having sex with only one uninfected partner 
who has no other partners? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
602 
 
Can a person get HIV from mosquito bites? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
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603 
 
Can a person reduce their risk of getting HIV 
by using a condom every time they have sex? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
604 
 
Can a person get HIV by sharing food with 
someone who has HIV? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
605 
 
Can a healthy-looking person have HIV? 
Now I would like to ask you some questions 
about people’s attitudes towards people living 
with HIV. 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
606 
 
Would you buy fresh vegetables from a shop 
keeper or vendor if you knew the person had 
HIV? 
 
YES =1 
NO =2 
DON’T KNOW/NOT SURE/DEPENDS =-8 
REFUSED =-9 
 
607 
 
Do you think children living with HIV should be 
allowed to attend school with children who do 
not have HIV? 
  
 
YES =1 
NO =2 
DON’T KNOW/NOT SURE/DEPENDS =-8  
REFUSED =-9 
  
  
608 
 
Do you think people hesitate to take an HIV 
test because they are afraid of how other 
people will react if the test result is positive for 
HIV? 
 
YES =1 
NO =2 
DON’T KNOW/NOT SURE/DEPENDS =-8 
REFUSED =-9 
 
609 
 
Do people talk badly about people who are 
living with HIV or who are thought to be living 
with HIV?  
  
 
YES =1 
NO =2 
DON’T KNOW/NOT SURE/DEPENDS =-8 
REFUSED =-9 
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610 
 
Do people living with HIV, or thought to be 
living with HIV, lose the respect of other 
people? 
 
YES =1 
NO =2 
DON’T KNOW/NOT SURE/DEPENDS =-8 
REFUSED =-9 
 
611 
 
Do you fear that you could get HIV if you 
come into contact with the saliva of a person 
living with HIV? 
  
 
YES =1 
NO =2 
DON’T KNOW/NOT SURE/DEPENDS =-8 
REFUSED =-9 
  
  
612 
 
Do you agree or disagree with the following 
statement: I would be ashamed if someone in 
my family had HIV.  
 
AGREE =1 
DISAGREE =2 
DON’T KNOW/NOT SURE/DEPENDS =-8 
REFUSED =-9 
 
 
MODULE 7: HIV TESTING 
 
Interviewer says: “I would now like to ask you some questions about HIV testing.” 
  
701 
 
Have you seen a doctor, clinical officer or 
nurse in a health facility in last 12 months? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 701 = 2,-8,-9 
Skip to 703 
702 
‘= 
During any of your visits to the health facility in 
the last 12 months, did a doctor, clinical officer 
or nurse offer you an HIV test? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
703 
 
Have you ever tested for HIV? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 703 = 1 
Skip to 704a 
IF 703=-8,-9 
SKIP TO 704b 
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704 
 
Why have you never been tested for HIV? 
SELECT ALL THAT APPLY. 
  
 
DON'T KNOW WHERE TO TEST  =A 
TEST COSTS TOO MUCH=B 
TRANSPORT  COSTS TOO MUCH =C 
TOO FAR AWAY =D 
AFRAID OTHERS WILL KNOW ABOUT 
TEST RESULTS =D 
DON'T NEED TEST/LOW RISK =F 
DID NOT RECEIVE PERMISSION FROM 
SPOUSE/FAMILY =G 
AFRAID SPOUSE/PARTNER/FAMILY  WILL 
KNOW RESULTS =H 
DON’T WANT TO KNOW I HAVE HIV =I 
CANNOT GET TREATMENT FOR HIV =J 
TEST KITS NOT AVAILABLE =K 
RELIGIOUS REASONS =L 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
  
704a 
 
To what extent do you agree with the following 
statement: All HIV-negative people should test 
for HIV every year. Do you strongly agree, 
agree, disagree, or strongly disagree? 
  
 
STRONGLY AGREE=1 
AGREE =2 
DISAGREE =3 
STRONGLY DISAGREE=4 
DON'T KNOW=-8 
REFUSED =-9 
  
  
704b 
 
If an HIV self-test kit were available in this 
country, would you use it? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 703= 2,-8,-9 
SKIP TO 801 
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705 
  
  
  
 
Have you had an HIV test since giving birth to 
[NAME]? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 705 = 1 
SKIP TO 708 
IF 705= -8,-9 
SKIP TO 712 
SKIP Q IF (308=2,-8,-9) 
& (312=2,-8 OR -9) & 
(325=2,-8,-9) 
SKIP Q IF 303 = 0,-8,-9 
SKIP Q IF 101=1 
 
706 
  
  
  
  
  
 
What month and year did you last test for 
HIV while you were pregnant with 
[NAME]? 
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR=date 
DON’T KNOW YEAR=-8 
REFUSED =-9 
 
SKIP Q IF (308=2,-8,-9) 
& (312=2,-8 OR -9) & 
(325=2,-8,-9) 
SKIP Q IF 303 = 0,-8,-9 
SKIP Q IF 101=1 
IF (309=2,-8,-9) & 
(315=2,3,4,-8,-9) & 
(326=2,3,4,-8,-9)  
SKIP TO 801 
 
707 
  
  
  
  
  
 
You mentioned earlier you received an 
HIV-positive result while you were 
pregnant with [NAME].  
What was the month and year of your first 
HIV-positive test result? Please give your 
best guess. 
This will be the very first HIV-positive test 
result that you have received 
PROBE TO VERIFY DATE. 
  
 
MONTH=date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR=-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 712 
SKIP Q IF (308=2,-8,-9) 
& (312=2,-8 OR -9) & 
(325=2,-8,-9) 
SKIP Q IF 303 = 0,-8,-9 
SKIP Q IF 101=1 
  
 
708 
  
  
  
 
What month and year was your last HIV test? 
  
 
MONTH=date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
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DON’T KNOW YEAR=-8 
REFUSED =-9 
 
709 
  
  
  
  
  
  
  
  
  
  
  
 
Where was the last test done? 
  
 
VCT FACILITY =1 
MOBILE VCT =2 
AT HOME =3 
HEALTH CLINIC / FACIITY =4 
HOSPITAL OUTPATIENT CLINIC =5 
TB CLINIC =6 
STI CLINIC =7 
HOSPITAL INPATIENT WARDS =8 
BLOOD DONATING CENTER =9 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
710 
  
  
  
  
  
 
What was the result of that HIV test? 
  
 
POSITIVE =1 
NEGATIVE =2 
UNCERTAIN/INDETERMINATE =3 
DID NOT RECEIVE THE RESULT =4 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 710 = 2,3,4,-8,-9 
SKIP TO 801 
  
 
711 
  
  
  
  
  
 
What was the month and year of your first 
HIV-positive test result? Please give your best 
guess. 
This will be the very first HIV-positive test 
result that you have received 
PROBE TO VERIFY DATE. 
  
 
MONTH=date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR=date=date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
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712 
  
  
  
  
  
  
  
 
Of the following people, who have you told 
that you are HIV positive?   
CHECK ALL THAT APPLY. 
  
 
NO ONE =A 
SPOUSE/SEX PARTNER =B 
DOCTOR =C 
FRIEND =D 
FAMILY MEMBER =E 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
IF 712_A=1 
SKIP TO 713 
SKIP Q IF 309!=1 AND 
315!=1 AND 326!=1 AND 
710!=1 
  
 
Interviewer says: “Now I would like to ask you questions about your experiences with health care 
providers.” 
IF 309!=1 & 315!=1 & 
326!=1 & 710!=1 
SKIP TO 801 
 
713 
  
  
  
  
 
In the last 12 months, have health care 
providers talked badly about you because of 
your HIV status? 
  
 
YES =1 
NO =2 
NO ONE KNOWS MY STATUS =3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
714 
  
  
  
  
 
In the last 12 months, when you sought health 
care in a facility where your HIV status is not 
known, did you feel you needed to hide your 
HIV status? 
 
YES =1 
NO, NO NEED TO HIDE =2 
NO, DID NOT ATTEND HEALTH FACILITY 
IN LAST 12 MONTHS =3 
DON’T KNOW =-8 
REFUSED =-9 
 
715 
  
  
  
  
 
In the last 12 months, have you been denied 
health services including dental care, because 
of your HIV status? 
  
 
YES =1 
NO =2 
NO ONE KNOWS MY STATUS =3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
MODULE 8: HIV STATUS, CARE AND TREATMENT 
 
Interviewer says: “Now I’m going to ask you more about your experience with HIV support, care and 
treatment.” 
 
IF 309!=1 & 315!=1 & 
326!=1 & 710!=1 
SKIP TO 901 
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 801       
  
  
  
 
After learning you had HIV, have you ever 
received HIV medical care from a doctor, 
clinical officer or nurse? 
  
 
YES =1 
NO =2 
DON'T KNOW=-8 
REFUSED=-9 
 
IF 801 = 1 
SKIP TO 803 
IF 801 = -8,-9 
  
      
802       
  
  
  
  
  
  
  
  
  
  
 
What is the main reason why you have never 
received HIV medical care from a doctor, 
clinical officer or nurse? 
 
FACILITY IS TOO FAR AWAY =1 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE =2 
COST OF CARE =3 
COST OF TRANSPORT =4 
I DO NOT NEED IT/I FEEL HEALTHY/NOT 
SICK  =5 
I FEAR PEOPLE WILL KNOW THAT I HAVE 
HIV IF I GO TO A CLINIC =6 
RELIGIOUS REASONS =7 
I’M TAKING TRADITIONAL MEDICINE =8 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 805a 
      
803       
  
  
  
  
  
 
After learning your HIV diagnosis, what month 
and year did you first see a doctor, clinical 
officer or nurse for HIV medical care? 
PROBE TO VERIFY DATE. 
  
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
  
  
      
804       
  
  
  
  
  
 
What month and year did you last see a 
doctor, clinical officer or nurse for HIV medical 
care? 
 
MONTH =date 
DON’T KNOW MONTH =-8 
REFUSED MONTH=-9 
YEAR=date 
DON’T KNOW YEAR =-8 
REFUSED =-9 
 
IF currentdate-804 <7 
MONTHS,-8,-9 
SKIP TO 805a 
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805       
  
  
  
  
  
  
  
  
  
  
  
 
What is the main reason for not seeing a 
doctor, clinical officer or nurse for HIV medical 
care in the past 6 months? 
  
 
FACILITY IS TOO FAR AWAY =1 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE =2 
COST OF CARE =3 
COST OF TRANSPORT=4 
I DO NOT NEED IT/I FEEL HEALTHY/NOT 
SICK  =5 
I FEAR PEOPLE WILL KNOW THAT I HAVE 
HIV IF I GO TO A CLINIC =6 
RELIGIOUS REASONS =7 
I’M TAKING TRADITIONAL MEDICINE=8 
NO APPOINTMENT SCHEDULED/DID NOT 
MISS MOST RECENT APPOINTMENT =9 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
805a 
  
  
  
  
 
At your last HIV care visit, approximately how 
long did it take you to travel from your home 
(or workplace) one-way? 
 
LESS THAN ONE HOUR=1 
ONE TO TWO HOURS=2 
MORE THAN TWO HOURS=3 
DON'T KNOW=-8 
REFUSED =-9 
 
 
806 
  
  
  
 
Have you ever had a CD4 count test?  
The CD4 count tells you how sick you are with 
HIV and if you need to take ARVs or other HIV 
medications. 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 806 = 2,-8,-9 
SKIP TO 808 
IF (806 = 2,-8,-9) & (801 
= 2,-8,-9) 
SKIP TO 901 
 
807 
  
  
  
  
  
 
What month and year were you last tested for 
your CD4 count? 
  
 
MONTH=date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR=date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
 
IF 801 = 2,-8,-9 
SKIP TO 901 
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808 
  
  
  
 
Have you ever taken ARVs, that is, 
antiretroviral medications to treat HIV 
infection? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 808 = 1 
SKIP TO 810 
IF 808 = -8,-9 
SKIP TO 815 
 
809 
  
  
  
  
  
  
  
  
  
  
  
 
What is the main reason you have never taken 
ARVs? 
  
 
NOT ELIGIBLE FOR TREATMENT=1 
HEALTH CARE PROVIDER DID NOT 
PRESCRIBE =2 
HIV MEDICINES NOT AVAILABLE =3 
I FEEL HEALTHY/NOT SICK =4 
COST OF MEDICATIONS =5 
COST OF TRANSPORT =6 
 RELIGIOUS REASONS =7 
TAKING TRADITIONAL MEDICATIONS =8 
NOT ATTENDING HIV CLINIC =9 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 815 
  
 
810 
  
  
  
  
  
 
What month and year did you first start taking 
ARVs? 
PROBE TO VERIFY DATE. 
 
MONTH=date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR=date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
 
 
811 
  
  
  
  
  
 
What month and year did you last receive 
ARVs? 
  
 
MONTH=date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR=date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
  
  
 
812 
  
  
  
 
Are you currently taking ARVs, that is, 
antiretroviral medications? 
By currently, I mean that you may have 
missed some doses but you are still taking 
ARVs. 
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 812=1 
SKIP TO 814 
IF 812 = -8,-9 
SKIP TO 815 
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813 
  
  
  
  
  
  
  
  
  
  
  
 
Can you tell me the main reason why you are 
not currently taking ARVs? 
  
 
I HAVE TROUBLE TAKING A TABLET 
EVERYDAY =1 
I HAD SIDE EFFECTS =2 
FACILITY TOO FAR AWAY FOR ME TO 
GET MEDICINE REGULARLY =3 
COST OF MEDICATIONS =4 
COST OF TRANSPORT=5 
I FEEL HEALTHY/NOT SICK =6 
 FACILITY WAS OUT OF STOCK =7 
RELIGIOUS REASONS =8 
TAKING TRADITIONAL MEDICATIONS =9 
OTHER=96 
DON’ T KNOW =-8 
REFUSED =-9 
 
ALL RESPONSES 
SKIP TO 815 
  
 
814 
  
  
 
People sometimes forget to take all of their 
ARVs every day. In the past 30 days, how 
many days have you missed taking any of 
your ARV pills? 
CODE ‘00’ IF NONE. 
 
NUMBER OF DAYS =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
 
815 
  
  
  
 
Are you currently taking Septrin or 
Cotrimoxazole?  
Septrin or cotrimoxazole is a medicine 
recommended for people with HIV, even if 
they have not started treatment for HIV. It 
helps prevent certain infections but it is not 
treatment for HIV. 
By currently, I mean that you may have 
missed some doses but you are still taking 
Septrin/Cotrimoxazole. 
  
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 815 = 1,-8,-9 
SKIP TO 817 
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816 
  
  
  
  
  
  
  
  
  
  
  
 
Can you tell me the main reason why you are 
not currently taking Septrin or Cotrimoxazole? 
 
WAS NOT PRESCRIBED=1 
I HAVE TROUBLE TAKING A TABLET 
EVERYDAY =2 
I HAD SIDE EFFECTS/RASH  
FACILITY TOO FAR AWAY FOR ME TO 
GET SEPTRIN OR COTRIMOXAZOLE 
REGULARLY  
DO NOT NEED IT/NOT SICK =5 
PHARMACY/FACILITY WAS OUT OF 
STOCK =6 
COST OF MEDICATIONS =7 
COST OF TRANSPORT =8 
DOCTOR SAID NO LONGER NEEDED =9 
OTHER=96 
DON’ T KNOW =-8 
REFUSED =-9 
 
 
817 
  
  
  
 
While receiving HIV care, has a health care 
provider or outreach worker spoken to you 
about family planning methods or 
contraceptives? 
  
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
818 
  
  
  
  
  
 
Have you ever attended a support group for 
people living with HIV? Was this in a facility or 
in the community? 
  
 
YES, IN A FACILITY/CLINIC=1 
YES, IN THE COMMUNITY=2 
NO, NOT INTERESTED=3 
NO, SUPPORT GROUP NOT AVAILABLE=4 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
Interviewer says: “Now I will ask you about HIV care and tuberculosis or TB.” 
IF 801 = 2,-8,-9 
SKIP TO 901 
 
821 
  
  
  
 
At your last HIV medical care visit, were you 
asked if you had any of the following TB 
symptoms: cough, fever, night sweats and 
weight loss?  
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
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822 
  
  
  
 
In the last 12 months, have you experienced 
any of the following TB symptoms: cough, 
fever, night sweats and weight loss? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 822 = 2,-8,-9 
SKIP TO 901 
  
 
823 
  
  
  
  
 
In the last 12 months, did you receive a chest 
x-ray or sputum test to look for TB?   
A sputum test is when the patient has to 
cough and collect the sample in a cup. 
SELECT ALL THAT APPLY. 
 
CHEST X-RAY =A 
SPUTUM TEST =B 
NONE OF THESE =C 
DON’T KNOW =Y 
REFUSED=Z 
 
 
MODULE 9: TUBERCULOSIS AND OTHER HEALTH ISSUES 
Interviewer says: “Now I will ask you about tuberculosis or TB” 
 
901 
  
  
  
 
Can TB be cured in people living with HIV? 
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
 
 
902 
  
  
  
 
Have you ever visited a TB clinic for TB 
diagnosis or treatment? 
  
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 902 = 2,-8,-9 
SKIP TO 913 
  
 
903 
  
  
  
  
 
Were you tested for HIV at the TB clinic? 
  
 
YES =1 
NO, WAS NOT TESTED FOR HIV =2 
NO, ALREADY HIV POSITIVE =3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
904 
  
  
  
 
Have you ever been told by a doctor, clinical 
officer or nurse that you had TB? 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 904 = 2,-8,-9 
SKIP TO 913 
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905 
  
  
  
  
  
 
What month and year did a doctor, clinical 
officer or nurse tell you that you have (had) 
TB? 
RECORD THE MOST RECENT TIME IF 
DIAGNOSED WITH TB MORE THAN ONCE. 
  
 
MONTH=date 
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date 
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
  
  
 
906 
  
  
  
 
Were you ever treated for TB? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 906 = 2,-8,-9 
SKIP TO 913 
 
907 
  
  
  
  
 
The last time you were treated for TB, did you 
complete at least 6 months of treatment? 
  
 
YES =1 
NO, MEDICINE WAS STOPPED IN LESS 
THAN 6 MONTHS =2 
NO, BUT I AM STILL ON TREATMENT=3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
Interviewer says: “Now I’m going to ask you about tests a health care provider can do to check for 
cervical cancer. The cervix connects the uterus to the vagina. The tests a health care provider can do 
to check for cervical cancer are called a pap smear, HPV test and VIA test. For a pap smear and HPV 
test, a health care provider puts a small stick inside the vagina to wipe the cervix and sends the 
sample to the laboratory. For a VIA test, a healthcare worker puts vinegar on the cervix and looks to 
see if the cervix changes color.”  
  
IF 101 = 1 
SKIP TO 918 
 
913 
  
  
  
 
Have you ever been tested for cervical 
cancer? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 913 = 2,-8.-9 
SKIP TO 918 
 
914 
  
  
  
  
  
 
What month and year was your last test for 
cervical cancer? 
  
 
MONTH =date  
DON’T KNOW MONTH =-8 
REFUSED MONTH =-9 
YEAR =date  
DON’T KNOW YEAR =-8 
REFUSED YEAR =-9 
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915 
  
  
  
  
  
  
 
What was the result of your last test for 
cervical cancer? 
 
NORMAL/NEGATIVE =1 
ABNORMAL/POSITIVE =2 
SUSPECT CANCER =3 
UNCLEAR/INCONCLUSIVE =4 
DID NOT RECEIVE RESULTS =5 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 915 = 1,4,5,-8,-9 
SKIP TO 918 
 
916 
  
  
  
  
 
Did you receive treatment after your last test 
for cervical cancer? Did you receive treatment 
on the same day or on a different day? 
  
 
YES, I WAS TREATED ON THE SAME DAY 
=1 
YES, I RECEIVED TREATMENT ON A 
DIFFERENT DAY =2 
NO =3 
DON'T KNOW=-8 
REFUSED=-9 
  
  
 
917 
  
  
  
 
Did you have any follow up visits because of 
your test results? 
 
YES  =1 
NO =2 
DON'T KNOW=-8 
REFUSED=-9 
 
 
Interviewer says: “Now I would like to ask you questions about sexual health.” 
IF (502 = 96,-8,-9) & 
(502a= 2,-8,-9) 
SKIP TO 1101 
 
917a 
  
  
  
 
During the last 12 months, have you had an 
abnormal discharge from your vagina or 
experienced pelvic pain? This may include an 
unusual smell, color, or texture. 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 101 = 1 
 
918 
  
  
  
 
During the last 12 months, have you had an 
ulcer or sore on or near your vagina? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 101 = 1 
  
 
919 
  
  
  
 
During the last 12 months, have you had an 
abnormal discharge from your penis? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 101 = 2 
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920 
  
  
  
 
During the last 12 months, have you had an 
ulcer or sore on or near your penis?  
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 101 = 2 
  
 
921 
  
  
  
 
During the last 12 months, have you had pain 
on urination? 
 
YES =1 
NO =2 
DON’T KNOW =8 
REFUSED =-9 
 
SKIP Q IF 101 = 2 
 
922 
  
  
  
 
Did you see a doctor, clinical officer or nurse 
because of these problems? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 101 = 2 & 
(917a= 2,-8,-OR 9) & 
918=2,-8, OR 9) 
SKIP Q IF 101 = 1 & 
((919=2,-8 OR -9) & 
(920=2,-8, OR 9) & 
(921=2,-8, OR -9)) 
  
 
923 
  
  
  
 
In the last 12 months, did a doctor, clinical 
officer, or nurse tell you that you had a 
sexually transmitted disease other than HIV? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
 
924 
  
  
  
 
Did you get treatment for these problems? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 919 = 2,-8,-9 
SKIP Q IF 917a-922!=1 
& 923!=1 
SKIP TO  1101 
  
 
925 
  
  
  
  
  
 
Where did you go to get treatment? Did you 
go to a public facility, a private facility or a 
pharmacy? 
SELECT ALL THAT APPLY. 
 
PUBLIC CLINIC/HOSPITAL =A 
PRIVATE CLINIC/HOSPITAL =B 
PHARMACY =C 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
 
SKIP Q IF 917a-922!=1 
& 923!=1 
 
  
 244 
 
MODULE 11: GENDER NORMS 
 
Interviewer says: “Now I would like to ask you questions on decision-making in your home.” 
 
     
1101      
  
  
  
  
  
 
Who usually makes decisions about health 
care for yourself: you, your (spouse/partner), 
you and your (spouse/partner) together, or 
someone else? 
 
I DO =1 
SPOUSE/PARTNER =2 
WE BOTH DO =3 
SOMEONE ELSE =4 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 204 !=1,2 
 
1102 
  
  
  
  
  
 
Who generally decides about how the money 
you receive is spent: you, your 
(spouse/partner), you and your 
(spouse/partner) together, or someone else?  
  
 
I DO =1 
SPOUSE/PARTNER =2 
WE BOTH DO  =3 
SOMEONE ELSE =4 
DON’T KNOW =-8 
REFUSED =-9 
 
SKIP Q IF 204 !=1,2 
  
 
1105 
  
  
  
  
 
Who should decide when to have sex - men, 
women or together? 
  
 
MEN ONLY=1 
WOMEN ONLY=2 
TOGETHER=3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
1106 
  
  
  
 
Do you believe married men need to have sex 
with women they are not married to, even if 
they have good relationships with their wives? 
  
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
1107 
  
  
  
 
Do you believe women who carry condoms 
have sex with a lot of men? 
  
 
YES =1 
NO=2 
DON’T KNOW =-8 
REFUSED =-9 
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MODULE 12: VIOLENCE 
 
Interviewer says: “You have been selected to be asked questions on other important aspects of a person’s life. I know that 
some of these questions are very personal. However, your answers are important for helping to understand the condition of 
men and women in Zambia. Let me assure you that your answers are completely confidential and will not be told to anyone and 
no one in your household will know that you were asked these questions.”  
  
  
 
1207 
  
  
 
How many times has anyone ever touched 
you in a sexual way without your permission, 
but did not try and force you to have sex? 
Touching in a sexual way without permission 
includes fondling, pinching, grabbing, or 
touching you on or around your sexual body 
parts. 
CODE ‘00’ IF NONE. 
 
NUMBER OF TIMES =integer 
DON’T KNOW =-8 
 REFUSED =-9 
 
 
IF 1207 = 0,-8,-9 
SKIP TO 1210 
  
 
1208 
  
  
 
How old were you the first time this 
happened? 
  
 
AGE IN YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
1210 
  
  
 
How many times in your life has anyone tried 
to make you have sex against your will but did 
not succeed? This includes someone using 
harassment, threats, tricks, or physical force. 
CODE ‘00’ IF NONE. 
 
NUMBER OF TIMES =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 1210 = 0,-8,-9 
SKIP TO 1212 
 
1211 
  
  
 
How old were you the first time someone tried 
to make you have sex against your will but did 
not succeed? 
  
 
AGE IN YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
1212 
  
  
 
How many times in your life have you been 
physically forced to have sex? 
CODE ‘00’ IF NONE. 
 
NUMBER OF TIMES =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 1212 =0,-8,-9 
SKIP TO 1217 
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1213 
  
  
 
How old were you the first time someone 
physically forced you to have sex? 
  
 
AGE IN YEARS=integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
1215 
  
  
  
 
In the past 12 months, did someone physically 
force you to have sex?  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
IF 1215 = 2,-8,-9 
SKIP TO 1217 
 
1216 
  
  
  
  
In the past 12 months, did a partner physically 
force you to have sex? 
By partner, I mean a live-in partner whether or 
not you were married at the time.  
  
 
YES =1 
NO, DID NOT FORCE =2 
NO, DID NOT HAVE A LIVE-IN PARTNER IN 
THE LAST 12 MONTHS=3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
1217 
  
  
How many times in your life has someone 
pressured you to have sex through 
harassment, threats and tricks and did 
succeed?   
CODE ‘00’ IF NONE. 
Being pressured can include being worn down 
by someone who repeatedly asks for sex, 
feeling pressured by being lied to, being told 
promises that were untrue, having someone 
threaten to end a relationship or spread 
rumors or sexual pressure due to someone 
using their influence or authority. 
NUMBER OF TIMES =integer 
DON’T KNOW =-8 
REFUSED =-9 
IF 1217 = 0,-8,-9 
SKIP TO 1222 
1218 
  
  
How old were you the first time someone 
pressured you to have sex and did succeed? 
  
AGE IN YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
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1220 
  
  
  
In the past 12 months, did someone pressure 
you to have sex and did succeed?  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 1220 = 2,-8,-9 
SKIP TO 1222 
1221 
  
  
  
  
In the past 12 months, did a partner pressure 
you to have sex and did succeed? 
By partner, I mean a live-in partner, whether 
or not you were married at the time. 
  
 
YES =1 
NO, DID NOT PRESSURE AND SUCCEED 
=2 
NO, DID NOT HAVE A LIVE-IN PARTNER IN 
THE LAST 12 MONTHS=3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
1222 
  
  
  
  
  
  
  
After any of these unwanted sexual 
experiences, did you try to seek professional 
help or services from any of the following? 
SELECT ALL THAT APPLY. 
 
I DID NOT TRY TO SEEK HELP =A 
HEALTHCARE PROFESSIONAL  =B 
POLICE OR OTHER SECURITY 
PERSONNEL  =C 
SOCIAL WORKER, COUNSELOR OR NON-
GOVERNMENTAL ORGANIZATION  =D 
RELIGIOUS LEADER  =E 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
IF 1222_B-1222_Z=1 
SKIP TO 1201 
SKIP Q IF (1207=0,-8,-9) 
& (1210=0,-8,-9) & 
(1212=0,-8,-9) & 
(1217=0,-8,-9) 
  
1223 
  
  
  
  
What was the main reason that you did not try 
to seek professional help or services? 
  
 
DID NOT KNOW SERVICES WERE 
AVAILABLE =1 
SERVICES NOT AVAILABLE =2 
AFRAID OF GETTING IN TROUBLE =3 
ASHAMED FOR SELF/FAMILY =4 
COULD NOT AFFORD SERVICES =5 
DID NOT THINK IT WAS A PROBLEM =6 
FELT IT WAS MY FAULT =7 
AFRAID OF BEING ABANDONED =8 
SKIP Q IF (1207=0,-8,-9) 
& (1210=0,-8,-9) & 
(1212=0,-8,-9) & 
(1217=0,-8,-9) 
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DID NOT NEED/WANT SERVICES =9 
AFRAID OF MAKING SITUATION WORSE 
=10 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
1201 
  
  
  
  
  
Has anyone ever done any of these things to 
you: 
-       Punched, kicked, whipped, or beat you 
with an object 
-       Slapped you, threw something at you 
that could hurt you, pushed you or shoved you 
-       Choked smothered, tried to drown you, 
or burned you intentionally 
-       Used or threatened you with a knife, gun 
or other weapon? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 1201 = 2,-8,-9 
SKIP TO 1224 
1202 
  
  
How old were you the first time one of these 
things happened to you? 
  
 
AGE IN YEARS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
1203 
  
  
  
  
  
In the past 12 months, how many times did 
someone: 
-       Punched, kicked, whipped, or beat you 
with an object 
-       Slapped you, threw something at you 
that could hurt you, pushed you or shoved you 
-       Choked smothered, tried to drown you, 
or burned you intentionally 
-       Used or threatened you with a knife, gun 
or other weapon? 
 
NOT IN LAST 12 MONTHS =1 
ONCE =2 
FEW =3 
MANY =4 
DON’T KNOW =-8 
REFUSED =-9 
IF 1203 = 1,-8,-9 
SKIP TO 1205 
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1204 
  
  
  
  
In the past 12 months, did a partner do any of 
these things to you? 
By partner, I mean a live-in partner, whether 
or not you were married at the time. 
  
 
YES =1 
NO, PARTNER DID NOT=2 
NO, DID NOT HAVE A LIVE-IN PARTNER IN 
THE LAST 12 MONTHS=3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
1205 
  
  
  
  
  
  
  
Thinking about all these experiences that we 
just discussed, whether someone has done 
the following: 
-       Punched, kicked, whipped, or beat you 
with an object 
-       Slapped you, threw something at you 
that could hurt you, pushed you or shoved you 
-       Choked smothered, tried to drown you, 
or burned you intentionally 
-       Used or threatened you with a knife, gun 
or other weapon 
Did you try to seek professional help or 
services for any of these incidents from any of 
the following? 
SELECT ALL THAT APPLY. 
 
I DID NOT TRY TO SEEK HELP =A 
HEALTHCARE PROFESSIONAL  =B 
POLICE OR OTHER SECURITY 
PERSONNEL  =C 
SOCIAL WORKER, COUNSELOR OR NON-
GOVERNMENTAL ORGANIZATION  =D 
RELIGIOUS LEADER   =E 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
IF 1205_A=1 
SKIP TO 1206 
IF 1205_B-1205_Z=1 
SKIP TO 1224 
  
1206 
  
  
  
  
  
  
 
  
What was the main reason that you did not try 
to seek professional help or services? 
 
DID NOT KNOW SERVICES WERE  
AVAILABLE =1 
SERVICES NOT AVAILABLE =2 
AFRAID OF GETTING IN TROUBLE =3 
ASHAMED FOR SELF/FAMILY =4 
COULD NOT AFFORD SERVICES =5 
DID NOT THINK IT WAS A PROBLEM =6 
FELT IT WAS MY FAULT =7 
AFRAID OF BEING ABANDONED =8 
DID NOT NEED/WANT SERVICES =9 
AFRAID OF MAKING SITUATION WORSE 
=10 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
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Interviewer says: “Thank you for sharing your personal experiences with me. I know it may have been difficult for you to talk 
about your experiences with me. If you would like to talk further about these experiences, I can refer you to a place that can 
provide you with help. “ 
  
SKIP Q IF (1201=0,-8,-9) & (1207=0,-8,-9) & (1210=0,-8,-9) & (1212=0,-8,-9) & (1217=0,-8,-9) 
  
PROVIDE PARTICIPANT WITH LIST OF ORGANIZATIONS. 
  
 
Interviewer says: “You mentioned earlier that you have sold sex for money. Thank you for sharing your personal experiences 
with me. If you want to talk further about these experiences, I can refer you to a place that can provide you with help.” 
  
SKIP IF (102>18) & ((510!=7) OR (526!=1)) 
  
FILL OUT REFERRAL FORM FOR CHILDREN IDENTIFIED AS TRAFFICKED MINORS. FILL OUT SUMMARY OF REFERRED 
TRAFFICKED MINORS. PROVIDE PARTICIPANT WITH LIST OF ORGANIZATIONS, IF NOT ALREADY GIVEN. 
  
  
 
Interviewer says: “Thank you for taking the time to participate in this survey. Your responses will be very helpful to the Ministry 
of Health to better understand how to improve health programs in the country.” 
  
  
  
PROVIDE PARTICIPANT WITH LIST OF ORGANIZATIONS, IF NOT ALREADY GIVEN. 
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THIS QUESTIONNAIRE IS ADMINISTERED TO ELIGIBLE CHILDREN AGED BETWEEN 10-14 YEARS AFTER INFORMED 
PARENTAL/GUARDIAN CONSENT AND MINOR ASSENT.  
L1 
  
  
  
   
  
LANGUAGE OF QUESTIONNAIRE 
  
 
ENGLISH =1 
BEMBA =2 
KAONDE =3 
LOZI =4 
LUNDA =5 
LUVALE =6 
NYANJA =7 
TONGA =8 
  
  
L2 
  
  
  
  
  
  
LANGUAGE OF INTERVIEW 
 
ENGLISH =1 
BEMBA=2 
KAONDE =3 
LOZI =4 
LUNDA =5 
LUVALE =6 
NYANJA =7 
TONGA =8 
OTHER =9 
  
  
APPENDIX G ADOLESCENT QUESTIONNAIRE 
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L3 
  
  
  
   
  
NATIVE LANGUAGE OF PARTICIPANT 
  
 
ENGLISH =1 
BEMBA =2 
KAONDE =3 
LOZI =4 
LUNDA =5 
LUVALE =6 
NYANJA =7 
TONGA =8 
OTHER =9 
  
L4 
  
TRANSLATOR USED 
  
 
YES =1 
NO =2 
  
  
000 ENTER NAME OF CHILD:   NAME OF CHILD =text   
000 ENTER LINE NUMBER OF THE CHILD FROM THE HOUSEHOLD LISTING =integer 
 
 
MODULE 1: SOCIO-DEMOGRAPHIC CHARACTERISTICS 
101 
  
IS THE RESPONDENT MALE OR FEMALE? 
  
 
MALE =1 
FEMALE =2 
  
  
102 
  
  
How old were you at your last birthday? 
  
 
AGE IN COMPLETED YEARS=integer 
DON’T KNOW AGE =-8 
REFUSED -9 
  
  
 
109 
   
 
Have you ever attended school? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
 
IF 109 = 2,-8,-9 
SKIP TO 102c 
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111 
  
  
  
What is the highest level and grade that you 
have completed? 
  
 
LEVEL =integer 
GRADE=integer 
DON'T KNOW =-8 
REFUSED =-9 
  
  
102c 
  
  
  
  
  
  
  
   
What is the main reason you have never 
attended school? 
  
 
I HAVE BEEN SICK =1 
I DON'T FEEL SAFE TRAVELING TO SCHOOL 
=2 
I DON'T FEEL SAFE WHILE IN SCHOOL =3 
I DON'T LIKE SCHOOL =4 
I HAVE TO LOOK AFTER MY FAMILY =5 
THERE'S NOT ENOUGH MONEY TO SEND ME 
TO SCHOOL  =6 
SCHOOL IS TOO FAR AWAY =7 
I HAVE TO WORK =8 
I HAVE A CHILD OR I AM PREGNANT  =9 
I MISSED TOO MUCH SCHOOL BECAUSE OF 
MY PERIOD (MENSTRUATION)   =10 
OTHER =96  
DON'T KNOW =-8 
REFUSED =-9 
ALL RESPONSES 
 SKIP TO 201 
103 
  
  
Are you currently attending school? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 103 = 2,-8,-9  
SKIP TO 108 
  
106 
  
  
What level and grade are you in now? 
  
 
LEVEL =integer 
GRADE -integer 
DON'T KNOW =-8 
REFUSED =-9 
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104 
  
  
  
 
During the last school week, did you miss any 
school days for any reason? 
  
 
YES  =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 104 = 2,-8,-9  
SKIP TO 104 
  
105 
  
  
  
  
  
  
  
  
  
  
Why did you miss school? 
  
 
I AM TOO SICK TO ATTEND SCHOOL =1 
I DON'T LIKE SCHOOL =4 
I HAVE TO CARE FOR HOUSEHOLD 
MEMBERS =5 
SCHOOL IS TOO FAR AWAY / NO SCHOOL 
=7 
I HAVE TO WORK =8 
NO MONEY FOR SCHOOL MATERIALS / 
TRANSPORT =11 
PARENTS / GUARDIAN DOES NOT WANT 
ME TO GO TO SCHOOL  =12 
SCHOOL WAS NOT IN SESSION =13 
OTHER =96 
DON'T KNOW =-8 
REFUSED  =-9 
ALL RESPONSES 
SKIP TO 201 
  
107 
  
  
  
What level and grade were you in last year? 
  
 
LEVEL =integer 
GRADE =integer 
DON’T KNOW =-8 
REFUSED =-9 
ALL RESPONSES  
SKIP TO 201 
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108 
  
  
  
  
  
  
  
   
What is the main reason you are not currently 
attending school? 
  
 
I AM TOO SICK TO ATTEND SCHOOL =1 
I DON'T LIKE SCHOOL =4 
I HAVE TO CARE FOR HOUSEHOLD 
MEMBERS =5 
SCHOOL IS TOO FAR AWAY / NO SCHOOL 
=7 
I HAVE TO WORK =8 
NO MONEY FOR SCHOOL MATERIALS / 
TRANSPORT =11 
PARENTS / GUARDIAN DOES NOT WANT 
ME TO GO TO SCHOOL   =12 
SCHOOL WAS NOT IN SESSION =13 
OTHER =96 
DON'T KNOW =-8 
REFUSED =-9  
  
  
 
MODULE 2: HIV KNOWLEDGE 
Interviewer says: “Now I would like to ask you some questions about what you know about some things related to health.” 
201 
  
  
  
Have you ever heard of HIV?  
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 201 = 2,-8,-9 
SKIP TO 302 
  
 
 
256 
 
202 
  
  
  
  
  
  
  
From where have you heard about HIV?  
PROBE: Anywhere else? 
RECORD ALL MENTIONED 
  
 
SCHOOLS / TEACHERS =A 
PARENTS / GUARDIAN / FAMILY  =B 
FRIENDS =C 
RELIGIOUS LEADERS =D 
INTERNET =E 
MOBILE PHONE =F 
HEALTH PROVIDERS / DOCTORS / NURSES / 
CLINICAL OFFICERS =G 
TELEVISION / FILM =H 
RADIO =I 
COMMUNITY HEALTH WORKERS =J 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
  
  
203 
  
  
  
Have you ever discussed HIV with your parents 
or guardian? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
204 
  
   
Can a person reduce their chance of getting 
HIV by not having sex?    
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
205 
  
  
Can a person reduce their chance of getting 
HIV by using condoms when having sex? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
206 
  
   
Can a healthy-looking person have HIV or 
AIDS? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
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REFUSED =-9 
207 
  
 
Can a mother with HIV pass HIV to her unborn 
baby? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED  =-9 
  
  
208 
  
   
Are there medicines that people with HIV or 
AIDS can take to help them live longer? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8  
REFUSED =-9 
  
  
209 
  
Can male circumcision help prevent HIV 
infection? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
MODULE 3: HIV PREVENTION INTERVENTIONS 
301 
   
  
Have you taken part in any of the following HIV 
prevention programs? 
SHOW CHILD LOGO FOR EACH PROGRAM 
SELECT ALL THAT APPLY 
 
FAMILIES MATTER PROGRAM =A 
HEALTHY CHOICES =B 
LIFE SKILLS PROGRAM =C 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
  
OTHER SPECIFY 
302 
  
  
Do you know where to get a condom? 
  
 
YES =1 
NO =2 
DON’T KNOW WHAT A CONDOM IS =3 
REFUSED =-9 
IF 302 = 2, 3, -9 
SKIP TO 402 
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303 
  
  
  
  
Where can a person go to get a condom? 
SELECT ALL THAT APPLY 
 
CLINIC / HOSPITAL =A 
KIOSK / SHOP =B 
PHARMACY =C 
LOCAL FREE DISPENSER =D 
FRIENDS / PEERS =E 
BOYFRIEND / GIRLFRIEND =F 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
 
  
 
 
MODULE 4: SEXUAL BEHAVIOR 
Interviewer says: “The next questions ask about sexual behavior. There is no right or wrong answer. Your responses will not be 
linked to you in any way or shared with anyone, including your parents. “   
401 
  
  
  
Do you know what sex is? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 102<=12 & 401= 2, 
-8, -9 
SKIP TO 501  
  
402 
  
  
  
Have you ever had sex?   
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 402 = 2, -8, -9 
 SKIP TO 1105 
403 
  
  
How old were you when you had sex for the 
first time? 
  
 
AGE IN YEARS =integer 
DON’T KNOW AGE =-8 
REFUSED =-9 
  
  
 
 
259 
 
406 
  
  
  
  
  
  
  
  
  
What was the main reason that you had sex 
for the first time? 
  
 
IT JUST HAPPENED =1 
MY FRIENDS PRESSURED ME TO HAVE SEX 
=2 
TO SHOW MY LOVE / TO FEEL LOVED =3 
I WANTED TO HAVE SEX / CURIOUS =4 
MY BOYFRIEND / GIRLFRIEND WANTED TO 
HAVE SEX =5 
I WAS TRICKED, THREATENED, OR FORCED 
FOR MONEY / GIFTS  =6 
I WANTED TO HAVE A BABY =7 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
  
  
407 
  
  
  
  
   
How old was the person you first had sex with? 
Please give your best guess. 
  
 
10 OR MORE YEARS OLDER =1 
5-9 YEARS OLDER =2 
1-4 YEARS OLDER =3 
SAME AGE AS MYSELF =4 
YOUNGER THAN ME =5 
DON’T KNOW AGE =-8 
REFUSED =-9 
  
  
404 
  
  
  
The first time you had sex, was it because you 
wanted to or because you were forced? 
  
 
WANTED TO =1 
FORCED =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 404 = 2, -8, -9 
SKIP TO 408 
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405 
  
The first time you had sex, were you 
physically forced or were you pressured into 
having sex through harassment, threats or 
tricks? 
 
PHYSICALLY FORCED =1 
PRESSURED =2 
DON’T KNOW =-8 
REFUSED =-9 
  
Interviewer says: “Now we will ask you some general questions about sex. “ 
408 
  
  
  
  
The first time you had sex, was a condom 
used? 
  
 
YES =1 
NO =2 
DON’T KNOW WHAT A CONDOM IS =3 
DON’T KNOW =-8 
REFUSED =-9 
  
  
409 
  
  
In total, how many different people have you 
had sex with? Please give your best guess. 
  
 
NUMBER OF PARTNERS =integer 
DON’T KNOW =-8 
REFUSED =-9 
  
  
410 
  
  
  
The last time you had sex was a condom used? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 408=3 
  
411 
  
  
  
How often do you use a condom during sex? 
 
ALWAYS =1 
SOMETIMES =2 
NEVER =3 
DON’T REMEMBER =4 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 408=3 
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412 
  
  
  
Sometimes people have sex to get material 
support. Material support means helping 
you to pay for things or giving you gifts or 
things. 
Have you ever had sex with someone because 
you expected material support? 
  
 
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
  
  
413 
  
  
Have you ever been pregnant?  
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 101=1 
  
 
MODULE 11: VIOLENCE 
 
Interviewer says: “Now I would like to ask you questions about some other important aspects of a person’s life. I know that 
some of these questions are very personal. However, your answers are important for helping to understand the condition of 
children in Zambia. Let me assure you that your answers are completely confidential and will not be told to anyone.”  
1105 
  
  
Has anyone ever tried to make you have sex 
against your will but did not succeed? 
  
 
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
 
1106 
  
  
  
Has anyone ever pressured you to have sex, 
through harassment, threats or tricks and did 
succeed? 
  
 
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
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1107 
  
  
  
Has anyone ever physically forced you to have 
sex and did succeed? 
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
1108 
  
  
  
 
The last time you were pressured or forced to 
have sex, what was your relationship to the 
person who did this? 
 
 
BOYFRIEND / GIRLFRIEND / SPOUSE =1 
RELATIVE / FAMILY MEMBER =2 
CLASSMATE / SCHOOLMATE =3 
TEACHER =4 
POLICE / SECURITY OFFICER / SOLDIER =5 
EMPLOYER =6 
NEIGHBOR =7 
COMMUNITY RELIGIOUS LEADER =8 
FRIEND =9 
STRANGER =10 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF (1106 = 2, 
-8, -9 ) AND (1107 = 
2,-8,-9) 
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1109 
  
  
  
  
  
After any of these unwanted sexual 
experiences, did you try to seek professional 
help or services from any of the following? 
SELECT ALL THAT APPLY 
  
 
I DID NOT TRY TO SEEK HELP =A 
HEALTHCARE PROFESSIONAL =B 
POLICE OR OTHER SECURITY PERSONNEL 
=C 
SOCIAL WORKER, COUNSELOR OR NGO =D 
RELIGIOUS LEADER =E 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
IF 1109 = B, C, D, 
E, X, Y, Z 
SKIP Q IF  1105 = 2, 
-8, -9, & 1106 = 2, -
8, -9, & 1107 = 2, -8, 
-9  
 
SKIP TO 501 
  
1110 
  
  
  
  
  
  
  
  
  
  
  
What was the main reason that you did not try 
to seek professional help or services? 
  
 
DID NOT KNOW SERVICES WERE 
AVAILABLE=1 
SERVICES NOT AVAILABLE =2 
AFRAID OF GETTING IN TROUBLE =3 
ASHAMED FOR SELF/FAMILY =4 
COULD NOT AFFORD SERVICES =5 
DID NOT THINK IT WAS A PROBLEM =6 
FELT IT WAS MY FAULT =7 
AFRAID OF BEING ABANDONED =8 
DID NOT NEED/WANT SERVICES =9 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
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MODULE 5: HIV RISK PERCEPTIONS  
501 
  
  
  
How likely do you think it is for you to get HIV? 
  
 
VERY LIKELY =1 
SOMEWHAT LIKELY =2 
NOT LIKELY =3 
I ALREADY HAVE HIV =4 
DON’T KNOW =-8 
REFUSED =-9 
IF 501 = 3, 4, -8, -9 
SKIP Q IF 201=  2,-
8,-9 
SKIP TO 503 
  
502 
  
  
  
  
  
  
  
  
  
  
What is the main reason you think you are 
likely to get HIV? 
  
 
I HAVE HAD SEX WITHOUT A CONDOM =1 
I HAVE OR HAD MANY BOY/GIRLFRIENDS 
=2 
I HAVE HAD BLOOD TRANSFUSIONS =3 
MY MOTHER / FATHER / HAS HIV =4 
I DON’T TRUST MY BOY/GIRLFRIEND =5 
I AM SICK =6 
MY BOY/GIRLFRIEND IS SICK OR HAS DIED 
=7 
I DESERVE IT / I AM A BAD PERSON =8 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
ALL 
SKIP Q IF 201=  2,-8,-9 
 
SKIP TO 601 
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503 
  
  
  
  
  
  
   
What is the main reason you think you are not 
likely to get HIV? 
  
 
I AM ABSTINENT =1 
I WILL WAIT UNTIL MARRIAGE TO HAVE 
SEX =2 
I ALWAYS USE CONDOMS =3 
I TRUST MY PARTNER =4 
I HAVE ONLY ONE PARTNER =5 
I GO TO CHURCH =6 
I AM A GOOD PERSON =7 
OTHER =96 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 201=  2,-8,-9 
  
  
 
MODULE 6: SOCIAL NORMS, INTENTION TO ABSTAIN, SELF-EFFICACY AND ASSERTIVENESS 
Interviewer says: “Now I would like to ask you some questions about the future.” 
601 
  
  
  
  
  
  
Do you think all, many, some, a few or none of 
your friends are having sex? 
  
 
ALL =1 
MOST =2 
SOME =3 
A FEW =4 
NONE =5  
DON’T KNOW / DON’T KNOW WHAT SEX IS 
=-8  
REFUSED =-9 
  
  
602 
  
  
  
Are you pressured by your friends or boy/girl 
friend to have sex? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 401=  2,-8,-9 
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603 
  
  
  
If you did not want to have sex with someone, 
could you tell them that you do not want to 
have sex with them? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 401=  2,-8,-9 
  
 
MODULE 7: HIV TESTING 
Interviewer says: “I would now like to ask you some questions about HIV testing.”  
701 
  
  
  
Have you ever been tested for HIV? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 701 = 2, -8, -9 
SKIP Q IF 201=  2,-8,-9 
SKIP TO 801 
  
702 
  
  
  
Did you receive the results of any of your HIV 
tests? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 702 = 2, -8, -9 
SKIP Q IF 201=  2,-8,-9 
 
SKIP TO 801 
  
703 
  
  
  
What was the result of that HIV test? 
  
 
HIV POSITIVE =1 
HIV NEGATIVE =2 
UNKNOWN =-8 
REFUSED =-9 
IF 703 = 2, 3, -9 
SKIP Q IF 201=  2,-8,-9 
SKIP TO 801 
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MODULE 8: ALCOHOL AND DRUGS 
Interview says: “I would like to ask you some questions about alcohol and drugs or substances that you may have taken that 
were not given to you by doctor. Your answers will not be told to anyone, even your parents.” 
  
801 
  
  
  
Have you ever had alcohol, for example beer, 
wine or chibuku? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 801 = 2, -8, -9 
SKIP TO 803 
  
802 
  
  
During the past 1 month, on how many 
days did you have at least one drink 
containing alcohol? 
  
 
NUMBER OF DAYS =integer 
DON’T KNOW=-8 
REFUSED =-9 
  
  
803 
  
  
  
Have you ever tried drugs such as jenkem, 
cocaine, marijuana or others? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF 803 = 2, -8, -9 
SKIP TO 901 
  
804 
  
  
  
  
  
  
  
What drugs have you ever tried? 
DO NOT READ RESPONSES. 
PROBE FOR MULTIPLE RESPONSES. 
 
MARIJUANA =A 
COCAINE =B 
HEROIN =C 
MIRAA =D 
JENKEM =E 
BOSTIC GLUE =F 
ECSTACY =G 
DIAZEPAM =J 
OTHER =X 
DON’T KNOW =Y 
REFUSED =Z 
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MODULE 9: HIV STIGMA 
901 
  
  
  
Would you be willing to share food with 
someone who has HIV? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 201=2, -
8, -9 
  
902 
  
  
  
Would you play with someone who has 
HIV? 
  
 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP Q IF 201=2, -
8, -9 
  
  
Interview says: “This is the end of the survey. Thank you very much for your time and for your responses.”  
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Zambia Population-based HIV Impact Assessment: Consent for Household Interview 
 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
 
 
Hello. My name is___________. I would like to invite you to take part in this research study/survey 
about HIV in Zambia. The Ministry of Health and Central Statistical Office (CSO) are leading this survey in 
collaboration with the United States Centers for Disease Control and Prevention and ICAP at Columbia 
University.  
  
What is the purpose of this survey? 
HIV is the virus that causes AIDS. AIDS is a very serious illness. This survey will help us know how many 
people in Zambia have HIV and need health services. It will also tell us about people’s risk for getting 
HIV. About 16,000 households will join this survey. We would like your household to join the survey too. 
What you tell us will help the Ministry of Health make HIV services better in the country. 
 
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand. 
APPENDIX H SURVEY CONSENT FORM 
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What do you have to do if you agree to take part? 
There are three parts to this survey. The first part is the household interview. The second part is the 
individual interviews. The third part is blood testing. If you agree to take part in the household 
interview, I would ask you some questions about the people staying in your household, such as how 
many people live here, their relationship to you, their gender and age. I will also ask you about some of 
the things you have in your household. The household interview will take up to 30 minutes.  
After you complete the household interview, we will invite you and others living in your household to 
participate in individual interviews and then offer testing for HIV, hepatitis B and syphilis. Like HIV, 
hepatitis B and syphilis are infections that can cause very serious illnesses if left untreated.  
What are the potential risks? 
You may feel uncomfortable about some of the questions I will ask. If I ask you any questions you don’t 
want to answer, just let me know and I will go to the next question or you can stop the interview at any 
time.  
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
What are the potential benefits?  
There may be no direct benefit to you but the information you provide to us will be used to improve the 
health of Zambians. Your responses will help the Ministry of Health to develop more effective programs 
to fight HIV. 
 
What are the alternatives to taking part? 
You can decide not to not take part in this survey—your participation in this household interview is 
entirely voluntary. Your decision to take part or not take part will not affect your health care, but we 
hope you will agree to answer these questions since your views are important.  
 
What about confidentiality?  
All information you give us will be kept strictly confidential. Your name and signed consent form will be 
kept separate from the answers you give in this interview. Your name will not appear when we share 
survey results. Your answers to the questions will be identified only by a number.  
 
Only people working on the survey will be allowed to view the information we collect from you.  
 
The following individuals and agencies will be able to look at your interview records to help oversee the 
conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the 
conduct of this survey to ensure that we are protecting your rights as a participant. These 
include the Tropical Diseases Research Centre in Zambia (TDRC) and the Institutional Review 
Boards at the Centers for Disease Control and Prevention (CDC; Atlanta, USA), Columbia 
University Medical Center and Westat (a statistical survey research organization) 
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▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your rights as a participant in this survey 
▪ Survey staff and monitors 
 
The information we collect from you will not be released outside of the groups listed above unless there 
is an issue of safety. If we learn of anything that could harm you, we will contact you on where you can 
receive support. Your permission to allow us to use and share your information with the groups above 
will expire three years after the end of the survey.  
Who should you contact if you have questions? 
If you want to leave the survey, have any questions about the survey, or feel that you have been harmed 
by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the Ministry of Health, 
or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be reached at the number 
and address below. 
 
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia           
Office Phone: +260 211 253053     Cell phone: +260 0977 783527      
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
If you decide to leave the study, no more information will be collected from you. We will make every 
effort to delete the information we have collected from you. However, after today, we cannot 
guarantee we will be able to delete information that has already been shared. 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre, P.O Box 71769, Ndola, Zambia 
Office phone: +260 212 620737 
Cell phone: +260 966 787234 
Email: khondowes@tdrc.org.zm 
 
This survey has received approval from the Tropical Diseases Research Centre in Zambia and the 
Institutional Review Boards at the Centers for Disease Control and Prevention, Columbia University 
Medical Center and Westat. 
 
Are there any costs? 
 
There is no cost to you for answering the questions in the household interview. You should also know 
that you would not be paid to answer these questions. 
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Do you want to ask me anything about the survey? 
 
Consent Statement 
I have read this form and/or someone has read it to me. I was encouraged to ask questions and 
given time to ask questions. Any questions that I had have been answered satisfactorily. I agree to 
participate in the household interview. I know that after choosing to be in the interview, I may 
withdraw at any time. My participation is voluntary. I have been offered a copy of this consent form. 
Do you agree to do the household interview? ‘YES’ means that you agree to do the interview. ‘NO’ 
means that you will NOT do the interview. 
______Yes              ______No 
 
Head of household signature or mark________________________________ Date: ___/___/___            
Printed name of head of household_________________________________    
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
Printed name of person obtaining consent_____________________________   
Survey staff ID number _________________________________  
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Zambia Population-based HIV Impact Assessment: Consent for Adult Interview 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
 
Hello. My name is_________________. We are doing a research study/survey throughout Zambia to 
learn more about HIV in the country. The Ministry of Health and Central Statistical Office (CSO) are 
leading this survey in collaboration with the United States Centers for Disease Control and Prevention 
(CDC) and ICAP at Columbia University.  
 
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand. 
 
Why are we doing this survey? 
HIV is the virus that causes AIDS. AIDS is a very serious illness. This survey will help us know how many 
people in Zambia have HIV and need health services. It will also tell us about  people’s risk for getting 
HIV. We expect about 35,000 men, women, and children from 16,000 households throughout Zambia to 
join this survey. We would like to invite you to join this survey too. What you tell us will help the 
Ministry of Health make HIV services better in the country. 
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What do you have to do if you agree to take part? 
If you agree to join this survey, we will ask you questions about your age, what kind of work you do, if 
you had any experience with HIV services, and your sexual behaviors. This interview will take about 50 
minutes. 
 
After the interview, I will offer you blood tests for HIV, hepatitis B and syphilis. Like HIV, hepatitis B and 
syphilis are infections that can cause very serious illnesses if left untreated. This testing and counseling 
session will take about 40 minutes. You do not have to agree to the blood testing now. We are only 
asking you about this interview. We will give you a separate opportunity to agree to the blood testing. 
You can agree to the interview, but not agree to the blood testing.  
 
Lastly, it is possible that you may be eligible to participate in future studies related to the healht of 
Zambians. At the end of this form, I will ask for permission to contact you in the next two years if such 
an opportunity occurs. 
 
What are the potential risks? 
The risks to taking part in the interview are small. You may feel uncomfortable about some of the 
questions I will ask. If I ask you any questions you don’t want to answer, just let me know and I will go to 
the next question or you can stop the interview at any time.  
 As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
What are the potential benefits? 
There may be no direct benefit to you but your taking part in this survey could help us learn more about 
HIV in Zambia. It can also help us learn about how well HIV prevention and treatment programs are 
working. Your participation is important.  
 
What are alternatives to taking part? 
You can decide not to take part in this interview. Your decision to take part or not take part will not 
affect your health care. However, we hope you will agree to answer these questions since your views 
are important.  
 
What about confidentiality? 
All the information you give us will be kept strictly confidential. Your name and signed consent forms 
will be kept separate from the answers you give in this interview. Your name will not appear when we 
share survey results. Your answers to the questions will be identified only by a number.  
 
Only people working on the survey will be allowed to view the information we collect from you. The 
following individuals and agencies will be able to look at your interview record to help oversee the 
conduct of this survey: 
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▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the 
conduct of this survey to ensure that we are protecting your rights as a participant. These 
include the Tropical Diseases Research Centre in Zambia (TDRC) and the Institutional Review 
Boards at the Centers for Disease Control and Prevention (CDC; Atlanta, USA), Columbia 
University Medical Center and Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your rights as a participant in this survey 
▪ Survey staff and monitors 
The information we collect from you will not be released outside of the groups listed above unless there 
is an issue of safety. If we learn of anything that could harm you, we will contact you on where you can 
receive support. Your permission to allow us to use and share your information with the groups above 
will expire three years after the end of the survey.  
Who should you contact if you have questions? 
If you want to leave the survey, have any questions about the survey, or feel that you have been harmed 
by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the Ministry of Health, 
or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be reached at the number 
and address below.  
 
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
If you decide to leave the study, no more information will be collected from you. We will make every 
effort to delete the information we have collected from you. However, after today, we cannot 
guarantee we will be able to delete information that has already been shared. 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre 
         P.O. Box 71769, Ndola, Zambia 
Phone: +260 966 787234  
Email: khondowes@tdrc.org.zm 
 
Are there any costs?  
There is no cost to you for answering the questions in the interview. You should also know that you 
would not be paid to answer these questions. 
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Do you want to ask me anything about the survey? 
 
Consent Statement 
 
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and given 
time to ask questions. Any questions that I had were answered satisfactorily. I agree to participate in the 
individual interview. I know that after choosing to be in the individual interview, I may withdraw at any 
time. My participation is voluntary. I have been offered a copy of this consent form. 
1. Do you agree to do the interview? ‘YES’ means that you agree to do the interview. ‘NO’ means 
that you will NOT do the interview. 
______Yes              ______No    
 
2. FUTURE RESEARCH: It is possible that you may be eligible to participate in future studies related 
to health in Zambia. We are asking for your permission to contact you in the next two years if 
such an opportunity occurs. If we contact you, we will give you details about the new study and 
ask you to sign a separate consent form at that time. You may decide at that time that you do 
not want to take part in that study.  
If you do not wish to be contacted about future studies, it does not affect your involvement in 
this study. Do you agree to be contacted in the future? ‘YES’ means that you agree to be 
contacted in the future if a study opportunity arises. ‘NO’ means that you will NOT be contacted 
about future studies.  
 ________YES  ________NO 
 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
Printed name of participant________________________________________    
Participant ID number ____________________________________________ 
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
Printed name of person obtaining consent_____________________________    
Survey staff ID number _________________________________   
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Zambia Population-based HIV Impact Assessment: Consent for Blood Draw, ages 0-5  
 
Interviewer reads:  
 
What language do you prefer for our discussion today?  
  
___English  
  
___Bemba  
  
___Nyanja  
  
___Lozi  
  
___Tonga  
  
___Lunda  
  
___Luvale  
  
___Kaonde  
  
___Other Language:  Specify ___________________________    
 
Now I would like to ask you to let your child take part in the research study/survey.  
 
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand.  
   
What is the purpose of the survey?  
HIV is the virus that causes AIDS. AIDS is a very serious illness. This survey will help us learn more about 
the health of children in Zambia. We plan to ask thousands of children like yours to join this survey. We 
would like to invite your child to join the survey too. Your child’s participation will help the Ministry of 
Health make HIV services better.  
  
What will happen to your child if you agree to allow your child to take part?  
If you agree to allow your child to take part in the survey, and he/she is less than 2 years, a trained nurse 
will take a few drops of blood (about 1 mL) from your child’s finger or heel to perform HIV and hepatitis 
B tests here in your home. Like HIV, hepatitis B is a serious infection that can cause very serious illnesses 
if left untreated. If your child is 2 to 5 years of age, we will take about one teaspoon or about 5 mL of 
blood from your child’s arm. If it is not possible to take blood from your child’s arm, then we will try to 
take a few drops of blood from your child’s finger.  
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We will give you the results of these blood tests today. We will not share the results with your child 
unless you ask us to do so. We will also provide counseling about the results and discuss with you how 
to share the test results with your child if you decide to share them with him/her. If you would like, we 
can discuss the test results together with your child. The entire testing and counseling session will take 
about 40 minutes.  
  
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give you 
the result today. CD4 cells are the part of the immune system that fight HIV infection and other 
diseases. We will also test the amount of CD4 cells in children without HIV. In addition, if your child tests 
positive for HIV, we will send his/her blood to a laboratory to measure his/her viral load. Viral load is the 
amount of HIV in the blood. This information may help a doctor or nurse treat your child. We may also 
do other additional tests related to HIV. If we have test results that might guide your child’s care or 
treatment and you provide us with contact information, we will contact you to tell you how you and 
your child’s doctor or nurse may get these results.  
  
After the blood test, we will show you a list of the nearest Ministry of Health-approved and 
recommended health facilities for HIV, where you will be able to talk to trained doctors and nurses 
about your child’s HIV test results. We will give you a referral form to the health facility you select and 
information on today’s test results so that you and your child can consult with a doctor or nurse to learn 
more about his/her HIV test, CD4 count and overall health. Your child’s viral load test results will be 
ready in six to eight weeks. When the results are ready, we will send the results to your health facility of 
choice. If you provide us with your contact information, we will contact you to let you know the results 
are ready and encourage you to go to your health facility to discuss your child’s viral load results with a 
doctor or nurse.  
   
If your child tests positive for HIV, we will also measure his/her weight and height to track your child’s 
growth. We will also measure weight and height for some children without HIV. These results will be 
returned to you today and you will be able to talk to a doctor or nurse at your health facility of choice 
about the results.  
  
As I stated before, we will also test your child’s blood for hepatitis B. If your child test positive for 
hepatitis B, we will refer you to the nearest appropriate health facility for further testing for your child.  
  
[For children aged 0-<18 months only]  
The body makes antibodies to fight HIV. Antibodies from a mother with HIV can enter the baby’s blood 
during pregnancy. The test we perform on your child today will let us know if your child has been 
exposed to HIV. If it is positive, it does not mean your child has the virus in his/her blood. It just confirms 
that he/she has been exposed to HIV. We will need to send your child’s blood to a lab for a special test 
to confirm if he/she has HIV. We will send the result to the health facility of your choice in about six 
weeks from now. If you provide us with your contact information, we will contact you to inform you that 
the results have been sent to the facility and encourage you to go to the health facility to discuss your 
child’s HIV test results with a doctor or nurse.  
  
What will happen to your child’s leftover blood?  
We would like to ask your permission to store your child’s leftover blood for other additional HIV related 
tests such as tests for toxoplasmosis, cryptococcal meningitis, hepatitis C or cytomegalovirus. We would 
store your child’s leftover blood for the length of the study, but your child’s name will only be on the 
sample for three years. During this three year period, we will attempt to tell you about any tests results 
 279 
 
that are important for your child’s health. Your child’s leftover blood will not be sold or used for 
commercial reasons. If you do not agree to have your child’s blood samples stored for other additional 
HIV related tests, we will destroy your child’s blood samples after survey-related testing has been 
completed.  
  
What are the potential risks?   
The finger prick or needle may be uncomfortable for your child. Experienced staff will do the tests under 
safe and clean conditions in order to protect your child against any risk.   
  
You may learn that your child is infected with HIV and/or hepatitis B. Learning that your child has HIV 
and/or hepatitis B may cause some emotional discomfort. You will decide when your child should be 
told of the test results. We will support whatever decision you make. We will provide counseling on how 
to cope with learning that your child has HIV and/or hepatitis B. We will also tell you where he/she may 
go for care and treatment.  
  
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
  
What are the potential benefits?  
The main benefit for your child to be in the survey is the chance to learn more about his/her health 
today. Some children who participate will test positive for HIV and/or hepatitis B. If this happens to your 
child, the benefit is that you will learn his/her HIV and hepatitis B status and will learn where to take 
your child for life-saving treatment. Care and treatment provided by the Ministry of Health is free. If you 
already know that your child is HIV positive and he/she is on treatment, the CD4 and viral load tests can 
help your child’s doctor or nurse judge how well the treatment is working. Your child taking part in this 
survey could help us learn more about children, HIV and hepatitis B in Zambia. It can help us learn about 
how well HIV prevention and treatment programs are working. It can also help improve these programs 
and services for Zambians.  
  
What are alternatives to taking part?  
You can decide to allow or not allow your child to take part in this survey. Or you can decide to allow 
your child to get his or her blood tested for HIV and hepatitis B, but not agree to have his or her blood 
stored for other additional HIV related tests... Your decision to allow your child to take part or not take 
part in this survey will not affect your child’s health care in any way. However, we hope you will agree to 
allow your child to take part in this survey as getting HIV and hepatitis B tests can help your child. If your 
child tests positive for HIV and/or hepatitis B, he/she can start medication to keep him/her healthy.  
  
What about confidentiality?  
Your child’s test results will be kept strictly confidential. We will only include your child’s name on the 
referral forms we may give you to help the doctors and nurses at your health facility of choice identify 
your child. In all other cases, your child’s name and the consent forms will be kept separate from his/her 
health information.  
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Your name and your child’s name will not appear when we share survey results. When we share results, 
the information we collect from your child will be identified by a number and not by your name or your 
child’s name. Only people working on the survey will have access to the data during the survey.  
  
The following individuals and agencies will be able to look at your child’s survey records to help oversee 
the conduct of this survey:  
  
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the conduct of 
this survey to ensure that we are protecting your child’s rights as a participant. These include the 
Tropical Diseases Research Centre in Zambia (TDRC) and the Institutional Review Boards at the Centers 
for Disease Control and Prevention (CDC; Atlanta, USA), Columbia University Medical Center and Westat 
(a statistical survey research organization)  
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the safety 
of human subjects to ensure we are protecting your child’s rights as a participant in this survey  
▪ Survey staff and monitors   
 
  
The information we collect from your child will not be released outside of the survey groups listed above 
unless there is an issue of safety. If we learn of anything that could harm you or your child, we will 
provide information on where you can receive support. Your permission to allow us to use and share 
your child’s name and contact information with the groups above will end three years after the end of 
the survey.  
  
Who should you contact if you have questions?  
If you want your child to leave the survey, have any questions about the survey, or feel that your child 
has been harmed by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the 
Ministry of Health, or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be 
reached at the number and address below.  
  
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
  
If you decide that your child should leave the study, no more information will be collected from your 
child. We will make every effort to delete the information we have collected from your child. However, 
after today, we cannot guarantee we will be able to delete information that has already been shared.  
  
If you have any questions about your child’s rights as a participant in this survey, you can contact:  
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Mr. Shepard Khondowe   
Address: Tropical Diseases Research Centre  
         P.O. Box 71769, Ndola, Zambia  
Phone: +260 966 787234   
Email: khondowes@tdrc.org.zm  
  
Are there any costs?   
There is no cost to you for your child being in the survey. You should also know that neither you nor 
your child would be paid for your child to be in the survey.  
   
  
Do you want to ask me anything about your child’s participation in the survey?  
  
  
Consent Statement  
  
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and given 
time to ask questions. Any questions I had have been answered satisfactorily. I agree for my child to take 
part in this survey. I know that after allowing my child to participate, I may change my mind and 
withdraw him/her from taking part in this survey at any time. I have been offered a copy of this consent 
form.  
  
  
1. Do you agree that your child will give blood for HIV and hepatitis B testing and related testing? ‘YES’ 
means that you give your permission to have the nurse collect a sample of your child’s blood for HIV and 
hepatitis B testing and related testing. ‘NO’ means that your child will NOT give blood for HIV and 
hepatitis B testing and related testing.  
 
______Yes              ______No  
(If “Yes” proceed to the next question)  
  
2. Do you agree to have your child’s leftover blood stored for other additional HIV related testing? ‘YES’ 
means that you give permission for your child’s blood samples to be stored for other additional HIV 
related testing. ‘NO’ means that your child’s blood samples will NOT be stored for other additional HIV 
related testing.  
 
______Yes              ______No  
  
  
Parent/guardian signature or mark_______________________________________ Date: ___/___/___             
Printed name of parent/guardian________________________________________     
Parent/guardian ID number________________________________ (If applicable. If not applicable check 
here __)  
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[For illiterate participants]  
Signature of witness______________________________________________ Date: ___/___/___           
Printed name of witness___________________________________________   
  
Signature of person obtaining consent_____________________ __________ Date: ___/___/___           
Printed name of person obtaining consent____________________________     
  
Survey staff ID number _________________________________    
  
  
Child’s name (print) ___________________________________  
  
Child’s participant ID number ___________________________________  
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Zambia Population-based HIV Impact Assessment: Consent for Blood Draw, ages 6-9 
 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
 
Now I would like to ask you to let your child take part in the research study/survey.  
 
This form might have some words in it that are not familiar to you. Please ask me to explain anything that you 
do not understand. 
 
What is the purpose of the survey? 
HIV is the virus that causes AIDS. AIDS is a very serious illness. This survey will help us learn more about 
the health of children in Zambia. We plan to ask thousands of children like yours to join this survey. We 
would like to invite your child to join the survey too. Your child’s participation will help the Ministry of 
Health make HIV services better.  
 
What will happen to your child if you agree to allow your child to take part? 
If you agree to allow your child to take part in the survey, a trained nurse will take about one teaspoon 
of blood (about 5 mL) from your child’s arm to perform HIV and hepatitis B tests here in your home. Like 
HIV, hepatitis B is a serious infection that can cause very serious illnesses if left untreated. If it is not 
possible to take blood from your child’s arm, then we will try to take a few drops of blood from your 
child’s finger. 
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We will give you the results of these blood tests today. We will not share the results with your child 
unless you ask us to do so. We will also provide counseling about the results and discuss with you how 
to share the test results with your child if you decide to share them with him/her. If you would like, we 
can discuss the test results together with your child. The entire testing and counseling session will take 
about 40 minutes. 
 
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give you 
the result today. CD4 cells are the part of the immune system that fight HIV infection and other 
diseases. We will also test the amount of CD4 cells in children without HIV. In addition, if your child tests 
positive for HIV,  we will send his/her blood to a laboratory to measure his/her viral load. Viral load is 
the amount of HIV in the blood. This information may help a doctor or nurse treat your child. We may 
also do other additional tests related to HIV. If we have test results that might guide your child’s care or 
treatment and you provide us with contact information, we will contact you to tell you how you and 
your child’s doctor or nurse may get these results. 
 
After the blood test, we will show you a list of the nearest Ministry of Health-approved and 
recommended health facilities for HIV, where you will be able to talk to trained doctors and nurses 
about your child’s HIV test results. We will give you a referral form to the health facility you select and 
information on today’s test results so that you and your child can consult with a doctor or nurse to learn 
more about his/her HIV test, CD4 count and overall health. Your child’s viral load test results will be 
ready in six to eight weeks. When the results are ready, we will send the results to your health facility of 
choice. If you provide us with your contact information we will contact you to let you know the results 
are ready and encourage you to go to your health facility to discuss your child’s viral load results with a 
doctor or nurse. 
 
As I stated before, we will also test your child’s blood for hepatitis B. If your child test positive for 
hepatitis B, we will refer you to the nearest appropriate health facility for further testing for your child.  
 
What will happen to your child’s leftover blood? 
We would like to ask your permission to store your child’s leftover blood for other additional HIV related 
tests such as tests for toxoplasmosis , cryptococcal meningitis, hepatitis C or cytomegalovirus. We would 
store your child’s leftover blood for the length of the study, but your child’s name will only be on the 
sample for three years. During this three year period, we will attempt to tell you about any tests results 
that are important for your child’s health. Your child’s leftover blood will not be sold or used for 
commercial reasons. If you do not agree to have your child’s blood samples stored for other additional 
HIV related tests, we will destroy your child’s blood samples after survey-related testing has been 
completed. 
 
What are the potential risks? 
The needle may be uncomfortable for your child when it is put into and taken out of his/her arm. 
Experienced staff will do the tests under safe and clean conditions in order to protect your child against 
any risk.  
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You may learn that your child is infected with HIV and/or hepatitis B. Learning that your child has HIV 
and/or hepatitis B may cause some emotional discomfort. You will decide when your child should be 
told of the test results. We will support whatever decision you make. We will provide counseling on how 
to cope with learning that your child has HIV and/or hepatitis B. We will also tell you where he/she may 
go for care and treatment.  
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
 
What are the potential benefits? 
The main benefit for your child to be in the survey is the chance to learn more about his/her health 
today. Some children who participate will test positive for HIV and/or hepatitis B. If this happens to your 
child, the benefit is that you will learn his/her HIV and hepatitis B status and will learn where to take 
your child for life-saving treatment. Care and treatment provided by the Ministry of Health is free. If you 
already know that your child is HIV positive and he/she is on treatment, the CD4 and viral load tests can 
help your child’s doctor or nurse judge how well the treatment is working. Your child taking part in this 
survey could help us learn more about children, HIV and hepatitis B in Zambia. It can help us learn about 
how well HIV prevention and treatment programs are working. It can also help improve these programs 
and services for Zambians.  
 
What are alternatives to taking part? 
You can decide to allow or not allow your child to take part in this survey. Or you can decide to allow 
your child to get his or her blood tested for HIV and hepatitis B, but not agree to have his or her blood 
stored for other additional HIV related tests. Your decision to allow your child to take part or not take 
part in this survey will not affect your child’s health care in any way. However, we hope you will agree to 
allow your child to take part in this survey as getting HIV and hepatitis B tests can help your child. If your 
child tests positive for HIV and/or hepatitis B, he/she can start medication to keep him/her healthy.  
 
What about confidentiality? 
Your child’s test results will be kept strictly confidential. We will only include your child’s name on the 
referral forms we may give you to help the doctors and nurses at your health facility of choice identify 
your child. In all other cases, your child’s name and the consent forms will be kept separate from his/her 
health information. Your name and your child’s name will not appear when we share survey results. 
When we share results, the information we collect from your child will be identified by a number and 
not by your name or your child’s name. Only people working on the survey will have access to the data 
during the survey. 
 
The following individuals and agencies will be able to look at your child’s survey records to help oversee 
the conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the 
conduct of this survey to ensure that we are protecting your child’s rights as a participant. These 
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include the Tropical Diseases Research Centre in Zambia (TDRC) and the Institutional Review 
Boards at the Centers for Disease Control and Prevention (CDC; Atlanta, USA), Columbia 
University Medical Center and Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your child’s rights as a participant in this 
survey 
▪ Survey staff and monitors  
 
The information we collect from your child will not be released outside of the survey groups listed above 
unless there is an issue of safety. If we learn of anything that could harm you or your child, we will 
provide information on where you can receive support. Your permission to allow us to use and share 
your child’s name and contact information with the groups above will end three years after the end of 
the survey.  
 
Who should you contact if you have questions? 
If you want your child to leave the survey, have any questions about the survey, or feel that your child 
has been harmed by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the 
Ministry of Health, or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be 
reached at the number and address below.  
 
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
If you decide that your child should leave the study, no more information will be collected from your child. 
We will make every effort to delete the information we have collected from your child. However, after 
today, we cannot guarantee we will be able to delete information that has already been shared. 
 
If you have any questions about your child’s rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre 
         P.O. Box 71769, Ndola, Zambia 
Phone: +260 966 787234  
Email: khondowes@tdrc.org.zm 
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Are there any costs?  
There is no cost to you for your child being in the survey. You should also know that neither you nor 
your child would be paid for your child to be in the survey. 
 
Do you want to ask me anything about your child’s participation in the survey? 
 
 
 
Consent Statement 
 
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and given 
time to ask questions. Any questions I had have been answered satisfactorily. I agree for my child to take 
part in this survey. I know that after allowing my child to participate, I may change my mind and 
withdraw him/her from taking part in this survey at any time. I have been offered a copy of this consent 
form. 
 
 
3. Do you agree that your child will give blood for HIV and hepatitis B testing and related testing? 
‘YES’ means that you give your permission to have the nurse collect a sample of your child’s 
blood for HIV and hepatitis B testing and related testing. ‘NO’ means that your child will NOT 
give blood for HIV and hepatitis B testing and related testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
4. Do you agree to have your child’s leftover blood stored for other additional HIV related testing? 
‘YES’ means that you give permission for your child’s blood samples to be stored for additional 
HIV related testing. ‘NO’ means that your child’s blood samples will NOT be stored for additional 
HIV related testing. 
______Yes              ______No 
 
 
Parent/guardian signature or mark_______________________________________ Date: 
___/___/___            
Printed name of parent/guardian________________________________________    
Parent/guardian ID number________________________________ (If applicable. If not applicable check 
here __) 
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[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining consent_____________________ __________ Date: ___/___/___          
Printed name of person obtaining consent____________________________    
 
Survey staff ID number _________________________________   
 
Child’s name (print) ___________________________________ 
 
Child’s participant ID number ___________________________________ 
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Zambia Population-based HIV Impact Assessment: Permission for Interview and Blood Draw, ages 10-14 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
 
 
Now I would like to ask you to give us permission to invite your child to take part in the research 
study/survey.  
  
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand. 
 
What is the purpose of the survey? 
HIV is the virus that causes AIDS. AIDS is a very serious illness. This survey will help us learn more about 
the health of children in Zambia. We plan to ask thousands of children like yours to join this survey. We 
would like to invite your child to join the survey too. Your child’s participation will help the Ministry of 
Health make HIV services better.  
 
What would happen to your child if you agree to allow your child to take part? 
If you agree to allow us to invite your child to take part in the survey, we will invite your child to do an 
interview with us and then offer him/her a blood test for HIV and hepatitis B. Like HIV, hepatitis B is an 
infection that can cause very serious illnesses if left untreated. 
 
In the interview, we will ask what your child knows about HIV. We will also ask about your child’s 
behaviors that may put him or her at risk for HIV. The interview will take about 30 minutes. Out of 
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respect for your child’s privacy, we will not share your child’s answers to the interview questions with 
you. The interview will take place in private here at your house or an area around your house.  
 
If you agree, after the interview, we will offer your child a blood test for HIV and hepatitis B. A trained 
nurse will take about one teaspoon of blood (about 5 mL) from your child’s arm to perform the tests 
here in your home. If it is not possible to take blood from your child’s arm, then we will try to take a few 
drops of blood from your child’s finger. 
 
We will give you the results of these blood tests today. We will not share the results with your child 
unless you ask us to do so. We will also provide counseling about the results and discuss with you how 
to share the test results with your child if you decide to share them with him/her. If you would like, we 
can discuss the test results together with your child. The entire testing and counseling session will take 
about 40 minutes. 
 
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give you 
the result today. CD4 cells are the part of the immune system that fight HIV infection and other 
diseases. We will also test the amount of CD4 cells in children without HIV. In addition, if your child tests 
positive for HIV,  we will send his/her blood to a laboratory to measure his/her viral load. Viral load is 
the amount of HIV in the blood. This information may help a doctor or nurse treat your child. We may 
also do other additional tests related to HIV. If we have test results that might guide your child’s care or 
treatment and you provide us with contact information, we will contact you to tell you how you and 
your child’s doctor or nurse may get these results. 
 
After the blood test, we will show you a list of the nearest Ministry of Health-approved and 
recommended health facilities for HIV, where you will be able to talk to trained doctors and nurses 
about your child’s HIV test results. We will give you a referral form to the health facility you select and 
information on today’s test results so that you and your child can consult with a doctor or nurse to learn 
more about his/her HIV test, CD4 count and overall health. Your child’s viral load test results will be 
ready in six to eight weeks. When the results are ready, we will send the results to your health facility of 
choice. If you provide us with your contact information, we will contact you to let you know the results 
are ready and encourage you to go to your health facility to discuss your child’s viral load results with a 
doctor or nurse. 
 
As I stated before, we will also test your child’s blood for hepatitis B. If your child tests positive for 
hepatitis B, we will refer you to the nearest appropriate health facility for further testing for your child.  
 
 
What will happen to your child’s leftover blood? 
We would like to ask your permission to store your child’s leftover blood for other additional HIV related 
tests such as test for toxoplasmosis , cryptococcal meningitis, hepatitis C or cytomegalovirus. We would 
store your child’s leftover blood for the length of the study, but your child’s name will only be on the 
sample for three years. During this three year period, we will attempt to tell you about any tests results 
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that are important for your child’s health. Your child’s leftover blood will not be sold or used for 
commercial reasons. If you do not agree to have your child’s blood samples stored for other additional 
HIV related tests, we will destroy your child’s blood samples after survey-related testing has been 
completed. 
 
What are the potential risks? 
Your child may feel uncomfortable about some of the questions I will ask. I do not wish this to happen. 
Your child does not need to answer any question(s) if they feel the question(s) are too personal or if it 
makes them uncomfortable.  
 
The needle may be uncomfortable for your child when it is put into and taken out of his/her arm. 
Experienced staff will do the tests under safe and clean conditions in order to protect your child against 
any risk.  
 
You may learn that your child is infected with HIV and/or hepatitis B. Learning that your child has HIV 
and/or hepatitis B may cause some emotional discomfort. You will decide when your child should be 
told of the test results. We will support whatever decision you make. We will provide counseling on how 
to cope with learning that your child has HIV and/or hepatitis B. We will also tell you where he/she may 
go for care and treatment.  
 
Lastly, as with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
 
What are the potential benefits? 
The main benefit for your child to be in the survey is the chance to learn more about his/her health 
today. Some children who participate will test positive for HIV and/or hepatitis B. If this happens to your 
child, the benefit is that you will learn his/her HIV and hepatitis B status and will learn where to take 
your child for life-saving treatment. Care and treatment provided by the Ministry of Health is free. If you 
already know that your child is HIV positive and he/she is on treatment, the CD4 and viral load tests can 
help your child’s doctor or nurse judge how well the treatment is working. Your child taking part in this 
survey could help us learn more about children, HIV and hepatitis B in Zambia. It can help us learn about 
how well HIV prevention and treatment programs are working. It can also help improve these programs 
and services for Zambians.  
 
 
What are alternatives to taking part? 
You can decide to not allow your child to take part in the survey. Or you can allow your child to take part 
in the interview, but not the blood testing. Or you can allow your child to take part in the interview and 
blood testing, but not agree to allow your child’s leftover blood to be stored for other additional HIV 
related tests.  
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Your decision to allow your child to take part or not take part in this survey will not affect your child’s 
health care in any way. However, we hope you will agree to allow your child to take part in this survey as 
getting HIV and hepatitis B tests can help your child. If your child tests positive for HIV and/or hepatitis 
B, he/she can start medication to keep him/her healthy.  
 
What about confidentiality? 
Your child’s test results will be kept strictly confidential. We will only include your child’s name on the 
referral forms we may give you to help the doctors and nurses at your health facility of choice identify 
your child. In all other cases, your child’s name and the consent forms will be kept separate from his/her 
health information. Your name and your child’s name will not appear when we share survey results. 
When we share results, the information we collect from your child will be identified by a number and 
not by your name or your child’s name. Only people working on the survey will have access to the data 
during the survey. 
 
The following individuals and agencies will be able to look at your child’s survey records to help oversee 
the conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the 
conduct of this survey to ensure that we are protecting your child’s rights as a participant. These 
include the Tropical Diseases Research Centre in Zambia (TDRC) and the Institutional Review 
Boards at the Centers for Disease Control and Prevention (CDC; Atlanta, USA), Columbia 
University Medical Center and Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your child’s rights as a participant in this 
survey 
▪ Survey staff and monitors  
 
The information we collect from your child will not be released outside of the survey groups listed above 
unless there is an issue of safety. If we learn of anything that could harm you or your child, we will 
provide information on where you can receive support. Your permission to allow us to use and share 
your child’s name and contact information with the groups above will end three years after the end of 
the survey.  
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Who should you contact if you have questions? 
If you want your child to leave the survey, have any questions about the survey, or feel that your child 
has been harmed by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the 
Ministry of Health, or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be 
reached at the number and address below.  
 
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
If you decide that your child should leave the study, no more information will be collected from your 
child. We will make every effort to delete the information we have collected from your child. However, 
after today, we cannot guarantee we will be able to delete information that has already been shared. 
 
If you have any questions about your child’s rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre 
         P.O. Box 71769, Ndola, Zambia 
Phone: +260 966 787234  
Email: khondowes@tdrc.org.zm 
 
Are there any costs?  
There is no cost to you for your child being in the survey. You should also know that neither you nor 
your child would be paid for your child to be in the survey. 
 
Do you want to ask me anything about your child’s participation in the survey? 
 
Permission Statement 
 
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and given 
time to ask questions. Any questions I had have been answered satisfactorily. I agree for my child to take 
part in this survey. I know that after allowing my child to participate, I may change my mind and 
withdraw him/her from taking part in this survey at any time.  
 
I agree to allow you to ask my child to be in this survey. I know that after allowing my child to decide 
whether he/she wants to be in this survey, he/she may withdraw at any time. His/her participation is 
voluntary. I have been offered a copy of this permission form. 
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5. Do you agree for us to ask your child to do the interview? YES’ means that you give your 
permission to have the survey staff ask your child to do the interview. ‘NO’ means that you will 
NOT give permission for us to ask your child to be interviewed. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
6. Do you agree for us to ask your child to give blood for HIV and hepatitis B testing and related 
testing? ‘YES’ means that you give your permission for us to ask your child to have the nurse 
collect a sample of your child’s blood for HIV and hepatitis B testing and related testing. ‘NO’ 
means that we will NOT ask your child to give blood for HIV and hepatitis B testing and related 
testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
7. Do you agree to have your child’s leftover blood stored for other additional HIV related testing? 
‘YES’ means that you give permission for your child’s blood samples to be stored for other 
additional HIV related testing. ‘NO’ means that your child’s blood samples will NOT be stored for 
other additional HIV related testing. 
______Yes              ______No 
 
 
Parent/guardian signature or mark_________________________________ Date: ___/___/___            
Printed name of parent/guardian________________________________________    
Parent/guardian ID number________________________________ (If applicable. If not applicable check 
here __) 
 
[For illiterate participants] 
Signature of witness_________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining permission_____________________ Date: ___/___/___          
Printed name of person obtaining permission____________________________    
 
Survey staff ID number _________________________________   
 
Child’s name (print) ___________________________________ 
 
Child’s participant ID number ___________________________________ 
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Zambia Population-based HIV Impact Assessment: Permission for Interview and Blood Draw, ages 15-17 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
 
 
Now I would like to ask you to give us permission to invite your child to take part in the research 
study/survey. 
 
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand. 
 
What is the purpose of the survey? 
HIV is the virus that causes AIDS. AIDS is a very serious illness. This survey will help us learn more about 
the health of children in Zambia. We plan to ask thousands of children like yours to join this survey. We 
would like to invite your child to join the survey too. Your child’s participation will help the Ministry of 
Health make HIV services better.  
 
What would happen to your child if you agree to allow your child to take part? 
If you agree to allow us to invite your child to take part in the survey, we will invite your child to do an 
interview with us and then offer him/her a blood test for HIV, hepatitis B and syphilis. Like HIV, hepatitis 
B and syphilis are infections that can cause very serious illnesses if left untreated. 
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In the interview, we will ask what your child knows about HIV. We will also ask about your child’s 
behaviors that may put him or her at risk for HIV. The questions are the same as the ones we will ask 
adults who agree to participate in the survey. The interview will take about 50 minutes. Out of respect 
for your child’s privacy, we will not share your child’s answers to the interview questions with you. The 
interview will take place in private here in your house or an area around your house. It is also possible 
that your child may be eligible to take part in future studies related to health in Zambia. We will also ask 
your child for permission to contact them in the next two years if such an opportunity occurs. 
 
If you agree, after the interview, we will offer your child a blood test for HIV, hepatitis B and syphilis. A 
trained nurse will take about three teaspoons or 14 mL of blood from your child’s arm to perform the 
tests here in your home. If it is not possible to take blood from your child’s arm, then we will try to take 
a few drops of blood from your child’s finger.  
 
We will give you the results of these blood tests today. We will not share the results with your child 
unless you ask us to do so. We will also provide counseling about the results and discuss with you how 
to share the test results with your child if you decide to share them with him/her. If you would like, we 
can discuss the test results together with your child. The entire testing and counseling session will take 
about 40 minutes. 
 
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give you 
the result today. CD4 cells are the part of the immune system that fight HIV infection and other 
diseases. We will also test the amount of CD4 cells in children without HIV. In addition, if your child tests 
positive for HIV,  we will send his/her blood to a laboratory to measure his/her viral load. Viral load is 
the amount of HIV in the blood. This information may help a doctor or nurse treat your child. We may 
also do other additional tests related to HIV. If we have test results that might guide your child’s care or 
treatment and you provide us with contact information, we will contact you to tell you how you and 
your child’s doctor or nurse may get these results. 
 
After the blood test, we will show you a list of the nearest Ministry of Health-approved and 
recommended health facilities for HIV, where you will be able to talk to trained doctors and nurses 
about your child’s HIV test results. We will give you a referral form to the health facility you select and 
information on today’s test results so that you and your child can consult with a doctor or nurse to learn 
more about his/her HIV test, CD4 count and overall health. Your child’s viral load test results will be 
ready in six to eight weeks. When the results are ready, we will send the results to your health facility of 
choice. If you provide us with your contact information, we will contact you to let you know the results 
are ready and encourage you to go to your health facility to discuss your child’s viral load results with a 
doctor or nurse. 
 
As I stated before, we will also test your child’s blood for hepatitis B and syphilis. If your child tests 
positive for hepatitis B  and/or syphilis, we will refer you to the nearest appropriate health facility for 
further testing for your child.  
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What will happen to your child’s leftover blood? 
We would like to ask your permission to store your child’s leftover blood for other additional HIV related 
tests such as tests for toxoplasmosis, cryptococcal meningitis, hepatitis C or cytomegalovirus. We would 
store your child’s leftover blood for the length of the study, but your child’s name will only be on the 
sample for three years. During this three year period, we will attempt to tell you about any tests results 
that are important for your child’s health. Your child’s leftover blood will not be sold or used for 
commercial reasons. If you do not agree to have your child’s blood samples stored for other additional 
HIV related tests, we will destroy your child’s blood samples after survey-related testing has been 
completed. 
 
What are the potential risks? 
Your child may feel uncomfortable about some of the questions I will ask. I do not wish this to happen. 
Your child does not need to answer any question(s) if they feel the question(s) are too personal or if it 
makes them uncomfortable.  
 
The needle may be uncomfortable for your child when it is put into and taken out of your child’s arm. 
Experienced staff will do the tests under safe and clean conditions in order to protect your child against 
any risk.  
 
You may learn that your child is infected with HIV, hepatitis B and/or syphilis. Learning that your child 
has HIV, hepatitis B and/or syphilis may cause some emotional discomfort. You will decide when your 
child should be told of the test results. We will support whatever decision you make. We will provide 
counseling on how to cope with learning that your child has HIV, hepatitis B and/or syphilis. We will also 
tell you where he/she may go for care and treatment.  
 
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
 
What are the potential benefits? 
The main benefit for your child to be in the survey is the chance to learn more about his/her health 
today. Some children who participate will test positive for HIV, hepatitis B and/or syphilis. If this 
happens to your child, the benefit is that you will learn his/her HIV, hepatitis B and syphilis status. You 
will also learn where to take your child for life-saving treatment. Care and treatment provided by the 
Ministry of Health is free. If you already know that your child is HIV positive and he/she is on treatment, 
the CD4 and viral load tests can help your child’s doctor or nurse judge how well the treatment is 
working. Your child’s taking part in this survey could help us learn more about children, HIV, hepatitis B 
and syphilis in Zambia. It can also help us learn about how well HIV prevention and treatment programs 
are working and how to improve these programs and services.  
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What are alternatives to taking part? 
You can decide to not allow your child to take part in any parts of the survey. Or you can allow your child 
to take part in the interview, but not the blood testing. Or you can allow your child to take part in the 
interview and blood testing, but not agree to allow your child’s leftover blood to be stored for other 
additional HIV related tests. 
 
Your decision to allow your child to take part or not take part in this survey will not affect your child’s 
health care in any way. However, we hope you will agree to allow your child to take part in this survey as 
getting HIV, hepatitis B and syphilis tests can help your child. If your child tests positive for HIV, hepatitis 
B and/or syphilis, he/she can start medication to keep him/her healthy.  
 
What about confidentiality? 
Your child’s test results will be kept strictly confidential. We will only include your child’s name on the 
referral forms we may give you to help the doctors and nurses at your health facility of choice identify 
your child. In all other cases, your child’s name and the consent forms will be kept separate from his/her 
health information. Your name and your child’s name will not appear when we share survey results. 
When we share results, the information we collect from your child will be identified by a number and 
not by your name or your child’s name. Only people working on the survey will have access to the data 
during the survey. 
 
The following individuals and agencies will be able to look at your child’s survey records to help oversee 
the conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the 
conduct of this survey to ensure that we are protecting your child’s rights as a participant. These 
include the Tropical Diseases Research Centre in Zambia (TDRC) and the Institutional Review 
Boards at the Centers for Disease Control and Prevention (CDC; Atlanta, USA), Columbia 
University Medical Center and Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your child’s rights as a participant in this 
survey 
▪ Survey staff and monitors  
 
The information we collect from your child will not be released outside of the survey groups listed above 
unless there is an issue of safety. If we learn of anything that could harm you or your child, we will 
provide information on where you can receive support. Your permission to allow us to use and share 
your child’s name and contact information with the groups above will end three years after the end of 
the survey.  
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Who should you contact if you have questions? 
If you want your child to leave the survey, have any questions about the survey, or feel that your child 
has been harmed by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the 
Ministry of Health, or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be 
reached at the number and address below.  
 
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
If you decide that your child should leave the study, no more information will be collected from your 
child. We will make every effort to delete the information we have collected from your child. However, 
after today, we cannot guarantee we will be able to delete information that has already been shared. 
 
If you have any questions about your child’s rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre 
         P.O. Box 71769, Ndola, Zambia 
Phone: +260 966 787234  
Email: khondowes@tdrc.org.zm 
 
Are there any costs?  
There is no cost to you for your child being in the survey. You should also know that neither you nor 
your child would be paid for your child to be in the survey. 
 
 
Do you want to ask me anything about your child’s participation in the survey? 
 
 
Permission Statement 
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and given 
time to ask questions. Any questions that I had have been answered satisfactorily. I agree for my child to 
take part in this survey. I know that after allowing my child to participate, I may change my mind and 
withdraw him/her from taking part in this survey at any time.  
 
I agree to allow you to ask my child to be in this survey. I know that after allowing my child to decide 
whether he/she wants to be in this survey, he/she may withdraw at any time. His/her participation is 
voluntary. I have been offered a copy of this permission form. 
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8. Do you agree for us to ask your child to do the interview? YES’ means that you give your 
permission to have the survey staff ask your child to do the interview. ‘NO’ means that you will 
NOT give permission for us to ask your child to be interviewed. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
9. Do you agree for us to ask your child to give blood for HIV, hepatitis B and syphilis testing and 
related testing? ‘YES’ means that you give your permission for us to ask your child to have the 
nurse collect a sample of your child’s blood for HIV, hepatitis B and syphilis testing and related 
testing. ‘NO’ means that we will NOT ask your child to give blood for HIV, hepatitis B and syphilis 
testing and related testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
10. Do you agree to have your child’s leftover blood stored for other additional HIV related testing? 
‘YES’ means that you give permission for your child’s blood samples to be stored for other 
additional HIV related testing. ‘NO’ means that your child’s blood samples will NOT be stored for 
other additional HIV related testing. 
______Yes              ______No   
 
 
Parent/guardian signature or mark_______________________________ Date: ___/___/___            
Printed name of parent/guardian________________________________________    
Parent/guardian ID number________________________________ (If applicable. If not applicable check 
here __) 
 
[For illiterate participants] 
Signature of witness______________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining permission_____________________ Date: ___/___/___          
Printed name of person obtaining permission____________________________    
 
Survey staff ID number _________________________________   
 
Child’s name (print) ___________________________________ 
 
Child’s participant ID number ___________________________ 
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Zambia Population-based HIV Impact Assessment: Assent for Interview, ages 10-14 
 
 
Interviewer reads: 
 
What language do you prefer to use for this discussion? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
 
Hello. My name is___________. I would like to invite you to take part in a research study/survey. 
Surveys help us learn new things.  
This form talks about our survey and the choice that you have to take part in it. I want you to ask me any 
questions that you have. You can ask questions any time.  
 
Why are we doing this survey?  
We are doing this survey to help us learn more about the health of children in Zambia. We plan to ask 
thousands of children like you to join this survey. We would like to invite you to join this survey too. 
Your parent/guardian said it was okay for us to ask you to join.  
 
This form might have some words that you may not have heard before. Please ask me to explain 
anything that you do not understand. 
  
 
What would happen if you joined this survey? 
If you decide to join the survey, here is what would happen: 
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• We will ask you questions about your age and some of your activities. We will also ask you 
what you know about a germ called HIV that makes people very sick. The interview will take 
place in private here in your home or an area around your home.  
• The interview will take about 30 minutes. 
• After we ask you the questions, we will also ask you if it is okay to take some of your blood 
to test for HIV and hepatitis B. Like HIV, hepatitis B is a germ that can make people very sick. 
We will also ask you if we can store your blood for future surveys. 
 
Could bad things happen to you if you joined this survey?  
You may feel uncomfortable answering some of the questions I will ask. If I ask you any questions you 
don’t want to answer, just let me know and I will go to the next question. You can stop the interview at 
any time.  
 
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this chance. 
 
Could the survey help you? 
Being in this survey may not help you. But you may help us figure out ways to help other children and 
learn more about HIV in Zambia. Taking part in this survey is important. 
 
What else should you know about this survey? 
If you don’t want to be in the survey, you don’t have to be. Nobody will get upset with you if you do not 
want to join the survey. 
 
It is also OK to say ‘yes’ and change your mind later. You can stop being in the survey at any time. If you 
want to stop, please tell us.  
We will not tell other people that you are in this survey. You can choose to tell your parent/guardian 
about the interview. However, we will not share your answers to the questions with your parent or 
guardian. We will not share information about you to anyone who does not work on the survey. Any 
information we share about you will have a number on it instead of your name.  
The following individuals and agencies will be able to look at your survey records: 
▪ Survey staff and monitors 
▪ Staff members from groups that protect your rights as a survey participant to make sure that we 
are protecting your rights as a participant 
 
If you have any questions about the survey, feel that you have been harmed by taking part, or no longer 
want to take part in the survey, you can contact Mr. Chipalo Kaliki or Ms. Nchimunya Nkombo:  
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Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
If you have any questions about your rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre 
  P.O Box 71769, Ndola, Zambia 
Phone: +260  966 787234  
Email: khondowes@tdrc.org.zm 
 
You should also know that you would not be paid to be in the study.  
You can ask questions any time. Take the time you need to make your choice.  
Do you want to ask me anything? 
 
If you want to be asked questions after we talk, please write your name below. We will write our name 
too. This shows we talked about the survey and that you want to take part. 
 
11. Do you agree to do the interview? ‘YES’ means that you agree to do the interview. ‘NO’ means 
that you will NOT do the interview. 
______Yes              ______No 
 
 
Child signature or mark_______________________________ Date: ___/___/___            
Printed name of child ________________________________________    
Child’s participant ID number ____________________________________________ 
Printed name of parent/guardian_____________________________    
[For illiterate child] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
 
Signature of person obtaining assent_____________________ __________ Date: ___/___/___          
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Printed name of person obtaining assent____________________________    
Survey staff ID number _________________________________   
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Zambia Population-based HIV Impact Assessment: Assent for Interview, ages 15-17 
 
 
Interviewer reads: 
 
What language do you prefer to use for this discussion? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
  
 
Hello. My name is___________. I would like to invite you to take part in a research study/survey about 
HIV in Zambia. A survey is a way to learn about something by interviewing and testing many people.  
 
This form talks about our survey and the choice that you have to take part in it. I want you to ask me any 
questions that you have. You can ask questions any time.  
 
Why are we doing this survey?  
HIV is the virus that causes AIDS. AIDS is a very serious illness. We are doing this survey to help us learn 
more about HIV, AIDS and the health of children in Zambia. We plan to ask thousands of children like 
you to join this survey. We would like to invite you to join this survey too. Your parent/guardian said it 
was okay for us to ask you to join.  
 
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand. 
 
 
 306 
 
What would happen if you joined this survey? 
If you agree to join, here is what would happen: 
• We will ask you questions about your age and your knowledge about HIV. We will also ask you if 
you experienced any behaviors that may increase your chance of getting HIV.  
• The interview will take about 50 minutes.  
• After the interview, we will ask you if it is okay to take some of your blood to test for HIV, 
hepatitis B and syphilis. Like HIV, hepatitis B and syphilis are infections that can make someone 
very sick if left untreated. The testing and counseling will take about 40 minutes. You do not 
have to agree to the blood testing now. We will give you a separate opportunity to agree to the 
blood testing. You can agree to the interview, but not agree to the blood testing.  
• Lastly, it is possible that you may be eligible to take part in future surveys related to health in 
Zambia. At the end of this form, we will ask you if it is okay to contact you in the next two years 
if such an opportunity occurs. 
 
Could bad things happen to you if you joined the survey? 
You may feel uncomfortable about some of the questions I will ask. If I ask you any questions you don’t 
want to answer, just let me know and I will go to the next question. You can stop the interview at any 
time.  
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk. 
 
Could this survey help you? 
Being in this survey may not help you. But you may help us figure out ways to help other children and 
learn more about HIV in Zambia. Taking part in this survey is important. 
 
What else should you know about this survey? 
If you don’t want to be in the survey, you don’t have to be. Nobody will get upset with you if you do not 
want to join the survey. Your decision to take part or not take part will not affect your health care, but 
we hope you will agree to answer these questions since your views are important.  
 
Will you share my answers in the interview with other people? 
All the information you share with us during the interview will be kept confidential. You can choose to 
tell your parent/guardian about the interview. However, we will not share your answers to the 
questions with your parent or guardian. We will not tell other people that you are in this survey. We will 
not share information about you to anyone who does not work on the survey. Any information we share 
about you will have a number on it instead of your name. Only people working on the survey will be 
allowed to view the information we collect from you.  
 
The following individuals and agencies will be able to look at your interview records to help oversee the 
conduct of this survey: 
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▪ Survey staff and monitors 
▪ Staff members from groups that protect your rights as a survey participant to make sure that we 
are protecting your rights as a participant 
 
Who should you contact if you have questions? 
If you want to leave the survey, have any questions about the survey, or feel that you have been harmed 
by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the Ministry of Health, 
or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be reached at the number 
and address below.  
 
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre 
  P.O Box 71769, Ndola, Zambia 
Office phone: +260 212 620737 
Cell phone: +260  966 787234  
Email: khondowes@tdrc.org.zm 
 
Are there any costs to taking part in the interview?  
There is no cost to you for answering the questions in the interview. You should also know that you 
would not be paid to answer these questions. 
 
You can ask questions any time. Take the time you need to make your choice. 
 
Do you want to ask me anything? 
 
 
Assent Statement 
 
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and was 
given time to ask questions. Any questions that I had were answered satisfactorily. I agree to take part in 
the individual interview. I know that after choosing to be in this individual interview, I may withdraw at 
any time. My participation is voluntary. I have been offered a copy of this assent form. 
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12. Do you agree to do the interview? ‘YES’ means that you agree to do the interview. ‘NO’ means 
that you will NOT do the interview. 
______Yes              ______No 
 
13. FUTURE RESEARCH: It is possible that you may be eligible to participate in future studies related 
to health in Zambia. We are asking for your permission to contact you in the next two years if 
such an opportunity occurs. If we contact you, we will give you details about the new study and 
ask you to sign a separate assent form at that time. You may decide at that time that you do not 
want to take part in that study.  
If you do not wish to be contacted about future studies, it does not affect your involvement in 
this study. Do you agree to be contacted in the future? ‘YES’ means that you agree to be 
contacted in the future if a study opportunity arises. ‘NO’ means that you will NOT be contacted 
about future studies.  
________YES  ________NO 
 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
Printed name of participant________________________________________    
Participant ID number ___________________________________________________ 
 
Printed name of parent/guardian_____________________________    
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining assent_____________________ ___________ Date: ___/___/___          
Printed name of person obtaining assent_____________________________    
 
Survey staff ID number _________________________________   
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Zambia Population-based HIV Impact Assessment: Consent for Blood Draw (18-59 years) and Special 
Case Minors (15-17 years)  
  
  
Interviewer reads:  
    
What language do you prefer to use for this discussion?  
  
___English  
  
___Bemba  
  
___Nyanja  
  
___Lozi  
  
___Tonga  
  
___Lunda  
  
___Luvale  
  
___Kaonde  
  
___Other Language:  Specify ___________________________    
  
  
Hello. My name is___________. I will give you information about blood testing options in this research 
study/survey.  
  
As a part of this survey, we are giving people who take part a chance to learn if they have HIV, hepatitis 
B and/or syphilis. HIV, hepatitis B and syphilis are infections that can cause very serious illness if left 
untreated. We are also asking people if we can keep some of their blood for other additional HIV related 
tests.  
  
This form might have some words in it that are not familiar to you. Please ask me to explain anything 
that you do not understand.  
  
What would happen to you if you agree to take part in the blood testing?  
If you agree to the HIV, hepatitis B and syphilis blood testing, a trained nurse will take about three 
teaspoons or about 14 mL of blood from your arm. If it is not possible to take blood from your arm, then 
we will try to take a few drops of blood from your finger. We will give you the results of these blood 
tests today. We will provide counseling about the results. The testing and counseling session will take 
about 40 minutes.  
  
If you test positive for HIV, we will also test the amount of CD4 cells in your blood and give you the 
result today. CD4 cells are the part of the immune system that fight HIV infection and other diseases. 
We will also test the amount of CD4 cells in people without HIV. If you test positive for HIV, we will send 
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your blood to a laboratory to measure your viral load. Viral load is the amount of HIV in the blood. This 
information will help a doctor or nurse treat you. We will also do other additional tests related to HIV. If 
we have test results that might guide your care or treatment and you provide us with contact 
information, we will contact you to tell you how you and your doctor or nurse may get these results.  
  
After this blood test, we will show you a list of the nearest  Ministry of Health-approved and 
recommended health facilities for HIV, where you will be able to talk to trained doctors and nurses 
about the your HIV test results. We will give you a referral form to the health facility you select and 
information on today’s test results so that you can consult with a doctor or nurse to learn more about 
your HIV test, CD4 count and overall health. Your viral load test results will be ready in six to eight 
weeks. When the results are ready, we will send the results to your health facility of choice. If you 
provide us with your contact information, we will contact you to let you know the results are ready and 
encourage you to go to your health facility to discuss your viral load results with a doctor or nurse.  
  
As I stated before, we will also test your blood for hepatitis B and syphilis. If you test positive for 
hepatitis B and/or syphilis, we will refer you to the nearest appropriate health facility for further testing.  
  
What will happen to your leftover blood?  
We would like to ask your permission to store your leftover blood for other additional HIV related tests 
such as tests for toxoplasmosis, cryptococcal meningitis, hepatitis C or cytomegalovirus. We would store 
your leftover blood for the length of the study, but your name will only be on the sample for three years. 
During this three year period, we will attempt to tell you about any tests results that are important for 
your health. Your leftover blood will not be sold or used for commercial reasons. If you do not agree to 
have your blood samples stored for other additional HIV related tests, we will destroy your blood 
samples after survey-related testing has been completed.  
  
What are the potential risks?  
The needle may hurt when it is put into and taken out of your arm. Experienced staff will do the test 
under safe and clean conditions in order to protect you against any risk.   
  
In addition, you may learn that you are infected with HIV, hepatitis B and/or syphilis. Learning that you 
have HIV, hepatitis B and/or syphilis may cause some emotional discomfort. We will provide counseling 
on how to cope with learning that you have HIV, hepatitis B and/or syphilis. We will also tell you where 
you may go for care and treatment.  
 
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
  
What are the potential benefits?  
The main benefit is the chance to learn more about your health today. Some people who participate will 
test positive for HIV, hepatitis B and/or syphilis. If this happens to you, the benefit is that you will learn 
your HIV, hepatitis B and syphilis status. You will also learn where to go for life-saving treatment. Care 
and treatment provided by the Ministry of Health is free. If you already know that you are HIV positive 
and are on treatment, the CD4 and viral load tests can help your doctor or nurse judge how well the 
treatment is working. Your taking part in this blood testing could help us learn more about HIV, hepatitis 
B and syphilis in Zambia. It can help us learn about how well HIV prevention and treatment programs are 
working. It can also help improve these programs and services for Zambians.  
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What are alternatives to taking part?  
You can decide to not take part in the blood testing. Or you can decide to take part in the blood testing, 
but not agree to allow your leftover blood to be stored for other additional HIV related tests.  
  
Your decision to take part or not take part in the blood testing will not affect your health care in any 
way. However, we hope you will agree to take part as getting an HIV, hepatitis B and syphilis tests can 
help you. If you test positive for HIV, hepatitis B and/or syphilis, you can start medication to keep 
healthy.  
  
What about confidentiality?  
Your blood test results will be kept strictly confidential. We will only include your name on the referral 
forms we may give you to help the doctors and nurses at your health facility of choice identify you. In all 
other cases, your name and signed forms will be kept separate from your health information. Your name 
will not appear when we share survey results. When we share survey results, the information we collect 
from you will be identified by a number and not by your name. Only people working on the survey will 
have access to the data during the survey.  
  
The following individuals and agencies will be able to look at your records to help oversee the conduct of 
this survey:  
  
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the conduct of 
this survey to ensure that we are protecting your rights as a participant. These include the Tropical 
Diseases Research Centre in Zambia (TDRC) and the Institutional Review Boards at the Centers for 
Disease Control and Prevention (CDC; Atlanta, USA), Columbia University Medical Center and Westat (a 
statistical survey research organization)  
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the safety 
of human subjects to ensure we are protecting your rights as a participant in this survey  
▪ Survey staff and monitors   
 
The information we collect from you will not be released outside of the survey groups listed above 
unless there is an issue of safety. If we learn of anything that could harm you, we will provide 
information on where you can receive support. Your permission to allow us to use and share your name 
and contact information with the groups above will end three years after the end of the survey.  
  
Who should you contact if you have questions?  
If you want to leave the survey, have any questions about the survey, or feel that you have been harmed 
by taking part, you should contact the Principal Investigator, Mr. Chipalo Kaliki at the Ministry of Health, 
or Ms. Nchimunya Nkombo at the Central Statistical Office (CSO), who can be reached at the number 
and address below.  
   
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
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If you decide to leave the study, no more information will be collected from you. We will make every 
effort to delete the information we have collected from you. However, after today, we cannot 
guarantee we will be able to delete information that has already been shared.  
  
If you have any questions about your rights as a participant in this survey, you can contact:  
  
Mr. Shepard Khondowe   
Address: Tropical Diseases Research Centre   
  P.O Box 71769, Ndola, Zambia  
Office phone: +260 212 620737  
Cell phone: +260 966 787234   
Email: khondowe@tdrc.org.zm  
  
Are there any costs?   
There is no cost to you for receiving the blood tests today. You should also know that you would not be 
paid to receive the blood tests.  
  
Do you want to ask me anything about:  
▪ Taking your blood for HIV and hepatitis B testing?  
▪ Testing in the laboratory?  
▪ Storage of blood for other additional HIV related tests?  
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Consent Statement  
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and was 
given time to ask questions. Any questions that I had were answered satisfactorily. I agree to be in this 
survey. I know that after choosing to be in this survey, I may withdraw at any time. My participation is 
voluntary. I have been offered a copy of this consent form.  
1. Do you agree to give blood for HIV, hepatitis B and syphilis testing and related testing? ‘YES’ means 
that you agree to give blood for HIV, hepatitis B, and syphilis testing and related testing. ‘NO’ means that 
you will NOT give blood for HIV, hepatitis B, and syphilis testing and related testing.  
 
______Yes              ______No    
(If “Yes” proceed to the next question)  
  
2. Do you agree to have your leftover blood stored for other additional HIV related testing? ‘YES’ means 
that you give permission for your blood samples to be stored for other additional HIV related testing. 
‘NO’ means that your blood samples will NOT be stored for other additional HIV related testing.  
 
______Yes              ______No  
  
  
Participant signature or mark_______________________________________ Date: ___/___/___             
Printed name of participant________________________________________     
Participant ID number ____________________________________________  
  
[For illiterate participants]  
Signature of witness______________________________________________ Date: ___/___/___           
Printed name of witness___________________________________________    
  
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___           
Printed name of person obtaining consent_____________________________     
  
Survey staff ID number _________________________________    
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Zambia Population-based HIV Impact Assessment: Assent for Blood Draw, ages 10-14  
  
Nurse counselor/Interviewer reads:  
  
What language do you prefer for our discussion today?  
  
___English  
  
___Bemba  
  
___Nyanja  
  
___Lozi  
  
___Tonga  
  
___Lunda  
  
___Luvale  
  
___Kaonde  
  
___Other Language:  Specify ___________________________    
  
  
Hello. My name is___________. I will give you information about the blood testing part of this research 
study/survey.  
  
As a part of this survey, we are giving people who take part a chance to learn if they have HIV or 
hepatitis B. HIV and hepatitis B are germs that can make people very sick. We are also asking people if 
we can keep some of their blood for other additional HIV related testing.  
  
This form might have some words in it that you may not understand. Please ask me to explain anything 
that you do not understand. You can ask me questions any time.  
  
What would happen if you joined the blood testing part of this survey?  
▪ If you decide to join the blood testing part of the survey, here is what would happen:  
▪ We will use a needle to take some of your blood from your arm and then we would test your 
blood for HIV and hepatitis B today in your home.  
▪ It will take about 40 minutes to do the test and to talk to your parents about the results.  
▪ If you test positive for HIV, we will do another test on the blood we have already collected to 
measure the cells in your blood that fight HIV and other infections. We will also measure these 
cells from some children without HIV. We will do this test here at your home.  
▪ If you test positive for HIV, we will send your blood to a laboratory to measure the amount of HIV 
in your blood.  
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We would like to ask you to store your leftover blood for other additional HIV related tests. We would 
store your leftover blood for the length of the study, but your name will only be on the sample for three 
years. During this three year period, we will attempt to tell your parents/guardians about any tests 
results that are important for your health. Your leftover blood will not be sold or used for commercial 
reasons. If you do not agree to have your blood samples stored for other additional HIV related tests, we 
will destroy your blood samples after survey-related testing has been completed.  
 
Could bad things happen if you take the blood tests?  
The needle may hurt when it is put into and taken out of your arm. This will go away after a while. We 
will do our best to make it hurt as little as possible. Experienced nurses will do the test under safe and 
clean conditions to protect you from any risks. You can say ‘no’ to what we ask you to do for the survey 
at any time and we will stop.  
  
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk.  
  
Could the blood testing help you?  
Taking the blood test may help you learn if you have HIV and/or hepatitis B. After the blood test, we 
would give your tests results to your parent/guardian and they would decide on the best time to tell you 
the results. If your parent/guardian wants us to tell you about your test results, we would talk with you 
about any questions or worries you might have about the results. If you have HIV and/or hepatitis B, we 
will tell your parent/guardian where they can take you for medical care and treatment. Treatment for 
HIV and hepatitis B is free. We hope to learn about HIV healthcare needs in this survey. And we hope it 
will help other children in Zambia in the future.  
  
What else should you know about the blood testing part of this survey?  
If you don’t want to take the blood tests, you don’t have to. Nobody will get upset if you do not want to 
get your blood tested. You can say ‘yes’ to the blood testing and storage for other additional HIV related 
tests. Or you can say ‘yes’ to the blood testing, but ‘no’ to storage for other additional HIV related tests. 
You can also say ‘yes’ and change your mind later. You can stop the blood testing at any time. If you 
want to stop, please tell us.  
  
We will not tell other people that you took a blood test today. We will not share information about you 
to anyone who does not work on the survey. Any information we share about you will have a number on 
it instead of your name.  
 
The following individuals and agencies will be able to look at your blood testing records:  
▪ Survey staff and monitors  
▪ Staff members from groups that protect your rights as a survey participant to ensure that we are 
protecting your rights as a participant  
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Who should you contact if you have questions?   
If you have any questions about the survey or blood test, feel that you have been harmed by taking part, 
or no longer want to participate in the survey, you can contact Mr. Chipalo Kaliki or Ms. Nchimunya 
Nkombo who can be reached at the number and address below:   
  
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
  
If you have any questions about your rights as a participant in this survey, you can contact:  
  
Mr. Shepard Khondowe   
Address: Tropical Diseases Research Centre  
   P.O Box 71769, Ndola, Zambia  
Phone: +260 966 787234   
Email: khondowe@tdrc.org.zm  
  
Will you or your parent/guardian have to pay to receive blood testing?  
There is no cost to you or your parent/guardian for receiving blood testing today. You should also know 
that you and your parent/guardian will not be paid for receiving blood testing.  
  
Take the time you need to make your choice.  
  
Do you want to ask me anything about:  
▪ Taking your blood for HIV and hepatitis B testing?  
▪ Testing in the laboratory?  
▪ Storage of blood for other additional HIV related tests?  
 
 
Assent statement 
 
If you want to get a blood test and give your blood for research after we talk, please write your name 
below. We will write our name too. This shows we talked about the blood testing and that you want to 
take part.  
  
1. Do you agree to give blood for HIV and hepatitis B testing and related testing? ‘YES’ means you want 
to receive HIV and hepatitis B testing and related testing. ‘NO’ means you do not want to receive HIV 
and hepatitis B testing and related testing.  
 
______Yes              ______No  
(If “Yes” proceed to the next question)  
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2. Do you agree to have your leftover blood stored for other additional HIV related testing? ‘YES’ means 
that you give permission for your blood samples to be stored for other additional HIV related testing. 
‘NO’ means that your blood samples will NOT be stored for other additional HIV related testing.  
 
______Yes              ______No  
  
  
Child’s signature or mark_______________________________ Date: ___/___/___             
Printed name of child ________________________________________     
Child’s participant ID number ____________________________________________  
  
  
Printed name of parent/guardian_____________________________     
  
  
[For illiterate participant]  
Signature of witness______________________________________________ Date: ___/___/___           
  
Printed name of witness___________________________________________    
  
  
Signature of person obtaining assent_____________________ __________ Date: ___/___/___           
  
Printed name of person obtaining assent____________________________     
  
Survey staff ID number _________________________________    
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Zambia Population-based HIV Impact Assessment: Assent for Blood Draw, ages 15-17 
 
Nurse counselor/Interviewer reads: 
 
What language do you prefer to use for this discussion? 
 
___English 
 
___Bemba 
 
___Nyanja 
 
___Lozi 
 
___Tonga 
 
___Lunda 
 
___Luvale 
 
___Kaonde 
 
___Other Language:  Specify ___________________________   
 
 
 
Hello. My name is___________. I will give you information about the blood testing part of this research 
study/survey. 
 
As a part of this survey, we are giving people who take part a chance to learn if they have HIV, hepatitis 
B and/or syphilis. HIV, hepatitis B and syphilis are infections that can make someone very sick if left 
untreated. We are also asking people if we can keep some of their blood for other additional HIV related 
testing.  
 
This form might have some words in it that you may not understand. Please ask me to explain anything 
that you do not understand. You can ask me questions any time. 
 
What would happen if you joined the blood testing part of this survey? 
If you decide to join the blood testing part of the survey, here is what would happen: 
• We will use a needle to take some of your blood from your arm and then we would test your 
blood for HIV, hepatitis B and syphilis today in your home.  
• It will take about 40 minutes to do the test and to talk to your parents about the results. 
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• If you test positive for HIV, we will do another test on the blood we have already collected to 
measure the cells in your blood that fight HIV and other infections. We will also measure these 
cells from some children without HIV. We will do this test here at your home. 
• If you test positive for HIV, we will send your blood to a laboratory to measure the amount of 
HIV in your blood. 
• Lastly, we will ask you if we can use your leftover blood for other additional HIV related tests. 
We would store your leftover blood for the length of the study, but your name will only be on 
the sample for three years. During this three year period, we will attempt to tell your 
parents/guardians about any tests results that are important for your health. Your leftover 
blood will not be sold or used for commercial reasons. If you do not agree to have your blood 
samples stored for other additional HIV related tests, we will destroy your blood samples after 
survey-related testing has been completed. 
 
Could bad things happen if you take the blood tests? 
The needle may hurt when it is put into and taken out of your arm. This will go away after a while. We 
will do our best to make it hurt as little as possible. Experienced nurses will do the test under safe and 
clean conditions to protect you from any risks. You can say ‘no’ to what we ask you to do for the survey 
at any time and we will stop. 
 
In addition, you may learn that you are infected with HIV, hepatitis B and/or syphilis. Learning that you 
have HIV, hepatitis B and/or syphilis may cause some emotional discomfort. If your parent/guardian 
agrees, we will provide counseling on how to cope with learning that you have HIV, hepatitis B and/or 
syphilis, and tell your parent/guardian where you may go for care and treatment.  
 
As with all surveys, there is a chance that confidentiality could be compromised. We are doing 
everything we can to minimize this risk. 
 
Could the blood testing help you? 
Taking the blood test may help you learn if you have HIV, hepatitis B and or syphilis. After the blood test, 
we would give your tests results to your parent/guardian and they would decide on the best time to tell 
you the results. If your parent/guardian wants us to tell you about your test results, we would talk with 
you about any questions or worries you might have about the results. If you have HIV, hepatitis B and/or 
syphilis, we will tell your parent/guardian where they can take you for medical care and treatment. 
Treatment for HIV, hepatitis B and syphilis is free. We hope to learn about HIV healthcare needs in this 
survey. And we hope it will help other children in Zambia in the future.  
 
What else should you know about the blood testing part of this survey? 
If you don’t want to take the blood tests, you don’t have to. Nobody will get upset if you do not want to 
get your blood tested. You can say ‘yes’ to the blood testing and storage for other additional HIV related 
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tests. Or you can say ‘yes’ to the blood testing, but ‘no’ to storage for other additional HIV related tests. 
You can also say ‘yes’ and change your mind later. You can stop the blood testing at any time. If you 
want to stop, please tell us.  
 
Your decision to take part or not take part in the blood testing will not affect your health care in any 
way. However, we hope you will agree to take part as getting an HIV, hepatitis B and syphilis tests can 
help you. If you test positive for HIV, hepatitis B and/or syphilis, you can start medication to keep 
healthy.  
 
We will not tell other people that you took a blood test today. We will not share information about you 
to anyone who does not work on the survey. Any information we share about you will have a number on 
it instead of your name.  
The following individuals and agencies will be able to look at your blood testing records: 
▪ Survey staff and monitors 
▪ Staff members from groups that protect your rights as a survey participant to ensure that we are 
protecting your rights as a participant 
  
Who should you contact if you have questions?  
If you have any questions about the survey or blood test, feel that you have been harmed by taking part, 
or no longer want to participate in the survey, you can contact Mr. Chipalo Kaliki or Ms. Nchimunya 
Nkombo, who can be reached at the number and address below:  
 
Mr. Chipalo Kaliki       Ms. Nchimunya Nkombo 
Address: Ministry of Health Headquarters, Ndeke house  Address: Central Statistical Office 
P.O. Box 30205, Lusaka, Zambia     P.O. Box 31908, Lusaka, Zambia          
Office Phone: +260 211 253053     Cell phone: +260 0977 783527       
Email: ckaliki@gmail.com     Office Phone: +260 211 251377     
                                   Email: nnkombo@hotmail.com  
 
If you have any questions about your rights as a participant in this survey, you can contact: 
 
Mr. Shepard Khondowe  
Address: Tropical Diseases Research Centre 
   P.O Box 71769, Ndola, Zambia 
Phone: +260 966 787234  
Email: khondowe@tdrc.org.zm 
 
Will you or your parent/guardian have to pay to receive blood testing? 
There is no cost to you or your parent/guardian for receiving blood testing today. You should also know 
that you and your parent/guardian will not be paid for receiving blood testing. 
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Take the time you need to make your choice.  
 
Do you want to ask me anything about: 
▪ Taking your blood for HIV, hepatitis B, and/or syphilis testing? 
▪ Testing in the laboratory? 
▪ Storage of blood for other additional HIV related tests? 
 
If you want to get a blood test and give your blood for research after we talk, please write your name 
below. We will write our name too. This shows we talked about the blood testing and that you want to 
take part. 
 
Assent statement 
 
I have read this form, and/or someone has read it to me. I was encouraged to ask questions and was 
given time to ask questions. Any questions that I had have been answered satisfactorily. I agree to be in 
this survey. I know that after choosing to be in this survey, I may withdraw at any time. My participation 
is voluntary. I have been offered a copy of this assent form. 
 
14. Do you agree to give blood for HIV, hepatitis B and syphilis testing and related testing? ‘YES’ 
means that you agree to give blood for HIV, hepatitis B, and syphilis testing and related testing. 
‘NO’ means that you will NOT give blood for HIV, hepatitis B, syphilis testing and related testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
15. Do you agree to have your leftover blood stored for other additional HIV related testing? ‘YES’ 
means that you give permission for your blood samples to be stored for other additional HIV 
related testing. ‘NO’ means that your blood samples will NOT be stored for other additional HIV 
related testing. 
______Yes              ______No 
 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
Printed name of participant________________________________________    
Participant ID number ____________________________________________ 
 
Printed name of parent/guardian_____________________________ 
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[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
 
Signature of person obtaining assent_____________________ __________ Date: ___/___/___          
Printed name of person obtaining assent____________________________    
Survey staff ID number _________________________________   
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This project is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC 
under the terms of cooperative agreement #U2GGH001226. The findings and conclusions are those of 
the authors and do not necessarily represent the official position of the funding agencies.  
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